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SUMMARY	  	  
NF-­‐κB	  is	  a	  family	  of	  transcription	  factors	  responsible	  for	  the	  regulation	  of	  hundreds	  of	  genes	  
controlling	   key	   cellular	   processes	   such	   as	   proliferation,	   apoptosis	   and	   inflammation.	   The	  
activation	  of	  NF-­‐κB	   is	   an	  Achilles	   heel	   of	  many	   lymphoid	  malignancies.	   Therefore,	   a	   lot	   of	  
effort	  is	  being	  made	  in	  investigating	  its	  regulatory	  mechanisms	  and	  exploring	  its	  therapeutic	  
potentials.	   In	  this	  doctoral	  thesis,	  we	  have	   investigated	  the	  NF-­‐κB	  pathway	   in	  non-­‐Hodgkin	  
lymphomas,	   with	   the	   aim	   of	   characterizing	   its	   expression	   and	   clinical	   impact	   in	   human	  
lymphomas	   and	   identifying	   putative	  molecular	   targets	   able	   to	   interfere	  with	   its	   activation	  
and	  lymphoma	  cell	  survival.	  	  
	  
Abnormal	  NF-­‐κB	  activation	  has	  been	   linked	   to	  Diffuse	   Large	  B-­‐cell	   Lymphoma	   (DLBCL)	  and	  
has	  been	  described	  to	  play	  a	  key	  role	  in	  the	  pathogenesis	  of	  a	  specific	  molecular	  subtype	  of	  
this	  malignancy,	  the	  ABC-­‐DLBCL.	  In	  the	  first	  part	  of	  this	  work,	  we	  evaluated	  the	  expression	  of	  
NF-­‐κB	  by	   immunohistochemistry	   in	   a	   large	   series	  of	  DLBCL	   cases.	   The	   five	  different	   family	  
members	  showed	  a	  heterogeneous	  and	   intricate	  expression	  pattern,	  but	  most	  remarkably,	  
NF-­‐κB	  signaling	  was	  found	  to	  be	  a	  prominent	  feature	  not	  only	  in	  ABC-­‐DLBCL,	  but	  also	  in	  GCB-­‐
DLBCL,	  a	  subtype	  of	  DLBCL	  previously	  described	  to	  lack	  NF-­‐κB	  activation.	  	  Furthermore,	  c-­‐Rel	  
expression	  was	  observed	  as	  a	  common	  feature	  in	  DLBCL	  and	  was	  able	  to	  identify	  a	  subset	  of	  
patients	  with	  enhanced	  overall	  survival.	  	  
	  
Peripheral	   T-­‐cell	   lymphomas	   (PTCL)	   are	   highly	   aggressive	   tumors	   with	   a	   current	   lack	   of	  
effective	  therapies,	  partly	  due	  to	  its	  unknown	  molecular	  pathology.	  In	  the	  second	  part	  of	  this	  
work,	  we	  investigated	  the	  function	  of	  the	  NF-­‐κB–inducing	  kinase	  (NIK)	  in	  NF-­‐κB	  signaling	  and	  
its	  potential	  as	  a	  molecular	  target	  in	  T-­‐cell	  lymphomas.	  We	  showed	  that	  the	  NF-­‐κB	  pathway	  
was	   activated	   in	   a	   subset	   of	   PTCLs	   associated	   with	   poor	   overall	   survival.	   NIK	   was	  
overexpressed	   in	  a	  number	  of	  PTCL	   cell	   lines	  and	  primary	   samples	  and	  a	   role	   for	  NIK	  as	  a	  
critical	   regulator	   of	   both	   classical	   and	   alternative	   NF-­‐κB	   activation	   was	   unveiled.	   Using	  
genetic	  silencing,	  we	  demonstrated	  a	  pivotal	  role	  for	  NIK	  in	  the	  survival	  of	  these	  tumor	  cells	  
as	  NIK	   depletion	   led	   to	   a	   dramatic	   induction	   of	   apoptosis	   in	  NIK-­‐overexpressing	   cells.	   The	  
knockdown	   of	   NIK	   led	   to	   a	   modulation	   of	   several	   key	   factors	   in	   cancer	   cell	   survival	   and	  
apoptosis	  evasion	  and	  had	  also	  an	  impact	  on	  other	  important	  survival	  pathways,	  apart	  from	  
NF-­‐κB,	  in	  PTCL	  pathogenesis.	  The	  results	  of	  this	  part	  of	  the	  study	  indicate	  that	  NIK	  could	  be	  a	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1.1	  Lymphomas	  
	  
1.1.1 General	  features	  	  
Lymphoma	  is	  a	  cancer	  of	  the	  lymphatic	  system.	  It	  arises	  from	  malignant	  transformation	  and	  
uncontrolled	  proliferation	  of	  B,	  T	  or	  NK	  cells,	   leading	  to	  the	  formation	  of	  tumors	   in	  several	  
parts	  of	  the	  body,	  including	  lymph	  nodes,	  spleen,	  blood,	  bone	  marrow	  or	  other	  organs.	  The	  
term	   lymphoma	  describes	  a	  heterogeneous	  group	  of	  neoplasms	   including	  over	  60	  entities,	  
presenting	  different	  clinical	  course,	  treatment	  response	  and	  prognosis.	  A	  proper	  lymphoma	  
classification	  is	  important	  for	  accurate	  clinical	  practice	  and	  treatment	  strategies.	  The	  World	  
Health	  Organization	   (WHO)	  classification	  of	  neoplasms	  of	   the	  hematopoietic	  and	   lymphoid	  
tissues	  (Swerdlow	  et	  al.	  2008)	  describes	  the	  most	  recent	  classification	  system,	  which	  is	  used	  
worldwide	   for	   the	   diagnosis	   of	   these	   tumors.	   Lymphomas	   are	   stratified	   according	   to	   their	  
cell	   lineage	  and	  their	  derivation	   from	   immature	  or	  mature	   lymphocytes.	  Many	   lymphomas	  
recapitulate	  stages	  of	  normal	   lymphocyte	  differentiation	  so	   that	  classification	  can	   to	  some	  
extent	   be	   made	   according	   to	   the	   corresponding	   normal	   stage.	   Classification	   criteria	   are	  
based	  on	  morphology,	  immunophenotype,	  genetic	  abnormalities	  and	  molecular	  and	  clinical	  
features	  (Puente	  et	  al.	  2011).	  
There	  are	  two	  major	  categories	  of	  lymphomas:	  Hodgkin	  lymphoma	  (HL,	  the	  first	  lymphoma	  
to	   be	   described	   by	   Thomas	   Hodgkin	   in	   1832)	   and	   non-­‐Hodgkin	   lymphoma	   (NHL).	   NHL	  
represents	   almost	   90%	   of	   all	   lymphomas	   and	   accounts	   for	   around	   3%	   of	   all	   cancers	   in	  
Europe,	   where	   7	   individuals	   out	   of	   100	   000	   get	   the	   disease	   each	   year	   (Data	   from	   the	  
International	   Agency	   of	   Cancer	   Research,	   IARC,	   Globocan	   2008).	   NHL	   can	   be	   further	  
stratified	  into	  B	  or	  T/NK	  cell	  neoplasms,	  where	  B	  cell	  lymphomas	  account	  for	  nearly	  85%	  of	  
all	  NHL.	  	  
In	   this	   section,	   the	   lymphoma	   types	   relevant	   for	   the	   work	   of	   this	   doctoral	   thesis,	   diffuse	  
large	  B	  cell	  lymphoma	  and	  peripheral	  T	  cell	  lymphoma,	  will	  be	  described.	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1.1.2	  Diffuse	  large	  B-­‐cell	  lymphoma	  	  
1.1.2.1	  General	  features	  
	  
Diffuse	   large	   B-­‐cell	   lymphoma	   (DLBCL)	   is	   the	  most	   common	   type	   of	   lymphoma	   in	   adults,	  
accounting	   for	  30	   to	  40%	  of	  all	  non-­‐Hodgkin	   lymphomas	   in	   the	  United	  States	  as	  well	  as	   in	  
Spain	   (Morton	   et	   al.	   2006;	   Novelli	   et	   al.	   2013).	   It	   is	   a	   form	   of	   mature	   B-­‐cell	   lymphoma	  
characterized	  by	  a	  diffuse	  growth	  pattern	  of	  neoplastic	  large	  B	  lymphocytes	  with	  large	  nuclei.	  
The	  median	  age	  of	  diagnosis	  is	  in	  the	  7th	  decade	  but	  children	  and	  young	  adults	  may	  also	  be	  
affected	   (Swerdlow	  et	  al.	   2008).	  Patients	  are	  often	  asymptomatic	  and	   the	  disease	   is	  often	  
detected	  as	   a	   rapidly	  enlarging	   tumor	  mass	  at	  either	  nodal	  or	  extranodal	   sites.	  DLBCL	   is	   a	  
molecularly	   and	   clinically	   heterogeneous	   entity	   and	   both	   morphologic	   and	   molecular	  
variants	  have	  been	  described	  (Swerdlow	  et	  al.	  2008).	  	  
	  
1.1.2.2	  Molecular	  characteristics	  and	  pathogenesis	  	  
Based	   on	   gene	   expression	   profiling,	   two	   different	   molecular	   subtypes	   of	   DLBCL	   are	  
recognized	  according	   to	   the	  putative	   cell	   of	   origin;	   the	   activated	  B-­‐cell-­‐like	   (ABC)	   subtype,	  
and	   the	   germinal	   center	   B-­‐cell-­‐like	   (GCB)	   subtype	   (Alizadeh	   et	   al.	   2000;	   Lenz	   et	   al.	   2008).	  
These	  subtypes	  reflect	  distinct	  differentiation	  stages	  of	  normal	  B-­‐cell	  development	  and	  differ	  
in	  their	  clinical	  presentation,	  cure	  rates	  and	  oncogenic	  pathways	  (Staudt	  et	  al.	  2005).	  GCB-­‐
DLBCLs	  express	  genes	  defining	  B	  cells	  of	  the	  germinal	  center,	  whereas	  the	  gene	  expression	  
profile	  of	  ABC-­‐DLBCL	  suggests	  that	  this	  subtype	  arises	  from	  post-­‐germinal	  center	  B	  cells	  that	  
are	   arrested	   in	   their	   differentiation	   process	   towards	   plasma	   cells.	   More	   recently,	   the	  
distinction	   into	   ABC	   and	   GCB	   subtypes	   has	   been	   performed	   with	   high	   accuracy	   using	  
immunohistochemistry	   of	   CD10,	   multiple	   myeloma	   oncogene	   1	   (MUM1)	   and	   B-­‐cell	  
lymphoma	   6	   (BCL6)	   (named	   Hans´algorithm	   (Hans	   et	   al.	   2004))	   or	   germinal	   center	   B-­‐cell	  
trascript	   1	   (GCET1),	   CD10,	   BCL6,	   MUM1	   and	   forkhead	   box	   protein	   P1	   (FOXP1)	   (Choi´s	  
algorithm	  (Choi	  et	  al.	  2009)).	  
	  
During	  the	  germinal-­‐center	  reaction,	  somatic	  hypermutation	  and	  class-­‐switch	  recombination	  
are	  two	  processes	  which	  induce	  modification	  in	  the	  B-­‐cell	   immunoglobulin	  DNA	  in	  order	  to	  
produce	   high	   affinity	   antibodies.	   These	   genetic	   modifications	   are	   necessary	   for	   normal	  
immune	  response,	  but	  they	  can	  also	  be	  a	  source	  of	  DNA	  damage	  that	  can	  become	  pathologic	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in	   lymphomas.	  A	   range	  of	   different	   genetic	   alterations	   has	   been	  described	   in	  DLBCL.	   Four	  
recent	   reports	   using	   next	   generation	   sequencing	   of	   the	   DLBCL	   exome,	   reveal	   extensive	  
genetic	  heterogeneity	  and	  >30	  genetic	  lesions	  per	  case	  (Morin	  et	  al.	  2011;	  Pasqualucci	  et	  al.	  
2011;	   Lohr	   et	   al.	   2012;	   Zhang	   et	   al.	   2013).	   Some	  of	   these	   are	   common	  between	  different	  
molecular	   subtypes,	   and	   others	   are	   subtype-­‐specific.	   BCL6	   gene	   translocation	   (involving	  
3q27)	  is	  the	  most	  common	  translocation	  reported	  in	  DLBCL,	  occurring	  in	  approximately	  30%	  
of	   patients	   (Pasqualucci	   et	   al.	   2003).	   BCL6	   is	   a	   repressor	   of	   transcription	   and	   a	   master	  
regulator	   of	   the	   germinal-­‐center	   phenotype	   where	   it	   represses	   genes	   involved	   in	  
differentiation	  of	  plasma	  cells,	  cell	  cycle,	  apoptosis,	  and	  response	  to	  DNA	  damage	  (Lenz	  et	  al.	  
2010).	   Other	   frequent	   gene	   alterations	   in	   DLBCL	   affect	   chromatin	   modification	   (with	  
approximately	  40%	  of	  cases	  harboring	  alterations	   in	  histone	  methyltransferases	  or	  histone	  
acetyltransferases)	  and	  immune	  recognition	  by	  T	  cells	  (Pasqualucci	  et	  al.	  2011).	   In	  the	  GCB	  
subtype,	   specific	   genetic	   lesions	   such	   as	   t(14;18)	   translocations	   (giving	   rise	   to	  
immunoglobulin-­‐driven	   BCL2	   expression),	   V-­‐myc	   avian	   myelocytomatosis	   viral	   oncogene	  
homolog	   (MYC)	   translocations,	   V-­‐rel	   avian	   reticuloendotheliosis	   viral	   oncogene	   homolog	  
(REL)	  amplifications,	  phosphatase	  and	  tensin	  homolog	   (PTEN)	  deletions,	  and	  tumor	  protein	  
53	   (TP53)	   mutations	   are	   recurrent	   (Rosenwald	   et	   al.	   2002;	   Lenz	   et	   al.	   2008).	   The	   ABC	  
subtype	  is	  characterized	  by	  prominent	  NF-­‐κB	  activation	  (Davis	  et	  al.	  2001),	  which	  can	  partly	  
be	  explained	  by	   frequent	  genetic	   lesions	   in	  mediators	  of	  NF-­‐κB	   signaling	   (Compagno	  et	  al.	  
2009)	   (described	   in	   detail	   in	   the	   NF-­‐κB	   section	   below).	   Inactivating	   lesions	   in	   PR	   domain	  
containing	   1	   (PRDM1,	   the	   gene	   encoding	   B-­‐lymphocyte	  maturation	   protein	   1	   (BLIMP1),	   a	  
master	   regulator	   of	   plasma	   cell	   differentiation)	   is	   also	   a	   common	   feature	   of	   ABC-­‐DLBCL	  
(Mandelbaum	  et	  al.	  2010).	  
	  
Additionally,	   the	   oncogenic	   virus	   Epstein-­‐Barr	   virus	   (EBV)	   has	   been	   associated	   with	   the	  
etiology	  of	  DLBCL	  in	  a	  subgroup	  of	  patients.	  EBV	  is	  a	  ubiquitous	  human	  γ-­‐herpesvirus,	  which	  
infects	   primarily	   B	   cells,	   where	   it	   stays	   as	   a	   latent	   infection	   throughout	   the	   life	   of	   the	  
individual	  (Kutok	  et	  al.	  2006).	  EBV	  can	  transform	  B	  cells	  in	  vitro	  (Kaye	  et	  al.	  1993)	  and	  even	  
though	  EBV	  infections	  are	  harmless	  in	  the	  vast	  majority	  of	  individuals,	  latent	  EBV	  infections	  
have	  been	  associated	  with	  several	  B-­‐cell	  malignancies	  (Saha	  et	  al.	  2011).	  EBV-­‐positive	  DLBCL	  
associated	   with	   advanced	   age	   was	   included	   as	   a	   separate	   entity	   of	   DLBCL	   in	   the	   WHO	  
classification	  system	  of	  hematological	  malignancies	  2008	  (Swerdlow	  et	  al.	  2008).	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1.1.2.3	  Treatment	  and	  prognosis	  	  
DLBCL	   is	   an	   aggressive	   lymphoma	   but	   can	   potentially	   be	   cured	   using	   anthracyclin-­‐based	  
chemotherapy,	   such	   as	   a	   combination	   of	   cyclophosphamide,	   doxorubicin,	   vincristine,	   and	  
prednisone	  (CHOP).	  The	  addition	  of	  the	  anti-­‐CD20	  monoclonal	  antibody,	  Rituximab,	  to	  CHOP	  
(R-­‐CHOP),	   has	   significantly	   improved	   the	   prognosis	   in	   DLBCL	   and	   is	   today	   the	   standard	  
treatment	  for	  DLBCL.	  Still,	  the	  cure	  rate	  of	  DLBCL	  is	  only	  40-­‐50%	  (Coiffier	  2007;	  Coiffier	  et	  al.	  
2010;	   Lenz	   et	   al.	   2010).	   The	  overall	   survival	   of	   patients	  of	   the	  ABC	   subtype	   is	   significantly	  
inferior	  than	  that	  of	  patients	  with	  GCB	  subtype	  (Alizadeh	  et	  al.	  2000;	  Lenz	  et	  al.	  2010).	  	  
	  
1.1.3	  Peripheral	  T-­‐cell	  lymphoma	  	  
1.1.3.1	  General	  Features	  	  
Peripheral	   T-­‐cell	   lymphomas	   (PTCLs),	   also	   called	   mature	   T-­‐cell	   lymphomas,	   comprise	   a	  
variety	   of	   malignancies	   that	   arise	   from	   abnormal	   growth	   of	   post-­‐thymic	   mature	   T	  
lymphocytes.	   Lymphomas	  derived	   from	  natural	   killer	   (NK)	   cells	   are	   also	   generally	   grouped	  
under	   this	   category.	   The	   vast	  majority	   of	   T-­‐cell	   lymphomas	   falls	   under	   the	   category	   PTCL,	  
since	  they	  arise	  from	  mature	   lymphocytes	   in	  the	  peripheral	   lymphoid	  tissue	  (lymph	  nodes,	  
spleen,	  mucosa-­‐associated	  lymphoid	  tissue).	  T-­‐cell	  lymphomas	  arising	  from	  immature	  T	  cells	  
in	   the	   central	   lymphoid	   tissue	   (bone	   marrow	   and	   thymus)	   are	   called	   immature	   T	   cell	  
lymphomas	  and	  will	  not	  be	  described	  in	  this	  work.	  PTCL	  is	  a	  heterogeneous	  group	  of	  over	  20	  
malignant	  entities	   that	  are	  generally	   associated	  with	  a	   very	  poor	  prognosis	   and	   treatment	  
response	   (Swerdlow	   et	   al.	   2008).	   Classification	   of	   PTCL	   is	   challenging	   and	   does	   not	   well	  
predict	   therapeutic	   strategies.	   The	   WHO	   2008	   classification	   of	   mature	   T-­‐	   and	   NK-­‐cell	  
neoplasms	   is	   based	   mainly	   on	   morphology	   and	   immunophenotype	   and	   the	   subtypes	   are	  
listed	   in	   Table	   1.1.	   PTCLs	   account	   for	   approximately	   12%	   of	   all	   NHL	   in	  Western	   countries	  
(Piccaluga	   et	   al.	   2011).	   Relative	   frequencies	   of	   PTCL	   subtypes	   from	   a	   study	   of	   an	  
international	  adult	  population	  of	  1314	  patients	  (Vose	  et	  al.	  2008)	  are	  shown	  in	  Figure	  1.1.	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The	   incidence	   of	   these	   neoplasms	   varies	   in	   different	   geographic	   regions	   and	   racial	  
populations,	  where	  PTCL-­‐NOS,	  AITL	  and	  ALCL	  are	  relatively	  more	  common	  in	  North	  America	  
and	  Europe,	  while	  NK-­‐TCL	  and	  ATLL	  are	  more	  frequent	  in	  Asia	  (Vose	  et	  al.	  2008).	  In	  general,	  
PTCLs	   have	   a	   higher	   incidence	   in	   Asia	   and	   South/Central	   America	   (Rudiger	   et	   al.	   2002;	  
Swerdlow	  et	  al.	  2008;	  de	  Leval	  et	  al.	  2011),	  partly	  overlapping	  with	  the	  endemicity	  of	  certain	  
viruses,	   such	   as	   human	   T-­‐lymphotropic	   virus-­‐1	   (HTLV1)	   and	   Epstein-­‐Barr	   virus	   (EBV),	  
described	  as	  risk	  factors	  for	  some	  subtypes	  of	  T-­‐cell	   lymphoma	  (Swerdlow	  et	  al.	  2008;	  Foss	  
et	  al.	  2011).	  A	  brief	  description	  of	  the	  PTCL	  subtypes	  used	  in	  this	  thesis	  project;	  peripheral	  T-­‐
cell	   lymphoma	   -­‐	  not	  otherwise	   specified	   (PTCL-­‐NOS),	   angioimmunoblastic	  T-­‐cell	   lymphoma	  
(AITL),	  anaplastic	  large	  cell	  lymphoma	  (ALCL)	  and	  cutaneous	  T-­‐cell	  lymphoma),	  can	  be	  found	  
in	  Table	  1.2.	  
	  
1.1.3.2	  Molecular	  characteristics	  and	  pathogenesis	  	  
The	  molecular	  pathogenesis	  of	  PTCL	  is	  still	  largely	  unknown.	  The	  heterogeneous	  background	  
of	   these	  malignancies,	   the	   low	   incidence,	  and	  a	   lack	  of	  experimental	  models	  contribute	   to	  
the	   poor	   understanding	   of	   the	   biology	   of	   these	   disorders.	   Apart	   from	   chromosomal	  
translocations	   involving	   the	  anaplastic	   lymphoma	  kinase	   (ALK)	  gene	   in	  ALCL,	   few	  recurrent	  
genetic	  disorders	  are	   reported	   that	   can	  help	  explaining	   the	  pathogenesis	  of	  PTCL.	  ALK	   is	  a	  
Figure	  1.1	  Relative	  frequencies	  of	  PTCL	  subtypes	  	  
Relative	  distribution	  of	  different	  PTCL	   subtypes	   in	   an	   international	  population	  of	  1314	  patients.	  
Data	   extracted	   from	   Vose	   J	   et	   al.,	   2008.	   NOS	   =	   not	   otherwise	   specified,	   ALK	   =	   anaplastic	  


























tyrosine	   kinase	   receptor	   of	   the	   insulin	   receptor	   superfamily	   and	   its	   expression	   is	   normally	  
absent	  in	  lymphoid	  cells	  (Morris	  et	  al.	  1994).	  A	  constitutively	  active	  ALK	  has	  been	  shown	  to	  
induce	   cell	   transformation	   and	   is	   involved	   in	   a	   complex	   signaling	   network	   including	  
activation	  of	  signal	  transducer	  and	  activator	  of	  transcription	  3	  (STAT3),	  phosphatidylinositol	  
3-­‐kinase	  /	  v-­‐akt	  murine	  thymoma	  viral	  oncogene	  homolog	  (PI3K/AKT)	  and	  RAS/	  Extracellular	  
signal-­‐regulated	  kinase	  (ERK)	  pathways	  (Ferreri	  et	  al.	  2012).	  The	  (2;5)(p23;q35)	  translocation	  
is	  the	  most	  common	  alteration	  giving	  rise	  to	  nucleophosmin	  (NPM)-­‐ALK	  fusion	  protein,	  but	  
variant	  ALK	  fusion	  partners	  have	  also	  been	  described	  and	  they	  all	  lead	  to	  an	  overexpression	  
and	  activation	  of	  the	  ALK	  protein	  (Ferreri	  et	  al.	  2012).	  Gene	  expression	  analysis	  of	  PTCL	  has	  
shown	   distinct	   molecular	   profiles	   in	   different	   subtypes	   of	   PTCL	   as	   well	   as	   within	   PTCL	  
subtypes	  (Piccaluga	  et	  al.	  2007;	  Piccaluga	  et	  al.	  2007;	   Iqbal	  et	  al.	  2010).	  Results	  from	  these	  
studies	   indicated	   NF-­‐κB	   activation	   and	   abnormal	  methylation	   patterns	   in	   a	   group	   of	   PTCL	  
(Martinez-­‐Delgado	  et	  al.	  2005;	  Costello	  et	  al.	  2010).	  
	  
	  
Table	  1.1	  WHO	  classification	  of	  Mature	  T-­‐cell	  and	  NK-­‐cell	  neoplasms	  	  
(Swerdlow	  et	  al.,	  2008)	  
	  T	  cell	  prolymphocytic	  leukemia	  	  
	  Chronic	  lymphoproliferative	  disorder	  of	  NK-­‐cells	  *	  	  
	  Aggressive	  NK	  cell	  leukaemia	  	  
	  Systemic	  EBV-­‐positive	  T-­‐cell	  lymphoproliferative	  disease	  of	  childhood	  	  
	  Hydroa	  vacciniforme-­‐like	  lymphoma	  	  
	  Adult	  T-­‐cell	  leukaemia/lymphoma	  	  
	  Extranodal	  NK/T	  cell	  lymphoma,	  nasal	  type	  	  
	  Enteropathy-­‐associated	  T-­‐cell	  lymphoma	  	  
	  Hepatosplenic	  T-­‐cell	  lymphoma	  	  
	  Subcutaneous	  panniculitis-­‐like	  T-­‐cell	  lymphoma	  	  
	  Mycosis	  fungoides	  	  
	  Sézary	  syndrome	  	  
	  Primary	  cutaneous	  CD30	  positive	  T-­‐cell	  lymphoproliferative	  disorders	  	  
	  	  	  	  	  	  	  	  	  Lymphomatoid	  papulosis	  	  
	  	  	  	  	  	  	  	  	  Primary	  cutaneous	  anaplastic	  large	  cell	  lymphoma	  	  
	  Primary	  cutaneous	  gamma-­‐delta	  T-­‐cell	  lymphoma	  	  
	  Primary	  cutaneos	  CD8	  positive	  aggressive	  epidermotropic	  cytotoxic	  T-­‐cell	  lymphoma	  *	  	  
	  Primary	  cutaneous	  CD4	  positive	  small/medium	  T-­‐cell	  lymphoma	  *	  	  
	  Peripheral	  T-­‐cell	  lymphoma,	  NOS	  	  
	  Angioimmunoblastic	  T-­‐cell	  lymphoma	  	  
	  Anaplastic	  large	  cell	  lymphoma,	  ALK	  positive	  	  
	  Anaplastic	  large	  cell	  lymphoma,	  ALK	  negative	  *	  	  
	  
	  
*	  represents	  provisional	  entities	  
Introduction	  	  
	   9	  
Molecular	   pathways	   that	  have	  been	   reported	   to	  be	   activated	   in	   T-­‐cell	   lymphomas	  are	   the	  
PI3K/AKT	   pathway,	  NF-­‐κB	   pathway,	  Notch	   pathway,	   Janus	   kinase	   (JAK)/STAT	   pathway	   and	  
the	  Mitogen-­‐activated	   protein	   kinase	   (MAPK)	   pathway	   (Zhao	   2010;	   Martin-­‐Sanchez	   et	   al.	  
2013).	  The	  presence	  of	  viral	  infections,	  such	  as	  EBV,	  human	  T	  lymphotropic	  virus	  (HTLV)	  and	  
human	  herpes	  virus	  6B	  (HHV6B)	  in	  association	  with	  some	  T	  or	  NK	  lymphomas	  has	  led	  to	  the	  
suggestion	  that	  these	  viruses	  might	  be	  involved	  in	  the	  etiology	  of	  PTCL	  (Quintanilla-­‐Martinez	  
et	  al.	  2000;	  Swerdlow	  et	  al.	  2008;	  Foss	  et	  al.	  2011).	  Further	   information	  of	  the	  genetic	  and	  
molecular	  aberrations	  of	  PTCL	  is	  summarized	  in	  Table	  1.2.	  
	  
1.1.3.3	  Treatment	  and	  prognosis	  of	  PTCL	  	  
The	  heterogeneous	  nature	  of	  PTCL	  tumors	  is	  also	  reflected	  in	  the	  clinical	  outcome	  of	  these	  
patients.	  In	  general	  terms,	  PTCLs	  are	  aggressive	  malignancies	  with	  a	  dismal	  prognosis.	  Figure	  
1.2	  shows	  the	  overall	  survival	  curves	  of	  different	  PTCL	  entities.	  	  
	  
Up	   to	   date,	  with	   the	   exception	   of	   some	   cutaneous	   T-­‐cell	   lymphomas	   that	   can	   be	   treated	  
with	   topical	   administration	   of	   corticoids,	   alkylating	   agents,	   bexarotene	   or	   ultraviolet	  
radiation	  (Wilcox	  2011),	  no	  PTCL-­‐specific	  or	  subtype-­‐specific	  treatment	  strategy	  is	  available.	  
PTCLs	   have	   in	   the	   past	   been	   grouped	   as	   a	   minority	   together	   with	   aggressive	   B-­‐cell	  
lymphomas	   in	   clinical	   trials,	   resulting	   in	   the	  use	  of	   treatment	   strategies	   adapted	   for	  B-­‐cell	  
lymphomas.	   The	   standard	   therapy	   for	   PTCLs	   today	   is	   CHOP	   (cyclophosphamadide,	  
doxorubicin,	   vincristine	  and	  prednisone)	  or	  CHOP-­‐like	   regimens	   that	  add	  anthracyclines,	   in	  
spite	  of	  reports	  showing	  that	  it	  is	  largely	  ineffective	  (Savage	  2011).	  Although	  without	  optimal	  
treatment	  outcome,	  ALCL	   is	   the	  only	  aggressive	  PTCL	  subtype	  where	  a	  significant	  group	  of	  
patients	   can	   be	   cured	   using	   CHOP-­‐based	   therapies	   (Armitage	   2012).	   High-­‐Dose	  
Chemotherapy	   and	   Autologous	   Stem	   Cell	   Transplantation	   HDC/ASCT	   is	   also	   performed	   in	  
eligible	  patients	  with	  refractory	  PTCL	  (Dearden	  et	  al.	  2011).	  	  
	  
Today,	   therapeutic	   trials	   for	   the	   different	   PTCL	   subtypes	   are	   beginning,	   with	   the	   hope	   of	  
finding	  more	  effective	  treatments.	  Early	  phase	  clinical	  trials	  combining	  CHOP	  with	  different	  
agents	   such	   as	   etoposide,	   the	   proteasome	   inhibitor	   Bortezomib	   or	  monoclonal	   antibodies	  
for	   CD52	   (alemtuzumab)	   or	   VEGF-­‐A	   (bevacizumab),	   are	   being	   performed	   and	   other	   novel	  
chemotherapy	  combinations	  including	  gemcitabine	  have	  shown	  variable	  response	  (Dearden	  
et	  al.	  2011;	  Savage	  2011;	  Armitage	  2012).	  Other	  new	   treatment	   strategies	   that	  have	  been	  
evaluated	   in	  early	  phase	  clinical	   trials	   in	  PTCLs	   include	  Pralatrexate	  (a	  novel	   folate	  analog),	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Bendamustine	   (alkylating	   agent),	   HDAC	   inhibitors	   (inhibitors	   of	   histone	   deacetylases),	  
Lenalidomide	   (immunosuppressive	   agent),	   Aurora	   A	   kinase	   inhibitors,	   and	   Bortezomib	  
(Savage	  2011).	  More	  extensive	   studies	   are	   though	  needed	   in	  order	   to	  decide	   their	   clinical	  
advantage.	  The	  lack	  of	  knowledge	  of	  the	  biological	  background	  of	  PTCL	  and	  the	  rarity	  of	  the	  
disease,	  have	  complicated	  the	  development	  of	  effective	  targeted	  therapies.	  
	  
	  
As	   in	   B-­‐cell	   lymphomas,	   the	   International	   Prognostic	   Index	   (IPI)	   is	   commonly	   used	   as	   a	  
prognostic	   tool	   in	   PTCL	   and	   is	   inversely	   related	   to	   survival	   (Armitage	   2012).	   The	   IPI	   is	  
calculated	   taking	   into	   account	   the	   Ann	   Arbor	   stage,	   lactate	   dehydrogenase	   (LDH)-­‐levels,	  
performance	   status	   (Eastern	   Cooperative	   Oncology	   Group,	   ECOG),	   number	   of	   extranodal	  
sites,	  and	  age	  at	  diagnosis	  (Swerdlow	  et	  al.	  2008).	  Apart	  from	  the	  IPI,	  several	  other	  markers	  
have	  been	  suggested	  to	  predict	  survival	  in	  PTCL,	  including	  p53,	  Ki67,	  CD30	  and	  EBV	  infection	  
(Pescarmona	  et	  al.	  2001;	  Rudiger	  et	  al.	  2002;	  Foss	  et	  al.	  2011).	  	   	  
	  
Figure	  1.2	  Kaplan-­‐Meir	  curves	  of	  overall	  survival	  of	  patients	  with	  different	  subtypes	  of	  PTCL.	  	  
A)	  Overall	  survival	  patients	  with	  the	  most	  common	  type	  of	  T	  cell	  lymphomas.	  B)	  Overall	  survival	  of	  
patients	  with	  less	  common	  subtypes.	  Reproduced	  from	  Vose	  J	  et	  al.	  2008.	  	  
hepatosplenic type, but was uncommon in nasal NKTCL, ALCL of
all types, enteropathy-type, and subcutaneous panniculitis-like
PTCL. The standard IPI11 was calculated for each subtype and is
shown in Table 2.
Outcomes
The overall survival for the various subtypes of PTCL and
NKTCL is shown in Figure 2A and Table 3. The 5-year OS for
PTCL-NOS, angioimmunoblastic, and all NKTCLs was 32% com-
pared with only 14% for ATLL (Fig 2A). Anaplastic large-cell
lymphoma, ALK positive, demonstrated the best 5-year OS (70%),
with ALCL, ALK negative, having an intermediate 5-year OS
(49%). The 5-year OS of the uncommon subtypes is shown in
Figure 2B. Although rare, primary cutaneous ALCL had an excel-
lent 5-year OS of 90%. The 5-year OS for subcutaneous
panniculitis-like PTCL was also good (64%) compared with
enteropathy-type (20%) and hepatosplenic PTCL (7%). Overall
survival for the subtypes of NKTCL is shown in Figure 2C. The
5-year OS for nasal NKTCL was 42%, with an apparent plateau,
compared with a 5-year OS of only 9% for extranasal NKTCL and
aggressive or unclassifiable NK-c ll leukemia/lymphoma. Five-
year FFS was as follows: PTCL-NOS (20%); angioimmunoblastic
(18%); ATLL (12%); nasal NKTCL (29%); extranasal NKTCL
(6%); ALCL, ALK positive (60%); andALCL, ALKnegative (36%).
For the less common subtypes, the 5-year FFS was as follows:
primary cutaneous ALCL (55%), subcutaneous panniculitis-like
PTCL (24%), enteropathy-type PTCL (4%), and hepatosplenic
PTCL (0%).
Prognostic Characteristics
The 5-year OS and FFS by low- and high-risk IPI for each histo-
logic subtype are shown in Table 3. Although the IPI was helpful for
most of the histologic types, even patients in the low-risk IPI groups
with ATLL, enteropathy-type, hepatosplenic PTCL, and extranasal
NKTCL, had poor outcomes. An example of the OS using the stan-
dard IPI for patients with PTCL-NOS is shown in Figure 3A. The
Prognostic Index forT-Cell Lymphomawas also calculated forPTCL-
NOSandwas slightlymorediscriminatory for that subtype.12Thiswill
be further discussed in a separate PTCL-NOS article.
Analysis of Treatments
Because this is a retrospective study of cases from 22 worldwide
centers, the initial therapeutic approaches variedwidely. Themajority
of patients (! 85%) with the most common subtypes such as PTCL-
NOS, angioimmunoblastic type, ATLL, and ALCL, ALK positive and
ALK negative, received an anthracycline-containing regimen. Radia-
tion therapy was used mostly for patients with localized disease, such
as primary cutaneous ALCL, and for patients with nasal NKTCL.
Unlike diffuse large B-cell lymphoma, the majority of patients with
PTCL or NKTCL, other than ALCL, ALK positive, did not benefit
from the use of an anthracycline-containing regimen over a non–
anthracycline-containing regimen.This is demonstrated inFigures 3B
and 3C for patients with PTCL-NOS and angioimmunoblastic
type, respectively.
DISCUSSION
This study represents the largest evaluation of PTCL andNKTCL to
our knowledge to date. The geographic variation in the relative
frequency of PTCL and NKTCL has been well documented previ-
ously, ranging from 21% of all NHL in Hong Kong to only 4.0% in
Vancouver, British Columbia.9 The current study validates these
geographic variations and presents new data on the various sub-
typ s of PTCL and NKTCL, such as the high prevalence of ATLL
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Fig 2. (A) Overall survival of patients with the common subtypes of periph-
eral T-cell lymphoma (PTCL). (B) Overall survival of patients with the less
common subtypes of PTCL. (C) Overall survival of patients with natural killer
T-cell lymphoma.
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1.2	  The	  NF-­‐κB	  family	  of	  transcription	  factors	  	  
Nuclear	   factor-­‐kappa	   B	   (NF-­‐κB)	   was	   first	   discovered	   in	   1986	   by	   David	   Baltimore	   and	   his	  
group	  as	  a	  transcription	  factor	  that	  binds	  to	  the	  enhancer	  of	  the	  kappa	  light	  chain	  gene	  in	  B	  
cells	   (Sen	   et	   al.	   1986).	   The	   NF-­‐κB	   transcription	   factors	   were	   then	   identified	   as	   major	  
regulators	   of	   innate	   and	   adaptive	   immunity	   as	  well	   as	   inflammation	   (Li	   et	   al.	   2002).	   After	  
several	  observations	  that	  the	  NF-­‐κB	  pathway	  was	  deregulated	  in	  numerous	  diseases	  such	  as	  
cancer,	   diabetes	   and	   inflammatory	   disorders,	   the	   function	   and	   regulation	   of	   these	  
transcription	  factors	  have	  been	  studied	  extensively.	  
	  
The	  NF-­‐κB	  family	  of	  transcription	  factors	  include	  5	  members	  in	  mammals:	  NF-­‐κB1	  (p50	  and	  
its	  precursor	  p105),	  NF-­‐κB2	  (p52	  and	  its	  precursor	  p100),	  RelA	  (also	  named	  p65),	  RelB,	  and	  c-­‐
Rel.	   All	   of	   them	   are	   characterized	   by	   a	   Rel	   Homology	   Domain	   (RHD)	   in	   their	   N-­‐terminal	  
(Hoffmann	   et	   al.	   2006).	   The	   RHD	   is	   responsible	   for	   homo-­‐	   and	   hetero-­‐dimerization	   of	   the	  
transcription	   factors,	   and	   specific	  DNA	  binding.	  Whereas	  RelA,	  RelB	  and	  c-­‐Rel	   contain	  a	  C-­‐
terminal	   transcription	   activation	   domain	   (TAD),	   p100/p52	   and	   p105/p50	   lack	   this	   domain	  
and	   must	   therefore	   heterodimerize	   with	   other	   factors	   in	   order	   to	   positively	   regulate	  
transcription(Hayden	  et	  al.	  2008).	  Although	  several	  dimers	  are	  possible,	  RelB	  preferentially	  
dimerize	   with	   p100/p52,	   while	   RelA	   and	   c-­‐Rel	   usually	   form	   heterodimers	   with	   p50/p105	  
(Vallabhapurapu	  et	  al.	  2009).	  
	  
Latent	   NF-­‐κB	   transcription	   factors	   are	   expressed	   in	   most	   mammalian	   cell	   types	   and	   can	  
regulate	   inducible	   gene	   transcription	   in	   response	   to	   a	   broad	   range	   of	   stimuli.	   NF-­‐κB	  
regulates	   the	   expression	   of	   hundreds	   of	   genes	   involved	   in	   cellular	   processes	   such	   as	  
inhibition	  of	  apoptosis	   (Beg	  et	  al.	  1996),	  stimulation	  of	  cell	  proliferation	  (Joyce	  et	  al.	  2001)	  
and	  promotion	  of	  cell	  migration	  and	  invasion	  (Huang	  et	  al.	  2001).	  NF-­‐κB	  dimers	  bind	  to	  DNA	  
sequences	   called	   κB	   sites	   (5´-­‐GGGRNWYYCC-­‐3´,	   where	   N	   is	   any	   base,	   R	   is	   purine,	   W	   is	  
adenine	   or	   thymine,	   and	   Y	   is	   pyrimidine)	   in	   the	   promoter	   and	   enhancer	   regions	   of	   target	  
genes.	   Target-­‐gene	   selectivity	   is	   achieved	   at	   several	   levels,	   including	   dimer	   composition,	  
post-­‐translational	  modifications,	  chromatin	  barriers,	  and	  synergy	  between	  NF-­‐κB	  and	  other	  
transcription	  factors	  and	  auxiliary	  proteins	  (Smale	  2011).	  The	  expression	  of	  genes	  regulated	  
by	  NF-­‐κB	  is	  essential	  to	  a	  normal	  development	  and	  function	  of	  the	  immune	  system	  (Hayden	  
et	  al.	  2011),	  skeletal	  system	  (Novack	  2011)	  and	  epithelium	  (Wullaert	  et	  al.	  2011).	  Up	  to	  date,	  
the	  majority	  of	  NF-­‐κB	  research	  has	  been	  focused	  on	  its	  function	  in	  immunology	  and	  its	  role	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in	  cancer.	  Much	  of	  our	  knowledge	  of	  the	  biological	  role	  of	  NF-­‐κB	  has	  come	  from	  a	  range	  of	  
different	   murine	   knockout	   models.	   NF-­‐κB	   has	   multiple	   roles	   in	   regulating	   normal	  
development	  and	   function	  of	   the	   immune	  system,	   including	   the	  development	  of	   lymphoid	  
structures,	  the	  differentiation	  of	  myeoloid	  and	  lymphoid	  cells	  and	  proliferation	  and	  survival	  
of	   lymphocytes	  (reviewed	  in	  Hayden	  et	  al.	  2011,	  Vallabhapurapu	  et	  al.	  2009	  and	  Hoffmann	  
et	  al.	  2006).	  The	  role	  of	  NF-­‐κB	  in	  cancer	  will	  be	  described	  below.	  
	  
1.2.1	  The	  NF-­‐κB	  signaling	  pathway	  	  
In	  most	  cell	  types,	  the	  NF-­‐κB	  dimers	  are	  held	  inactive	  in	  the	  cytoplasm	  by	  specific	  inhibitors,	  
called	   inhibitory	  kappa	  B	  proteins	   (IκBs).	  These	   IκB	  proteins,	   including	   IκBα,	   IκBβ	  and	   IκBε,	  
contain	  characteristic	  ankyrin	  repeats	  in	  their	  structure,	  which	  bind	  to	  the	  RHD	  of	  the	  NF-­‐κB	  
dimers	  and	  prevent	   their	  nuclear	   translocation.	   In	   the	  C-­‐terminal	  of	  p100	  and	  p105,	   these	  
ankyrin	   repeats	   are	   also	   present,	   which	   confer	   IκB	   functions	   to	   the	   full	   length	   of	   these	  
transcription	   factors	   (Karin	   et	   al.	   2000).	   The	   phosphorylation	   of	   p100	   or	   p105	   leads	   to	  
proteasomal	  partial	  degradation	  to	  form	  p52	  and	  p50,	  which	   lack	  the	  C-­‐terminal	   inhibitory	  
domain.	   Inducing	  stimuli,	   such	  as	  tumor	  necrosis	   factor	   (TNF)-­‐receptor	  or	  antigen-­‐receptor	  
activation,	   gives	   rise	   to	   the	   activation	   of	   the	   IκB	   kinase	   (IKK)	   complex,	   responsible	   for	   the	  
phosphorylation	   of	   IκB,	   leading	   to	   its	   subsequent	   ubiquitination	   and	   degradation.	   The	   IKK	  
complex	  contains	  two	  kinase	  subunits,	  IKKα	  and	  IKKβ,	  and	  one	  regulatory	  subunit,	  IKKγ	  (also	  
called	  NEMO).	  Specific	  IKK	  subunits	  have	  preferences	  for	  particular	  IκBs,	  which	  in	  turn	  have	  
certain	  predilections	   for	   specific	  NF-­‐κB	  dimers,	  although	   the	  patterns	  of	   these	  preferences	  
are	   not	   fully	   understood.	   The	   release	   of	   the	  NF-­‐κB	   dimers	   from	   the	   IκB	   proteins,	   permits	  
their	   nuclear	   translocation,	   DNA-­‐binding	   and	   transcription	   of	   target	   genes	   (Hayden	   et	   al.	  
2008).	  
	  
The	   NF-­‐κB	   signaling	   has	   been	   broadly	   divided	   into	   two	   major	   signaling	   pathways:	   the	  
classical	   (also	   called	   canonical)	   NF-­‐κB	   pathway,	   and	   the	   alternative	   (or	   non-­‐canonical)	  
pathway	   (Figure	   1.3).	   The	   classical	   pathway	   relies	   on	   inducible	   degradation	   of	   IκBs	   and	  
nuclear	   translocation	  of	  dimers	  containing	  p50,	  RelA	  or	  c-­‐Rel	   (Vallabhapurapu	  et	  al.	  2009).	  
Canonical	  NF-­‐κB	  is	  dependent	  on	  the	  kinase	  activity	  of	  the	  IKKβ	  subunit	  (Li	  et	  al.	  1999).	  The	  
alternative	   pathway,	   which	   was	   identified	   by	   Michael	   Karin	   and	   colleages	   in	   2001	  
(Senftleben	  et	  al.	  2001),	  is	  independent	  of	  IKKβ	  and	  NEMO	  and	  relies	  on	  the	  kinase	  activity	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of	  IKKα	  and	  the	  NF-­‐κB-­‐inducing	  kinase,	  NIK,	  leading	  to	  the	  inducible	  processing	  of	  p100	  and	  
liberation	  of	  preferentially	  p52/RelB	  dimers	  (Sun	  2011).	  
	  
	  
A	  diverse	  set	  of	  stimuli	  can	  activate	  the	  NF-­‐κB	  pathway	  through	  the	  engagement	  of	  a	  range	  
of	  different	  receptors.	  The	  mechanism	  by	  which	  the	  IKK	  complex	  is	  activated	  is	  complicated	  
and	  depends	  on	  the	  receptor	  and	  cell	  type.	  The	  classical	  arm	  of	  the	  NF-­‐κB	  pathway	  can	  be	  
activated	  by	  numerous	  stimuli	  and	  receptors,	  including	  TNF-­‐receptors,	  Toll-­‐like	  receptors,	  IL-­‐
	  
Figure	  1.3	  Classical	  and	  alternative	  NF-­‐κB	  signaling	  cascades	  	  
Prototypic	  schemes	  of	  classical	  (to	  the	  left)	  and	  alternative	  (to	  the	  right)	  NF-­‐κB	  pathways.	   In	  the	  
classical	   pathway,	   receptor	   stimulation	   leads	   to	   the	   phosphorylation	   of	   the	   IKK	   complex	   (IKKβ	  
phosphorylation	  is	  essential)	  which	  in	  turn	  phosphorylates	  IκB.	  Phosphorylated	  IκB	  is	  targeted	  for	  
proteasomal	   degradation,	   liberating	   the	   p50-­‐p65/c-­‐Rel	   dimer,	   allowing	   their	   nuclear	  
translocation.	   In	   the	   alternative	   pathway,	   receptor	   engagement	   leads	   to	   the	   recruitment	   and	  
decomposition	  of	  the	  TRAF2-­‐TRAF3-­‐cIAP1/2	  complex	  which	  is	  responsible	  for	  NIK	  degradation	  in	  
resting	  cells.	  NIK	  accumulation	  gives	  rise	  to	  IKKα	  and	  p100	  phosphorylation	  with	  subsequent	  p100	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1R	  and	  antigen	  receptors	  (T-­‐cell	  receptor,	  TCR,	  and	  B-­‐cell	  receptor,	  BCR)	  (Hayden	  et	  al.	  2012).	  
Upon	   binding	   of	   a	   ligand	   to	   the	   receptor,	   signaling	   proceeds	   by	   the	   binding	   of	   several	  
adapter	   proteins	   to	   the	   receptor.	   Of	   these,	   the	   receptor-­‐interacting	   proteins	   (RIPs)	   are	  
particularly	   important	   for	   classical	   NF-­‐κB	   activation.	   The	   adapter	   proteins	   facilitate	   the	  
recruitment	   of	   other	   adapter	   proteins	   with	   E3	   ubiquitin	   ligase	   activity,	   the	   TNF	   receptor-­‐
associated	   factors	   (TRAFs).	   TRAF	   can	   then	  ubiquitinate	  RIP	   and	   recruit	   the	   IKK	   complex	   to	  
the	  receptor	  complex	  where	  the	  recruitment	  of	  kinases	  that	  can	  activate	  the	  kinase	  activity	  
of	  IKK	  is	  facilitated	  (for	  review,	  see	  Vallabhapurapu	  et	  al.	  2009).	  For	  IKK	  phosphorylation,	  the	  
kinases	   transforming	   growth	   factor-­‐beta-­‐activated	   kinase	   1	   (TAK1)	   and	   MAPK/ERK	   kinase	  
kinase	  3	  (MEKK3)	  or	  autophosphorylation	  have	  been	  suggested	  (Wang	  et	  al.	  2001;	  Yang	  et	  al.	  
2001).	  
	  
The	   activation	   of	   the	   alternative	   arm	   has	   so	   far	   only	   been	   linked	   to	   a	   handful	   of	   signals.	  
These	   include	   members	   of	   the	   TNF	   receptor	   superfamily	   such	   as	   B-­‐cell	   activating	   factor	  
receptor	   (BAFFR),	   lymphotoxin	   β	   receptor	   (LTβR),	   CD40	   and	   receptor	   activator	   for	   NF-­‐κB	  
(RANK),	  Fn14	  and	  CD30	  (Claudio	  et	  al.	  2002;	  Coope	  et	  al.	  2002;	  Dejardin	  et	  al.	  2002;	  Saitoh	  et	  
al.	  2003;	  Sun	  2011).	  Additionally,	  it	  is	  known	  that	  both	  the	  classical	  and	  alternative	  pathway	  
can	  be	  activated	  by	  oncogenic	  viruses,	  such	  as	  EBV	  and	  HTLV-­‐1	  (Xiao	  et	  al.	  2001;	  Atkinson	  et	  
al.	   2003;	   Luftig	   et	   al.	   2004).	   In	   the	   alternative	   NF-­‐κB	   pathway,	   the	   stimulation	   of	   TNF	  
receptors	  gives	  rise	  to	  the	  activation	  of	  the	  NF-­‐κB-­‐inducing	  kinase	  (NIK).	  NIK	  is	  a	  kinase	  that	  
is	  essential	  for	  the	  activation	  of	  the	  alternative	  pathway	  (Xiao	  et	  al.	  2001).	  NIK	  activates	  IKKα,	  
which	  leads	  to	  the	  phosphorylation	  of	  p100,	  resulting	  in	  its	  polyubiquitination	  mediated	  by	  
the	   ubiquitin	   ligase	   β-­‐TrCP,	   and	   its	   subsequent	   proteasomal	   processing	   to	   p52.	   Nuclear	  
accumulation	   of	   mainly	   p52/RelB	   heterodimers	   is	   observed	   after	   activation	   of	   the	  
alternative	  pathway	   (reviewed	   in	  Razani	   et	   al.	   2011	  and	  Sun	  2011).	   It	   has	  been	   suggested	  
that	   NIK	   is	   regulated	   by	   a	   receptor-­‐associated	  multi-­‐protein	   complex	   consisting	   of	   TRAF2,	  
TRAF3	  and	  the	  cellular	   inhibitors	  of	  apoptosis	  1	  and	  2	  (c-­‐IAP1	  and	  c-­‐IAP2,	  also	  called	  BIRC2	  
and	   BIRC3).	   These	   proteins	   target	   NIK	   for	   ubiquitin-­‐dependent	   degradation.	   Receptor	  
activation	   leads	   to	   degradation	   of	   TRAF3,	   which	   prevents	   the	   association	   of	   NIK	   to	   the	  
complex	  resulting	  in	  NIK	  stabilization	  and	  activation	  (Zarnegar	  et	  al.	  2008).	  
	  
Figure	  1.3	  represents	  prototypic	  alternative	  and	  classical	  NF-­‐κB	  signaling	  cascades.	  The	  two	  
pathways	   are	   thought	   to	   give	   rise	   to	   the	   transcription	  of	   distinct	   sets	   of	   target	   genes	   and	  
also	  display	  different	  kinetics.	  The	  classical	  pathway	  is	  fast	  acting,	  responding	  within	  minutes	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after	  stimulation,	  whereas	  the	  alternative	  pathway	  responds	  more	  slowly	  and	  is	  dependent	  
of	  protein	  synthesis	  for	  its	  activation	  (Hoffmann	  et	  al.	  2006;	  Liang	  et	  al.	  2006).	  However,	  the	  
fact	   that	   both	   pathways	   can	   be	   activated	   at	   the	   same	   time	   and	   in	   cases	   by	   the	   same	  
receptors,	  the	  existence	  of	  crosstalk	  between	  the	  pathways,	  and	  the	  influence	  of	  numerous	  
known	  and	  unknown	   regulators,	  makes	   the	   gene	   expression	   induced	  by	   either	   one	  of	   the	  
two	  pathways	  hard	  to	  characterize.	  Biologically,	  the	  canonical	  pathway	  is	  largely	  responsible	  
for	   the	   regulation	   of	   inflammation	   and	   the	   control	   of	   lymphoid	   cell	   proliferation	   and	  
apoptosis	  during	  the	  immune	  response,	  and	  the	  alternative	  pathway	  is	  more	  associated	  with	  
the	  regulation	  of	  the	  development	  of	  the	  lymphoid	  organs	  (Bonizzi	  et	  al.	  2004).	  
	  
1.2.2	  The	  NF-­‐κB-­‐inducing	  kinase	  (NIK)	  
	  
NIK,	   encoded	  by	   the	   gene	  MAP3K14,	  was	  discovered	   in	  1997	  as	   a	   kinase	  mediating	  NF-­‐κB	  
activation	  downstream	  TNF	  and	  IL-­‐1	  receptors	  (Malinin	  et	  al.	  1997).	  NIK	  knockout	  mice	  (NIK-­‐
/-­‐)	   (Yin	   et	   al.	   2001)	   or	  mice	  harboring	   an	   inactivating	   point	  mutation	   in	  NIK	   (aly/aly	  mice)	  
(Shinkura	   et	   al.	   1999),	   however,	   showed	  no	  defects	   in	   TNFα-­‐induced	  NF-­‐κB	   activation.	  On	  
the	   other	   hand,	   p100	   processing	   was	   blocked	   and	   NIK	   was	   later	   identified	   as	   the	   kinase	  
necessary	   for	   p100	   processing	   and	   activation	   of	   the	   IKKα-­‐dependent	   alternative	   NF-­‐κB	  
pathway	  (Senftleben	  et	  al.	  2001;	  Xiao	  et	  al.	  2001).	  Both	  NIK-­‐/-­‐	  and	  aly/aly	  mice	  showed	  lack	  
of	   lymph	  nodes	  and	  Peyer´s	  patches,	  disorganized	  splenic	  and	   thymic	  structures,	  and	  poor	  
antibody	   response	   upon	   immunization.	   They	   also	   presented	   defects	   in	   B-­‐cell	   proliferation	  
and	  function	  (Yamada	  et	  al.	  2000),	  reduced	  number	  of	  CD4+CD5+	  regulatory	  T	  cells	  (Tregs)	  
(Kajiura	  et	  al.	  2004)	  and	  impairment	  in	  the	  differentation	  to	  Th17	  T	  cells	  (Jin	  Blood	  2009).	  	  
Hence,	   NIK	   is	   suggested	   to	   be	   important	   for	   proper	   lymphoid	   organogenesis,	   lymphocyte	  
differentiation	   and	   function,	   as	   well	   as	   controlling	   autoimmunity.	   NIK	   also	   plays	   a	   role	   in	  
bone	   microenvironment	   where	   it	   is	   needed	   for	   p100	   processing	   downstream	   RANKL	   for	  
proper	  osteoclast	  differentiation	  (Novack	  et	  al.	  2003).	  
	  
NIK	   is	   a	   serine/threonine	   kinase	  belonging	   to	   the	  mitogen-­‐activating	  protein	   kinase	   kinase	  
kinase	   (MAP3K)	   family	   (Figure	  1.4).	  NIK	  binds	   to	   and	  activates	   IKKα	  by	  phosphorylation	  of	  
IKKα	   residue	   Ser-­‐176	   (Ling	   et	   al.	   1998).	   Although	   with	   lower	   affinity,	   NIK	   has	   also	   been	  
reported	   to	   interact	   with	   and	   activate	   IKKβ	   (Woronicz	   et	   al.	   1997;	   Delhase	   et	   al.	   1999).	  
Activated	   IKKα	   binds	   and	   phosphorylates	   its	   substrate	   p100,	   leading	   to	   its	   ubiquitination,	  
partial	   proteasomal	   degradation	   and	   loss	   of	   its	   C-­‐terminal	   region	   (containing	   the	   IκB	   –like	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domain),	  forming	  p52.	  It	  appears	  that	  NIK	  not	  only	  activates	  IKKα,	  but	  also	  assist	  in	  docking	  
p100	   to	   IKKα	   (Xiao	  et	   al.	   2004).	  Moreover,	   it	   has	   also	  been	   reported	   that	  NIK	   can	  directly	  
phosphorylate	  p100	  (Xiao	  et	  al.	  2001).	  
	  
	  
Signals	  from	  a	  subset	  of	  TNFR	  family	  members	  have	  been	  reported	  to	  induce	  NIK-­‐dependent	  
NF-­‐ĸB	   activation.	   These	   include	   CD40,	   BAFFR,	   LTβR,	   RANK,	   Fn14,	   and	   CD27	   (Claudio	   et	   al.	  
2002;	  Pham	  et	  al.	  2011;	  Yin	  et	  al.	  2001;	  Coope	  et	  al.	  2002;	  Saitoh	  et	  al.	  2003;	  Ramakrishnan	  
et	  al.	  2004).	  NIK	  is	  an	  unstable	  protein	  and	  has	  a	  rapid	  turnover	  in	  nonstimulated	  cells	  due	  to	  
a	  constant	  ubiquitination-­‐dependent	  proteasomal	  degradation	  (Liao	  et	  al.	  2004).	  Controlling	  
NIK	  protein	  stability	  has	  appeared	  as	  a	  central	  mechanism	  for	   regulating	  alternative	  NF-­‐κB	  
signaling.	  Upon	  stimulation	  of	  one	  of	  the	  receptors	  above	  mentioned,	  NIK	   is	  stabilized	  and	  
the	   accumulation	   of	   NIK	   protein	   leads	   to	   its	   activation	   and	   induction	   of	   p100	   processing	  
(Figure	   1.5).	   The	   mechanism	   of	   receptor-­‐induced	   NIK	   stabilization	   has	   recently	   been	  
revealed	  in	  several	  studies.	  TRAF3	  was	  first	  shown	  to	  interact	  with	  the	  N-­‐terminal	  domain	  of	  
NIK	   and	   to	   target	   its	   ubiquitination	   and	   degradation	   and	   has	   been	   identified	   as	   a	   major	  
negative	  regulator	  of	  NIK	  stability	  (Liao	  et	  al.	  2004).	  TRAF3	  knockout	  mice	  (TRAF3-­‐/-­‐)	  exhibit	  
NIK	   stabilization	   and	   activation	   of	   the	   alternative	   NF-­‐κB	   pathway,	   while	   TRAF3	  
overexpression	  induces	  NIK	  proteasomal	  degradation	  (Liao	  et	  al.	  2004;	  He	  et	  al.	  2006).	  It	  was	  
later	   demonstrated	   that	   TRAF3	   is	   a	   part	   of	   a	   multi-­‐subunit	   ubiquitin	   ligase	   complex	  
composed	  by	  TRAF2,	  TRAF3,	  cIAP1	  and	  cIAP2,	  where	  TRAF3	  serves	  as	  and	  adapter	  molecule	  
and	   cIAP1	   and	   CIAP2	   are	   the	   E3	   ubiquitin	   ligases	   responsible	   for	   NIK	   ubiquitination	   and	  
degradation	   in	   unstimulated	   cells	   (Varfolomeev	   et	   al.	   2007).	   Deletion	   of	   TRAF2,	   TRAF3	   or	  
	  
Figure	  1.4	  Schematic	  diagram	  of	  human	  NIK	  protein	  	  
Human	  NIK	  is	  a	  947-­‐amino	  acid	  protein	  with	  a	  molecular	  weight	  of	  104	  kD.	  In	  its	  N-­‐terminal	  there	  
is	  a	  TRAF-­‐binding	  motif	  and	  a	  nuclear	   localization	  signal,	  whereas	   the	  binding	  of	   IKKα	  and	  p100	  
occurs	   in	   the	   C-­‐terminal	   region.	   NIK	   has	   a	   core	   kinase	   domain	   with	   flanked	   N-­‐	   and	   C-­‐terminal	  
regions	  that	  are	  conserved	  between	  species	  but	  differ	  from	  other	  serine/threonine	  kinases.	  	  















cIAP1/2	   leads	   to	   increased	   NIK	   accumulation	   and	   p100	   processing	   (Vallabhapurapu	   et	   al.	  
2008;	   Zarnegar	   et	   al.	   2008).	   The	   stimulation	   of	   CD40	   or	   BAFFR	   starts	   an	   ubiquitination	  
cascade	   within	   the	   TRAF2/3-­‐cIAP1/2	   complex,	   terminating	   in	   the	   polyubiquitination	   and	  
degradation	  of	  TRAF3,	  and	  liberation	  of	  NIK	  from	  the	  ubiquitin	  ligase	  complex	  (Hostager	  et	  al.	  
2003;	  Vallabhapurapu	  et	  al.	  2008).	  
	  
	  
Apart	  from	  protein	  stabilization,	  NIK	  may	  also	  require	  phosphorylation	  in	  its	  activation	  loop	  
for	  kinase	  activity.	  Since	  NIK	  protein	  accumulation	  without	  additional	  stimuli	  is	  sufficient	  for	  
	  
Figure	  1.5.	  NIK	  activation	  by	  protein	  degradation	  and	  stabilization	  	  
The	   proposed	  model	   of	  NIK	   regulation.	   In	   a	   nonstimulated	   cell	   (to	   the	   left),	  NIK	   is	   continuously	  
degraded	   by	   the	   proteasome	   due	   to	   K48-­‐linked	   ubiquitination	   targeted	   by	   the	  
TRAF2/TRAF3/cIAP1/2-­‐complex.	  p100/RelB	  dimers	  are	   retained	   in	   the	   cytoplasm.	  Upon	   receptor	  
stimulation	   (to	   the	   right),	   the	  TRAF2/TRAF3/cIAP1/2-­‐complex	   is	   recruited	   to	   the	   receptor	  where	  
TRAF2	   activates	   cIAP1/2	   through	   K63-­‐linked	   ubiquitination.	   cIAP1/2	   in	   turn	   target	   TRAF3	   for	  
degradation.	   The	   resultant	   TRAF3	   degradation	   allows	   for	   the	   accumulation	   of	   NIK	   and	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NIK-­‐dependent	  activation	  of	  NF-­‐κB,	   it	  has	  been	  suggested	  that	  accumulation	  of	  NIK	  dimers	  
leads	  to	  autophosphorylation	  of	  NIK,	  or	  that	  some	  constitutitive	  cellular	  kinase	  is	  responsible	  
for	  the	  phosphorylation	  of	  NIK,	  although	  the	  precise	  mechanism	  is	  unknown	  (Lin	  et	  al.	  1998;	  
Razani	  et	  al.	  2011).	  On	  the	  contrary,	  two	  recent	  studies	  exploring	  the	  structure	  of	  NIK,	  show	  
no	   evidence	   of	   NIK	   phosphorylation	   and	   suggest	   that	   NIK	   exhibit	   a	   constitutively	   active	  
kinase	  domain	  without	  the	  requirement	  of	  phosphorylation	  (de	  Leon-­‐Boenig	  et	  al.	  2012;	  Liu	  
et	  al.	  2012).	  
	  
NIK	  is	  essential	  for	  the	  processing	  of	  p100	  to	  p52	  and	  activation	  of	  the	  alternative	  pathway,	  
but	   its	  role	   in	  the	  classical	  pathway	  has	  been	  debated.	  Whether	  NIK	   is	   involved	   in	  classical	  
pathway	   activation	   or	   not,	   seems	   to	   be	   cell	   type	   and	   receptor	   specific,	   but	   how	   this	  
specificity	  works	  is	  still	  to	  be	  defined	  (Xiao	  et	  al.	  2001;	  Thu	  et	  al.	  2010).	  Stabilization	  of	  NIK	  
has	  been	  reported	  to	   induce	  classical	  NF-­‐κB	  activation	  through	  IKKβ	  activation	  (Annunziata	  
et	  al.	  2007;	  Zarnegar	  et	  al.	  2008).	  However	  NIK	  is	  not	  strictly	  necessary	  for	  classical	  pathway	  
activation	  and	  seems	  to	  be	  required	  only	  in	  response	  to	  certain	  ligands	  (Thu	  et	  al.	  2010).	  	  
	  
Although	  the	  major	  function	  of	  NIK	  appears	  to	  be	  the	  regulation	  of	  NF-­‐κB	  activation,	  there	  
are	  a	  few	  studies	  reporting	  that	  NIK	  has	  substrates	  involved	  in	  other	  signaling	  pathways.	  As	  a	  
member	   of	   the	  MAP3K	   family,	   NIK	   has	   been	   reported	   to	   be	   involved	   in	   the	   activation	   of	  
MEK1/2	  and	  ERK1/2	  in	  the	  process	  of	  neural	  differentiation	  (Foehr	  et	  al.	  2000).	  STAT3	  and	  c-­‐
jun	  N-­‐terminal	  kinase	  (JNK)	  are	  other	  suggested	  targets	  (Akiba	  et	  al.	  1998;	  Nadiminty	  et	  al.	  
2007).	  
	  
Since	   the	   discovery	   of	   NIK	   as	   a	   core	   regulator	   of	   the	   alternative	   NF-­‐κB	   pathway	   and	   the	  
awareness	   of	   its	   involvement	   malignancies	   (described	   in	   the	   following	   section),	   a	   rapidly	  
increasing	  number	  of	  publications	  are	  emerging	   trying	   to	  decipher	   its	   function	  both	   in	   the	  
immune	  system	  and	  in	  cancer.	  	  
	  
1.2.3	  NIK	  and	  NF-­‐κB	  in	  tumorigenesis	  	  
A	  number	  of	  different	  tumors	  have	  been	  linked	  to	  an	  aberrant	  NF-­‐κB	  activation.	  Constitutive	  
NF-­‐κB	  activation	  has	  been	  observed	  in	  both	  solid	  tumors	  (breast,	  pancreas,	  prostate,	  renal,	  
lung	  and	  liver	  cancer	  to	  mention	  a	  few)	  and	  hematological	  malignancies	  (described	  below).	  If	  
we	  have	   a	   look	   at	   the	  numerous	   target	   genes	   of	  NF-­‐κB,	   it	   is	   not	   hard	   to	   realize	  why.	   The	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genes	   induced	   upon	   NF-­‐κB	   activation	   are	   involved	   in	   several	   central	   processes	   of	  
tumorigenesis,	   including	  proliferation,	   survival,	  angiogenesis,	   inflammation,	  metastasis	  and	  





In	  solid	  tumors,	  NF-­‐κB	  activation	  may	  be	  the	  result	  of	  exposure	  to	  pro-­‐inflammatory	  stimuli	  
from	  the	  tumor	  microenvironment	  (DiDonato	  et	  al.	  2012).	   In	  lymphoid	  malignancies	  on	  the	  
other	  hand,	  constitutive	  NF-­‐κB	  signaling	  can	  be	  a	  result	  of	  oncogenic	  activating	  mutations	  in	  
different	   components	   of	   the	   NF-­‐κB	   pathway.	   Many	   subtypes	   of	   lymphomas	   are	  
characterized	  by	  aberrant	  NF-­‐κB	  activation,	   including	  both	  B-­‐	  and	  T-­‐cell	   lymphomas	  as	  well	  
as	  Hodgkin	  lymphomas	  (Jost	  et	  al.	  2007).	  Several	  lymphomas	  depend	  on	  NF-­‐κB	  activation	  for	  
proliferation	  and	  survival	  and	  NF-­‐κB	  targeting	  has	  therefore	  been	  suggested	  as	  a	  therapeutic	  
potential	   in	   these	   tumors	   (Staudt	  2010).	  One	  of	   the	  earliest	  notions	  suggesting	   that	  NF-­‐κB	  
had	  oncogenic	  properties,	  was	  the	  identification	  of	  NFKB2	  gene	  rearrangements	  in	  B-­‐	  and	  T-­‐
cell	  lymphomas,	  giving	  rise	  to	  a	  truncated	  p100	  protein	  lacking	  the	  IκB-­‐like	  domain	  (Neri	  et	  al.	  
1991;	   Chang	   et	   al.	   1995).	   In	   Hodgkin	   lymphoma	   and	   DLBCL,	   amplifications	   of	   the	   locus	  
	  
Figure	  6.	  NF-­‐κB	  target	  genes	  involved	  in	  cancer	  development	  and	  progression.	  	  
NF-­‐κB	   target	   genes	   are	   involved	   in	   several	   key	   processes	   important	   for	   tumorigenesis,	   such	   as	  
survival,	  inflammation,	  proliferation,	  angiogenesis,	  metastasis	  and	  apoptosis.	  Adapted	  from	  Baud	  
and	  Karin	  et	  al.,	  2008.	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encoding	   c-­‐Rel	   (REL)	   occur	   in	   a	   significant	   number	   of	   patients	   (Martin-­‐Subero	   et	   al.	   2002;	  
Barth	  et	  al.	  2003;	  Lenz	  et	  al.	  2008).	  
	  
Aside	  from	  NFKB2	  and	  REL	  aberrations,	  most	  genetic	  lesions	  affecting	  NF-­‐κB	  signaling	  occur	  
in	   members	   acting	   upstream	   in	   the	   signaling	   cascade.	   A	   hallmark	   of	   the	   ABC	   subtype	   of	  
DLBCL	  is	  constitutive	  NF-­‐κB	  activation	  and	  a	  disruption	  of	  this	  activation	  in	  induces	  apoptosis	  
in	  DLBCL	  cell	   lines	  (Davis	  et	  al.	  2001).	  Several	  recurrent	  genetic	  aberrations	  affecting	  NF-­‐κB	  
signaling	  have	  been	  described	  in	  over	  50%	  of	  ABC-­‐DLBCL	  (Compagno	  et	  al.	  2009).	  Oncogenic	  
mutations	   in	   Caspase	   recruitment	   domain	   family,	   member	   11	   (CARD11)	   or	   mutations	   in	  
CD79	   are	   involved	   in	   the	   activation	   of	  NF-­‐κB	   downstream	  BCR	   and	   has	   been	   proposed	   to	  
account	   for	   the	  NF-­‐κB	  activation	   in	   about	  a	   third	  of	  ABC-­‐DLBCL	  patients	   (Lenz	  et	   al.	   2008;	  
Davis	   et	   al.	   2010;	   Staudt	   2010).	   Another	   frequent	   genetic	   alteration	   in	   ABC-­‐DLBCL	   is	  
inactivating	  mutation	  or	  deletion	  of	  tumor	  necrosis	  factor	  alpha	  inducing	  protein	  3	  (TNFAIP3,	  
encoding	  the	  protein	  A20),	  observed	  in	  approximately	  30%	  of	  the	  patients	  (Compagno	  et	  al.	  
2009).	  A20	  is	  a	  deubiquitinase	  that	  acts	  as	  a	  negative	  regulator	  of	  NF-­‐κB	  activation	  (Lin	  et	  al.	  
2008).	   Frequent	   TNFAIP3	   deletions	   or	   inactivating	   mutations	   have	   also	   been	   detected	   in	  
Hodgkin	   lymphoma	   (Schmitz	  et	  al.	  2009)	  and	  several	   subtypes	  of	  non-­‐Hodgkin	   lymphomas	  
including	   mantle	   cell	   lymphoma,	   mucosa-­‐associated	   lymphoid	   tissue	   (MALT)	   lymphoma,	  
follicular	   lymphoma	   and	   PTCL	   (Honma	   et	   al.	   2009;	   Braun	   et	   al.	   2011).	   A20	   deletions	   have	  
been	  shown	  to	  have	  functional	  relevance	   in	   lymphomagenesis	  since	  overexpression	  of	  A20	  
leads	   to	   apoptosis	   and	   silencing	   of	   A20	   is	   associated	   with	   resistance	   to	   apoptosis	   in	  
lymphoma	   cell	   lines	   (Compagno	   et	   al.	   2009;	   Honma	   et	   al.	   2009).	   Morevoer,	   a	   recurrent	  
oncogenic	  mutation	   in	  myeloid	  differentiation	  primary	   response	  88	   (MYD88),	  encoding	   for	  
an	  adaptor	  protein	  involved	  in	  NF-­‐κB	  signaling	  downstream	  TLRs	  and	  interleukin	  receptors,	  
was	   recently	   described	   in	   DLBCL,	   MALT	   lymphoma,	   Waldenström's	   macroglobulinemia	  
(Lymphoplasmacytic	  lymphoma)	  and	  chronic	  lymphocytic	  leukemia	  (Ngo	  et	  al.	  2011;	  Landau	  
et	  al.	  2013;	  Varettoni	  et	  al.	  2013).	  Other	  mutations	  described	  that	  give	  rise	  to	  an	  activation	  
of	   NF-­‐κB	   include	   translocations	   involving	  MALT1	   in	   MALT	   lymphoma	   (Lucas	   et	   al.	   2001),	  
mutations	  of	  the	  deubiquitin	  ligase	  cylindromatosis	  (CYLD)	  in	  multiple	  myeloma	  (Annunziata	  
et	  al.	  2007)	  and	  inactivating	  mutations	  of	  the	  genes	  for	  IκBα	  and	  IκBε	  in	  Hodgkin	  lymphoma	  
(Cabannes	  et	  al.	  1999;	  Emmerich	  et	  al.	  2003).	  
	  
An	   activated	   alternative	  NF-­‐κB	   pathway	  with	  NIK	   overexpression	   or	   stabilization	   has	   been	  
described	   in	   several	   lymphomas,	   such	  as	  DLBCL,	  Hodgkin	   lymphoma,	  Adult	  T-­‐cell	   leukemia	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(ATL),	  MALT-­‐lymphoma	  and	  multiple	  myeloma	  (Keats	  et	  al.	  2007;	  Saitoh	  et	  al.	  2008;	  Pham	  et	  
al.	  2011;	  Rosebeck	  et	  al.	  2011;	  Ranuncolo	  et	  al.	  2012).	  NIK	  has	  additionally	  been	  reported	  to	  
be	  important	  in	  the	  biology	  of	  other	  tumors,	  such	  as	  pancreatic	  cancer	  and	  melanoma	  (Thu	  
et	   al.	   2012;	   Doppler	   et	   al.	   2013).	   Both	  mutations	   in	   the	  members	   of	   the	   ubiquitin	   ligase	  
complex	   responsible	   for	   NIK	   degradation,	   or	   excessive	   upstream	   receptor	   signaling	   have	  
been	   described	   as	   causes	   of	   constitutive	   NIK	   and	   NF-­‐κB	   activation	   in	   lymphomas.	   The	  
alternative	  NF-­‐κB	  pathway	  has	  been	  shown	  to	  play	  an	  important	  role	  in	  the	  pathogenesis	  of	  
multiple	   myeloma,	   a	   neoplasm	   affecting	   the	   plasma	   cells,	   where	   numerous	   genetic	  
alterations	   with	   the	   common	  mechanism	   of	   NIK	   stabilization	   and/or	   NF-­‐κB	   activation	   are	  
described	   (Annunziata	   et	   al.	   2007;	   Keats	   et	   al.	   2007).	   Frequent	   inactivating	   mutations	   or	  
deletions	  of	  members	  of	  the	  NIK	  degradation	  complex	  (TRAF2,	  TRAF3	  or	  BIRC2/3)	  have	  been	  
reported	   as	  well	   as	   activating	  mutations	   in	   upstream	   receptors	   LTBR,	   CD40	   and	   TACI	   and	  
mutations	  in	  NFKB1	  and	  NFKB2.	  Amplifications	  or	  translocations	  of	  NIK	  locus	  (MAP3K14)	  has	  
also	  been	   reported	   in	   a	   few	  multiple	  myeloma	  and	  Hodgkin	   lymphoma	   cases	   (Keats	   et	   al.	  
2007;	  Otto	  et	  al.	  2012).	  The	  API2-­‐MALT1	  fusion	  protein	  expressed	  in	  MALT-­‐lymphoma,	  was	  
recently	   described	   to	   induce	  proteolytic	   cleavage	  of	  NIK	  with	   subsequent	  NIK	   stabilization	  
and	   alternative	   pathway	   activation	   (Rosebeck	   et	   al.	   2011).	   In	   support	   of	   NIK	   having	  
oncogenic	  properties,	  NIK	  overexpression	   can	   transform	   rat	   fibroblast	   and	  a	  B-­‐cell-­‐specific	  
NIK	   overexpression	   in	  mice,	   or	   particularly,	  mice	   overexpressing	   a	   form	   of	   NIK	   lacking	   its	  
TRAF3-­‐bindig	  domain,	  gives	  rise	  to	  a	  dramatic	  accumulation	  of	  mature	  B	  cells	  (Saitoh	  et	  al.	  
2008;	  Sasaki	  et	  al.	  2008).	  
	  
Other	   triggers	   of	   NF-­‐κB	   activation	   in	   lymphomas	   are	   oncogenic	   viruses,	   such	   as	   EBV	   and	  
HTLV,	  which	  are	  associated	  with	  several	  lymphomas	  and	  are	  suggested	  to	  play	  a	  role	  in	  their	  
pathogenesis	  (Vallabhapurapu	  et	  al.	  2009).	  
	  
The	  frequent	  activation	  and	  occurrence	  of	  genetic	  aberrations	  affecting	  the	  NF-­‐κB	  pathway	  
in	  lymphomas	  (Figure	  1.7),	  highlight	  the	  importance	  of	  this	  pathway	  in	  the	  pathogenesis	  of	  
these	   malignancies	   and	   encourage	   researchers	   to	   explore	   this	   pathway	   for	   effective	  
therapeutic	   targeting.	  However,	   still,	   there	   is	  a	   lack	  of	  specific	  NF-­‐κB	   inhibitors	   to	  properly	  
study	   its	   potential	   as	   therapeutic	   target.	   Clinical	   benefit	   has	   been	   achieved	   in	   multiple	  
myeloma	  and	  refractory	  B	  cell	  lymphoma	  using	  the	  proteasome	  inhibitor	  Bortezomib	  (Staudt	  
2010;	   DiDonato	   et	   al.	   2012).	   Although	   inhibition	   of	   NF-­‐κB	   has	   been	   attributed	   to	   the	  
mechanism	   of	   action	   of	   Bortezomib,	   the	   proteasome	   targets	   a	   tremendous	   number	   of	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proteins	   and	   cannot	   be	   considered	   NF-­‐κB-­‐specific.	   IKKβ	   is	   the	   component	   of	   the	   NF-­‐κB	  
pathway	   that	   has	   been	  most	   efficiently	   targeted.	   A	   range	   of	   different	   IKKβ	   inhibitors	   are	  
available	  and	  have	  shown	  antitumor	  effect	  in	  experimental	  models.	  Nevertheless,	  up	  to	  date,	  










Figure	  7.	  Genetic	  alterations	  affecting	  NF-­‐κB	  in	  human	  cancer	  
Several	  genetic	  alterations	  have	  been	  described	   in	  human	  cancers,	   that	  give	  rise	  to	  an	  activated	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Deregulated	  NF-­‐κB	  activity	  plays	  a	  key	  role	  in	  the	  development	  of	  multiple	  malignancies	  and	  
constitutive	  activation	  of	  NF-­‐κB	  has	  been	  suggested	  to	  play	  a	  key	  role	  in	  several	  lymphomas.	  	  
In	  spite	  of	  numerous	  publications	  in	  the	  last	  decade	  concerning	  the	  NF-­‐κB	  pathway,	  the	  role	  
of	   NF-­‐κB	   signaling	   in	   lymphomagenesis	   and	   its	   therapeutic	   potential	   is	   far	   from	   being	  
understood.	  	  
	  
The	   first	  part	  of	   the	  project	   is	   focused	  on	  the	  NF-­‐κB	  pathway	   in	  DLBCL,	  where	  constitutive	  
NF-­‐κB	  activation	  is	  one	  of	  the	  proposed	  oncogenic	  mechanisms	  in	  the	  ABC	  subtype.	  However,	  
the	   actual	   expression	   of	   NF-­‐κB	   in	   DLBCL	   tumors	   and	   the	   presence	   of	   both	   classical	   and	  
alternative	   signaling,	   as	   well	   as	   their	   clinical	   correlation,	   have	   not	   been	   well	   studied.	  
Consequently,	  the	  aims	  of	  the	  first	  part	  of	  this	  thesis	  were	  the	  following:	  	  	  
	  
a. To	   characterize	   the	   expression	   pattern	   of	   the	   different	   NF-­‐κB	  members	   in	   human	  
DLBCL	  tumor	  samples	  and	  evaluate	  their	  impact	  on	  patient	  survival.	  
b. To	  analyze	  the	  relationship	  between	  DLBCL	  molecular	  subtypes	  (GCB	  and	  ABC)	  and	  
NF-­‐κB	  expression.	  	  
PTCL	   is	   a	   group	  of	  aggressive	   lymphomas,	  presenting	  dismal	   clinical	  outcome	  with	   current	  
therapies.	   The	   molecular	   pathology	   of	   PTCL	   is	   largely	   unknown	   and	   the	   lack	   of	   efficient	  
therapies	  demands	  further	  studies	  to	  clarify	  their	  molecular	  background	  and	  to	  identify	  new	  
therapeutic	  targets. Previous	  data	  indicate	  that	  NF-­‐κB	  could	  be	  involved	  in	  the	  pathogenesis	  
of	   these	  malignancies.	  However,	   the	  characterization	  of	   the	  pathway	   in	  PTCL	   is	   vague	  and	  
there	  are	  no	  specific	  NF-­‐κB	  inhibitor	  drugs	  in	  clinical	  use	  for	  PTCL	  today,	  indicating	  a	  need	  for	  
more	  detailed	  studies	  and	  the	  identification	  of	  novel	  molecular	  targets	  able	  to	  interfere	  with	  
NF-­‐κB	  activation.	  The	  aims	  of	  this	  part	  of	  the	  projects	  were	  thus	  the	  following:	  	  
	  
c. To	  characterize	  the	  expression	  of	  NF-­‐κB	  in	  different	  PTCL	  subtypes	  and	  its	  impact	  on	  
clinical	  outcome.	  
d. To	  investigate	  the	  role	  of	  NIK	  in	  the	  regulation	  of	  the	  NF-­‐κB	  signaling	  pathway	  and	  of	  
downstream	  gene	  expression	  in	  PTCL.	  	  e. To	  study	  the	  role	  of	  NIK	  and	  other	  NF-­‐κB	  components	  in	  PTCL	  cell	  survival	  in	  order	  to	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2.1	  Patient	  samples	  and	  cell	  lines	  	  
2.1.1	  Primary	  tumor	  samples	  	  
The	   use	   of	   all	   patient	   samples	   in	   this	   study	  was	   approved	   by	   the	   Clinical	   Research	   Ethics	  
Committee	   of	   Hospital	   Universitario	   Marqués	   de	   Valdecilla,	   HUMV	   (Santander,	   Spain).	  
Tumor	  biopsies	  were	  obtained	  from	  several	  hospitals	  around	  Spain	  and	  administered	  by	  the	  
tumor	  banks	  of	  CNIO	  (Madrid,	  Spain)	  and	  HUMV	  (Santander,	  Spain).	  Samples	  were	  obtained	  
before	  treatment	  and	  were	  diagnosed	  according	  to	  the	  criteria	  of	  the	  WHO	  (Swerdlow	  et	  al.	  
2008).	   For	   the	   gene	   expression	   data	   analysis,	   37	   frozen	   PTCL	   cases	   were	   used.	   Paraffin-­‐
embedded	  tissues	   from	  127	  PTCL,	  260	  DLBCL,	  30	  splenic	  marginal	  zone	   lymphoma	  (SMZL),	  
32	  mantle	  cell	  lymphoma	  (MCL),	  35	  Hodgkin	  lymphoma	  (HL),	  and	  33	  follicular	  lymphoma	  (FL)	  
samples,	  arranged	  into	  tissue	  microarrays	  were	  used	  for	   immunohistochemistry	  and	   in	  situ	  
hybridization.	  The	  clinical	  parameters	  of	  the	  different	  patient	  series	  included	  in	  the	  survival	  
analyses	  in	  this	  study,	  are	  summarized	  in	  Tables	  2.1	  –	  2.3.	  	  	  
	  
Table	  2.1	  Clinical	  characteristics	  for	  88	  DLBCL	  patients.	  	  
Characteristics	   Number	  of	  patients	   Percentage	  
Gender	   	  	   	  	  
Male	   42	   47.7%	  
Female	   46	   52.3%	  
Age	  (years)	   	  	   	  	  
Average	  (63.6	  years)	   	  	   	  	  
≤60	   36	   49.9%	  
>60	   51	   58.0%	  
-­‐	   1	   0.0%	  
IPI	   	  	   	  	  
0-­‐2	   45	   51.1%	  
3-­‐5	   38	   43.2%	  
-­‐	   5	   5.7%	  
DLBCL	  subtype	  (CHOI)	   	  	   	  	  
GCB	   41	   46.6%	  
ABC	   46	   52.3%	  
-­‐	   1	   0.0%	  
Total	   88	   	  100%	  
Note:	  DLBCL	  subclassification	  was	  performed	  using	  immunohistochemistry	  and	  the	  algorithm	  of	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Table	  2.2	  Clinical	  characteristics	  for	  PTCL-­‐NOS	  and	  AITL	  patients.	  	  
Characteristics	   Number	  of	  patients	   Percentage	  
Gender	   	   	  
Male	   46	   59.7%	  
Female	   31	   40.3%	  
Age	  (years)	   	   	  
Average	   63.2	   	  
≤60	   32	   41.6%	  
>60	   45	   58.4%	  
Ann	  Arbor	  Stage	   	   	  
I-­‐II	   17	   22.1%	  
III-­‐IV	   60	   37.9%	  
ECOG	   	   	  
0-­‐1	   53	   68.8%	  
2-­‐4	   24	   31.2%	  
IPI	   	   	  
0-­‐2	   34	   44.2%	  
3-­‐5	   41	   53.2%	  
	  -­‐	  	   2	   2.6%	  
LDH	  level	   	   	  
Normal	   34	   44.2%	  
High	   42	   54.5%	  
-­‐	   1	   1.3%	  
PTCL	  subtype	   	   	  
AITL	   29	   37.7%	  
PTCL-­‐NOS	   48	   62.3%	  
Total	   77	   100.0%	  
Abbreviations:	  ECOG	  =	  Eastern	  Cooperative	  Oncology	  Group,	  IPI	  =	  International	  Prognostic	  Index,	  
LDH	  =	  lactate	  dehydrogenase.	  
	  
Table	  2.3	  Clinical	  characteristics	  for	  ALCL	  patients	  
Characteristics	   Number	  of	  patients	   Percentage	  
Gender	   	   	  
Male	   15	   62.5%	  
Female	   9	   37.5%	  
Age	  (years)	   	   	  
Average	   44.6	   	  
≤60	   18	   75.0%	  
>60	   6	   25.0%	  
Ann	  Arbor	  Stage	   	  
I-­‐II	   10	   41.7%	  
III-­‐IV	   14	   58.3%	  
ECOG	   	   	  
0-­‐1	   18	   75.0%	  
2-­‐4	   6	   25.0%	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IPI	   	   	  
0-­‐2	   19	   79.2%	  
3-­‐5	   5	   20.8%	  
LDH	  level	   	   	  
Normal	   18	   75.0%	  
High	   6	   25.0%	  
ALK	  status	   	   	  
ALK	  positive	   8	   33.3%	  
ALK	  negative	   16	   66.7%	  
Total	   24	   100.0%	  
Abbreviations:	  ECOG	  =	  Eastern	  Cooperative	  Oncology	  Group,	  IPI	  =	  International	  Prognostic	  Index,	  
LDH	  =	  lactate	  dehydrogenase.	  
	  
2.1.2	  Isolation	  of	  T	  cells	  from	  peripheral	  blood	  	  
T	  cells	   from	  peripheral	  blood	  of	  healthy	  donors	  or	  Sézary	  syndrome	  patients	  were	   isolated	  
through	   negative	   selection	   using	   the	   RosetteSep	   Kit	   (StemCell	   Technologies,	   Grenoble,	  
France).	   The	   protocol	  was	   performed	   according	   to	   the	  manufacturer’s	   instruction	   starting	  
with	   10	   ml	   of	   peripheral	   blood	   in	   tubes	   containing	   Heparin	   as	   an	   anticoagulant.	   Briefly,	  
human	  T	  cell	  enrichment	  cocktail	  (containing	  a	  mixture	  of	  monoclonal	  antibodies	  for	  CD16,	  
CD19,	  CD36,	  CD56,	  CD66b	  and	  glycophorin	  A)	  was	  added	   to	   the	  blood	  sample	  at	  50	  µl/ml	  
and	   incubated	   for	   20	   min	   at	   room	   temperature	   to	   allow	   for	   unwanted	   cells	   to	   form	  
complexes	  with	  antibodies	  and	  red	  blood	  cells.	  Dilution	  with	  an	  equal	  volume	  of	  phosphate	  
buffer	  saline,	  PBS	  (NaCl	  137	  mM,	  Na2HPO4	  10	  mM,	  KCl	  2.7	  mM,	  KH2PO4	  2	  mM,	  pH	  7.4)	  +	  2%	  
fetal	  bovine	  serum	  (FBS)	  and	  centrifugation	  in	  RossetteSep	  density	  medium	  (20	  min	  at	  1200	  
x	  g	  in	  room	  temperature	  with	  the	  brake	  off)	  separated	  the	  enriched	  cells	  (including	  T	  cells)	  
from	   the	   unwanted	   complexes	   and	   plasma.	   The	   enriched	   cell	   layer	   was	   collected	   and	  
washed	  with	  PBS.	  Remaining	   red	  blood	  cells	  were	   lysed	  resuspending	   the	  pellet	   in	  2	  ml	  of	  
erythrocyte	   lysis	   buffer	   (Buffer	   EL,	   Quiagen,	   Hilden,	   Germany)	   on	   ice	   for	   10	  minutes.	   The	  
sample	  was	   then	  washed	   again	   and	   resuspended	   in	   culture	  medium.	   If	   cells	  were	   left	   for	  
later	   use,	   they	   were	   frozen	   slowly	   in	   90%	   FBS	   and	   10%	   dimethyl	   sulfoxide	   (DMSO)	   and	  
stored	   in	   liquid	   nitrogen	  until	   use.	   In	   order	   to	   check	   the	  purity	   of	   the	   samples,	   cells	  were	  
labeled	  with	  CD3-­‐fluorescein	   isothiocyanate	   (FITC)	   (BD	  Biosciences,	  San	  José,	  CA,	  USA)	  and	  
CD19-­‐Phycoerythrin	   (PE)	   (Miltenyi	  Biotec,	  #	  130-­‐091-­‐247)	  antibodies	   for	  15	  minutes	  at	  RT,	  
washed	   and	   resuspended	   in	   PBS	   and	   analyzed	   with	   a	   FACS	   Canto	   II	   flow	   cytometer	   (BD	  
Biosciences).	  The	  proportion	  of	  T	  cells	  (CD3+)	  in	  the	  samples	  was	  ensured	  to	  be	  >90%.	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2.1.3	  Culture	  and	  stimulation	  of	  isolated	  T	  cells	  	  
To	  stimulate	  proliferation	  of	  healthy	  T	  cells,	  the	  isolated	  T	  cells	  were	  grown	  in	  Roswell	  Park	  
Memorial	  Institute	  (RPMI)	  medium	  supplemented	  with	  20%	  FBS,	  1%	  penicillin/streptomycin	  
and	  the	  T	  stimulatory	  reagents	  Concanavalin	  A	  (ConA)	  (10	  µg/mL,	  Sigma-­‐Aldrich	  Co.	  St.	  Louis,	  
MO,	  USA)	  and	  interleukin-­‐2	  (IL-­‐2)	  (1500U/mL,	  PeproTech,	  Rocky	  Hill,	  NJ,	  USA).	  Control	  cells	  
were	  grown	   in	  medium	  without	  ConA	  and	   IL-­‐2.	  Cells	  were	  plated	   in	   triplicate	  and	  the	  cells	  
were	  counted	  manually	  using	  a	  Neubauer	   chamber	  at	  day	  0,	  2,	  4,	  and	  7.	  Whereas	  control	  
cells	  died	  or	  proliferated	  slowly,	  cells	  treated	  with	  ConA	  and	  IL-­‐2	  were	  induced	  to	  proliferate.	  
Cells	   were	   harvested	   for	   RNA	   extraction	   and	  NIK	   (MAP3K14)	   expression	   analysis	   at	   day	   4	  
when	  T	  cells	  were	  proliferating.	  	  
	  
2.1.4	  Cell	  lines	  and	  culture	  conditions	  	  
The	   human	   cell	   lines	   used	   in	   the	   study	   are	   summarized	   in	   Table	   2.4.	   The	   cell	   lines	   were	  
purchased	   from	   the	   German	   Collection	   of	   Microorganism	   and	   Cell	   Cultures	   (DSMZ,	  
Braunschweig,	  Germany),	  the	  American	  Type	  Culture	  Collection	  (ATCC,	  Rockville,	  MD,	  USA),	  
the	  European	  Collection	  of	  Cell	  Cultures	  (ECACC,	  Wiltshire,	  UK),	  or	  a	  supplied	  as	  a	  kind	  gift	  
from	  Dr.	  Martínez-­‐Climent	  at	  the	  Centre	  of	  Applied	  Medical	  Research	  (Pamplona,	  Spain).	  Cell	  
lines	   were	   grown	   in	   RPMI	   1640	   medium	   (Sigma	   Chemical,	   St	   Louis,	   MO,	   USA),	   Iscove´s	  
modified	  Dulbecco´s	  medium	  (IMDM,	  Invitrogen,	  Carlsbad,	  CA,	  USA),	  or	  Dulbecco´s	  modified	  
eagle	  medium	   (DMEM,	   Sigma	  Chemical)	   supplemented	  with	   10-­‐20%	  heat-­‐inactivated	   fetal	  
bovine	   serum,	   FBS,	   (Invitrogen)	   and	   1%	   penicillin/streptomycin.	   Interleukin	   2	   (PeproTech,	  
Rocky	   Hill,	   NJ,	   USA)	   was	   added	   to	   the	   culture	   medium	   of	   DERL-­‐7	   at	   a	   concentration	   of	  
20ng/ml.	  Cells	  were	  maintained	  at	  37°C	  in	  a	  humidified	  5%	  CO2	  incubator.	  All	  cell	  lines	  were	  
authenticated	   (year	  2010-­‐2011)	  by	  DSMZ.	  Cells	  were	  counted	   in	  a	  Neubauer	  chamber	  and	  
Trypan	  Blue	  (Sigma	  Chemical)	  was	  used	  to	  distinguish	  dead	  (blue)	  and	  alive	  (uncolored)	  cells.	  
For	  proliferation	  curves,	  cells	  were	  plated	   in	   triplicate	  at	  a	  density	  of	  100	  000	  cells/ml	  and	  
viable	  cells	  were	  counted	  at	  determined	  time	  points.	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Table	  2.4.	  Description	  of	  the	  cell	  lines	  used	  in	  the	  study	  
Cell	  line	   Lymphoma	  type	   Growth	  medium	   Growth	   Origin	  
My-­‐La	   Mycosis	  Fungoides	   RPMI	  +	  10%	  FBS	   Suspension	   ECACC	  
SR-­‐786	  	   Anaplastic	  large	  T	  cell	  lymphoma,	  ALK+	   RPMI	  +	  10%	  FBS	   Suspension	   DSMZ	  
DERL-­‐7	  	   Hepatosplenic	  gamma-­‐delta	  T	  cell	  lymphoma	  
RPMI	  +	  20%	  FBS	  +	  
IL2	   Suspension	   DSMZ	  
HuT	  78	   Sezary	  Syndrome	   RPMI	  +	  10%	  FBS	   Suspension	   ATCC	  
HH	   Cutaneous	  T	  cell	  lymphoma	   RPMI	  +	  10%	  FBS	   Suspension	   ATCC	  
MJ	   Peripheral	  T	  cell	  lymphoma,	  HTLV+	   IMDM	  +	  10%	  FBS	   Suspension	   ATCC	  
FARAGE	   Diffuse	  large	  B-­‐cell	  lymphoma,	  EBV+	   RPMI	  +	  20%	  FBS	   Suspension	   DSMZ	  
DOHH-­‐2	   Diffuse	  large	  B-­‐cell	  lymphoma,	  EBV+	   RPMI	  +	  20%	  FBS	   Suspension	   DSMZ	  
SUDHL-­‐4	   Diffuse	  large	  B-­‐cell	  lymphoma	   RPMI	  +	  10%	  FBS	   Suspension	   DSMZ	  
SUDHL-­‐6	   Diffuse	  large	  B-­‐cell	  lymphoma	   RPMI	  +	  10%	  FBS	   Suspension	   DSMZ	  








KARPAS-­‐422	   Diffuse	  large	  B-­‐cell	  lymphoma	   RPMI	  +	  10%	  FBS	   Suspension	   DSMZ	  
HEK	  293T	   Embryonic	  kidney	   DMEM	  +	  10%	  FBS	   Adherent	   ATCC	  
Abbreviations:	  FBS	  =	  Fetal	  bovine	  serum,	  EBV	  =	  Epstein-­‐Barr	  virus,	  ECACC	  =	  European	  Collection	  of	  
Cell	  Cultures,	  DSMZ	  =	  German	  Collection	  of	  Microorganism	  and	  Cell	  Cultures,	  ATCC	  =	  American	  Type	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2.2.	  Immunohistochemistry	  	  
Tissue	  microarray	   contruction	   and	   immunohistochemical	   stainings	  were	   performed	   at	   the	  
Histology	  and	  Immunohistochemistry	  Unit	  at	  the	  CNIO.	  	  
	  
2.2.1.	  Tissue	  microarray	  construction	  	  	  
Tissue	   microarrays	   (TMAs)	   are	   arrays	   containing	   small	   tissue	   biopsies	   (0.6-­‐2	   mm)	   from	  
different	   tissue	  blocks	  organized	   into	  one	  block.	   This	  permits	   the	   simultaneous	   staining	  of	  
many	  tumor	  samples	  on	  one	  unique	  slide.	  Representative	  areas	  from	  formalin-­‐fixed	  paraffin-­‐
embedded	   tumors	   and	   healthy	   lymph	   nodes	   were	   selected	   from	   hematoxylin	   and	   eosin	  
stained	  sections	  and	  two	  different	  1-­‐2	  mm	  tissue	  cores	  were	  extracted	  from	  each	  sample,	  so	  
that	   each	   sample	  was	   represented	   in	   duplicate	   on	   the	   TMA.	  A	   TMA	  workstation	   (Beecher	  
Instruments,	  Silver	  Spring,	  MD)	  was	  used	  to	  arrange	  the	  cores	  into	  a	  unique	  paraffin	  block,	  
using	  previously	  described	  methods	  (Kallioniemi	  et	  al.	  2001).	  	  
	  
2.2.2.	  Immunohistochemical	  staining	  	  
Antibodies	   and	   conditions	   used	   for	   immunohistochemistry	   are	   summarized	   in	   Table	   2.5.	  
Briefly,	   formalin-­‐fixed,	   paraffin-­‐embedded	   tissue	   sections	   were	   subjected	   to	  
deparaffinization	   and	   hydration	   by	   incubation	   at	   56º	   overnight,	   followed	   by	   immersion	   in	  
xylene	   and	   a	   decreasing	   ethanol	   gradient.	   A	   heat-­‐induced	   epitope	   retrieval	   step	  was	   then	  
performed	   by	   pressure-­‐cooking	   the	   slide	   at	   98º	   for	   20	   minutes	   in	   the	   antigen	   retrieval	  
buffers	   specified	   in	   Table	   2.5.	   The	   deparaffinization,	   hydration	   and	   antigen	   retrieval	   steps	  
were	   performed	   in	   PT	   Link	   instrument	   (DAKO,	   Glostrup,	   Denmark).	   Immunohistochemical	  
staining	   was	   then	   performed	   in	   a	   robotized	   system	   using	   Autostainer	   Link	   (DAKO)	   and	  
EnVision	   FLEX	   –	   horseradish	   peroxidase	   (HRP)	   visualization	   system	   (DAKO),	   applying	   the	  
following	  steps.	  Endogenous	  peroxidase	  activity	  was	  blocked	  by	   incubation	  of	   the	  slides	   in	  
peroxidase-­‐blocking	   reagent	   (0.03%	   hydrogen	   peroxidase	   containing	   sodium	   azide)	   for	   5	  
minutes	   at	   room	   temperature.	   Slides	   were	   then	   washed	   in	   wash	   buffer	   (0.05	   mol/L	   Tris	  
Buffered	   Saline,	   TBS,	   with	   Tween)	   and	   incubated	   with	   the	   primary	   antibodies	   at	   room	  
temperature	  for	  30	  minutes	  (see	  dilutions	  in	  Table	  2.5).	  After	  another	  wash	  step,	  slides	  were	  
incubated	  with	  secondary	  antibodies	  conjugated	  with	  HRP-­‐labeled	  polymer	  for	  30	  minutes,	  
washed	   again,	   and	   immersed	   in	   a	   buffer	   containing	   the	   substrate	   and	   chromogen	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diaminobenzidine	  (DAB)	  for	  10	  minutes.	  Preparations	  were	  contra-­‐stained	  with	  hematoxylin	  
for	   one	   minute,	   washed	   and	   dehydrated	   through	   consecutive	   incubations	   in	   increasing	  
concentration	  of	  ethanol	  and	  xylene,	  and	  then	  mounted	  automatically	  in	  Autostainer	  Link.	  	  
	  
Table	  2.5	  Antibodies	  and	  conditions	  for	  immunohistochemistry.	  	  
Antibody	   Species	  (clone)	   Company	   Dilution	  
Antigen	  
Retrieval	  
p100/p52	   mouse	  monoclonal	  
Millipore	  (Billerica,	  MA,	  
USA)	   1/1000	  
Citrate	  pH	  6	  +	  
Proteinase	  K	  
p105/p50	   rabbit	  polyclonal	  
GeneTex	  (Irvine,	  CA,	  
USA)	   1/1	   Citrate	  pH	  6	  
RelB	   rabbit	  polyclonal	  
Santa	  Cruz	  
biotechnlogy	  (Santa	  
Cruz,	  CA,	  USA)	  






biotechnlogy	   1/350	   Citrate	  pH	  6	  
c-­‐REL	   rabbit	  polyclonal	  
Calbiochem	  






UK)	   1/50	  











CNIO	  (Madrid,	  Spain)	   1/4	   Citrate	  pH	  6	  +	  Proteinase	  K	  
MUM1/IRF4	   goat	  polyclonal	  
Santa	  Cruz	  










CNIO	   1/100	   Citrate	  pH	  6	  
	  
2.2.3.	  Scoring	  	  
To	   assess	   NF-­‐κB	   activation	   in	   human	   tumors,	   nuclear	   expression	   of	   p50,	   p52,	   p65	   (RelA),	  
RelB	   or	   c-­‐Rel	  was	   evaluated.	   For	   PTCL	   samples,	   a	   scoring	   system	   including	   three	   different	  
levels	  was	  followed;	  negative,	  positive	  grade	  1	  (pos	  +),	  and	  positive	  grade	  2	  (pos	  ++).	  Cases	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presenting	  nuclear	  staining	  in	  >20%	  of	  tumor	  cells	  were	  considered	  positive,	  grade	  1	  (pos	  +),	  
while	  cases	  with	  strong	  nuclear	  staining	   in	  >50%	  of	  cells	  were	  considered	  positive,	  grade	  2	  
(pos	  ++).	  For	  DLBCL	  cases,	  a	  threshold	  of	  30%	  of	  positive	  tumoral	  nuclei	  was	  used,	  based	  on	  
previous	  reports	  in	  DLBCL	  (Hans	  et	  al.	  2004;	  Compagno	  et	  al.	  2009).	  Cases	  with	  inconsistent	  
results	   between	   the	   duplicated	   cores	   or	   those	   showing	   no	   reactivity	   in	   none	   of	   the	   cells	  
were	  discarded	  from	  the	  study.	  The	  evaluation	  of	  the	  stained	  tumors	  was	  done	  next	  to	  two	  
different	  pathologists	  with	  expertise	  in	  hematological	  malignancies.	  	  
	  
2.2.4.	  Statistical	  Analysis	  	  
To	  determine	  the	   independence	  of	  variables	  analyzed	  by	   immunohistochemistry,	  crosstabs	  
applying	   a	   Pearson’s	   χ2	   test	  was	  used.	   SPSS	   version	  15.0	   (SPSS	   Inc.,	   Chicago,	   IL,	  USA)	  was	  
used	  to	  carry	  out	  these	  tests.	  Values	  of	  p<0.05	  were	  considered	  statistically	  significant.	  	  
	  
2.2.5.	  DLBCL	  subclassification	  
	  
To	   classify	  DLBCL	   cases	   into	  molecular	   subtypes,	   immunohistochemistry	   of	   a	   panel	   of	   five	  
markers	  (GCET1,	  CD10,	  BCL6,	  MUM1	  and	  FOXP1)	  was	  performed	  and	  the	  classification	  into	  
GCB	  or	  ABC	  was	  done	  according	  to	   the	  algorithm	  of	  Choi	   (Choi	  et	  al.	  2009).	  This	  approach	  
was	   described	   to	   classify	   DLBCL	   samples	   with	   93%	   concordance	   compared	   to	   gene	  
expression	  profiling	   (Choi	  et	  al.	  2009),	  which	   is	   considered	  as	   the	  gold	   standard	   for	  DLBCL	  
classification.	  Tissues	  from	  60	  additional	  DLBCL	  samples,	  kindly	  provided	  by	  Dr.	  Ken	  H	  Young	  
(MD	   Anderson,	   TX,	   USA)	   were	   previously	   classified	   as	   GCB	   or	   ABC	   using	   gene	   expression	  
profiling	  (Wright	  et	  al.	  2003;	  Hu	  et	  al.	  2013).	  In	  our	  cases,	  91.7%	  concordance	  was	  obtained	  
between	  immunohistochemistry	  and	  gene	  expression	  profiling.	  	  
	  
2.3	  In	  Situ	  Hybridization	  of	  EBER	  	  
The	  presence	  of	  EBV	   in	   the	  tumor	  specimens	  were	  analyzed	  on	  paraffin-­‐embedded	  tissues	  
using	  In	  Situ	  hybridization	  of	  Epstein-­‐Barr	  Virus	  encoded	  RNA	  (EBER)	  as	  in	  (Chang	  et	  al.	  1992).	  
A	  specific	  probe	  for	  EBER	  (Bond	  ISH	  EBER	  probe,	  Vision	  BioSystem,	  Wetzlar,	  Germany)	  was	  
used	   and	   Bond–maX	   autostainer	   (Vision	   BioSystem)	   was	   used	   for	   automatic	   In	   Situ	  
hybridization	  at	  the	  Histology	  and	  Immunohistochemistry	  Unit	  at	  the	  CNIO.	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2.4.	  Survival	  Analysis	  	  
All	   statistical	   analyses	   were	   performed	   using	   SPSS	   software	   version	   15.0	   (SPSS	   Inc).	   As	  
clinical	  endpoint,	  overall	  survival	  was	  chosen.	  Overall	  survival	  is	  defined	  as	  the	  time	  interval	  
between	  diagnosis	  and	  death	  due	  to	   lymphoma	  or	  any	  other	  cause.	  Clinical	  parameters	  of	  
the	   patients	   included	   in	   the	   survival	   analyses	   are	   summarized	   in	   Table	   2.1-­‐2.3.	   The	   PTCL	  
series	   included	   77	   PTCL	   samples	   of	   which	   48	   were	   PTCL-­‐NOS	   and	   29	   were	   AITL.	   These	  
patients	  were	  followed	  between	  the	  years	  1994	  and	  2010	  and	  had	  an	  average	  follow-­‐up	  of	  
24	  months.	  In	  the	  ALCL	  series,	  24	  patients	  were	  followed	  between	  the	  years	  2001	  and	  2010	  
and	  had	  an	  average	  follow-­‐up	  of	  33	  months.	  The	  88	  DLBCL	  patients	  were	  followed	  between	  
the	  years	  2002	  and	  2013	  and	  presented	  an	  average	  follow-­‐up	  time	  of	  46	  months.	  	  
	  
2.4.1	  Kaplan-­‐Meier	  Analysis	  	  
The	  Kaplan-­‐Meier	  method	  applying	  the	  log-­‐rank	  test	  was	  used	  to	  estimate	  the	  differences	  in	  
overall	  survival	  between	  NF-­‐κB-­‐positive	  and	  negative	  cases	  in	  different	  patient	  series.	  For	  T-­‐
cell	  lymphomas,	  samples	  presenting	  nuclear	  staining	  of	  NF-­‐κB	  (either	  p52,	  p50,	  RelB,	  p65	  or	  
c-­‐Rel)	   in	  over	  50%	  (pos++)	  of	  tumor	  cells	  were	  considered	  positive	  for	  NF-­‐κB.	   In	  the	  DLBCL	  
series,	  a	  30%	  positivity	  threshold	  was	  used	  and	  the	  individual	  NF-­‐κB	  members	  were	  analyzed	  
separately.	  	  
	  
2.4.2	  Multivariate	  Cox	  Regression	  analysis	  	  
To	   adjust	   for	   the	   effect	   of	   other	   covariates	   on	   survival	   in	   PTCL,	   a	   multivariate	   survival	  
analysis	   was	   performed	   using	   a	   Cox	   proportional	   hazard	   regression	   model.	   Clinical	  
parameters	   included	   in	   the	   analysis	   were	   age	   (>60	   years),	   Ann-­‐Arbor	   stage	   (>2),	   ECOG	  
performance	   status	   (>1),	   extranodal	   sites	   (>1)	   and	   LDH	   levels.	   The	   combined	   presence	   or	  
absence	  of	  these	  symptoms	  is	  used	  to	  calculate	  the	  international	  prognostic	  index	  (IPI)	  in	  a	  
scale	  from	  1-­‐5	  (summing	  one	  point	  for	  the	  presence	  of	  any	  of	  these	  risk	  factors).	  The	  clinical	  
impact	  of	  NF-­‐κB	  was	  estimated	  both	  adjusting	  for	  the	  covariates	  age,	  stage,	  extranodal	  sites,	  
ECOG,	  LDH	  levels	  and	  adjusting	  for	  IPI	  as	  a	  prognostic	  covariate.	  The	  Enter	  model	  was	  used	  
for	  entering	  the	  covariates	  into	  the	  analysis	  and	  p-­‐values	  <0.05	  were	  considered	  statistically	  
significant.	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2.	  5.	  Protein	  extraction	  and	  Western	  blotting	  	  
2.5.1.	  Total	  protein	  extraction	  	  
Cells	  in	  culture	  were	  collected	  by	  centrifugation,	  washed	  two	  times	  in	  PBS	  and	  pellets	  were	  
stored	   at	   -­‐80oC	   until	   use.	   Protein	   was	   extracted	   using	   radio	   immunoprecipitation	   assay	  
(RIPA)	   lysis	   buffer	   (150mM	  NaCl,	   1.0%	   IGEPAL®	   CA-­‐630,	   0.5%	   sodium	   deoxycholate,	   0.1%	  
SDS,	   and	   50mM	   Tris,	   pH	   8.0;	   Sigma-­‐Aldrich	   Inc.)	   supplemented	   with	   protease	   and	  
phosphatase	   inhibitors	   (PhosSTOP	   and	   Complete	   cocktail	   tablets,	   Roche	   Diagnostics,	  
Inidanapolis,	   IN,	  USA)	  and	  phenylmethylsulfonyl	  fluoride	  (PMSF,	  Roche	  Diagnostics).	  Pellets	  
were	   resuspended	   in	   the	   lysis	   buffer	   and	   incubated	   on	   ice	   for	   30	   minutes.	   After	   a	  
centrifugation	   step	   (maximum	   speed,	   4ºC,	   30	  min),	   the	   supernatant	   was	   transferred	   to	   a	  
clean	   tube	  and	  protein	  concentrations	  were	  measured	  using	   the	  Bio-­‐Rad	  DC	  Protein	  Assay	  
(Bio-­‐Rad,	   Hercules,	   CA,	   USA)	   following	   the	   manufacturer’s	   instructions	   and	   using	   bovine	  
serum	  albumin	  (BSA)	  as	  a	  standard	  and	  98-­‐well	  microplates	  for	  sample	  preparation.	  The	  Bio-­‐
Rad	  DC	  Protein	  Assay	   is	  a	  colorimetric	  assay	   for	  protein	  concentration	  based	  on	  the	  Lowry	  
assay	   principles	   (Lowry	   et	   al.	   1951).	   Concentrations	   were	   calculated	   after	   reading	   the	  
absorbance	  at	  750	  nM	  in	  a	  spectrophotometer	  plate	  reader	  (Bio-­‐Rad).	  	  
	  
2.5.2	  Nucleus/cytoplasm	  separation	  	  
Pellets	  were	  collected	  by	  centrifugation	  (1,200	  x	  g,	  5	  min	  at	  room	  temperature)	  and	  washed	  
in	  PBS.	  Pellets	  were	   immediately	   subjected	   to	   the	  extraction	  protocol	  and	  never	   stored	  or	  
frozen	  prior	  to	  nuclear	  separation	  in	  order	  to	  avoid	  rupture	  of	  cellular	  membranes.	  Nuclear	  
fractions	   were	   separated	   from	   cytosolic	   fractions	   using	   the	   BioVision	   nuclear/cytosol	  
fractionation	   kit	   (#K266-­‐25,	   BioVision,	   Mountain	   View,	   CA,	   USA)	   according	   to	   the	  
manufacturer’s	   instructions.	   Briefly,	   cells	   were	   first	   resuspended	   in	   a	   cytosolic	   extraction	  
buffer	   and	   incubated	   on	   ice	   for	   10	   minutes.	   After	   the	   addition	   of	   a	   second	   cytosolic	  
extraction	  buffer	  and	  a	  short	  incubation	  on	  ice,	  cells	  were	  centrifuged	  and	  the	  supernatant	  
(the	   cytoplasmic	   fraction)	   is	   collected.	   The	   pellet	   was	   then	   resuspended	   in	   a	   nuclear	  
extraction	   buffer	   and	   incubated	   on	   ice	   for	   40	   minutes	   with	   repeated	   vortexing	   every	   10	  
minutes.	   After	   centrifugation,	   the	   supernatant,	   which	   contains	   the	   nuclear	   extract,	   was	  
collected.	   Proteins	   were	   quantified	   using	   the	   Bio-­‐Rad	   DC	   Protein	   Assay	   as	   mentioned	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previously	  and	  stored	  at	  -­‐80ºC.	  To	  verify	  a	  proper	  separation	  of	  the	  two	  compartments,	  the	  
expression	  of	  Lamin	  B1	  (nuclear)	  and	  α-­‐tubulin	  	  (cytoplasmic)	  was	  analyzed	  by	  Western	  blot.	  	  	  
2.5.3.	  Western	  blot	  	  
After	   protein	   extraction	   and	   quantification,	   Laemmli	   sample	   buffer	   (4X	   composition:	  
62.5mM	  TrisHCl	   pH	   6.8,	   glycerol	   20%,	   SDS	   2%,	   2-­‐mercaptoethanol	   5%,	   bromophenol	   blue	  
0.025%)	  was	   added	   to	   the	   extract	   and	   heated	   for	   5	  minutes	   at	   99oC.	   Samples	  were	   then	  
immediately	   put	   on	   ice	   and	   subjected	   to	   western	   blot	   or	   stored	   at	   -­‐80oC	   until	   later	   use.	  	  
Western	  blot	  was	  performed	  following	  standard	  protocols.	  For	  NIK	  detection,	  cell	  lines	  were	  
treated	  for	  3	  hours	  with	  20	  µM	  proteasome	  inhibitor	  MG132	  (C2211,	  Sigma,	  Missouri,	  USA)	  
prior	  harvesting.	  MG132	  was	  exclusively	  added	  to	  cells	  only	  for	  NIK	  detection	  and	  separate	  
untreated	  cells	  were	  collected	   for	  detection	  of	  other	  proteins.	  Twenty	   to	  40	  µg	  of	  protein	  
were	   loaded	   and	   separated	   by	   electrophoresis	   on	   6-­‐12%	   sodium	   dodecyl	   sulfate	  
polyacrylamide	   (SDS-­‐PAGE)	   gels	   in	   electrophoresis	   buffer	   (5X	   composition:	   TrisHCl	   0.13M,	  
glycine	  0.95M,	  SDS	  0.5%).	  Following	  electrophoresis,	  the	  proteins	  were	  wet-­‐transferred	  onto	  
nitrocellulose	   membranes	   (Whatman,	   Dassel,	   DE)	   using	   Mini	   Trans-­‐Blot	   Cell	   equipment	  
(BioRad).	  Transference	  was	  performed	  in	  transfer	  buffer	  (TrisHCl	  0.025M,	  glycine	  0.2M,	  20%	  
of	  methanol)	  at	  40	  mA	  overnight	  or	  400	  mA	  during	  1.5	  hour	  at	  4ºC.	  Membranes	  were	  then	  
blocked	  in	  5%	  milk	  in	  PBS-­‐T	  (phosphate-­‐buffered	  saline	  with	  0.1%	  Tween-­‐20)	  for	  1	  hour	  with	  
continuous	   shaking	   and	   incubated	   with	   the	   primary	   antibody	   diluted	   in	   5%	   BSA	   PBS-­‐T.	  
Primary	  antibodies	  and	  their	  conditions	  are	  summarized	  in	  Table	  2.6.	  Membranes	  were	  then	  
washed	   in	   PBS-­‐T	   (3	   x	   5	  minutes	   on	   a	   shaker)	   and	   incubated	   for	   1	   hour	   (in	   darkness	   on	   a	  
shaker)	  with	  a	   fluorescent-­‐labeled	  secondary	  antibody	   (Alexa	  680	  and	  Alexa800,	  Rockland,	  
Gilbertsville,	  PA,	  USA)	  diluted	  in	  5%	  BSA	  PBS-­‐T.	  The	  membranes	  were	  then	  again	  washed	  in	  
PBS-­‐T	   (3	   x	   5	  min)	   and	   the	   signal	  was	   read	   in	   an	  Odyssey	   Infrared	   System	  Scanner	   (LI-­‐COR	  
Biosciences,	   Lincoln,	   NE,	   USA).	   Band	   intensities	   were	   quantified	   using	   the	   ImageJ	   1.34S	  
software	   (National	   Institute	   of	   Health,	   Bethesda,	   MD,	   USA)	   and	   normalized	   against	   the	  
loading	  control	  (α-­‐tubulin	  or	  GAPDH).	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Table	  2.6.	  Characteristics	  of	  primary	  antibodies	  used	  in	  western	  blot.	  	  
Antibody	   Species	  (clone)	   Dilution	   Incubation	  time	   Manufacturer	  









p105/p50	   Rabbit	  polyclonal	   1/1000	   1h	   Novus	  Biologicals	  
α-­‐tubulin	   Mouse	  monoclonal	  (DM1A)	   1/10	  000	   30	  min	  
Sigma-­‐Aldrich	  
Inc.,	  St.	  Louis,	  
MO,	  USA	  
α-­‐tubulin	   Rabbit	  polyclonal	  (B-­‐5-­‐1-­‐2)	   1/10	  000	   30	  min	  
Abcam	  plc,	  
Cambridge,	  UK	  
Caspase-­‐3	   Rabbit	  polyclonal	   1/1000	   overnight	   Cell	  Signaling	  
IKK	  alpha	   Rabbit	  polyclonal	   1/1000	   2h	   Cell	  Signaling	  
IKK	  beta	   Rabbit	  polyclonal	   1/500	   overnight	   Cell	  Signaling	  
pStat-­‐3	  
(Tyr705)	   Rabbit	  polyclonal	   1/1000	   overnight	   Cell	  Signaling	  
Lamin	  B1	   Rabbit	  polyclonal	   1/1000	   2h	   Abcam	  
Stat3	   Mouse	  monoclonal	  (124H6)	   1/1000	   overnight	   Cell	  Signaling	  
PARP	   Rabbit	  polyclonal	   1/1000	   overnight	   Cell	  Signaling	  
C-­‐Rel	   Rabbit	  polyclonal	   1/1000	   overnight	   Cell	  Signaling	  
RelB	   Mouse	  monoclonal	   1/1000	   overnight	   Active	  Motif	  
pStat-­‐5	   Mouse	  monoclonal	  (Y694)	   1/1000	   overnight	   BD	  Biosciences	  





(C84E11)	   1/500	   overnight	   Cell	  Signaling	  
GAPDH	   Rabbit	  monoclonal	  (14C10)	   1/1000	   1h	   Cell	  Signaling	  
LMP1	   Mouse	  monoclonal	  (CS.	  1-­‐4)	   1/1	  	   2h	   DAKO	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2.6.	  RNA	  extraction	  	  
2.6.1	  RNA	  extraction	  from	  cell	  lines	  and	  isolated	  T	  cells	  	  	  
Total	  mRNA	  was	  extracted	  from	  cell	   lines	  or	   isolated	  primary	  T	  cells	  using	  the	  RNeasy	  Mini	  
Kit	   (Qiagen,	  Hilden,	  Germany)	   according	   to	   the	   guidelines	   described	   by	   the	  manufacturer.	  
Briefly,	   approximately	   106	   cells	  were	   harvested	   and	  washed	   in	   PBS.	   Then,	   350µL	   RLT	   lysis	  
buffer	   (supplemented	   with	   10%	   β-­‐mercaptoethanol)	   were	   added	   to	   the	   pellet	   and	   the	  
suspension	  was	  passed	  several	  times	  through	  a	  23G	  syringe	  needle	  to	  allow	  homogenization.	  
The	  same	  volume	  of	  70%	  ethanol	  was	  then	  added	  and	  the	  suspension	  was	  transferred	  to	  an	  
RNeasy	   mini	   column	   (containing	   a	   silica-­‐gel	   membrane	   that	   selectively	   binds	   RNA).	   The	  
contaminant	  DNA	  was	  digested	  by	  adding	  DNAse	  I	   (RNase-­‐free	  DNase	  I	  Set;	  Qiagen)	  to	  the	  
membrane	  and	   incubating	   for	  15	  minutes.	  After	   a	   few	  wash	   steps,	   the	  RNA	  was	  eluted	   in	  
RNase-­‐free	  water.	  RNA	  integrity	  and	  concentration	  were	  checked	  by	  gel	  electrophoresis	  and	  
analysis	  by	  NanoDrop	  ND-­‐100	  (NanoDrop,	  Wilmington,	  DE).	  	  
	  
2.6.2.	  RNA	  extraction	  from	  tissues	  	  
Total	   RNA	   extraction	   from	   whole	   frozen	   tissue	   was	   carried	   out	   using	   the	   TRIzol	   reagent	  
(Invitrogen,	  Carlsbad,	  CA,	  USA)	  as	   follows:	  Frozen	   tissues	  were	  cut	  with	  a	  cryostat	  and	   the	  
sections	  were	  then	  homogenized	  using	  a	  Polytron	  homogenizer	  (Capitol	  scientific,	  Inc;	  Austin,	  
TX).	   The	   homogenized	   samples	   were	   lysed	   by	   addition	   of	   1	   mL	   of	   TRIzol	   (a	   monophasic	  
solution	   of	   phenol	   and	   guanidine	   isothiocyanate	   that	   maintains	   the	   integrity	   of	   the	   RNA	  
while	  disrupting	  cellular	  components).	  Then,	  200	  μL	  of	  chloroform	  were	  added,	  mixed	  and	  
the	   sample	   was	   centrifuged	   at	   12,000	   rpm	   for	   15	   minutes	   at	   4oC.	   The	   aqueous	   phase,	  
containing	   the	   RNA,	   was	   transferred	   to	   a	   clean	   tube	   and	   the	   RNA	   was	   recovered	   by	  
isopropanol	   precipitation.	   The	   pellet	   was	   washed	   with	   70%	   ethanol	   and	   resuspended	   in	  
RNAse-­‐free	  water.	  The	  resulting	  RNA	  was	  further	  purified	  using	  the	  RNeasy	  kit	  (Qiagen	  Inc.,	  
Valencia,	   CA)	   and	   digested	   with	   RNase-­‐free	   DNase	   I	   following	   the	   manufacturer’s	  
instructions	   and	   procedures	   described	   in	   section	   2.6.1.	   The	   integrity	   and	   concentration	   of	  
RNA	   was	   verified	   by	   electrophoresis	   and	   measured	   by	   NanoDrop	   ND-­‐100	   (NanoDrop,	  
Wilmington,	  DE)	  or	  by	  the	  2100	  Bioanalyzer	  (Agilent	  Technologies,	  Inc.,	  Santa	  Clara,	  CA,	  USA).	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2.7.	  Gene	  expression	  microarrays	  	  
Gene	  expression	  microarrays	  are	  high-­‐throughput	  techniques	  that	  allow	  the	  analysis	  of	  the	  
expression	   of	   thousands	   of	   genes	   simultaneously.	   In	   this	   study	  we	  used	   the	   4x44K	  Whole	  
Human	   Genome	   Microarray	   (Agilent	   Technologies),	   a	   microarray	   containing	   60-­‐mer	  
oligonucleotides	  representing	  19,596	  Entrez	  gene	  RNAs	  covering	  the	  whole	  human	  genome.	  
For	   the	   gene	   expression	   analysis	   in	   primary	   samples,	   38	   frozen	   PTCL	   cases	   were	   used,	  
including	  20	  PTCL-­‐NOS,	  15	  AITL	  and	  3	  ALCL	  (1	  ALCL	  ALK+	  and	  2	  ALCL	  ALK-­‐).	  RNA	  extraction	  
was	  performed	   from	   frozen	   sections	  as	  described	   in	  2.6.2.	   For	  analysis	  of	  gene	  expression	  
after	   NIK	   knockdown	   in	   T	   cell	   lymphoma	   cell	   lines,	   pellets	   were	   collected	   48	   hours	   after	  
siRNA	   transfection	   and	   RNA	  was	   extracted	   using	   the	   RNeasy	  Mini	   Kit	   as	   described	   above.	  
Three	   independent	   experiments	  were	   performed	   and	   each	   sample	  was	   hybridized	   onto	   a	  
separate	   microarray.	   Purification,	   amplification,	   labeling	   and	   hybridization	   onto	   4x44K	  
Whole	   Human	   Genome	   Oligo	   Microarray	   was	   done	   according	   to	   the	   manufacturer´s	  
instructions	  (Agilent	  Technologies)	  as	  follows.	  	  
	  
2.7.1.	  cDNA	  synthesis	  from	  total	  RNA	  	  
Two	   μg	   of	   total	   RNA	   was	  mixed	   with	   2	   μl	   of	   a	   5,000-­‐fold	   dilution	   of	   Agilent's	   Two-­‐Color	  
Spike-­‐in	  RNA	  control	   and	  amplified	  using	  Agilent	   Low	  RNA	   Input	   Fluorescent	  Amplification	  
Kit	   (Agilent	   Technologies).	   The	  mixture	   in	   a	   final	   volume	   of	   6.5	   μl	   (total	   concentration	   at	  
least	  5ng/μl)	  was	  mixed	  with	  5	  μl	  of	  T7	  promoter	  primer.	  The	  primer	  and	  the	  template	  were	  
denatured	   by	   incubating	   the	   reaction	   at	   65OC	   for	   10min	   and	   placing	   on	   ice	   for	   5min.	  
Following,	   8.5	  μl	   of	   cDNA	  Master	  Mix	  was	   added	  and	   the	   samples	  were	   incubated	   first	   at	  
40OC	   in	   a	   circulating	  water	   bath	   for	   2h	   and	   then	   at	   65OC	   in	   a	   heating	  block	   for	   15	  min	   to	  
inactivate	  Moloney	  murine	  leukemia	  virus	  reverse	  transcriptase	  (MMLV-­‐RT).	  Following	  that	  
time,	  the	  samples	  were	  incubated	  on	  ice	  for	  5	  min.	  
	  
cDNA	  Master	  Mix	  composition:	  4μl	  of	  5X	  First	  strand	  buffer,	  0.1M	  DTT	  2	  μl,	  10mM	  dNTP	  mix	  
1	  μl,	  1	  μl	  of	  MMLV-­‐RT	  and	  0.5	  μl	  of	  RNaseOUT.	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2.7.2.	  Fluorescent	  cRNA	  synthesis:	  In	  vitro	  trasnscription	  and	  incorporation	  
of	  fluorochromes	  	  
To	   each	   sample	   tube,	   either	   2.4	   μl	   of	   10mM	   cyanine	   3-­‐CTP	   (sample)	   or	   2.4	   μl	   of	   10	  mM	  
cyanine	   5-­‐CTP	   (Stratagene	   Universal	   Human	   Reference	   RNA)	   was	   added	   and	   mixed.	  
Following,	  to	  each	  sample,	  57.6	  μl	  of	  Transcription	  Master	  Mix	  was	  added	  an	  incubated	  in	  a	  
circulated	  water	  bath	  at	  40OC	  for	  2h.	  Following	  amplification	  and	  labeling,	  each	  sample	  was	  
assessed	  on	  the	  Nanodrop	  ND-­‐1000	  to	  measure	  yield	  and	  specific	  activity.	  
	  
Transcription	   Master	   Mix	   composition:	   15.3	   μl	   of	   Nuclease-­‐free	   water,	   20μl	   of	   4X	  
Transcription	  buffer,	  6μl	  0.1M	  DTT,	  8μl	  of	  NTP	  mix,	  6.4μl	  50%	  PEG,	  0.5μl	  of	  RNase	  OUT,	  0.6μl	  
of	  inorganic	  pyrophosphatase	  and	  0.8μl	  T7	  RNA	  Polymerase.	  
	  
2.7.3.	  Hybridization	  	  
cRNA	   target	  was	  prepared	  as	   follows:	  0.75	  μg	  cyanine	  3-­‐labeled,	   linearly	  amplified	   sample	  
cRNA	   was	   mixed	   with	   0.75	   μg	   cyanine	   5-­‐labeled,	   linearly	   amplified	   reference	   pool	   cRNA,	  
50μl	   of	   10X	   control	   targets	   and	   nuclease-­‐free	   water	   to	   final	   volume	   of	   240	   μl.	   The	  
hybridization	  solution	  was	  prepared	  by	  adding	  240	  μl	  of	  2X	  target	  solution	  to	  10	  μl	  of	  25X	  
fragmentation	  buffer.	   The	  mixture	  was	   incubated	  at	  60OC	   in	   the	  heating	  block	   for	  30	  min.	  
Following,	   250	   μl	   of	   2X	   hybridization	   buffer	   (from	   In	   situ	   Hybridization	   kit)	   to	   the	   final	  
volume	  of	  500	  μl,	  mixed,	  spinned	  and	  490	  μl	  of	  the	  hybridization	  solution	  was	  applied	  to	  60-­‐
mer	   Agilent	   44K	   (or	   4X	   44K)	   Human	   Whole	   Genome	   oligonucleotide	   microarrays	   and	  
assembled	   in	   microarray	   hybridization	   chamber	   (G2534A).	   Once	   fully	   assembled,	   the	  
chambers	  were	   loaded	   into	   the	  hybridization	   rotator	   rack	   and	   set	   to	   rotate	  at	   4	   rpm.	  The	  
hybridization	  was	  performed	  in	  a	  rotating	  oven	  at	  60OC	  for	  17h.	  
	  
All	   the	   washing	   steps	   were	   performed	   at	   room	   temperature.	   First	   the	   sandwiched	   slides	  
were	   submerged	   in	   Wash	   Solution	   1	   to	   remove	   oligo	   microarray	   slide.	   The	   slides	   were	  
washed	   for	   1min	   in	   the	   Wash	   Solution	   1	   with	   the	   magnetic	   stir.	   The	   slides	   were	   then	  
transferred	  to	  the	  staining	  dish	  containing	  Wash	  Solution	  2	  and	  washed	  for	  1	  min.	  Following,	  
the	  slides	  were	  transferred	  to	  the	  staining	  dish	  containing	  the	  Wash	  Solution	  3	  and	  washed	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for	   30	   sec.	   All	   steps	   were	   performed	   in	   the	   dark.	   The	   dried	   slides	   were	   scanned	   with	   a	  
G2565BA	  Microarray	  Scanner	  System	  (Agilent	  Technologies).	  	  
Wash	  solution	  1	  composition:	  6X	  SSPE,	  0.005%	  N-­‐Lauroylsarcosine,	  deionized	  nuclease	  free	  
water.	  
Wash	   solution	   2	   composition:	   0.06X	   SSPE,	   0.005%	   N-­‐Lauroylsarcosine,	   deionized	   nuclease	  
free	  water.	  
The	  buffers	  1	  and	  2	  are	  passed	  through	  a	  0.2μm	  sterile	  filtration	  unit	  before	  use.	  
	  
Wash	  solution	  3	  composition:	  The	  Agilent	  Stabilization	  and	  Drying	  Solution	  contain	  an	  ozone	  
scavenging	  compound	  dissolved	  in	  acetonitrile.	  
	  
2.7.4.	  Data	  analysis	  	  
Feature	   extraction	   software	   (Agilent	   Technologies,	   version	  10.7.3.1)	  was	  used	   to	   read	   and	  
process	   the	   microarray	   images.	   Lowess	   intraarray	   and	   quantiles	   interarray	   normalization	  
was	  applied	  and	  subsequent	  statistical	  analyses	  were	  performed.	  
	  
2.7.4.1.	  Gene	  Set	  Enrichment	  Analysis	  	  
The	  Gene	  Set	  Enrichment	  Analysis	  tool	   (http://www.broad.mit.edu/gsea/)	   (Subramanian	  et	  
al.	  2005)	  was	  used	  to	  classify	  gene	  expression	  profiles	   into	   functional	  pathways.	  Gene	  sets	  
were	   selected	   using	   the	   Molecular	   Signature	   Database	  
(http://www.broadinstitute.org/gsea/msigdb/),	   including	   those	   relevant	   to	  either	   lymphoid	  
cell	   biology	   or	   cancer.	   The	   gene	   set	   for	   the	   NF-­‐κB	   target	   genes	  was	  manually	   added	   and	  
described	   in	   (Compagno	  et	  al.	  2009).	  A	  minimum	  of	  15	  and	  a	  maximum	  of	  500	  genes	   in	  a	  
gene	  set	  were	  required	  to	  qualify	   for	   further	  analysis.	  The	  gene	  sets	  co	  regulated	  with	  NIK	  
expression	   in	   primary	   samples	   were	   identified	   using	   Pearson	   correlation	   comparing	   the	  
expression	   of	   NIK	   with	   the	   expression	   of	   the	   rest	   of	   the	   genes	   in	   the	   genome	   in	   the	   37	  
primary	  PTCL	  samples.	  To	  identify	  pathways	  up-­‐	  or	  downregulated	  in	  NIK	  knockdown	  cells,	  a	  
limma	  t-­‐test	  was	  performed	  between	  NIK	  silenced	  and	  control	  cells.	  Gene	  sets	  with	  a	  false	  
discovery	  rate	  (FDR)	  below	  0.15	  were	  considered	  statistically	  significant.	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2.7.4.2.	  Differential	  gene	  expression	  analysis	  	  
Genes	   differentially	   expressed	   between	   control	   cells	   and	   NIK	   knockdown	   cells	   were	  
identified	   using	   a	   paired	   t-­‐test	   using	   the	   Pomelo	   tool	   for	   class	   comparisons	  
(http://pomelo2.bioinfo.cnio.es)	  and	  visualized	  using	  Gene	  Cluster	  and	  Treeview	  softwares	  
(http://rana.lbl.gov/EisenSoftware.htm).	   Genes	   presenting	   an	   FDR<0.05	   and	   a	   foldchange	  
>±1.6	  were	   considered	   significant.	   Venn	   diagrams	  were	   created	   using	   the	   free	   online	   tool	  
VENNY	  (http://bioinfogp.cnb.csic.es/tools/venny/index.html).	  
	  
2.8.	  Reverse	  transcription	  quantitative	  PCR	  (RT-­‐qPCR)	  	  
2.8.1	  Retrotranscription	  	  
RNA	  was	  isolated	  from	  cell	  lines	  and	  primary	  samples	  using	  the	  RNeasy	  Mini	  Kit	  as	  described	  
in	  2.6.1.	  cDNA	  was	  synthesized	  from	  500	  ng	  DNaseI-­‐treated	  RNA	  with	  SuperScript	  II	  Reverse	  
Transcriptase	   (Invitrogen)	   and	   random	   primers	   following	   the	   recommendations	   of	   the	  
manufacturer.	  Briefly,	  500	  ng	  of	  RNA	  were	  mixed	  with	  50	  ng	  of	  random	  primers,	  1	  1	  μL	  of	  10	  
mM	   dNTPs	   mix	   and	   water	   was	   added	   to	   a	   final	   volume	   of	   12	   μL.	   The	   RNA	   was	   then	  
denaturated	   by	   a	   heating	   step	   at	   65º	   C	   for	   5	   minutes.	   The	   following	   components	   were	  
added:	  4	  μl	  of	  5X	   first	   strand	  buffer,	  2	  μL	  of	  0.1	  M	  DTT	  and	  1	  μL	  of	   ribonuclease	   inhibitor	  
(RNAsin)	  at	  40	  U/μL	  and	  the	  mixture	  was	  incubated	  for	  2	  minutes	  at	  25oC	  prior	  to	  adding	  1	  
μL	  of	  200	  U/μL	  SuperScript.	  The	  samples	  were	  then	  put	  in	  a	  thermocycler	  where	  they	  were	  
first	  hold	  for	  10	  minutes	  at	  25oC,	  then	  for	  50	  minutes	  at	  42oC,	  and	  finally	  an	  inactivation	  step	  
at	  70oC	  for	  15	  minutes.	  
	  
2.8.2.	  Quantitative	  PCR	  	  	  
Primers	   used	   for	   quantitative	   PCR	   (qPCR)	   are	   listed	   in	   table	   2.7.	   For	   NIK	   (MAP3K14)	   and	  
BCL2-­‐like	   1	   (BCL2L1)	   detection,	   TaqMan	   assays	   (Applied	   Biosystems)	  were	   performed.	   For	  
the	  rest	  of	  the	  genes	  analyzed	   in	  this	  study,	  quantification	  of	  RNA	  expression	  was	  done	  by	  
labeling	  the	  RNA	  with	  SYBR	  Green	  (Applied	  Biosystems).	  Human	  glucuronidase	  beta	  (GUSB)	  
and	  18S	  FAM	  primers	  or	  probes	  were	  used	  as	  endogenous	  controls	  in	  samples	  and	  cell	  lines.	  
All	  samples	  were	  analyzed	  in	  a	  7900HT	  Fast	  Real-­‐Time	  PCR	  System	  (Applied	  Biosystems).	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Table	  2.7	  Primer	  sequences	  for	  quantitative	  PCR	  
Gene	   Forward	  primer	  (5´-­‐-­‐>	  3´)	   Reverse	  primer	  	  (5´-­‐-­‐>	  3´)	  
MAP3K14*	   GGCCTGGGAAAGTCCTTG	   CTGCTCCAGACATCCACCTT	  
IL6	   GAAAGGAGACATGTAACAAGAGT	   GATTTTCACCAGGCAAGTCT	  
IL21	   AGCTGAAGAGGAAACCACCTTC	   GAATCACATGAAGGGCATGTTAG	  
KLF2	   CAAGAGTTCGCATCTGAAGGC-­‐3	   TGTGCTTTCGGTAGTGGCG	  
NFKBIA	   CAACTACAATGGCCACACGTG	   GCAGTCCGGCCATTACAG	  
YAP1	   GACATCTTCTGGTCAGAGATACT	   ACTGATTCTCTGGTTCATGG	  
CFLAR	   CTGATGGCAGAGATTGGTGAG	   GGCAACCAGATTTAGTTTCTCCA	  
CCND2	   AGCTGCTGGAGTGGGAACTGGT	   CTTAAAGTCGGTGGCACACAGAGC	  
GUSB	   GGCTCCGAATCACTATCGC	   CCTTGGGATACTTGGAGGTG	  
*	  Primers	  for	  MAP3K14	  are	  used	  together	  with	  probe	  17	  (Roche	  Diagnostics)	  for	  TaqMan	  analysis	  
	  
2.8.2.1	  TaqMan	  assays	  	  
Two	  μL	  of	  cDNA	  were	  mixed	  with	  7.5	  μL	  of	  2X	  Universal	  Master	  Mix	   (Applied	  Biosystems),	  
0.75	  μL	  of	  the	  specific	  TaqMan	  Assay	  and	  water	  up	  to	  a	  final	  volume	  of	  15	  μL.	  Samples	  were	  
added	  in	  triplicate	  on	  a	  384-­‐well	  MicroAmp	  optical	  reaction	  plate	  (Applied	  Biosystems).	  The	  
PCR	  cycling	  conditions	  were	  standard:	  95oC	  for	  10	  minutes	  (one	  step),	  95oC	  for	  15	  seconds,	  
and	  60oC	  for	  1	  minute	  (40	  cycles).	  The	  relative	  changes	  in	  gene	  expression	  were	  calculated	  
by	   the	   ΔΔ Ct	   method	   using	   the	   Sequence	   Detection	   System	   (SDS)	   2.1	   software	   (Applied	  
Biosystems).	   The	  ΔΔ Ct	  method	   gives	   the	   amount	   of	   target	   normalized	   to	   an	   endogenous	  
reference	  and	  relative	  to	  calibrator.	  The	  level	  of	  each	  transcript	  was	  quantified	  by	  the	  cycle	  
at	   which	   the	   PCR	   amplification	   was	   in	   log	   phase	   where	   there	   was	   significant	   fluorescent	  
signal	   (Ct)	   with	   glucuronidase	   beta	   (GUSB)	   or	   human	   18S	   ribosomal	   RNA	   (18S),	   as	  
endogenous	  controls.	  	  
	  
2.8.2.2	  SYBR	  Green	  assays	  	  
Two	  μL	  of	  cDNA	  were	  mixed	  with	  5	  μL	  SYBR	  Green	  PCR	  Master	  Mix	  (Applied	  Biosystems),	  0.3	  
μL	  of	  specific	  forward	  and	  reverse	  primers	  (Table	  X)	  and	  2.4	  μL	  of	  water.	  As	  in	  the	  TaqMan	  
assays,	  samples	  were	  added	  in	  triplicate	  on	  a	  384-­‐well	  plate.	  The	  PCR	  cycles	  were	  as	  follow:	  
50oC	  for	  2	  minutes	  (one	  step),	  95oC	  for	  10	  minutes	  (one	  step),	  95oC	  for	  15	  seconds,	  60oC	  for	  
30	  seconds	  and	  72º	  C	  for	  30	  seconds	  (40	  cycles)	  and	  then	  a	  dissociation	  step	  involving	  95oC	  
for	  15	  seconds	  and	  then	  a	  slow	  increase	  of	  the	  temperature	  from	  60oC	  to	  95oC.	  The	  relative	  
changes	   in	   gene	   expression	   were	   calculated	   by	   the	   ΔΔ Ct	   method	   using	   the	   Sequence	  
Detection	  System	  (SDS)	  2.1	  software	  (Applied	  Biosystems),	  as	  in	  the	  TaqMan	  assays.	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2.9	  NF-­‐κB	  binding	  activity	  assay	  	  
Nuclear	   fractions	   were	   separated	   from	   cytosolic	   fractions	   using	   the	   BioVision	  
Nuclear/Cytosol	  Fractionation	  Kit	   (see	  section	  2.5.2)	  and	  5	  μg	  of	  nuclear	  extract	  were	  used	  
to	  quantify	  the	  NF-­‐κB	  transcription	  activation	  using	  the	  ELISA-­‐based	  TransAM	  NF-­‐κB	  Family	  
Transcription	  Factor	  Assay	  Kit	  (Active	  Motif,	  Carlsbad,	  CA,	  USA).	  The	  protocol	  was	  carried	  out	  
following	  the	  manufacturer´s	  instructions.	  In	  brief,	  nuclear	  extracts	  were	  added	  to	  a	  96-­‐well	  
plate	   containing	   immobilized	  NF-­‐κB	   consensus	  oligonucleotide	   sequences.	   The	  active	   form	  
of	  NF-­‐κB	  then	  binds	  to	  the	  immobilized	  sequence	  and	  the	  addition	  of	  specific	  NF-­‐κB	  subunit	  
antibodies	  and	  secondary	  HRP-­‐conjugated	  antibodies	  provide	  a	  colorimetric	  readout	  for	  the	  
amount	   of	  DNA-­‐bound	   transcription	   factor.	  Nuclear	   extracts	  were	   plated	   in	   triplicate.	   The	  
specificity	   of	   the	   assay	  was	   confirmed	  performing	   a	   competition	   assay	  with	  wild-­‐type	   and	  
mutated	  consensus	  oligonucleotides.	  	  
	  
2.10	  Flow	  cytometry	  techniques	  	  
All	  analyses	  were	  performed	  in	  a	  FACS	  Canto	  II	  flow	  cytometer	  (BD	  Biosciences)	  using	  the	  BD	  
FACS	  Diva	  software	  6.0	  (BD	  Biosciences).	  Ten	  thousand	  events	  were	  acquired	  in	  each	  sample.	  
Acquired	  data	  were	  then	  analyzed	  and	  quantified	  with	  the	  FlowJo	  software	  (FlowJo	  version	  
7.6.1,	  TreeStar	  Inc.,	  Ashland,	  OR,	  USA).	  	  
	  
2.10.1	  Analysis	  of	  apoptosis	  by	  AnnexinV	  staining	  	  
In	   order	   to	   meassure	   cell	   viability	   in	   cell	   lines	   after	   transfection,	   double	   staining	   with	  
Annexin	  V	   and	  4',6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI)	  was	   carried	  out.	  Annexin	  V	   is	   a	   35-­‐36	  
kDa	   Ca2+	   dependent	   phospholipid-­‐binding	   protein	   that	   has	   a	   high	   affinity	   for	  
phosphatidylserine,	   and	   binds	   to	   cells	   with	   exposed	   phosphatidylserine.	   Loss	   of	   plasma	  
membrane	   asymmetry,	   that	   includes	   flipping	   of	   phosphatidylserine	   from	   the	   inner	   to	   the	  
outer	  leaflet	  of	  the	  plasma	  membrane,	  is	  an	  early	  event	  in	  apoptosis.	  Thus	  annexin	  V	  stains	  
cells	  that	  are	  undergoing	  apoptosis.	  DAPI	  is	  a	  DNA	  intercalating	  molecule	  that	  stains	  nucleic	  
acids.	   It	   is	  used	  to	  stain	  dead	  cells	  that	  have	   lost	  their	  membrane	   integrity.	  Since	  DAPI	   is	  a	  
cell	  membrane	   impermeable	  compound,	   it	   is	  excluded	   from	  alive	  and	  early	  apoptotic	  cells	  
while	  staining	  late	  apoptotic	  and	  necrotic	  cells.	  Double	  staining	  with	  these	  two	  compounds	  
allows	   the	   discrimination	   between	   alive	   (double	   negative),	   early	   apoptotic	   (annexin	   V	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positive,	   DAPI	   negative)	   and	   late	   apoptotic/necrotic	   cells	   (double	   positive).	   Small	  
interference	   RNA	   (siRNA)-­‐transfected	   cells	   were	   harvested	   48,	   72	   and	   96	   hours	   after	  
microporation,	  washed	  with	  PBS	   and	   resuspended	   in	   200	  μl	  Annexin	  V	  binding	  buffer	   (BD	  
Biosciences)	  (10	  mM	  HEPES,	  pH	  7.4;	  140	  mM	  NaCl;	  2.5	  mM	  CaCl2).	  Two	  μL	  allophycocyanin	  
(APC)-­‐Annexin	  V	  (BD	  Biosciences)	  were	  added	  to	  each	  tube	  and	  cells	  were	  incubated	  in	  the	  
dark	   for	   15-­‐20	  minutes.	   Before	   acquisition	   in	   the	   cytometer,	   DAPI	   (final	   concentration	   10	  
μg/ml)	  was	  added	  and	   the	  viable	   cell	  population	   (DAPI/AnnexinV	  negative)	  was	  quantified	  
using	   FlowJo	   software	   (FlowJo	   version	   7.6.1,	   TreeStar	   Inc.,	   Ashland,	   OR,	   USA).	   Thus,	   the	  
proportion	  of	  non-­‐viable	  cells	  plotted	   in	   the	  cell	   viability	  graphs	  considers	  all	   cells	  positive	  
for	  either	  DAPI	  or	  Annexin	  V.	  	  
	  
2.10.2	  Cell	  cycle	  analysis	  	  
To	  analyze	  the	  distribution	  of	  cells	  in	  the	  different	  stages	  of	  the	  cell	  cycle,	  cells	  were	  stained	  
with	  propidium	  iodide	  (PI)	  and	  analyzed	  by	  flow	  cytometry.	  PI	  is	  able	  to	  indicate	  the	  amount	  
of	  DNA	  in	  permeabilized	  cells.	  PI	  fluorescence	  signal	  is	  directly	  proportional	  to	  the	  amount	  of	  
DNA	  inside	  the	  cell	  and	  can	  thus	  distinguish	  between	  different	  cell	  cycle	  stages	  by	  the	  DNA	  
amount.	  Cells	  were	  collected	  24,	  48	  and	  72	  hours	  after	  siRNA	  transfection,	  washed	  with	  PBS	  
and	  fixed	  with	  chilled	  70%	  ethanol.	  Before	  acquisition	  in	  the	  cytometer,	  cells	  were	  washed	  in	  
PBS	  and	  200	  ng/ul	  RNase	  A	  (Qiagen)	  was	  added.	  After	  30	  minutes	  of	  incubation,	  10	  μL	  of	  PI	  
(P4864,	  Sigma	  Aldrich)	  was	  added	  and	  cells	  were	  acquired	  in	  the	  cytometer.	  	  	  
	  
2.11	  RNA	  interference	  	  
RNA	   interference	   is	   a	   powerful	   technology	   for	   loss-­‐of-­‐function	   studies.	   RNA	   interference	  
takes	   advantage	   of	   the	   cell´s	   natural	   machinery	   to	   knock	   down	   a	   gene	   of	   interest.	  
Short/small	   interfering	   RNAs	   (siRNAs)	   are	   synthetic	   20-­‐25	   base	   pair	   (usually	   21	   base	   pair)	  
RNA	  duplexes.	  Once	  introduced	  into	  a	  cell	  by	  transfection,	  the	  antisense	  strand	  of	  the	  siRNA	  
duplex	   becomes	   part	   of	   a	   multiprotein	   complex	   (RNA-­‐induced	   silencing	   complex,	   RISC),	  
which	   identifies	  the	  corresponding	  mRNA	  sequence	  from	  the	  gene	  of	   interest.	  RISC	   is	  then	  
able	  to	  cleave	  the	  mRNA	  molecule,	  targeting	  its	  degradation	  and	  subsequent	  loss	  of	  protein	  
expression	   (Elbashir	   et	   al.	   2001).	   	   All	   the	   siRNAs	  used	   for	   gene	   knock	  down	   in	   this	   thesis,	  
were	   purchased	   from	   Invitrogen	   (Stealth	   type	   siRNAs).	   SiRNA	   sequences	   are	   presented	   in	  
table	  2.8.	  A	  non-­‐template	  control	  (NTC)	  (Stealth	  siRNA	  negative	  control	  LO	  GC,	   Invitrogen),	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which	   is	   not	   homologous	   to	   any	   mRNA	   in	   the	   vertebrate	   transcriptome,	   was	   used	   as	   a	  
control	   in	   all	   experiments.	   The	   concentration	   of	   siRNA	   in	   the	   final	   culture	   medium	   after	  
transfection	   was	   100	   nM	   in	   all	   experiments.	   If	   several	   siRNAs	   were	   used	   in	   the	   same	  
transfection,	  a	  total	  concentration	  of	  100	  nM	  was	  used.	  SiRNAs	  were	  efficiently	  introduced	  
into	   the	   cell	   lines	   by	   microporation	   (see	   below).	   Twenty-­‐four,	   48,	   72	   and	   96	   hours	   after	  
transfection,	  cells	  were	  harvested	   for	  measurement	  of	  cell	  viability,	  protein	  extraction	  and	  
RNA	  extraction.	  Experiments	  were	  conducted	  as	  independent	  triplicates.	  	  
	  
2.11.1	  Microporation	  	  
Microporation	   is	   a	   transfection	  method	  based	  on	   electroporation	   technology	   that	   permits	  
the	  transfection	  of	  cells	  with	  high	  efficiency	  and	  survival	  rate.	  All	  microporation	  experiments	  
were	   done	   using	   the	   MicroPorator	   MP100	   (NanoEnTek	   Inc.	   Seoul,	   Korea)	   with	   Neon	  
tranfection	  system	  kit	  (100	  μL	  tips,	  Invitrogen)	  using	  a	  gold	  capillary	  tip,	  which	  permits	  a	  less	  
harmfull	  electroporation	  compared	  to	  a	  cuvette.	  One	  day	  prior	  to	  microporation,	  cells	  were	  
seeded	   in	   fresh	   medium	   without	   antibiotics.	   The	   next	   day,	   cells	   were	   washed	   in	   PBS,	  
counted,	  and	  2x106	  cells	  were	  resuspended	  in	  110	  μL	  buffer	  R	  in	  a	  2	  mL	  eppendorf	  tube.	  The	  
siRNA	  was	  added	   (so	   that	  a	   final	   concentration	  of	  100nM	  siRNA	  would	  be	  achieved	   in	   the	  
culture	  medium)	   and	   100	   μL	   of	   cell	   suspension	  was	   then	   taken	  with	   the	   gold	   tip	   and	   the	  
pipette	  was	  inserted	  into	  the	  MicroPorator.	  After	  the	  electroporation	  cells	  were	  seeded	  in	  3	  
mL	   of	   culture	  medium	   and	   incubated	   at	   37oC	   until	   analysis.	   To	   optimize	   the	   transfection	  
efficiency	  and	  minimize	  cell	  death,	  microporation	  conditions	  were	  set	  for	  each	  individual	  cell	  
line.	  Briefly,	  3x105	   cells	  were	   resuspended	   in	  10	  μL	  buffer	  R	  and	  50	  nM	  of	   SiGLO	   (Thermo	  
Fisher	   Scientific	   Inc.,	  Waltham,	  MA,	  USA),	   a	   fluorescent	   oligonucleotide	   for	   assessment	   of	  
uptake	   into	   cells,	  was	  added.	  Ten	  μL	  of	   cell	   suspension	  were	  microporated	  using	  different	  
conditions,	   varying	   pulse	   voltage	   (900	   to	   1600	   V),	   pulse	   width	   (from	   10	   to	   40	   ms)	   and	  
number	  of	  pulses	  (1-­‐3),	  and	  then	  incubated	  in	  0,5	  mL	  of	  culture	  medium	  for	  24h.	  Cells	  were	  
then	   analyzed	   by	   flow	   cytometry	   and	   the	   porcentage	   of	   positive	   (Cy3	   positive	   for	   SiGLO	  
uptake)	   and	   viable	   cells	   (Annexin	   V	   and	   DAPI	   negative)	   were	   assessed.	   The	   condition	  
presenting	  the	  highest	  efficiency	  with	  the	   lowest	  effect	  on	  cell	  viability	  was	  chosen	  for	  the	  
siRNA	  experiments.	  Table	  2.9	  shows	  the	  microporation	  conditions	  for	  the	  cells	  used	   in	  this	  
thesis.	   For	   all	   gene	   silencing	   experiments,	   a	   transfection	   efficiency	   greater	   than	   95%	  was	  
achieved,	  as	  estimated	  in	  a	  parallel	  microporation	  using	  siGLO.	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Table	  2.8.	  SiRNA	  sequences	  used	  for	  gene	  knockdown.	  	  
siRNA	  name	   Gene	   Sequence	   Reference	  name	  
siNIK	  1	   MAP3K14	   AUCUGAUCAAGACUCUCGGACUGGC	   MAP3K14VHS40827	  
siNIK	  2	   MAP3K14	   CCCAAGCUAUUUCAAUGGUGUGAA	   MAP3K14HSS113310	  
siIKKα	  1	   CHUK	   GGGCCAUUUGCUUCCAGAAGUUUAU	   CHUKHSS101936	  
siIKKα	  2	   CHUK	   CAGCAAUGUUAAGUCUUCUUAGAUA	   CHUKHSS174353	  
siIKKβ	  1	   IKBKB	   CCGCCAUGAUGAAUCUCCUCCGAAA	   IKBKBHSS105292	  
siIKKβ	  2	   IKBKB	   GCGAAGACUUGAAUGGAACGGUGAA	   IKBKBHSS105294	  
siNFKB1	  1	   NFKB1	   CCAUCCUGGAACUACUAAAUCUAAU	   NFKB1HSS107143	  
siNFKB1	  2	   NFKB1	   GCCAGAGUUUACAUCUGAUGAUUUA	   NFKB1HSS107145	  
siNFKB2	  3	   NFKB1	   GGGAGGAAAUUUAUCUUCUUUGUGA	   NFKB1HSS181512	  
siNFKB2	  1	   NFKB1	   CCCAGGUCUGGAUGGUAUUAUUGAA	   NFKB2HSS107146	  
siNFKB2	  2	   NFKB1	   GAUUUCAAAUUGAACUCCUCCAUUG	   NFKB2HSS107147	  
siNFKB2	  3	   NFKB1	   GGGUGGAGAUGAAGUUUAUCUGCUU	   NFKB2HSS107148	  
siRELB	  1	   RELB	   GAGGACAUAUCAGUGGUGUUCAGCA	   RELBHSS109162	  
siRELB	  2	   RELB	   GCGAGGAGCUCUACUUGCUCUGCGA	   RELBHSS184267	  
siRELB	  3	   RELB	   CCCUACAACGCUGGGUCCCUGAAGA	   RELBHSS184268	  
siCREL	  1	   CREL	   CCUCCGGUGCGUAUAACCCGUAUAU	   RELHSS109157	  
siCREL	  2	   CREL	   ACAUGGUAAUUUGACGACUGCUCUU	   RELHSS109158	  
siCREL	  3	   CREL	   CAGAAUUAAGGAUUUGUCGUGUAAA	   RELHSS184261	  
siKLF2	  1	   KLF2	   GCUGGAAGUUUGCGCGCUCAGACGA	   KLF2HSS145585	  
siKLF2	  2	   KLF2	   GGCCAUUCCAGUGCCAUCUGUGCGA	   KLF2HSS145586	  
siKLF2	  3	   KLF2	   CCUACACCAAGAGUUCGCAUCUGAA	   KLF2HSS173585	  
siSTAT3	  1	   STAT3	   GCAGUUUCUUCAGAGCAGGUAUCUU	   STAT3VHS40491	  
siSTAT3	  2	   STAT3	   CCUGCAAGAGUCGAAUGUUCUCUAU	   STAT3VHS40497	  
siLMP1	  A	   LMP1	   GAGCCCUUUGUAUACUCCUACUGAU	   Custum	  design	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Table	  2.9.	  Microporation	  conditions	  for	  lymphoma	  cell	  lines	  
Cell	  line	   Pulse	  Voltage	   Pulse	  Width	   Pulse	  Number	  
My-­‐La	   1300	  V	   20	  ms	   2	  
SR-­‐786	   900	  V	   30	  ms	   2	  
DERL-­‐7	   1100	  V	   20	  ms	   2	  
HuT78	   1150	  V	   20	  ms	   2	  
FARAGE	   1100	  V	   20	  ms	   2	  
	  
2.12	  Cloning	  of	  human	  MAP3K14	  into	  pCDNA3.1	  vector	  	  
MAP3K14	  cDNA	  (encoding	  full	   length	  human	  NIK)	  inserted	  into	  pENTR/D-­‐TOPO	  (Invitrogen)	  
was	   kindly	   provided	   by	   the	   CNIO	   Proteomics	   Unit.	   The	  MAP3K14	   cDNA	  was	   amplified	   by	  
polymerase	   chain	   reaction	   (PCR)	   from	   pENTR/D-­‐TOPO-­‐MAP3K14	   and	   subcloned	   into	   the	  
pCDNA3.1	   vector	   (Invitrogen)	   using	   the	   EcoRI	   and	   XhoI	   restriction	   sites	   in	   the	   multiple	  
cloning	  site.	  The	  sequence	  of	  the	  forward	  primer	  including	  an	  EcoRI	  site	  and	  Kozak	  sequence	  
(for	   enhanced	   expression	   in	   mammalian	   cells)	   was	   5´-­‐	  
CCTAGAATTCGCCACCATGGCAGTGATGGAAATGGC	   –	   3´,	   and	   the	   sequence	   of	   the	   reverse	  
primer	   including	   XhoI	   restriction	   site	   was	   5´-­‐CTAGCTCGAGCTAGGGCCTGTTCTCCAGC	   –	   3´.	  
Shortly,	  KOD	  proofreading	  DNA	  polymerase	  (Toyobo	  Co.,	  Osaka,	  Japan)	  was	  used	  to	  amplify	  
MAP3K14	  cDNA	  by	  PCR	  from	  60	  ng	  of	  pENTR/D-­‐TOPO-­‐MAP3K14	  by	  standard	  PCR	  following	  
the	   manufacturer´s	   instructions	   for	   KOD	   Polymerase.	   PCR	   reactions	   took	   place	   in	   a	  
GeneAmp®	   PCR	   System	   9700	   (Applied	   Biosystems).	   The	   PCR	   product	   was	   cleaned	   by	  
QIAquick	  PCR	  Purification	  Kit	   (Qiagen)	  and	  then	  digested	  at	  37oC	  overnight	  with	  EcoRI	  and	  
XhoI	  (New	  England	  Biolabs	  Inc.,	  Ipswich,	  MA,	  USA)	  as	  was	  the	  destination	  vector,	  pCDNA3.1	  
(Invitrogen).	  The	  digested	  DNA	  was	  then	  loaded	  onto	  a	  1%	  agarose	  gel	  and	  the	  bands	  were	  
excised	   and	   purified	   using	   QIAquick	   Gel	   Extraction	   Kit	   (Qiagen).	   The	   ligation	   of	  MAP3K14	  
with	   pCDNA3.1	  was	   performed	  with	   a	   vector:insert	   ratio	   of	   1:3	  with	   T4	   DNA	   ligase	   (New	  
England	  Biolabs	  Inc.)	  at	  16ºC	  overnight.	  The	  ligation	  was	  then	  used	  to	  Heat-­‐Shock	  transform	  
One	   Shot®	   TOP10	  Chemically	   Competent	   E.	   coli	   (Invitrogen)	   and	   the	   transformed	  bacteria	  
culture	  was	  plated	  on	  an	  agar	  plate	  with	  ampicillin	  (the	  resistance	  cassette	  of	  pCDNA3.1)	  at	  
37oC	  overnight.	  Colonies	  were	  picked,	  grown	  in	  3	  mL	  Luria-­‐Bertani	  (LB)	  broth	  (supplemented	  
with	   100	   ug/mL	   ampicillin)	   at	   37oC	   in	   continuous	   shaking	   (225	   rpm)	   for	   approximately	   16	  
hours.	   To	   isolate	   the	   plasmid	   from	   the	   bacterias,	   the	   PureYield	   Plasmid	  Miniprep	   System	  
(Promega)	  was	  used	   following	   the	  protocol	  of	   the	  manufacturer.	  Colonies	  presenting	  DNA	  
with	   a	   correct	   restriction	   enzyme	  pattern	   (after	   digestion	  with	   EcoRI	   and	  XhoI)	  were	   then	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sequenced	  (conventional	  Sanger	  sequencing)	   to	  confirm	  a	  proper	  cloning	  process.	   In	  order	  
to	   obtain	   high	   quality	   plasmids	   for	   further	   use	   in	   cell	   culture,	   the	   convenient	   colony	  was	  
expanded	   and	   the	   plasmid	   isolated	   by	   PureYield	   Plasmid	   Maxiprep	   System	   (Promega)	  
following	  the	  provided	  instructions.	  	  
	  
2.13	  Transfection	  of	  HEK	  293T	  cells	  using	  FUGENE	  HD	  
transfection	  reagent	  	  
For	   the	   overexpression	   of	   NIK,	   HEK293T	   cells	   were	   transfected	   with	   pCDNA3.1-­‐MAP3K14	  
using	   FuGene®	   HD	   Transfection	   Reagent	   (Roche,	   Basel,	   Switzerland).	   FuGene®	   HD	   is	   a	  
reagent	   containing	   lipids	   and	   other	   components	   that	   form	   complexes	   with	   DNA	   that	   are	  
transported	   into	   the	  cells.	  The	  HD	   formulation	  allows	   transfection	  of	   cells	   cultured	  at	  high	  
density	   (80-­‐90%	   confluence).	   The	   transfection	   was	   done	   following	   the	   manufacturer’s	  
recommendations.	  The	  day	  before	  the	  tranfection,	  4.5	  million	  cells	  were	  seeded	  in	  a	  10	  cm	  
plate.	  The	  next	  day	  the	  medium	  was	  replaced	  by	  10	  mL	  of	  fresh	  medium	  and	  the	  cells	  were	  
put	   back	   into	   the	   incubator.	   9	   μg	   of	   plasmid	   (pCDNA3.1-­‐MAP3K14	   or	   pCDNA3.1	   empty	  
control	  vector)	  were	  mixed	  in	  500	  μL	  of	  prewarmed	  OPTIMEM®	  medium	  (Invitrogen)	  with	  27	  
μL	  of	  FuGene®	  HD.	  The	  mixture	  was	  incubated	  for	  30	  minutes	  with	  gentle	  shaking	  every	  5-­‐10	  
minutes	  at	   room	  temperature.	  The	  mixture	  was	   then	  added	  dropwise	   to	   the	  cells	  and	   the	  
cells	  were	  cultured	  normally.	  Fourty-­‐eight	  hours	  after	  tranfection,	  cells	  were	  trypsinized	  and	  
washed	   and	   the	   pellet	   was	   stored	   at	   -­‐80ºC	   for	   later	   protein	   extraction	   and	   analysis	   by	  
western	  blot.	   	  A	  control	  vector	  expressing	  green	  fluorescent	  protein	  (GFP)	  (pCDNA3.1-­‐GFP)	  
was	  transfected	  in	  parallel	  to	  estimate	  the	  transfection	  efficiency	  which	  was	  around	  80%.	  	  
	  
2.14	  Dominant	  negative	  NIK	  	  
NIK	  (KK/AA)	   is	  a	  dominant	  negative	  form	  of	  NIK	  containing	  two	  amino	  acid	  substitutions	   in	  
the	  kinase	  domain	  (KK429-­‐430AA),	  forming	  a	  kinase-­‐dead	  protein	   (Malinin	  et	  al.	  1997).	  The	  
expression	  vector	  pCDNA3.1-­‐NIK(KK/AA)	  was	  a	  kind	  gift	  from	  the	  Experimental	  Therapeutics	  
Programme	   at	   the	   CNIO.	   My-­‐La	   and	   SR-­‐786	   cells	   were	   transfected	   with	   pCDNA3.1–
NIK(KK/AA)	  using	  microporation	  (see	  section	  2.11.1).	  Ten	  μg	  DNA	  and	  2x106	  cells	  were	  used	  
for	   each	   transfection	   and	   the	   microporation	   conditions	   are	   represented	   in	   table	   2.9.	  
pCDNA3.1	  empty	  vector	  was	  used	  as	  a	  control	  and	  pCDNA3.1-­‐GFP	  was	  used	  to	  estimate	  the	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transfection	   efficiency,	   which	   ranged	   between	   40	   and	   60%	   in	   the	   different	   experiments.	  
After	  24	  and	  48	  hours,	  cells	  were	  harvested	  for	  cell	  viablility	  assay	  and	  protein	  extraction.	  	  
	  
2.15	  Immunofluorescence	  	  
Immunofluorescence	   staining	  of	   c-­‐Rel	  was	  made	  48	  hours	   after	   transfecting	   the	   cells	  with	  
siNIK	  or	  a	  non-­‐template	  control.	  To	  attach	  cells	  to	  a	  coverslip,	  Poly-­‐L-­‐Lysine	  (10%	  diluted	  in	  
water)	  was	  first	  added	  to	  the	  coverslip	  and	  incubated	  at	  37oC	  for	  1	  hour.	  The	  coverslip	  was	  
washed	  once	  in	  PBX	  1X,	  put	  into	  a	  well	  of	  a	  24-­‐well	  plate,	  and	  approximately	  400	  000	  cells	  in	  
its	  growth	  medium	  were	  added	  to	  the	  well.	  Cells	  were	  incubated	  at	  37oC	  until	  the	  cells	  had	  
attached	  to	  the	  coverslip	  (approximately	  1-­‐2	  hours).	  Cells	  were	  then	  washed	  in	  PBS	  1X	  and	  
fixed	  with	  4%	  paraformaldehyde	  for	  10	  minutes	  at	  room	  temperature.	  	  After	  two	  wash	  steps	  
(2	  x	  3	  minutes)	  in	  PBS	  1X,	  0.5%	  Triton	  was	  added	  and	  cells	  were	  incubated	  for	  5	  minutes	  at	  
room	  temperature.	  Cells	  were	  washed	  twice	  and	  then	  blocked	  with	  5%	  FBS	  	  (diluted	  in	  PBS)	  
for	  30	  minutes	  at	  37oC.	  Coverslips	  were	  placed	  in	  a	  humid	  chamber	  and	  the	  c-­‐Rel	  antibody	  
was	   added	   (1/100	   in	   1%	   PBS,	   Cell	   Signaling	   4727)	   and	   incubated	   for	   1	   hour	   at	   room	  
temperature.	  Coverslips	  were	  then	  washed	  2	  x	  3	  minutes	  in	  PBS	  and	  the	  secondary	  antibody	  
was	  added	  (Alexa	  488	  Donkey	  anti-­‐Rabbit,	  Invitrogen	  A21206)	  and	  incubated	  in	  darkness	  for	  
1	   hour	   at	   room	   temperature.	   Coverslips	   were	   washed	   in	   PBS	   1X	   once	   and	   were	   then	  
incubated	   in	  DAPI	   solution	   (100ng/mL)	   for	  10	  minutes.	  After	  another	  wash	   step	  coverslips	  
were	   rapidly	   dipped	   in	   water	   and	   then	   mounted	   on	   slides	   using	   Prolong	   Gold	   reagent	  
(Invitrogen).	  Slides	  were	  left	  to	  dry	  horizontally	  in	  darkness	  overnight.	  Images	  were	  obtained	  
by	   a	   Leica	   SP5	  MP	   confocal	  microscope	   (Leica	  Microsystems,	   Germany)	  with	   LAS	   AF	   v.3.x	  
software	  (Leica	  Microsystems).	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3.1	  NF-­‐κB	  expression	  in	  different	  human	  lymphomas	  	  
Aberrant	  NF-­‐κB	   signaling	  has	  been	   reported	   in	   several	   types	  of	   lymphomas	  and	  NF-­‐κB	  has	  
been	  suggested	   to	  play	  a	   role	   in	   the	  underlying	  pathogenesis	  of	   some	  of	   these	  neoplasms	  
(Jost	  et	  al.	  2007).	  However,	  there	  is	  a	  lack	  of	  studies	  including	  patient	  samples	  and	  there	  are	  
only	   few	   studies	   involving	   the	   alternative	   pathway.	  We	   therefore	   decided	   to	   analyze	   the	  
expression	  of	  both	  classical	  and	  alternative	  NF-­‐κB	   factors	   in	  patient	   tumor	  samples	   from	  a	  
variety	  of	   different	   lymphoma	   types;	   splenic	  marginal	   zone	   lymphoma	   (SMZL),	  mantle	   cell	  
lymphoma	   (MCL),	   Hodgkin	   lymphoma	   (HL),	   follicular	   lymphoma	   (FL),	   diffuse	   large	   B-­‐cell	  
lymphoma	   (DLBCL)	   and	   peripheral	   T	   cell	   lymphoma	   (PTCL).	   As	   the	   activation	   of	   the	  NF-­‐κB	  
pathway	   results	   in	   translocation	   of	   the	   transcription	   factor	   dimers	   to	   the	   nucleus,	   we	  
evaluated	   the	   nuclear	   expression	   of	   NF-­‐κB	   as	   a	   measure	   of	   an	   activated	   NF-­‐κB	   signaling,	  
using	   immunohistochemistry	  on	  paraffin-­‐embedded	   tissues.	  As	   readout	   for	   the	  alternative	  
NF-­‐κB	   pathway,	   we	   used	   nuclear	   p52,	   and	   for	   the	   classical	   pathway,	   nuclear	   p50	   was	  
assessed	  (Figure	  3.1	  A).	  From	  here	  on,	  if	  not	  otherwise	  specified,	  when	  we	  talk	  about	  NF-­‐κB	  
expression	   or	   NF-­‐κB-­‐positive	   tumors,	   we	   refer	   to	   nuclear	   expression	   of	   these	   proteins.	   If	  
more	   than	  30%	  of	   the	   tumoral	   cells	   presented	  nuclear	   staining	  by	   immunohistochemistry,	  
the	  tumor	  was	  considered	  positive	  for	  NF-­‐κB.	  In	  six	  B	  cell	  lymphoma	  cell	  lines,	  we	  performed	  
both	  immunohistochemistry	  and	  an	  ELISA	  assay,	  which	  assessed	  the	  DNA-­‐binding	  activity	  of	  
the	   NF-­‐κB	   factors	   (Figure	   3.1	   B).	   This	   comparison	   showed	   that	   cell	   lines	   that	   presented	  
nuclear	  staining	  of	  p50	  or	  p52,	  also	  had	  an	  increased	  DNA-­‐binding	  activity	  of	  these	  proteins,	  
suggesting	  that	  nuclear	  expression	  of	  NF-­‐κB	  corresponds	  to	  active	  NF-­‐κB.	  	  
	  
The	  frequencies	  of	  nuclear	  p52	  and	  p50	  expression	  in	  various	  tumors	  are	  shown	  in	  Figure	  3.1	  
C.	  While	   classical	  NF-­‐κB	   signaling	   (p50)	  was	  present	   in	   a	   significant	   proportion	  of	   cases	   of	  
most	   types	   of	   lymphomas,	   alternative	   NF-­‐κB	   signaling	   was	   practically	   absent	   in	   some	  
lymphoma	   types,	   such	   as	   FL	   and	   SMZL.	   The	   highest	   frequencies	   of	   nuclear	   p52	   and	   p50	  
expression	   were	   observed	   in	   PTCL	   and	   Hodgkin	   lymphoma,	   where	   the	   vast	   majority	   of	  
tumors	  were	  positive	  for	  both	  markers.	  	  Both	  pathways	  were	  also	  activated	  in	  approximately	  
a	   third	   of	   DLBCL	   tumors.	   In	   this	  work,	   the	   pathway	   has	   been	   further	   studied	   in	   PTCL	   and	  
DLBCL,	  given	  its	  frequent	  activation	  and	  relevance	  to	  the	  pathogenesis	  of	  these	  diseases.	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Figure	  3.1	  Expression	  of	  p100/p52	  and	  p105/p50	  in	  human	  lymphoma	  tissue.	  	  
A)	  Immunohistochemistry	  showing	  nuclear	  staining	  of	  p52	  and	  p50	  in	  different	  lymphoma	  types.	  
B)	  Comparison	  between	  immunohistochemistry	  and	  DNA-­‐binding	  activity	  in	  lymphoma	  cell	   lines.	  
Graphs	  represent	  the	  DNA-­‐binding	  activity	  of	  p52	  and	  p50	  measured	  by	  an	  ELISA	  TransAM	  assay.	  
Black	  bars	  represent	  cell	  lines	  with	  nuclear	  expression	  of	  p52	  and	  p50	  and	  grey	  bars	  indicate	  cell	  
lines	  that	  lack	  nuclear	  p52	  or	  p50,	  as	  assessed	  by	  immunohistochemistry.	  C)	  Percentages	  of	  cases	  
positive	   for	   nuclear	   p52	   (black	   bars)	   or	   p50	   (grey	   bars)	   among	   different	   lymphoma	   types.	   The	  
numbers	   below	   the	   graph	   indicate	   the	   number	   of	   tumors	   analyzed	   in	   each	   category.	   SMZL	   =	  
splenic	  marginal	   zone	   lymphoma	   ,	  MCL	  =	  mantle	   cell	   lymphoma,	  HL	  =	  Hodgkin	   lymphoma,	  FL	  =	  
follicular	  lymphoma,	  DLBCL	  =	  diffuse	  large	  b-­‐cell	  lymphoma,	  PTCL	  =	  peripheral	  T	  cell	  lymphoma.	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3.2	  NF-­‐κB	  activation	  in	  DLBCL	  	  
Even	   though	   constitutive	   NF-­‐κB	   activation	   is	   one	   of	   the	   proposed	   oncogenic	  mechanisms	  
underlying	   the	   molecular	   pathology	   of	   DLBCL,	   particularly	   the	   ABC	   subtype,	   the	   actual	  
expression	   of	   NF-­‐κB	   in	   DLBCL	   tumor	   specimens	   and	   the	   presence	   of	   both	   classical	   and	  
alternative	   signaling	   component	   as	   well	   as	   their	   clinical	   correlation,	   has	   not	   been	   well	  
studied.	  Bearing	   in	  mind	  that	  the	  NF-­‐κB	  pathway	  was	  found	  to	  be	  activated	  in	  a	  significant	  
group	  of	  DLBCL	   samples	   (as	   shown	   in	   Figure	   1),	   and	   its	   proven	   importance	   in	   this	   kind	   of	  
malignancy	   (Davis	   et	   al.	   2001),	   we	   decided	   to	   study	   this	   pathway	   further	   in	   an	   extended	  
series	  of	  DLBCL	  samples.	  
	  
3.2.1	  Correlation	  between	  EBV,	  LMP1	  and	  NF-­‐κB	  in	  DLBCL	  	  
EBV-­‐positive	  DLBCL	  of	  the	  elderly	  has	  been	  recognized	  as	  a	  provisional	  separate	  lymphoma	  
entity	   in	   the	   latest	  WHO	  classification	   (Swerdlow	  et	  al.	  2008),	  due	  to	   its	  distinct	  molecular	  
and	   clinical	   profile.	   EBV-­‐positive	   DLBCL	   has	   a	   more	   aggressive	   clinical	   course	   than	   EBV-­‐
negative	  DLBCL	  (Montes-­‐Moreno	  et	  al.	  2012).	  Experimental	  studies	  have	  demonstrated	  that	  
EBV	  can	  induce	  NF-­‐ĸB	  activation	  (Devergne	  et	  al.	  1996;	  Keller	  et	  al.	  2006;	  de	  Oliveira	  et	  al.	  
2010).	  The	  extent	  and	  features	  of	  this	  phenomenon	  in	   lymphoma	  primary	  samples	  has	  not	  
yet	   been	   elucidated,	   however.	   For	   that	   reason,	   we	   examined	   whether	   there	   was	   any	  
connection	  between	  EBV	  status	  and	  the	  expression	  of	  nuclear	  p52	  or	  p50	   in	  human	  DLBCL	  
samples.	  In	  a	  large	  series	  of	  260	  DLBCL	  tumor	  samples,	  8.1%	  of	  the	  tumors	  were	  EBV	  positive,	  
as	  established	  by	  EBV-­‐encoded	  RNA	  (EBER)	  in	  situ	  hybridization.	  Additionally,	  we	  evaluated	  
the	  expression	  of	  the	  EBV-­‐derived	  antigen	  latent	  membrane	  protein	  1	  (LMP1)	  in	  our	  samples,	  
because	   it	   has	   been	   suggested	   as	   one	   of	   the	   triggers	   of	   EBV-­‐induced	   NF-­‐κB	   activation	  
(Eliopoulos	  et	  al.	  2001).	  Only	  5.4%	  of	  all	  cases	  in	  our	  series	  expressed	  LMP1.	  Overall,	  in	  the	  
cohort	  of	  260	  tumors,	  34.2%	  were	  positive	  for	  p52	  and	  38.8%	  were	  positive	  for	  p50.	  In	  the	  
EBV-­‐positive	  cases	  (EBER-­‐positive),	  this	  number	  was	  raised	  to	  71.4%	  and	  61.9%,	  respectively	  
(Figure	  3.2	  A).	  Hence,	   there	  was	   a	  positive	   and	  highly	   significant	   correlation	  between	  EBV	  
status	  and	  nuclear	  p52	  and	  p50	  in	  our	  series	  (Chi-­‐square	  test,	  p=0.0002	  for	  p52	  and	  p=0.02	  
for	  p50).	  Interestingly,	  this	  correlation	  was	  even	  stronger	  when	  evaluating	  the	  expression	  of	  
LMP1,	  where	  92.8%	  and	  85.7%	  of	  the	  LMP1-­‐positive	  cases	  were	  positive	  for	  nuclear	  p52	  and	  
p50,	  respectively	  (Figure	  3.2	  A,	  p=0.000002	  for	  p52	  and	  p=0.0002	  for	  p50).	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Notably,	  in	  cases	  positive	  for	  EBER	  but	  negative	  for	  LMP1,	  only	  28.6%	  expressed	  nucear	  p52	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Figure	  3.2	  Correlation	  between	  EBV,	  LMP1	  and	  NF-­‐κB	  in	  DLBCL.	  	  
A)	   Percentages	   of	   primary	   DLBCL	   cases	   expressing	   nuclear	   p52	   or	   p50	   depending	   on	   EBV	   and	  
LMP1	   status.	   One	   asterisk	  means	   p<0.05	   and	   two	   asterisks	   stand	   for	   p<0.01,	   estimated	  with	   a	  
Student´s	   t-­‐test.	   B)	   Comparison	   of	   nuclear	   NF-­‐kB	   expression	   in	   EBV-­‐positive	   DLBCL,	   taking	   into	  
account	  the	  status	  of	  LMP1.	  C)	  Images	  of	  the	  expression	  of	  EBER	  (in	  situ	  hybridization),	  LMP1,	  p50	  
and	  p52	   (immunohistochemistry)	   in	   two	  EBV-­‐positive	  DLBCL	   cell	   lines,	   FARAGE	  and	  DOHH-­‐2.	  D)	  
Proliferation	  assay	  after	   LMP1	  knockdown	   in	  FARAGE	  cell	   line.	  The	  graph	   represents	  number	  of	  
viable	  cells	  after	  0,	  48	  and	  96	  hours	  after	  LMP1	  knockdown.	  E)	  Western	  blot	  showing	  the	  levels	  of	  
LMP1,	  p52	  and	  p50	  after	   LMP1	   silencing.	   The	  quantification	  of	  p50	  and	  p52,	  normalized	   to	   the	  
levels	  of	  α-­‐tubulin	  and	  represented	  as	  a	  ratio	  to	  NTC,	  is	  shown	  below	  each	  panel.	  EBV	  =	  Epsten-­‐
Barr	  virus,	  EBER	  =	  EBV-­‐encoded	  RNA,	  LMP1	  =	  Latent	  membrane	  protein	  1.	  
	  
Results	  I	  	  
	   63	  
κB	   activation	   	   (Figure	   3.2	   B).	  Moreover,	   in	   two	   EBV-­‐positive	  DLBCL	   cell	   lines	   (FARAGE	   and	  
DOHH-­‐2),	   only	   the	   one	   expressing	   high	   levels	   of	   LMP1	   (FARAGE)	   showed	   nuclear	   NF-­‐κB	  
localization	  (Figure	  3.2	  C).	  	  
	  
Knockdown	  of	  LMP1	  with	  two	  siRNAs	  (siLMP1A	  and	  siLMP1B,	  with	  only	  siLMP1B	  producing	  
an	   effective	   knockdown)	   in	   FARAGE	   cell	   line	   led	   to	   reduced	   cell	   growth	   (Figure	   3.2	   D)	  
compared	   to	   untransfected	   cells	   (MOCK)	   or	   non-­‐template	   control	   (NTC)-­‐transfected	   cells,	  
confirming	  the	  role	  of	  LMP1	  for	  cell	  growth	  and	  survival	  of	  infected	  lymphocytes	  (de	  Oliveira	  
et	  al.	  2010)	  Analyzing	  the	  effect	  of	  LMP1	  knockdown	  on	  downstream	  NF-­‐κB	  expression,	  we	  
observed	   a	   reduction	   of	   both	   p50	   and	   p52	   expression	   (Figure	   3.2	   E),	   suggesting	   a	   role	   of	  
LMP1	   in	  the	  regulation	  of	   the	  alternative	  and	  classical	  pathways	   in	  DLBCL.	  Taken	  together,	  
these	  results	  indicate	  that	  EBV-­‐positive	  DLBCL	  is	  characterized	  by	  frequent	  NF-­‐κB	  activation	  
and	   suggest	   that	   one	   of	   the	   possible	   triggers	   for	   both	   alternative	   and	   classical	   NF-­‐κB	  
activation	   in	  DLBCL	   is	   LMP1.	   Even	   though	   the	   relationship	  between	  EBV,	   LMP1	  and	  NF-­‐κB	  
has	   previously	   been	   shown	   in	   experimental	   models,	   our	   results	   provide	   animportant	  
verification	  that	  this	  correlation	  also	  exists	  in	  primary	  tumors	  from	  patients	  with	  DLBCL	  and	  
identify	  NF-­‐κB	  expression	  as	  a	  cardinal	  feature	  of	  LMP1-­‐positive	  DLBCL	  tumors.	  	  
	  
3.2.2	  Expression	  pattern	  of	  different	  NF-­‐ĸB	  members	  in	  EBV-­‐negative	  DLBCL	  
	  
Since	  the	  family	  of	  NF-­‐ĸB	  consists	  of	  5	  different	  transcription	  factors,	  we	  decided	  to	  evaluate	  
the	  expression	  of	  all	  of	  them	  in	  order	  to	  get	  a	  complete	  picture	  of	  the	  expression	  pattern	  in	  
these	  tumors.	   In	  a	  series	  of	  113	  consecutive	  EBV-­‐negative	  human	  DLBCL	  biopsies,	   taken	  at	  
the	  time	  of	  diagnosis,	  the	  nuclear	  expression	  of	  p50,	  p52,	  RelB,	  p65	  and	  c-­‐Rel	  was	  assessed	  
(Figure	  3.3	  A).	   If	  more	  than	  30%	  of	  the	  tumoral	  cells	  presented	  nuclear	  staining,	  the	  tumor	  
was	  considered	  positive.	  This	  threshold	  was	  chosen	  because	  it	  has	  previously	  been	  used	  for	  
NF-­‐κB	  expression	  in	  DLBCL	  (Compagno	  et	  al.	  2009;	  Pham	  et	  al.	  2011)	  and	  is	  also	  a	  threshold	  
commonly	   used	   for	   standard	   immunohistochemistry	   markers	   in	   DLBCL	   (Hans	   et	   al.	   2004;	  
Choi	   et	   al.	   2009).	   In	   addition	   to	   the	   association	   observed	   between	   nuclear	  NF-­‐ĸB	   staining	  
and	  DNA-­‐binding	  activity	   (Figure	  3.1	  B),	  Compagno	  and	  coworkers	   (Compagno	  et	  al.	  2009)	  
showed	  that	  nuclear	  expression	  of	  p50	  or	  p52	  in	  DLBCL,	  evaluated	  by	  immunohistochemistry,	  
was	   associated	   with	   enhanced	   transcription	   of	   NF-­‐κB	   target	   genes,	   suggesting	   that	  
immunohistochemical	   analysis	   of	   nuclear	   NF-­‐κB	   could	   be	   a	   valid	   approach	   for	   assessing	  
active	  NF-­‐κB	  signaling.	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The	  percentages	  of	  positive	  cases	  for	  each	  of	  the	  NF-­‐κB	  proteins	  are	  respresented	  in	  Figure	  
3.B.	  Interestingly,	  only	  12.4%	  of	  cases	  lacked	  the	  expression	  of	  all	  NF-­‐κB	  subunits.	  Of	  the	  five	  
proteins,	   c-­‐Rel	  was	   the	  most	   commonly	   expressed	   (63.7%),	   followed	  by	  RelB	   (42.5%),	   p50	  
(43.4%)	   and	   p52	   (29.2%).	   Surprisingly,	   nuclear	   p65	   was	   only	   detected	   in	   11.5%	   of	   the	  
samples.	  The	  relationship	  between	  the	  expression	  of	  the	  different	  subunits	  is	  represented	  in	  
the	  Venn	  diagram	  in	  figure	  3.3	  C..3	  	  
	  
Notably,	   the	  expression	  pattern	  of	   the	  different	   factors	   is	  complex,	  and	  doesn’t	   follow	  the	  
classical	   outline	   of	   the	   NF-­‐κB	   pathway.	   There	   is	   a	   significant	   correlation	   between	   the	  
Figure	  3.3	  Expression	  of	  different	  NF-­‐κB	  proteins	  in	  EBV-­‐negative	  DLBCL	  	  
A)	   	   Immunohistochemical	   staining	   shows	   nuclear	   staining	   of	   p50,	   p52,	   RelB,	   c-­‐Rel	   and	   p65	   in	  
representative	  DLBCL	  samples.	  B)	  Porcentages	  of	  DLBCL	  cases	  staining	  positive	  for	  NF-­‐κB	  subunits	  
(nuclear	  staining	  in	  >30%	  of	  the	  tumoral	  cells)	  in	  a	  series	  of	  113	  tumors.	  NF-­‐κB	  in	  the	  last	  column	  
represents	   the	   porcentage	   of	   cases	   staining	   positive	   for	   any	   NF-­‐κB	   subunit.	   C)	   Venn	   diagram	  
showing	  the	  overlap	  in	  number	  of	  positive	  cases,	  between	  the	  different	  NF-­‐κB	  factors.	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expression	  of	  factors	  of	  the	  classical	  and	  alternative	  pathway,	  such	  as	  between	  p50	  and	  p52	  
(p=0.000052),	   p52	   and	   p65	   (p=0.006),	   and	   between	   p50	   and	   RelB	   (p=0.006)	   (Table	   3.1),	  
indicating	   an	   overlap	   between	   classical	   and	   alternative	   factors	   and	   suggesting	   that	   no	  
precise	   line	   exists	   distinguishing	   these	   two	   pathways.	   It	   is	   also	   remarkable	   that	   23	   c-­‐Rel-­‐
positive	  cases	  do	  not	  express	  any	  other	  NF-­‐κB	  factor.	  
	  
3.2.3	  Correlation	  between	  NF-­‐κB	  expression	  and	  DLBCL	  subclassification	  	  
Based	   on	   gene	   expression	   profiling,	   two	   different	   molecular	   subtypes	   of	   DLBCL	   were	  
recognized	  according	  to	  the	  putative	  cell	  of	  origin:	  the	  more	  aggressive	  activated	  B-­‐cell-­‐like	  
(ABC)	  subtype	  and	  the	  germinal	  center	  B-­‐cell-­‐like	  (GCB)	  subtype	  (Alizadeh	  et	  al.	  2000;	  Wright	  
et	   al.	   2003).	   Due	   to	   practical	   reasons,	   algorithms	   to	   classify	   these	   subtypes	   using	  
immunohistochemistry	   of	   a	   few	   markers	   instead	   of	   gene	   expression	   profiling	   have	   been	  
developed	   and	   extensively	   used	   (Hans	   et	   al.	   2004;	   Choi	   et	   al.	   2009).	   These	   subtypes	   also	  
differ	   in	   their	   oncogenic	   programs	   and	   several	   subtype-­‐specific	   genetic	   alterations	   have	  
been	  described	  (Lenz	  et	  al.	  2010;	  Pasqualucci	  et	  al.	  2011;	  Zhang	  et	  al.	  2013).	  A	  hallmark	  of	  
ABC-­‐DLBCL	   is	   constitutive	   NF-­‐κB	   activation,	   and	   a	   disruption	   of	   this	   activation	   induces	  
apoptosis	   in	  ABC-­‐DLBCL	  cell	   lines	   (Davis	  et	  al.	  2001).	  The	  overall	  survival	  of	  patients	  of	   the	  
ABC	  subtype	  is	  significantly	  inferior	  than	  that	  of	  patients	  with	  GCB	  subtype	  (Rosenwald	  et	  al.	  
2002).	   Since	   ABC-­‐DLBCL	   is	   characterized	   by	   prominent	   NF-­‐κB	   activation,	   we	   wanted	   to	  
explore	   how	   the	   expression	   of	   the	   five	   transcription	   factors	   was	   distributed	   between	   the	  
GCB	  and	  ABC	  subtypes.	  In	  our	  series	  of	  113	  tumors,	  DLBCL	  subclassification	  was	  done	  using	  
immunohistochemistry	  according	  to	  the	  algorithm	  of	  Choi	  (Choi	  et	  al.	  2009).	  Surprisingly,	  we	  
see	  a	  fairly	  even	  distribution	  of	  NF-­‐κB-­‐positive	  staining	  of	  all	  subunits	  between	  the	  subtypes,	  
with	  only	   a	   slight	  but	  not	   significant	   increase	  of	  positive	   cases	   in	  ABC-­‐DLBCL	   (Figure	  3.4	  A	  
and	  Table	  3.1).	  
	  
To	   validate	   this	   finding,	  we	   performed	   the	   study	   in	   a	   second	   series	   of	   60	  DLBCL	   samples,	  
where	   subclassification	   had	   been	   done	   using	   gene	   expression	   profiling	   (described	   and	  
published	  in	  (Hu	  et	  al.	  2013).	  Still,	  the	  expression	  of	  NF-­‐κB	  showed	  no	  correlation	  with	  DLBCL	  
subtype	   (Figure	   3.4	   B).	   Moreover,	   only	   5	   out	   of	   60	   cases	   were	   misclassified	   using	  
immunohistochemistry	  for	  subclassification	  in	  this	  series	  (concordance	  of	  91.7%),	  suggesting	  
that	  this	  is	  a	  valid	  approach	  for	  GCB/ABC	  stratification	  in	  our	  cohorts.	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neg pos neg pos neg pos neg pos neg pos GCB ABC
neg 55 25 52 28 32 48 75 5 34 46
pos 9 24 13 20 9 24 25 8 12 21
neg 44 20 28 36 60 4 31 33
pos 21 28 13 36 40 9 15 34
neg 23 42 59 6 26 39
pos 18 30 41 7 20 28
neg 38 3 20 21










GCB/ABC 0.546 0.056 0.859 0.187
c'Rel 0.201 0.059 0.817













































Figure	  3.4	  Analysis	  of	  the	  expression	  of	  NF-­‐κB	  family	  members	  and	  their	  distribution	  between	  
DLBCL	  molecular	  subtypes.	  	  
A)	  113	  primary	  DLBCL	  tumors	  were	  analyzed.	  The	  graph	  shows	  the	  percentage	  of	  positive	  cases	  in	  
each	   DLBCL	   subtype	   (black	   columns	   represent	   ABC-­‐DLBCL,	   and	   white	   columns	   represent	   GCB-­‐
DLBCL).	   DLBCL	   classification	   was	   performed	   using	   immunohistochemistry.	   B)	   Comparison	   of	  
percentage	  of	  positive	  cases	  for	  p50	  and	  p52	  in	  different	  DLBCL	  subtypes	  when	  classification	  was	  
performed	  using	  gene	  expression	  profiling.	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3.2.4	  Clinical	  correlation	  of	  NF-­‐κB	  in	  DLBCL	  	  
Samples	   from	   a	   cohort	   of	   88	   DLBCL	   patients	   treated	   with	   R-­‐CHOP	   immunochemotherapy	  
(Rituximab	   combined	   with	   cyclophosphamide,	   doxorubicin,	   vincristine,	   and	   prednisone)	  
were	   used	   to	   estimate	   if	   NF-­‐κB	   expression	   had	   any	   impact	   on	   the	   clinical	   course	   of	   the	  
malignancy	  (See	  Table	  2.1	  in	  the	  materials	  and	  methods	  section	  for	  patient	  characteristics).	  
Of	   all	   the	   five	  NF-­‐κB	   subunits,	   only	   c-­‐Rel	   had	  a	   significant	   impact	  on	   the	   clinical	   outcome.	  
Patients	   having	   c-­‐Rel-­‐positive	   tumors	   had	   a	   significantly	   superior	   overall	   survival	   than	  
patients	  with	   c-­‐Rel-­‐negative	   tumors	   (with	   estimated	   5-­‐year	   overall	   survival	   rates	   of	   73.7%	  
versus	  59.7%,	  Figure	  3.5,	  p=0.041).	  The	  expression	  of	  p52	  was	  also	  associated	  with	  enhanced	  







Figure	  3.5.	  Clinical	  impact	  of	  NF-­‐κB	  expression	  in	  DLBCL.	  	  
Kaplan-­‐Meier	   plots	   estimating	   the	   overall	   survival	   in	   patients	   with	   positive	   (red	   line)	   or	   negative	  
tumors	   (blue	   line)	   for	   the	   five	   different	   NF-­‐κB	   subunits.	   Tumors	   positive	   for	   c-­‐Rel	   are	   significantly	  
associated	  with	  a	  superior	  overall	  survival	  (p=0.042,	  Log-­‐Rank	  test).	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In	  order	   to	   take	   into	  account	  other	   important	  prognostic	   features	   in	  DLBCL,	  a	  multivariate	  
analysis,	   including	  DLBCL	   subclassification	  and	   the	   international	  prognostic	   index	   (IPI),	  was	  
performed	   (Table	  3.3).	   Interestingly,	   c-­‐Rel	  was	  proven	   to	  be	  a	   favorable	  prognostic	   factor,	  
independently	  of	  both	  GCB/ABC	  classification	  and	  IPI.	  	  	  
	  
Table	  3.3	  Results	  from	  c-­‐Rel	  multivariate	  survival	  analysis	  
Variable	   p-­‐value	   Hazard	  ratio	  (CI	  95%)	  
c-­‐Rel	   0.038	   0.442	  (0.205-­‐0.953)	  
IPI	  (≥3)	   0.025	   2,454	  (1.122-­‐5.368)	  
GCB/ABC	   0.165	   1.793	  (0.787-­‐4.086)	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  NF-­‐κB	  pathway	  in	  T	  cell	  lymphomas:	  NIK	  
as	  a	  regulator	  of	  classical	  and	  alternative	  
signaling	  and	  cell	  survival	  
	  
	  
Results	  II	  	  
	  
	  
Results	  II	  	  
	   71	  
4.1	  NF-­‐κB	  expression	  in	  human	  PTCL	  samples	  	  
NF-­‐κB	   activation	   has	   been	   reported	   in	   PTCL,	   but	   there	   are	   few	   studies	   including	   patient	  
material	  and	  the	  expression	  pattern	  of	  the	  various	  NF-­‐κB	  members	  has	  not	  been	  described	  
in	   detail.	   In	   order	   to	   characterize	   the	   expression	   of	   NF-­‐κB	   in	   PTCL,	   we	   performed	  
immunohistochemistry	  on	  paraffin-­‐embedded	  tissues	  from	  patients	  with	  the	  most	  common	  
types	   of	   PTCL:	   angioimmunoblastic	   T-­‐cell	   lymphoma	   (AITL),	   PTCL-­‐not	   otherwise	   specified	  
(PTCL-­‐NOS),	   and	   anaplastic	   large	   T-­‐cell	   lymphoma	   (ALCL)	   (Figure	   4.1	   A).	   All	   samples	   were	  
taken	   at	   diagnosis.	   The	   nuclear	   expression	   of	   the	   five	   NF-­‐κB	   proteins	   was	   evaluated.	   To	  
represent	  different	   levels	  of	  NF-­‐κB	  expression	  among	  the	  tumors,	  two	  positivity	  thresholds	  
were	  used	  based	  on	  the	  number	  of	  tumor	  cells	  with	  nuclear	  staining;	  20%	  (pos	  +)	  and	  50%	  
(pos	  ++)	  (Figure	  4.1	  B).	  	  
	  
The	  frequencies	  of	  NF-­‐κB	  expression	  among	  the	  different	  PTCL	  subtypes	  are	  summarized	  in	  
Table	  4.1.	  Nuclear	  expression	  of	  components	  defining	  both	  the	  classical	  (p50	  and	  c-­‐Rel)	  and	  
Figure	  4.1:	  Immunohistochemistry	  staining	  of	  NF-­‐κB	  in	  PTCL	  tumors	  
A)	   Protein	   expression	   of	   the	   different	   NF-­‐κB	   factors	   in	   representative	   paraffin-­‐embedded	   PTCL	  
tumors.	  B)	  Cases	  were	  categorized	  into	  three	  different	  levels	  according	  to	  their	  nuclear	  staining	  of	  
NF-­‐κB:	  negative,	  pos	  +,	  or	  pos	  ++.	  Tumors	  with	  over	  20%	  positive	  nuclei	  are	  grouped	  into	  category	  
pos	  +,	  while	  tumors	  with	  more	  than	  50%	  positive	  nuclei	  are	  grouped	  under	  category	  pos	  ++.	  C)	  A	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alternative	  (p52	  and	  RelB)	  pathways	  was	  detected	  in	  the	  majority	  of	  PTCLs.	  Surprisingly,	  the	  
commonly	   used	  marker	   for	   NF-­‐κB	   activation,	   p65,	   showed	   only	   cytoplasmic	   expression	   in	  
most	  cases,	  suggesting	  that	  other	  factors	  of	  the	  family	  are	  more	  frequently	  involved	  in	  NF-­‐κB	  
signaling	   in	   PTCL.	   Moreover,	   as	   we	   observed	   in	   B	   cell	   lymphomas,	   a	   significant	   positive	  
correlation	  (p<0.05)	  was	  established	  between	  nuclear	  p50	  and	  p52	  expression	  (Figure	  4.1	  C),	  




Table	  4.1:	  NF-­‐κB	  expression	  in	  human	  PTCL	  tumors	  
	  
PTCL	  subtype	   Antigen	   Evaluable	  cores	   neg	   pos	  +	   pos	  ++	  
ALCL	  
p52	   28	   4	  (14.3)	   9	  (32.1)	   15	  (53.6)	  
p50	   28	   3	  (10.7)	   8	  (28.6)	   17	  (60.7)	  
RelB	   28	   7	  (25.0)	   12	  (42.9)	   9	  (32.1)	  
c-­‐Rel	   28	   7	  (25.0)	   16	  (57.1)	   5	  (17.9)	  
p65	   13	   11	  (84.6)	   2	  (15.4)	   0	  (0.0)	  
PTCL-­‐NOS	  
p52	   57	   17	  (29.8)	   35	  (61.4)	   5	  (8.8)	  
p50	   57	   11	  (19.3)	   34	  (59.6)	   12	  (21.1)	  
RelB	   57	   14	  (24.6)	   38	  (66.7)	   5	  (8.8)	  
c-­‐Rel	   57	   17	  (29.8)	   35	  (61.4)	   5	  (8.8)	  
p65	   35	   34	  (97.1)	   1	  (2.9)	   0	  (0.0)	  
AITL	  
p52	   42	   4	  (9.5)	   35	  (83.3)	   3	  (7.1)	  
p50	   42	   1	  (2.4)	   27	  (64.3)	   14	  (33.3)	  
RelB	   42	   4	  (9.5)	   35	  (83.3)	   3	  (7.1)	  
c-­‐Rel	   42	   7	  (16.7)	   33	  (78.6)	   2	  (4.8)	  
p65	   35	   34	  (97.1)	   1	  (2.9)	   0	  (0.0)	  
Note:	   The	   number	   and	   percentages	   (in	   parenthesis)	   of	   PTCL	   tumors	   that	   are	   negative	   or	   positive	   for	   NF-­‐κB	  
among	   different	   PTCL	   subtypes	   are	   represented	   in	   the	   table.	   Abbreviations:	   ALCL	   =	   Anaplastic	   large	   T-­‐cell	  




4.2	  Impact	  of	  NF-­‐κB	  on	  T	  cell	  lymphoma	  patient	  survival	  	  
The	   biological	   and	   prognostic	   importance	   of	   NF-­‐κB	   activation	   is	   still	   unknown	   and	  
contradictory	   results	   have	   been	   reported	   for	   the	   clinical	   correlation	   of	   NF-­‐κB	   in	   different	  
tumors.	  Apart	  from	  ALK-­‐expression,	  there	  is	  a	  lack	  of	  prognostic	  markers	  as	  well	  as	  markers	  
for	   treatment	   prediction	   in	   PTCL.	   PTCL	   patients	   still	   present	   a	   highly	   aggressive	   clinical	  
course	  with	  poor	  management	  options.	  To	  estimate	  the	  impact	  of	  nuclear	  NF-­‐κB	  expression	  
on	   the	   clinical	   outcome	   of	   patients	   with	   PTCL,	   we	   performed	   a	   Kaplan-­‐Meier	   analysis	   to	  
compare	   the	   overall	   survival	   between	   NF-­‐κB-­‐positive	   and	   negative	   tumors.	   Tumors	   with	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>50%	   positive	   nuclei	   (tumors	   included	   in	   category	   pos	   ++)	   for	   any	   NF-­‐κB	   factor	   were	  
considered	  positive.	  Similar	  thresholds	  have	  previously	  been	  used	  for	  immunohistochemistry	  
of	  NF-­‐κB	  in	  other	  studies	  in	  the	  lymphoma	  field	   (Piccaluga	  et	  al.	  2007;	  Espinosa	  et	  al.	  2008;	  
Compagno	   et	   al.	   2009).	   In	   our	   series	   of	   77	   PTCL-­‐NOS	   and	   AITL	   cases	   (see	   patient	  
characteristics	  in	  Table	  2.2),	  31.2%	  of	  the	  cases	  were	  positive	  for	  NF-­‐κB.	  The	  PTCL-­‐NOS	  and	  
AITL	   subtypes	   were	   included	   in	   the	   same	   survival	   analysis,	   since	   these	   patients	   did	   not	  
present	  any	  significant	  difference	  in	  basal	  OS	  due	  to	  PTCL	  subtype	  in	  our	  series	  (Figure	  4.2	  A)	  
or	   in	   studies	  published	  by	  others	   (Vose	  et	   al.	   2008).	  When	  NF-­‐κB	  was	   taken	   into	   account,	  
however,	   patients	   with	   NF-­‐κB-­‐positive	   tumors	   had	   a	   significantly	   inferior	   overall	   survival	  
compared	  with	  the	  negative	  group	  (Figure	  4.2	  B,	  log	  rank	  test,	  p=0.003).	  The	  2-­‐year	  overall	  
survival	   in	   the	  NF-­‐κB-­‐positive	   group	  was	  only	  41.7%	  compared	  with	  67.9%	   in	   the	  negative	  
group.	  NF-­‐κB	  activation	  in	  PTCL	  was	  still	  significantly	  associated	  with	  inferior	  overall	  survival	  
when	  the	  impact	  of	  other	  	  clinical	  covariates	  was	  taken	  into	  account	  (age,	  extranodal	  sites,	  
LDH	  levels,	  ECOG	  performance	  status	  and	  Ann	  Arbor	  stage).	  The	  IPI,	  which	  is	  a	  combination	  
of	   these	   clinical	   variables,	   was	   though	   still	   a	   more	   accurate	   estimate	   of	   prognosis	   in	   our	  
series	  (Table	  4.2	  and	  4.3).	  	  
	  
ALCL	   tumors	  were	  studied	   in	  a	   separate	  analysis	  due	   to	   their	  distinct	  clinical	  behavior	  and	  
biology.	  	  In	  a	  series	  of	  24	  ALCL	  cases	  (see	  table	  2.3	  in	  the	  material	  and	  methods	  section	  for	  
patient	  characteristics),	  NF-­‐κB	  was	  positive	  in	  75.0%	  of	  the	  tumors.	  As	  seen	  in	  PTCL-­‐NOS	  and	  
AITL,	  NF-­‐κB	  expression	  was	  once	  again	  correlated	  with	  inferior	  overall	  survival,	  although	  the	  
number	  of	  patients	  was	  too	  low	  to	  reach	  statistical	  significance	  (Figure	  4.2	  C,	   log	  rank	  test,	  
p=0.153).	  ALCLs	  are	  usually	  subcategorized	  into	  ALK-­‐negative	  or	  ALK-­‐positive	  tumors,	  where	  
ALK-­‐positivity	   is	   associated	   with	   a	   favorable	   outcome	   and	   recently,	   ALK	   inhibitors	   are	  
emerging	   which	  might	   improve	   their	   outcome	   even	  more.	   Interestingly,	   NF-­‐κB	   was	   more	  
frequently	   activated	   in	   the	   ALK-­‐negative	   tumors	   (Figure	   4.2	   D,	   p=	   0.007)	   which	   are	  
characterized	   by	   an	   aggressive	   clinical	   course	   (Figure	   4.2	   E)	   and	   where	   novel	   treatment	  
strategies	  are	  needed.	  	  
	  
The	  observation	  that	  NF-­‐κB	  signaling	  is	  activated	  in	  a	  subset	  of	  T-­‐cell	   lymphomas	  with	  very	  


































Figure	  4.2.	  Impact	  of	  NF-­‐κB	  on	  overall	  survival	  in	  PTCL	  
A)	   Kaplan-­‐Meir	   analysis	   comparing	   the	  OS	   curves	   of	   48	   PTCL-­‐NOS	   and	   29	  AITL	   cases.	  No	   significant	  
difference	  in	  OS	  was	  observed	  between	  these	  subtypes	  (p=0.476).	  B)	  Kaplan-­‐Meir	  analysis	  in	  a	  series	  
of	   77	   PTCL	   cases	   comparing	   NF-­‐κB	   positive	   and	   negative	   tumors.	   NF-­‐κB	   was	   associated	   with	   a	  
significantly	  worse	  OS	   (p=0.003).	  C)	  Kaplan-­‐Meir	  analysis	  of	  24	  ALCL	  cases	  comparing	  NF-­‐κB	  positive	  
and	  negative	  tumors.	  NF-­‐κB	  positive	  cases	  presented	  a	  poorer	  OS,	  although	  statistical	  significance	  was	  
not	   archieved	   (p=0.153).	   D)	  NF-­‐κB	   expression	   in	   ALK	   positive	   and	  ALK	   negative	   ALCL	   tumors.	  NF-­‐κB	  
expression	  was	  more	   frequent	   in	   ALK	   negative	   tumors	   (p=0.007).	   AITL	   =	   Angioimmunoblastic	   T-­‐cell	  
lymphoma,	   PTCL-­‐NOS	   =	   Peripheral	   T-­‐cell	   lymphoma	   –	   Not	   otherwise	   specified,	   ALK	   =	   anaplastic	  
lymphoma	  kinase.	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Table	  4.2.	  Results	  from	  NF-­‐κB	  multivariate	  analysis	  
Variable	   p-­‐value	   Hazard	  ratio	  (CI	  95%)	  
NF-­‐κB	   0.047	   2.145	  (1.009-­‐4.560)	  
Age	   0.17	   1.860	  (0.767-­‐4.511)	  
Extranodal	  sites	   0.97	   1.018	  (0.401-­‐2.585)	  
LDH	   0.012	   2.890	  (1.268-­‐6.591)	  
ECOG	   0.451	   1.329	  (0.635-­‐2.783)	  
Stage	   0.993	   0.996	  (0.383-­‐2.587)	  




Table	  4.3.	  Results	  from	  multivariate	  analysis,	  including	  NF-­‐κB	  and	  IPI	  
Variable	   p-­‐value	   Hazard	  ratio	  (CI	  95%)	  
NF-­‐κB	   0.065	   1.820	  (0.964-­‐3.438)	  
IPI	   0.016	   1.378	  (1.061-­‐1.790)	  
Abbreviations:	  IPI	  =	  International	  Prognostic	  Index	  
	  
	  
4.3	  NIK	  expression	  in	  PTCL	  
	  
The	  NF-­‐κB	  inducing	  kinase,	  NIK,	  is	  involved	  in	  the	  activation	  of	  NF-­‐κB	  signaling	  in	  some	  cells	  
and	  settings	  and	  has	  been	  described	  as	  a	  molecular	  target	  for	  therapy	  in	  malignancies.	  Given	  
our	   observation	   that	   NF-­‐κB	   signaling	   is	   activated	   in	   a	   subset	   of	   T	   cell	   lymphomas	   and	  
associated	  with	  an	  aggressive	  phenotype,	  we	  wanted	  to	  examine	  whether	  NIK	  was	  involved	  
in	   NF-­‐κB	   activation	   in	   these	   tumors.	   Analyzing	   the	   expression	   levels	   of	   NIK	   by	   qPCR,	   we	  
observed	  a	   remarkable	  overexpression	  of	  NIK	  mRNA	   in	   several	  PTCL	  cell	   lines	  and	  primary	  
Sézary	   Syndrome	   samples	   (Figure	  4.3	  A	  and	  B).	   Sézary	   Syndrome	   is	   a	   leukemic	   subtype	  of	  
PTCL	   and	  was	   here	   used	   as	   a	  model	   since	   its	   neoplastic	   T	   cells	   easily	   can	   be	   purified	   and	  
extracted	  from	  the	  peripheral	  blood	  of	  the	  patient,	  in	  contrast	  to	  other	  PTCL	  subtypes.	  The	  
expression	  levels	  were	  compared	  with	  the	  expression	  of	  NIK	  in	  T	  lymphocytes	  from	  healthy	  
donors	  (Figure	  4.3	  A	  and	  B).	  To	  rule	  out	  the	  possibility	  that	  NIK	  expression	  is	  higher	  in	  tumor	  
cells	  due	  to	  an	  increased	  proliferation	  and	  hence	  transcriptional	  activity,	  healthy	  T	  cells	  were	  
induced	   to	   proliferate	   by	   the	   addition	   of	   interleukin	   2	   (IL2)	   and	   Concanavalin	   A	   (ConA).	  
Proliferating	   healthy	   T	   cells	   did	   not	   present	   any	   increase	   in	  NIK	   expression	   (Figure	   4.3	   C),	  
confirming	   that	   NIK	   overexpression	   is	   associated	   with	   malignant	   T	   cells.	   The	   cell	   lines	  
expressing	  high	  levels	  of	  NIK	  mRNA,	  also	  expressed	  elevated	  protein	  levels	  of	  NIK	  (Figure	  4.3	  
D).	   To	   obtain	   detectable	   levels	   of	   NIK	   proteins	   in	   cell	   lines,	   cells	   were	   treated	   with	   the	  
proteasome	   inhibitor	  MF-­‐132	   3	   hours	   prior	   to	   harvesting.	   It’s	   important	   to	   note,	   that	   this	  
was	  exclusively	  done	  in	  cells	  pelleted	  for	  NIK	  detection;	  the	  detection	  of	  all	  other	  proteins	  in	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this	  work	  is	  done	  in	  untreated	  cells.	  Immunohistochemistry	  on	  paraffin-­‐embedded	  cells	  was	  
used	   to	   assess	   the	  nuclear	   expression	  of	   the	  different	  NF-­‐κB	   factors	   in	   this	   panel	   of	   T	   cell	  
lymphoma	   cell	   lines	   (Table	   4.4).	   As	   NIK	   has	   been	   described	   as	   a	   regulator	   of	   mainly	   the	  
alternative	  pathway	  through	  the	   induction	  of	  p100	  processing	  and	  nuclear	  translocation	  of	  
p52,	   a	   clear	   correlation	   between	   NIK	   expression	   and	   p52	   was	   expected.	   Indeed,	   cells	  
expressing	  NIK	  also	  expressed	  nuclear	  p52	  and	   to	   less	  extent,	  RelB.	  Classical	  NF-­‐κB	   factors	  
were	  expressed	  both	  in	  NIK-­‐negative	  and	  NIK-­‐positive	  cell	  lines.	  	  
	  
While	  one	  of	  the	  NIK-­‐negative	  cell	  lines,	  DERL-­‐7,	  lacked	  nuclear	  expression	  of	  alternative	  NF-­‐
κB	   factors	   (p52	   and	  RelB),	   the	  other	   cell	   line	  with	   low	  NIK	   levels,	  HuT	   78,	   expressed	  both	  
Figure	  4.3.	  NIK	  expression	  in	  T	  cell	  lymphoma	  cell	  lines	  and	  samples.	  	  
A)	  RT-­‐qPCR	  analysis	  of	  NIK	  expression	  in	  PTCL	  cell	  lines	  showed	  variable	  expression	  of	  NIK	  as	  well	  as	  a	  
marked	  overexpression	   in	  some	  of	   the	  cell	   lines,	  compared	  with	  healthy	  T	  cells	   (Control	  1-­‐3).	  B)	  RT-­‐
qPCR	   analysis	   of	  NIK	   expression	   in	   isolated	   T	   cells	   from	   Sézary	   Syndrome	  patients	   (SS1-­‐SS5).	   C)	   RT-­‐
qPCR	  analysis	  of	  NIK	  expression	  in	  resting	  and	  proliferating	  healthy	  T	  cells.	  The	  T	  cells	  were	  induced	  to	  
proliferate	  by	  the	  addition	  of	  Interleukin-­‐2	  (IL-­‐2)	  and	  Concanavalin	  A	  (ConA).	  D)	  Western	  blot	  showing	  
NIK,	  p100	  and	  p105	  expression	  in	  T	  cell	  lymphoma	  cell	  lines.	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nuclear	  p52	  and	  RelB	  (Table	  4.4)	  To	  explain	  this	  finding,	  HuT	  78	  expresses	  a	  truncated	  form	  
of	   p100	   (Figure	   4.3	   D)	   which	   has	   previously	   been	   described	   to	   activate	   the	   alternative	  
pathway	  in	  a	  NIK-­‐independent	  manner	  (Thakur	  et	  al.	  1994).	  
	  
Table	  4.4	  Nuclear	  expression	  of	  NF-­‐κB	  in	  PTCL	  cell	  lines	  measured	  by	  
immunohistochemistry	  
	   p52	   RelB	   p50	   c-­‐Rel	   p65	  
My-­‐La	   +++	   +	   +++	   ++	   +	  
SR-­‐786	   +++	   +	   +++	   ++	   +	  
HuT	  78	   ++	   ++	   +++	   +	   +	  
DERL-­‐7	   -­‐	   -­‐	   +++	   +++	   +++	  
HH	   +++	   +	   +++	   +++	   ++	  
MJ	   +++	   ++	   +++	   +++	   ++	  
Note:	  The	  nucear	  expression	  of	  NF-­‐κB	  was	  categorized	  into	  strong	  (+++),	  medium	  (++),	  weak	  (+)	  or	  negative	  (-­‐).	  	  
	  
4.4	  TRAF3	  expression	  in	  PTCL	  cell	  lines	  	  
A	   common	  mechanism	   for	   NIK	   protein	   accumulation	   and	   activation	   is	   the	   lack	   of	   one	   or	  
several	  of	  the	  components	  in	  the	  protein	  complex	  responsible	  for	  NIK	  degradation.	  The	  most	  
frequently	   reported	  alteration	   is	   loss	  of	  TRAF3	  by	  genetic	  deletions	  or	  mutations.	   For	   that	  
reason,	  we	  analyzed	  the	  expression	  of	  TRAF3	  in	  our	  panel	  of	  PTCL	  cell	  lines,	  by	  western	  blot	  
(Figure	  4.4).	  Curiously,	  the	  levels	  of	  TRAF3	  are	  inversely	  correlated	  to	  the	  levels	  of	  NIK,	  and	  
My-­‐La	  and	  SR-­‐786	  cells	  lack	  expression	  of	  TRAF3	  or	  present	  very	  low	  TRAF3	  levels	  compared	  
to	  DERL-­‐7	  and	  HuT	  78.	  These	  results	  support,	  although	  do	  not	  confirm,	  a	  role	  for	  TRAF3	  as	  a	  
























Figure	   4.4	   Expression	   of	   TRAF3	   in	   T	   cell	  
lymphoma	  cell	  lines.	  	  
Western	   blot	   analysis	   of	   basal	   levels	   of	   TRAF3	  
protein.	   Cell	   lines	   expressing	   high	   levels	   of	   NIK	  
(My-­‐La	   and	   SR-­‐786)	   present	   strongly	   reduced	  
levels	  of	  TRAF3.	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4.5	  Pathways	  correlated	  with	  NIK	  expression	  in	  PTCL	  tumors	  	  
In	   order	   to	   detect	   NIK	   protein	   levels	   in	   primary	   PTCL	   samples,	   we	   tested	   a	   handful	   of	  
different	  NIK	  antibodies	  in	  paraffin-­‐embedded	  tissues,	  but	  none	  of	  these	  provided	  consistent	  
results.	  For	  that	  reason	  we	  used	  gene	  expression	  microarray	  data	  to	  compare	  the	  expression	  
of	  NIK	   (MAP3K14)	  with	   the	   expression	   of	  NF-­‐κB	   target	   genes	   (Compagno	   et	   al.	   2009)	   and	  
other	   biological	   pathways.	   Gene	   expression	   data	   from	   37	   PTCL	   samples	   (including	   the	  
subtypes	   PTCL-­‐NOS,	   AITL	   and	   ALCL)	   were	   used	   and	   to	   determine	   the	   gene	   sets	   that	   are	  
statistically	   correlated	   to	   NIK	   expression	   we	   performed	   a	   Gene	   Set	   Enrichment	   Analysis	  
(GSEA).	  This	  analysis	  revealed	  a	  significant	  and	  positive	  correlation	  between	  the	  expression	  
of	  NIK	  and	  NF-­‐κB	  target	  genes	  (Figure	  4.5),	  suggesting	  that	  NIK	  possibly	  is	  involved	  in	  NF-­‐κB	  
signaling	  in	  these	  tumors.	  	  
	  
	  
Other	  gene	  sets	  significantly	  correlated	  with	  the	  expression	  of	  NIK	  are	  listed	  in	  Table	  4.5,	  and	  
include	   CD40	   signaling,	   interleukin	   signaling,	   PI3K/AKT	   pathway,	   TCR	   signaling,	   MAPK	  
pathway	   and	   JAK/STAT	   signaling,	   among	   others	   (FDR<0.15).	   No	   gene	   set	   had	   a	   significant	  
Figure	  4.5	  GSEA	  enrichment	  plot.	  	  
The	  graph	   represents	  NF-­‐κB	   target	  genes	  positively	   correlated	  with	  NIK	  expression	   in	  37	  human	  
PTCL	   tumors.	   Pearson	   correlation	   analysis	   gives	   a	   FDR	   of	   0.093.	   FDR<	   0.15	   is	   considered	  
statistically	  significant	  
2
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negative	  correlation	  with	  NIK	  expression.	  The	  NF-­‐κB	  target	  genes	  that	  were	  correlated	  with	  
NIK	  expression,	  are	  also	  involved	  in	  many	  other	  signaling	  pathways,	  such	  as	  tumor	  necrosis	  
factor	  receptor	  2	  (TNFR2),	  interleukin	  2	  (IL-­‐2),	  interleukin	  1	  (IL-­‐1)	  and	  TNF-­‐	  and	  APOL-­‐related	  
leukocyte	  expressed	  ligand	  1	  (TALL1)	  pathway.	  These	  pathways	  also	  result	  in	  an	  activation	  of	  
NF-­‐κB,	  which	  might	  be	  the	  reason	  why	  these	  pathways	  appeared	  significant	  in	  our	  study.	  	  
	  
Table	  4.5	  Pathways	  positively	  correlated	  with	  NIK	  expression	  in	  PTCL	  
NAME	   NES	   FDR	  q-­‐val	   SIZE	  
CD40	  SIGNALING	  DURING	  GC	  DEVELOPMENT	   1.688	   0.090	   159	  
IL1R	  PATHWAY	   1.677	   0.091	   31	  
NFKB	  TARGET	  GENES	  	   1.642	   0.093	   111	  
EXTRINSIC	  APOPTOSIS	   1.690	   0.097	   78	  
IL2	  PATHWAY	   1.644	   0.098	   23	  
TALL1PATHWAY	   1.651	   0.101	   15	  
TNFR2	  PATHWAY	   1.934	   0.102	   18	  
T	  CELL	  CYTOKINE	  SIGNALING	   1.690	   0.106	   158	  
BLIMP-­‐1	  TARGETS	   1.601	   0.108	   153	  
APOPTOSIS	  SIGNALING	   1.614	   0.109	   109	  
B-­‐CELL	  ANERGY	   1.605	   0.111	   22	  
DEATH	  PATHWAY	   1.693	   0.112	   31	  
TCR	  PATHWAY	   1.737	   0.118	   43	  
PI3K/AKT	  SIGNALING	   1.575	   0.120	   34	  
NKT	  PATHWAY	   1.564	   0.121	   27	  
MAPK	  PATHWAY	   1.697	   0.123	   86	  
JAK-­‐STAT	  SIGNALING	  PATHWAY	   1.847	   0.133	   82	  
IL2RB	  PATHWAY	   1.698	   0.139	   35	  
BCELL-­‐TCELLCELL	  CALCIUM	  SIGNALING	   1.738	   0.140	   140	  
Note:	  Gene	  sets	  correlated	  with	  NIK	  expression	  in	  a	  series	  of	  37	  PTCL	  samples,	  analyzed	  by	  Gene	  Set	  
Enrichment	  Analysis,	  are	  presented	  (FDR<0.15).	  NES	  =	  Normalized	  Enrichment	  Score,	  FDR	  =	  False	  Discovery	  
Rate,	  SIZE	  =	  number	  of	  genes	  included	  in	  the	  gene	  sets.	  
	  
	  
4.6	  The	  role	  of	  NIK	  in	  NF-­‐κB	  signaling	  in	  T	  cell	  lymphomas	  
	  
NIK	   has	   been	   described	   to	   regulate	   the	   alternative	   axis	   of	   the	   NF-­‐κB	   pathway,	   through	  
phosphorylation	  of	   IKKα	  and	  subsequent	  p100	  processing,	  but	   its	   role	   in	  classical	   signaling	  
has	   been	   debated	   and	   seems	   to	   be	   signal-­‐	   and	   cell-­‐type	   specific.	   As	   expected,	   transient	  
overexpression	   of	   NIK	   in	   HEK-­‐293T	   cells	   led	   to	   increased	   levels	   of	   p52,	   indicating	   an	  
activation	   of	   the	   alternative	   axis	   (Figure	   4.6	   A).	   On	   the	   other	   hand,	   the	   levels	   of	   p50	  
remained	  unchanged.	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For	  the	   functional	  assays	  aiming	  to	  study	  the	  role	  of	  NIK	   in	  T	  cell	   lymphoma	  cells,	   two	  cell	  
lines	   presenting	   high	   NIK	  mRNA	   and	   protein	   levels	   (My-­‐La	   and	   SR-­‐786)	   and	   two	   cell	   lines	  
with	   low	  NIK	  mRNA	   levels	  and	  absent	  protein	  expression	   (DERL-­‐7	  and	  HuT	  78),	  were	  used	  
throughout	   the	   study.	   To	   knock	   down	  NIK	   and	   other	   genes	   in	   these	   cells,	  we	   used	   siRNA	  
transfection	  by	  microporation,	  which	  gave	  us	   reproducible	  and	  effective	  gene	  knockdown,	  
which	   lasted	   for	   approximately	   4-­‐5	   days.	   Stable	   knockdown	   using	   a	   handful	   of	   different	  
lentiviral	   and	   retroviral	   constructs	   and	   techniques	   was	   also	   performed	   but	   all	   with	   an	  
insufficient	  knockdown	  efficiency	  in	  these	  lymphoid	  cell	  lines,	  which	  are	  difficult	  to	  transfect	  
or	  infect.	  	  
	  
We	  knocked	  down	  NIK	  in	  two	  PTCL	  cell	  lines,	  My-­‐La	  and	  SR-­‐786,	  and	  analyzed	  the	  expression	  
of	   downstream	   targets.	  We	   used	   two	   different	   siRNA	   sequences	   (siNIK1	   and	   siNIK2)	   that	  
induced	  different	  levels	  of	  knockdown	  efficiencies	  (siNIK2	  always	  having	  a	  higher	  knockdown	  
efficieny	   than	   siNIK1,	   Figure	   4.6	   B),	   allowing	   us	   to	   study	   the	   effect	   of	   a	   dose-­‐dependent	  
decrease	   in	  NIK.	  As	  expected,	   the	   levels	  of	  p52	  were	  reduced	  and	  the	   levels	  of	  p100	  were	  
initially	  (at	  24	  hours)	  increased	  after	  NIK	  knockdown	  compared	  with	  cells	  transfected	  with	  a	  
non-­‐templated	   control	   (siNTC),	   indicating	   an	   attenuation	   of	   p100	   processing.	   We	   also	  
observed	   a	   similar	   but	   somewhat	   delayed	   decrease	   of	   p50	   levels	   and	   an	   increase	   of	   the	  
levels	  of	  p105,	  linking	  NIK	  to	  the	  regulation	  of	  classical	  NF-­‐κB	  activation	  as	  well	  (Figure	  4.6	  B	  
and	   C).	   To	   ensure	   that	   the	   levels	   of	   NF-­‐κB	   did	   not	   remain	   unchanged	   in	   the	   nucleus,	   we	  
analyzed	  the	  nuclear	  cell	  fraction	  for	  these	  proteins	  and	  observed	  that	  indeed,	  nuclear	  levels	  
of	  both	  p50	  and	  p52	  were	  also	  decreased	  after	  NIK	  knockdown	   (Figure	  4.7	  A).	   To	   confirm	  
that	   the	   reduction	  of	  NF-­‐κB	  observed	  corresponded	  to	  a	   reduction	  of	  active	  NF-­‐κB,	  and	   to	  
analyze	  the	  effect	  of	  the	  rest	  of	  NF-­‐κB	  members	  as	  well	  (c-­‐Rel,	  p65	  and	  RelB),	  we	  analyzed	  
the	   NF-­‐κB	   DNA-­‐binding	   activity	   after	   NIK	   knockdown,	  measured	   by	   TransAM	   ELISA	   assay.	  
Interestingly,	   we	   could	   observe	   a	   decrease	   in	   the	   activity	   of	   all	   five	   transcription	   factors	  
(Figure	  4.7	  B)	  upon	  NIK	  depletion.	  These	  results	  confirm	  the	  role	  of	  NIK	  as	  an	  alternative	  NF-­‐
κB	  regulator,	  but	  also	  support	  a	  role	  for	  NIK	  in	  the	  regulation	  of	  classical	  NF-­‐κB	  activation	  in	  
PTCL.	  
Results	  II	  	  
	   81	  
	  
	   	  
Figure	  4.6	  The	  role	  of	  NIK	  in	  NF-­‐κB	  signaling.	  	  
A)	  NIK	  (MAP3K14)	  was	  overexpressed	  in	  293T	  cells	  and	  downstream	  p52	  and	  p50	  levels	  were	  observed	  by	  
western	  blot.	  B)	  NIK	  was	  knocked	  down	  using	  2	  siRNAs	  (siNIK1	  and	  siNIK2)	  or	  a	  NTC	  (siNTC)	  in	  My-­‐La	  and	  SR-­‐
786.	  After	  NIK	  knockdown,	  the	  expression	  of	  NIK,	  p100/p52,	  and	  p105/p50	  was	  analyzed	  by	  Western	  blot	  
analysis.	  C	  and	  D)	  Quantification	  of	  the	  immunoblots	  confirms	  a	  decrease	  in	  the	  levels	  of	  both	  p50	  and	  p52	  
after	  NIK	  knockdown.	  The	  data	  are	  represented	  as	  the	  mean	  and	  standard	  derivation	  (SD)	  of	  3	  independent	  
experiments.	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p52 and p50 expression in My-La after NIK knockdown 
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4.7	  The	  effect	  of	  NIK	  on	  PTCL	  cell	  survival	  
	  
Since	  we	  have	  shown	  that	  NF-­‐κB	  and	  NIK	  are	  overexpressed	  in	  a	  subset	  of	  T	  cell	  lymphomas	  
and	  that	  NIK	  acts	  as	  a	  central	  regulator	  of	  NF-­‐κB	  activation	  in	  these	  cells,	  we	  asked	  whether	  
NIK	  had	  any	  effect	  on	  cell	  viability.	  To	  assess	  how	  NIK	  knockdown	  affected	  PTCL	  cell	  viability,	  
we	  measured	  Annexin	  V	  and	  DAPI	  by	  flow	  cytometry	  and	  estimated	  the	  cell	  death	  induced	  at	  
different	   time	   points	   after	   NIK	   knockdown.	   Interestingly,	   in	   My-­‐La	   and	   SR-­‐786	   T	   cell	  
lymphoma	  cells,	  NIK	  knockdown	  led	  to	  a	  dramatic	  increase	  in	  cell	  death	  compared	  with	  non-­‐
template	   control	   (NTC)	   transfected	   cells	   (Figure	   4.8	   A).	   The	   cell	   death	   observed	   after	   NIK	  
knockdown	  increased	  as	  knockdown	  became	  more	  efficient	  with	  siNIK2.	  The	  appearance	  of	  
cleaved	  caspase	  3	  and	  cleaved	  poly	  (ADP-­‐ribose)	  polymerase	  1	  (PARP)	  after	  NIK	  knockdown	  	  
in	  both	  My-­‐La	  and	  SR-­‐786,	  indicates	  an	  induction	  of	  a	  caspase-­‐dependent	  apoptotic	  pathway	  
as	   a	   result	   of	   NIK	   depletion	   (Figure	   4.8	   B).	   To	   study	   the	   effect	   of	   NIK	   knockdown	   over	   a	  
longer	   period,	   we	   repeated	   the	   siRNA	   transfection	   4	   days	   after	   the	   first	   microporation.	  
Strikingly,	  after	  1	  week	  of	  NIK	  depletion,	  nearly	  all	   cells	   (98.8	  %)had	  undergone	  apoptosis,	  
demonstrating	   the	  essential	   role	  of	  NIK	   in	   the	  viability	  of	   these	   tumor	   cells	   (Figure	  4.9	  A).	  
Importantly,	  NIK	  silencing	   in	  DERL-­‐7	  or	  HuT	  78	  cell	   lines,	  presenting	   low	  NIK	   levels,	  had	  no	  
effect	  on	  cell	  survival	  (Figure	  4.9	  B).	  	  
Figure	   4.7	   Effect	   of	   NIK	   knockdown	   on	   NF-­‐κB	  activity.	   A)	   Nuclear	   levels	   of	   p52	   and	   p50	   after	   NIK	  
knockdown.	  Numbers	  indicate	  quantification	  of	  the	  band	  intensity,	  normalized	  to	  the	  loading	  control	  
and	  as	  a	  ratio	  to	  the	  non-­‐template	  control	  (NTC).	  B)	  DNA-­‐binding	  activity	  of	  p52,	  RelB,	  p50,	  p65,	  and	  c-­‐
Rel	  48	  hours	  after	  NIK	  knockdown	  was	  measured	  (in	  triplicate)	  using	  the	  ELISA-­‐based	  TransAM	  assay	  
and	  reveals	  a	  reduction	  of	  classical	  and	  alternative	  NF-­‐κB	  activation.	  The	  graph	  represent	  the	  mean	  +/-­‐	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Figure	  4.8.	  The	  effect	  of	  NIK	  knockdown	  on	  PTCL	  cell	  survival.	  	  
A)	   NIK	   knockdown	   (siNIK)	   induces	   cell	   death	   in	   My-­‐La	   and	   SR-­‐786	   cells	   compared	   with	  
untransfected	  (MOCK)	  or	  non-­‐template-­‐transfected	  (siNTC)	  cells,	  as	  measured	  by	  flowcytometry	  
using	  DAPI	   and	  AnnexinV	   staining	   96	  hours	   after	   transfection.	   The	  data	   are	   represented	   as	   the	  
mean	   +	   SD	   of	   3	   independent	   knockdown	   experiments.	   B)	   Detection	   of	   cleaved	   Caspase-­‐3	   and	  
PARP	  after	  NIK	  depletion	   in	  both	  MyLa	  and	  SR-­‐786	  cells.	  *	   indicates	  p	  <	  0.05	  and	  **	  means	  p	  <	  
0.01.	  	  
Figure	  4.9.	  Cell	  	  viability	  after	  NIK	  knockdown	  in	  PTCL	  cells.	  	  
A)	   Only	   1.26%	   of	   cells	   remain	   viable	   7	   days	   after	   NIK	   knockdown	   in	   My-­‐La	   (DAPI/AnnexinV–
negative).	   B)	   Increase	   in	   cell	   death	   in	   cell	   lines	   with	   high	   (My-­‐La	   andSR-­‐786)	   or	   low	   (HuT	   78	  
andDERL-­‐7)	   NIK	   expression,	   represented	   as	   the	   ratio	   between	   the	   values	   of	   cell	   death	   in	   NIK	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To	   confirm	   the	   cell	   killing	   effect	   of	  NIK	   depletion	   using	   another	   approach,	  we	   transfected	  
My-­‐La	   cells	   with	   a	   dominant	   negative	   form	   of	   NIK,	   NIK	   (KK/AA)	   (Malinin	   et	   al.	   1997),	  
presenting	   two	  point	  mutations	   in	   the	  kinase	  domain,	   that	  abolish	   its	   kinase	  activity.	   	   The	  
expression	  of	  NIK	  (KK/AA)	   in	  My-­‐La	  cells	  also	  resulted	   in	  a	  significant	   increase	   in	  cell	  death	  
compared	  with	  cells	  transfected	  with	  a	  control	  vector	  (Figure	  6.10).	  	  
	  
These	  results	  indicate	  that	  NIK	  is	  necessary	  for	  cell	  survival	  of	  NIK-­‐overexpressing	  PTCL	  cells	  
and	   suggest	   that	  NIK	   targeting	  has	   a	   selective	  effect	  only	  on	   the	   cells	   presenting	  elevated	  




To	  investigate	  whether	  NIK	  apart	  from	  affecting	  cell	  survival,	  also	  gave	  rise	  to	  any	  cell	  cycle	  
perturbations,	  we	  analyzed	  the	  fraction	  of	  cells	  in	  each	  phase	  of	  the	  cell	  cycle	  in	  control	  and	  
NIK-­‐knockdown	  My-­‐La	   cells	   by	   propidium	   iodide	   staining	   and	   flow	   cytometry.	   Figure	   4.11	  
shows	  that	  no	  major	  changes	  in	  cell	  cycle	  distribution	  were	  induced	  by	  NIK	  silencing,	  apart	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Figure	  4.10	  NIK	  dominant	  negative	  expression	  in	  My-­‐La.	  	  
A)	   Expression	   of	   	   NIK	   dominant	   negative,	   NIK	   (KK/AA)	   after	   transfection	   in	  My-­‐La	   cells.	   B)	   Cell	  
death	   induced	   in	  My-­‐La	  48	  hours	  after	  NIK	   (KK/AA)	   transfection.	  Cell	   viability	  was	  measured	  by	  
DAPI/AnnexinV-­‐staining	  by	  flow	  cytometry.	  **	  indicates	  p<0.01	  as	  a	  result	  of	  a	  Student´s	  t-­‐test.	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4.8	  Knockdown	  of	  other	  members	  of	  the	  NF-­‐κB	  pathway	  in	  
PTCL	  
	  
4.8.1	  IKKβ	  and	  IKKα	  knockdown	  	  
The	   IKKs	   are	   upsteam	   kinases	   in	   the	   NF-­‐κB	   cascade	   and	   are	   central	   regulators	   of	   its	  
activation.	   The	   IKK	   complex	   phosphorylates	   the	   IκB	   proteins,	   leading	   to	   the	   liberation	   of	  
sequestered	   NF-­‐κB	   dimers	   and	   thus	   permitting	   their	   nuclear	   translocation.	   IKKα	   is	   the	  
subunit	   of	   the	   IKK	   complex	   that	   is	   responsible	   and	   required	   for	   the	   activation	   of	   the	  
alternative	  pathway,	  while	  IKKβ	  is	  needed	  for	  activation	  of	  the	  classical	  pathway.	  Inhibition	  
of	   either	   IKKβ	   or	   IKKα	   has	   frequently	   been	   employed	   to	   selectively	   block	   the	   classical	   or	  
alternative	  NF-­‐κB	  axis.	  Furthermore,	  pharmacological	  inhibition	  of	  IKKβ	  with	  small	  molecule	  
inhibitors	  has	  been	  widely	  used	  in	  pre-­‐clinical	  models	  as	  a	  therapeutic	  option	  in	  a	  range	  of	  
different	  tumors,	  but	   its	  use	   in	  the	  clinic	  has	  not	  been	  proven	   (Lam	  et	  al.	  2005;	  Sors	  et	  al.	  
2008;	  Liu	  et	  al.	  2012).	  	  
	  
NIK	  can	  phosphorylate	  and	  activate	  IKKα,	  but	  IKKβ	  might	  also	  be	  a	  target	  for	  NIK	  mediated	  
phosphorylation	   under	   some	   circumstances	   (Woronicz	   et	   al.	   1997).	   In	   fact,	  measuring	   the	  
levels	   of	   phosphorylated	   IKK	   after	   NIK	   knockdown	   in	   My-­‐La	   cells,	   a	   reduction	   in	   both	  





















Figure	  4.11	  Cell	  cycle	  analysis	  after	  NIK	  knockdown.	  	  
The	  fraction	  of	  cells	  in	  each	  phase	  of	  the	  cell	  cycle	  24,	  48	  and	  72h	  after	  NIK	  knockdown	  in	  My-­‐La	  
cells.	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To	  rule	  out	  whether	  the	  toxicity	  of	  NIK	  knockdown	  was	  due	  to	  a	  blockade	  of	  the	  classical	  or	  
alternative	  NF-­‐κB	  pathway,	  we	  knocked	  down	  either	  IKKα,	  IKKβ,	  or	  both,	  in	  T	  cell	  lymphoma	  
cell	   lines	   (Figure	  4.12	  B	  and	  C).	  As	   can	  be	  observed	   in	  Figure	  4.12	  D	  and	  E,	  both	   IKKα	  and	  
IKKβ	  knockdown	  led	  to	  an	  increase	   in	  apoptosis.	  However,	  the	  effect	  on	  apoptosis	  was	  mild,	  
compared	  to	  NIK	  knockdown	  that	  gave	  rise	  to	  a	  considerably	  more	  potent	  cell	  killing	  effect.	  



































siNTC + - - - - - - + - - - - - -
siIKK ɲ - 1 2 - - 2 - - 1 2 - - 2 -
siIKK ɴ - - - 1 2 2 - - - - 1 2 2 -














































Figure	  4.12.	  Knockdown	  of	  IKKα	  and	  IKKβ	  in	  T	  cell	  lymphomas.	  	  
A)	  Expression	  of	  phosphorylated	  IKKα	  and	  IKKβ	  after	  NIK	  knockdown	  in	  My-­‐La	  cells.	  B)	  Knockdown	  of	  
IKKα,	   IKKβ	   or	   NIK	   in	   My-­‐La	   cells	   and	   analysis	   of	   downstream	   signaling	   72	   and	   96	   hours	   after	  
transfection.	  C)	  IKKα	  and	  IKKβ	  knockdown	  in	  SR-­‐786	  cells	  96	  hours	  after	  transfection.	  D)	  Estimation	  of	  
cell	   death	   in	   My-­‐La	   cells	   96	   hours	   after	   transfection.	   E)	   Cell	   death	   in	   SR-­‐	   786	   cells	   96	   hours	   after	  
transfection.	  Graphs	  represent	  means	  +SD	  from	  three	  independent	  experiments.	  *p<0.05,	  **p<0.01.	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knockdown	  of	  only	  one	  of	  the	  kinases,	  suggesting	  that	  blocking	  both	  kinases	  simultaneously	  
might	  be	  an	  advantage	  (Figure	  4.12	  D	  and	  E,	  using	  the	  combination	  of	  siIKKα	  2	  and	  siIKKβ	  2).	  
However,	   even	   the	   combined	   knockdown	   of	   both	   IKKα	   and	   IKKβ	   still	   had	   a	   much	   milder	  
effect	  on	  cell	  survival	  than	  had	  NIK	  knockdown.	  Reduced	  levels	  of	  both	  IKKα	  and	  IKKβ	  can	  be	  
seen	  after	  NIK	  knockdown	  (Figure	  4.12	  B),	  but	  interestingly,	  only	  the	  knockdown	  of	  NIK,	  but	  
not	  the	  knockdown	  of	  IKK,	  was	  able	  to	  strongly	  reduce	  the	  levels	  of	  p52	  and	  p50	  (Figure	  4.12	  
B).	   These	  results	  suggest	  that	  NIK-­‐induced	  survival	  signaling	  as	  well	  as	  NIK-­‐regulated	  NF-­‐κB	  
activation,	   at	   least	   in	   part,	   might	   be	   IKK-­‐independent	   mechanisms	   in	   these	   cells.	   Thus,	  
targeting	   NIK	   would	   be	   a	   more	   effective	   way	   to	   shut	   off	   NF-­‐κB	   activity	   and	   to	   induce	  
apoptosis	  than	  IKK	  inhibition	  in	  these	  tumor	  cells.	  
	  	  
4.8.2	  Knockdown	  of	  individual	  NF-­‐κB	  transcription	  factors	  	  
To	  explore	  whether	  any	  particular	  NF-­‐κB	  transcription	   factor	  was	  responsible	   for	  providing	  
survival	   signals	   in	   T	   cell	   lymphoma	   cells,	   we	   used	   siRNAs	   to	   knock	   down	   the	   NF-­‐κB	  
transcription	   factors	   that	  were	   seen	  highly	   expressed	   in	  human	  T	   cell	   lymphoma	   samples:	  
p52,	  p50,	  RelB	  and	  c-­‐Rel.	  All	  of	  these	  four	  transcription	  factors	  were	  silenced	  in	  the	  two	  NIK	  
overexpressing	  cell	   lines	  (My-­‐La	  and	  SR-­‐786,	  Figure	  4.13	  A)	  using	  three	  different	  siRNAs	  for	  
each	  gene.	  Measuring	  cell	  viability	  by	  AnnexinV	  and	  DAPI	  staining	  by	  flow	  cytometry	  (Figure	  
4.13	   B)	   96	   hours	   after	   tranfection,	   we	   observed	   that	   the	   apoptotic	   effect	   of	   silencing	   an	  
individual	  NF-­‐κB	  factor	  was	  minimal.	  Of	  the	  four	  transcription	  factors,	  only	  the	  knockdown	  
of	   c-­‐Rel	   gave	   rise	   to	   a	   significant	   increase	   in	   apoptosis	   (t-­‐test	   between	   NTC	   and	   siCREL,	  
p<0.05).	  Neither	  the	  knockdown	  of	  p52	  or	  RelB,	  or	  the	  combined	  depletion	  of	  both	  p52	  and	  
RelB,	   were	   able	   to	   reduce	   cell	   viability	   (Figure	   4.13	   C),	   suggesting	   that	   the	   reduction	   of	  
alternative	  NF-­‐κB	  activity	  alone	  is	  not	  sufficient	  to	  induce	  apoptosis	  in	  these	  cells.	  Combined	  
knockdown	  of	  p50	  and	  p52	  was	  not	  able	  to	  reduce	  tumor	  cell	  viability	  either	  (Figure	  4.13	  C).	  
Interestingly,	   the	   activity	   of	   c-­‐Rel	   transcription	   factor	   seems	   to	   be	   important	   for	   T	   cell	  
lymphoma	  survival.	  	  In	  My-­‐La	  cells,	  the	  reduction	  of	  c-­‐Rel	  levels	  led	  to	  a	  3-­‐	  to	  5-­‐fold	  increase	  
in	   cell	   death	   (Figure	   4.13	   B).	   The	   effect	   in	   SR-­‐786	   cells	  was	  milder	   (2-­‐fold	   increase	   in	   cell	  
death),	   probably	   due	   to	   the	   lower	   knockdown	   efficiency	   of	   c-­‐Rel	   in	   this	   cell	   line,	   where	  
significant	   levels	  of	  protein	  are	  still	  present	  after	   the	  knockdown	  (Figure	  4.13	  A).	  We	  have	  
already	   shown	   that	   NIK	   knockdown	   led	   to	   a	   reduced	   activity	   of	   c-­‐Rel	   (Figure	   4.7	   B).	  
Immunoflourescence	   staining	   of	   c-­‐Rel	   in	  My-­‐La	   cells	   confirms	   a	   reduction	   of	   nuclear	   c-­‐Rel	  
expression	  after	  NIK	  knockdown	  (Figure	  4.13	  C).	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Cleaved	  caspase	  3	   is	  expressed	  after	  c-­‐Rel	  knockdown	   in	  T	  cell	   lymphoma	  cells,	  confirming	  
the	  induction	  of	  apoptosis	  (Figure	  4.13	  D).	  DERL-­‐7	  and	  HuT	  78	  are	  NIK-­‐negative	  cell	  lines	  that	  
express	  nuclear	  c-­‐Rel.	  We	  asked	  whether	  c-­‐Rel	  was	  required	  for	  survival	  in	  these	  cells	  as	  well.	  
However,	  knockdown	  of	  c-­‐Rel	  in	  these	  cell	  lines	  did	  not	  affect	  cell	  viability,	  indicating	  that	  c-­‐
Figure	  4.13	  Knockdown	  of	  different	  NF-­‐κB	  members	  in	  PTCL	  cells.	  	  
A)	  siRNA	  knockdown	  of	  p52/p100,	  p50/p105,	  RelB	  and	  c-­‐Rel	   in	  My-­‐La	  and	  SR-­‐786	  cells	  96	  hours	  
after	   transfection.	   B)	   Cell	   viability	   assay	   96	   hours	   after	   siRNA	   transfection.	   C)	   Estimation	   of	   cell	  
death	  after	   the	   combined	  knockdown	  of	  p52	  and	  RelB,	  or	  p52	  and	  p50	   in	  My-­‐La	   cells	   96	  hours	  
after	  transfection.	  D)	  Immunoflourescence	  staining	  of	  c-­‐Rel	  48	  hours	  after	  NIK	  knockdown	  in	  My-­‐
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Rel	  regulate	  different	  processes	   in	  different	  contexts	  and	   is	  not	  always	  necessary	   for	  T	  cell	  
survival	   (Figure	   4.14).	   Surprisingly,	   knocking	   down	   p100/p52	   in	   HuT	   78,	   the	   cell	   line	  
expressing	   an	   oncogenic	   truncated	   p100	   protein,	   did	   not	   induce	   cell	   death	   either	   (Figure	  
4.14	  B).	  	  
	  
Taken	  together,	  these	  results	  suggest	  that	  c-­‐Rel	  is	  important	  for	  survival	  of	  T	  cell	  lymphoma	  
cells	   and	   the	   reduction	   of	   c-­‐Rel	   could	   be	   responsible	   for	   part	   of	   the	   cell	   killing	   effect	  
observed	  after	  NIK	  silencing.	  However,	  NIK	  depletion	  still	  has	  a	  more	  drastic	  and	  profound	  
effect	   on	   T	   cell	   lymphoma	   cell	   viability	   and	   cannot	   solely	   be	   confined	   to	   the	   effect	   of	   a	  





4.9	  Changes	  in	  gene	  expression	  after	  NIK	  knockdown	  	  
To	   gain	   a	   better	   insight	   into	   the	   mechanisms	   involved	   in	   NIK-­‐dependent	   survival,	   we	  
analyzed	  the	  gene	  expression	  profile	  induced	  by	  NIK	  silencing	  in	  T	  cell	  lymphoma	  cells.	  Using	  
whole	   genome	   microarray	   analysis,	   we	   explored	   the	   impact	   of	   NIK	   silencing	   on	   the	  
expression	   of	   genes	   and	   pathways	   in	  My-­‐La	   and	   SR-­‐786	   cells	   48	   hours	   after	   transfection.	  
Three	  independent	  experimental	  replicates	  were	  performed	  for	  each	  cell	  line	  and	  siRNA,	  and	  
knockdown	   efficiencies	   from	   each	   experiment	   are	   shown	   in	   Supplementary	   figure	   1	   (in	  
Appendix	  I).	  For	  pathway	  analysis,	  Gene	  Set	  Enrichment	  Analysis	  applying	  a	  t-­‐test	  comparing	  
siNIK1	   and	   siNIK2	   with	   control	   cells	   was	   performed.	   The	   gene	   sets	   significantly	   lost	  
Figure	  4.14	  Knockdown	  of	  c-­‐Rel	  and	  p100/p52	  in	  DERL-­‐7	  and	  HuT	  78.	  	  
A)	  Percentages	  of	  dead	  DERL-­‐7	  and	  HuT	  78	  cells	  96	  hours	  after	  c-­‐Rel	  silencing.	  B)	  Cell	  viability	  and	  



















































Results	  II	  	  
	  90	  
(FDR<0.15)	  in	  the	  siNIK	  cells,	  and	  thus	  enriched	  in	  the	  control	  cells,	  are	  described	  in	  Table	  4.6.	  
No	   gene	   set	   was	   significantly	   upregulated	   after	   NIK	   knockdown.	   The	   NF-­‐κB	   target	   genes	  
were	  significantly	  underrepresented	  after	  NIK	  knockdown	  in	  both	  cell	  lines,	  indicating	  again	  
a	   pivotal	   role	   for	   NIK	   in	   NF-­‐κB	   activation	   (Figure	   4.15	   A).	   Other	   gene	   sets	   that	   were	  
underrepresented	   after	   NIK	   depletion,	   were	   X-­‐box	   binding	   protein	   1	   (XBP1)	   target	   genes,	  
interleukin	  pathways,	  JAK-­‐STAT	  signaling	  and	  BCL6	  target	  genes.	  	  
	  
	  
Table	  4.6	  Gene	  sets	  enriched	  in	  control	  cells	  after	  NIK	  knockdown	  	  
MYLA	  
Gene	  Set	   NES	   FDR	   Size	   Genes	  in	  core	  enrichment	  
XBP1	  
TARGETS	   -­‐2.133	   0.001	   58	  
SSR3,	  RPN1,	  FTSJ1,	  ITGAM,	  SSR1,	  PDIA4,	  SPCS3,	  GLRX,	  
SLC33A1,	  DNAJC10,	  SYVN1,	  LMAN1,	  TMED10,	  HM13,	  
PDIA5,	  ARF3,	  SEC24C,SPOP,	  SLC3A2,	  SEC23B,	  FKBP14,	  




-­‐1.977	   0.004	   106	  
ICAM1,	  BCL2L1,	  EMR1,	  SDC4,	  NFKBIA,	  HLA-­‐F,	  IL6,	  
TNFAIP3,	  CD44,	  PLEK,	  STAT5A,	  VIM,	  LTA,	  CFLAR,	  STX4,	  
SMAD7,	  CD40LG,	  BUB1B,	  PRKCD,	  CEP110,	  BIRC3,	  
STAT1,	  CCL3,	  IRF1,	  FNDC3A,	  CD83,	  GADD45B,	  CCND2,	  
REL,	  FAS,	  RRAS2,	  LSP1,	  ELL2,	  IER2,	  MAP3K1,	  RFTN1,	  




-­‐1.757	   0.053	   75	  
AURKA,	  KIF2C,	  SKP2,	  TOP2A,	  MDC1,	  BUB1,	  CCNH,	  
BUB1B,	  CUL1,	  BRSK1,	  CCNB3,	  MDM2,	  CENPA,	  
GADD45B,	  UBD,	  BUB3,	  IRF5,	  CDC20,	  PRC1,	  TTK,	  
ZC3HC1,	  HMMR,	  STIL,	  CDC16,	  CENPF,	  CCNF,	  PRKDC,	  
PLK1,	  BRCA1,	  CDC6,	  CDKN2D,	  CHEK2,	  CCNB1,	  SFN,	  
BIRC5,	  CDC34,	  KIF11	  
IL3PATHWAY	   -­‐1.664	   0.094	   15	   MAP2K1,	  IL3RA,	  STAT5A,	  STAT5B,	  MAPK3,	  CSF2RB,	  IL3	  
SR786	  
Gene	  Set	   NES	   FDR	  	   Size	   Genes	  in	  core	  enrichment	  
XBP1	  
TARGETS	   -­‐2.098	   0.001	   58	  
SSR3,	  ISG20,	  GLRX,	  DNAJC10,	  FKBP14,	  SLC33A1,	  
SRP54,	  PDIA4,	  LMAN1,	  SPCS3,	  PDIA3,	  PDIA5,	  SPOP,	  
PPIB,	  SLC3A2,	  ARF3,	  DAD1,	  HSP90B1,	  RPN1,	  RHOQ,	  








-­‐1.738	   0.056	   106	  
CD44,	  ID2,	  IL6,	  ICAM1,	  EMR1,	  SPI1,	  STAT5A,	  BIRC2,	  
TNFAIP3,	  GADD45B,	  IER2,	  CCL3,	  STX4,	  STAT1,	  LTA,	  
RFTN1,	  NFKBIA,	  CFLAR,	  VIM,	  PLEK,	  CD40LG,	  CSF2,	  
BCL2A1,	  HLA-­‐F,	  RET,	  BANK1,	  IL10,	  SDC4,	  JUNB,	  TNF,	  
BIRC3,	  NFKB2,	  PRKCD,	  NFKB1,	  SMAD7,	  FNDC3A,	  
SLAMF7	  
BCL6	  
TARGETS	   -­‐1.592	   0.148	   17	  
CD44,	  ID2,	  CCL3,	  STAT1,	  CD80,	  NFKB1,	  CDKN1B,	  
CCND2,	  IFITM3,	  CDKN1A	  
IL7	  PATHWAY	   -­‐1.564	   0.146	   15	   IL7,	  STAT5A,	  STAT5B	  
Abbreviations:	  NES	  =	  Normalized	  Enrichment	  Score,	  FDR	  =	  False	  Discovery	  Rate,	  Size	  =	  number	  of	  gene	  in	  the	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Figure	  4.15	  Gene	  expression	  profile	  after	  NIK	  knockdown.	  	  
Whole	   genome	  microarray	   analysis	  was	   conducted	   48	  hours	   after	  NIK	   knockdown	   in	  My-­‐La	   and	   SR-­‐
786.	  A)	  GSEA	  enrichment	  plot	   of	   the	  NF-­‐κB	   target	   genes.	   The	  NF-­‐κB	   target	   genes	  were	   significantly	  
underrepresented	   in	   the	  NIK	  knockdown	  cells.	  B)	  Heatmaps	  of	  differentially	  expressed	  genes	   (FDR	  <	  
0.05	  and	  log2	  fold	  change	  >	  0.6)	  between	  control	  and	  NIK	  knockdown	  cells.	  The	  numbers	  on	  top	  of	  the	  
heatmap	   represent	   the	   sequence	   of	   siNIK	   used	   (1	   or	   2)	   in	   a	   particular	   experiment.	   Negative	   log2	  
foldchanges	  (ratio	  siNIK/control)	  are	  represented	  in	  green	  (downregulation	  in	  siNIK	  cells)	  and	  positive	  
fold	  changes	  are	  represented	  in	  red	  (upregulation	  in	  siNIK	  cells).	  C)	  Venn	  diagram	  showing	  the	  overlap	  
of	  differentially	  expressed	  genes	   in	  My-­‐La	  and	  SR-­‐786	  cells.	  D)	  Relative	  gene	  expression	   in	  siNIK	  cells	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Analyzing	  the	  altered	  gene	  expression	  induced	  by	  NIK	  at	  the	  individual	  gene	  level,	  a	  paired	  t-­‐
test	   revealed	   395	   genes	   in	   My-­‐La,	   and	   94	   genes	   in	   SR-­‐786,	   that	   were	   significantly	   and	  
differentially	  expressed	  (FDR<0.05	  and	  log2	  foldchange	  >0.6	  in	  either	  direction)	  between	  NIK	  
knockdown	  and	  control	  cells	  (Figure	  4.15	  B,	  see	  Supplementary	  Table	  1	  (Appendix	  I)	  for	  the	  
complete	   list	   of	   genes).	   Of	   these	   genes,	   77	   were	   common	   between	   My-­‐La	   and	   SR-­‐786	  
(Figure	  4.15	  C).	  This	  number	  might	  seem	  low,	  but	  having	  in	  mind	  that	  SR-­‐786	  only	  presented	  
94	   significantly	   differentially	   expressed	   genes,	   this	   means	   that	   82%	   of	   the	   differentially	  
expressed	   genes	   in	   SR-­‐786	   were	   shared	   by	   My-­‐La.	   RT-­‐qPCR	   was	   performed	   on	   selected	  
genes	  to	  validate	  the	  gene	  expression	  data	  (Figure	  4.15	  C	  and	  D).	  Several	  NF-­‐κB	  target	  genes	  
involved	   in	   cancer	   cell	   survival	   were	   downregulated	   upon	   NIK	   silencing,	   such	   as	   the	  
antiapoptotic	  BCL2L1	  (Bcl-­‐x(L))	  and	  CFLAR	  (c-­‐FLIP)	  as	  well	  as	  several	  interleukins.	  Interleukin	  
6	  (IL-­‐6)	  and	  interleukin	  21	  (IL-­‐21)	  are	  cytokines	  with	  known	  functions	  in	  cell	  proliferation	  and	  
survival	   of	   cancer	   cells	   and	   were	   strongly	   downregulated	   after	   NIK	   depletion	   in	   both	   cell	  
lines.	  Apart	  from	  known	  NF-­‐κB	  target	  genes,	  NIK	  depletion	  also	  modulated	  the	  expression	  of	  
other	  genes	  involved	  in	  tumorigenesis,	  such	  as	  Yes-­‐associated	  protein	  1	  (YAP1),	  paraoxonase	  
2	  (PON2)	  and	  Kruppel-­‐like	  factor	  2	  (KLF2).	  In	  summary,	  NIK	  knockdown	  leads	  to	  a	  decrease	  in	  
the	  expression	  of	  NF-­‐κB	  target	  genes	  and	  modulates	  the	  expression	  of	  many	  genes	  involved	  
in	  tumor	  growth	  and	  survival.	  
	  
4.10	  NIK	  and	  the	  JAK/STAT	  pathway	  	  
The	  JAK/STAT	  pathway	  is	  activated	  by	  cytokines	  and	  growth	  factors	  and	  mediates	  a	  range	  of	  
different	   cellular	   responses	   such	   as	   proliferation,	   differentiation,	   apoptosis,	  migration	   and	  
cell	   survival	   (Vainchenker	   et	   al.	   2013).	   Briefly,	   activation	   of	   cytokine	   or	   growth	   factor	  
receptors,	  leads	  to	  the	  phosphorylation	  of	  STATs	  by	  the	  JAKs,	  which	  then	  results	  in	  activation	  
and	  nuclear	  translocation	  of	  the	  STAT	  transcription	  factors.	  There	  are	  several	  STATs,	  but	  the	  
involvement	  of	  STAT3	  and	  STAT5	  has	  been	  reported	   in	   lymphoid	  malignancies,	  where	  they	  
have	  been	  described	  to	  be	  persistently	  phosphorylated	  and	  active	  (Eriksen	  et	  al.	  2001;	  Meier	  
et	  al.	  2009;	  Vainchenker	  et	  al.	  2013).	  	  
	  
One	  of	  the	  affected	  pathways	  in	  T	  cell	  lymphoma	  cells	  after	  NIK	  knockdown	  apart	  from	  the	  
NF-­‐κB	  pathway,	  was	  the	  JAK/STAT	  pathway	  (table	  4.6).	  Furthermore,	  this	  pathway	  was	  also	  
positively	  correlated	  with	  NIK	  expression	   in	  our	  series	  of	  primary	  PTCL	  samples	   (table	  4.5).	  
To	  explore	  the	  suggested	  relationship	  between	  NIK	  and	  the	  JAK/STAT	  signaling	  pathway,	  we	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analyzed	   the	   expression	   of	   phosphorylated	   STAT3	   and	   STAT5	   in	   our	   T	   cell	   lymphoma	   cell	  
lines	   by	   Western	   blot.	   Curiously,	   only	   the	   NIK-­‐expressing	   cell	   lines	   (My-­‐La	   and	   SR-­‐786)	  
expressed	  the	  phosphorylated	  form	  of	  STAT3	  (p-­‐STAT3)	  (Figure	  4.16	  A).	  This	  was	  confirmed	  
by	   immunohistochemical	   staining	   of	   p-­‐STAT3	   in	   the	   nucleus	   of	   these	   cells	   (Figure	   4.16	   B),	  
proposing	  that	  this	  transcription	  factor	  is	  active	  in	  NIK-­‐expressing	  cells.	  They	  also	  expressed	  
higher	  levels	  of	  phospho-­‐STAT5	  than	  did	  the	  NIK-­‐negative	  cell	  lines	  (Figure	  4.16	  A).	  We	  then	  
analyzed	   the	   expression	   of	   phosphorylated	   STAT	   after	   NIK	   knockdown.	   Interestingly,	   the	  
levels	   of	   p-­‐STAT3	   decreased	   markedly	   upon	   NIK	   depletion	   (Figure	   4.16	   C).	   Decreased	   p-­‐
STAT5	   levels	  were	  also	  observed,	  although	  the	  effect	  on	  p-­‐STAT5	  was	  not	  as	  prominent	  as	  
the	  effect	  on	  p-­‐STAT3.	  This	  was	  also	  accompanied	  by	  a	  decrease	  in	  total	  STAT3	  levels.	  STAT3,	  
as	  well	   as	   STAT5	   are	  NF-­‐κB	   target	   genes,	  which	  may	   explain	   the	   decrease	   in	   total	   protein	  
expression	  levels	  observed	  upon	  NIK	  silencing.	  	  
	  
IL-­‐6	   is	  a	  known	  trigger	  of	  activation	  of	   the	  JAK/STAT	  signaling	  pathway	  and	  can	   induce	  the	  
phosphorylation	  of	  STAT3	   (Sansone	  et	  al.	  2012).	  Additionally,	  in	  T	  cell	   lymphoma,	  IL-­‐21	  has	  
been	   reported	   as	   a	   trigger	   for	   STAT3	   activation	   (Dien	   Bard	   et	   al.	   2009;	   van	   der	   Fits	   et	   al.	  
2012).	   In	   Figure	   4.15	   we	   observed	   a	   consistent	   and	   profound	   decrease	   of	   IL-­‐6	   and	   IL-­‐21	  
levels	  as	  a	  result	  of	  decreased	  NIK	  protein.	  Strikingly,	  following	  the	  same	  expression	  pattern	  
as	  p-­‐STAT3,	  IL-­‐6	  and	  IL-­‐21	  are	  strongly	  expressed	  only	  in	  the	  NIK	  expressing	  cell	  lines	  My-­‐La	  
and	   SR-­‐786	   compared	   to	   HuT	   78	   and	   DERL7	   (Figure	   4.17	   A).	   This	   is	   independent	   of	   the	  
presence	   of	   NF-­‐κB	   activation,	   since	   HuT	   78	   and	   DERL-­‐7	   also	   present	   an	   activated	   NF-­‐κB	  
pathway.	  We	  asked	  whether	   the	  decrease	  of	   these	   cytokines	   could	  be	   responsible	   for	   the	  
reduced	  phosphorylation	  of	  STAT3	  and	  STAT5	  seen	  after	  NIK	  depletion.	  After	  adding	  IL-­‐6	  or	  
IL-­‐21	  to	  the	  culture	  medium	  of	  My-­‐La	  and	  SR-­‐786	  cells,	  we	  observed	  that	  the	  addition	  of	  IL-­‐
21,	  but	  not	   IL-­‐6,	  was	  able	   to	   restore	  p-­‐STAT3	   levels	   (and	   to	  a	   lesser	  extent,	  p-­‐STAT5)	  after	  
NIK	   knockdown	   (Figure	   4.17	   B).	   This	   can	   suggest	   that	   IL21	   is	   involved	   in	   the	   crosstalk	  
between	  NIK	  and	  the	  JAK/STAT	  pathway.	  However,	   the	  addition	  of	   IL21	  24	  hours	  after	  NIK	  
knockdown,	  was	  not	  able	  to	  rescue	  the	  apoptotic	  effect	  induced	  by	  NIK	  knockdown	  (Figure	  
4.17	  C).	  Consistent	  with	   this,	   knockdown	  of	  STAT3	  alone	   in	  My-­‐La,	  was	  not	  able	   to	   induce	  
cell	  death,	  suggesting	  that	  STAT3	  is	  not	  by	  itself	  sufficient	  to	  induce	  cell	  survival	  in	  these	  cells	  
(Figure	  4.17	  D).	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4.11	  NIK	  and	  KLF-­‐2	  	  
KLF-­‐2	   is	   a	   transcription	   factor	   to	  which	   tumor	   suppressive	   roles	   such	  as	   growth-­‐inhibition,	  
apoptosis	   induction	   and	   inhibition	   of	   angiogenesis,	   have	   been	   assigned	   (Wu	   et	   al.	   2004;	  
Bhattacharya	   et	   al.	   2005;	   Wang	   et	   al.	   2005).	   KLF2	   expression	   is	   diminished	   in	   several	  
malignancies,	   such	   as	  prostate,	   ovarian	   and	  breast	   cancer	   and	   the	   reintroduction	  of	   KLF-­‐2	  
into	  tumor	  cells	  shows	  antitumor	  effects	   (Taniguchi	  et	  al.	  2012).	  A	  dramatic	  upregulation	  of	  
KLF-­‐2	  was	  seen	  by	  gene	  expression	  microarray	  after	  NIK	  depletion	  in	  T	  cell	   lymphoma	  cells	  
(Figure	   4.15).	   Here,	   we	   confirm	   by	   RT-­‐qPCR	   the	   strong	   overexpression	   of	   KLF-­‐2	   after	   NIK	  
knockdown	   in	   My-­‐La	   and	   SR-­‐786	   (Figure	   4.18	   A).	   Considering	   the	   tumor	   suppressive	  
functions	  of	  KLF2,	   it	  was	  tempting	  to	  knock	  down	  KLF-­‐2	   in	  our	  cells	  and	  see	  if	  this	  had	  any	  
effect	   on	   the	   NIK-­‐induced	   apoptosis.	   Using	   siRNAs	   for	   KLF-­‐2,	   we	   knocked	   down	   the	  
expression	  of	  KLF-­‐2	  in	  My-­‐La.	  KLF-­‐2	  knockdown	  was	  not	  toxic	  by	  itself	  (Figure	  4.18	  B).	  When	  
combined	  with	  siNIK,	  cells	  were	  first	  transfected	  with	  siKLF2,	  and	  the	  next	  day,	  with	  siNIK.	  At	  
day	  4,	  cells	  were	  collected	  for	  RT-­‐qPCR	  and	  apoptosis	  assays.	  As	  can	  be	  seen	  in	  Figure	  4.18	  C	  
and	  D,	  restoring	  the	  levels	  of	  KLF2	  close	  to	  initial	   levels,	  did	  not	  have	  any	  effect	  on	  the	  cell	  
death	   induced	   by	   siNIK	   in	   My-­‐La.	   In	   SR-­‐786,	   we	   were	   unable	   to	   revert	   the	   strong	  
upregulation	  of	  KLF-­‐2	   induced	  by	  NIK	  knockdown,	  by	  the	  use	  of	  KLF2	  siRNA.	  Moreover,	  we	  
Figure	  4.16	  Association	  between	  NIK,	  p-­‐STAT3	  and	  p-­‐STAT5.	  	  
A)	  Basal	  levels	  of	  p-­‐STAT3	  and	  p-­‐STAT5	  in	  PTCL	  cell	  lines.	  B)	  Nuclear	  expression	  of	  p-­‐STAT3	  in	  PTCL	  
cell	  lines	  analyzed	  by	  immunohistochemistry.	  C)	  Reduction	  of	  p-­‐STAT3	  and	  p-­‐STAT5	  protein	  levels	  
48	  hours	  after	  NIK	  knockdown	  in	  My-­‐La	  cells.	  The	  numbers	  under	  the	  p-­‐STAT3	  and	  p-­‐STAT5	  panels	  
represent	   the	   quantification	   of	   the	   band	   intensities	   normalized	   to	   the	   loading	   control	   and	   as	   a	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were	  not	  able	  to	  confirm	  the	  knockdown	  efficiency	  of	  KLF2	  at	  the	  protein	  levels,	  due	  to	  the	  
lack	  of	  a	  reliable	  antibody.	  Taken	  together,	  these	  results	  indicate	  that	  NIK	  depletion	  permits	  
the	   upregulated	   expression	   of	   KLF2	   in	   T	   cell	   lymphoma	   cells.	   Even	   though	   KLF-­‐2	   was	  
described	  to	  have	  tumor-­‐suppressor	  functions	  in	  T	  cells,	  KLF2	  knockdown	  alone	  was	  not	  able	  




4.17.	  Role	  of	  IL-­‐6	  and	  IL-­‐21	  in	  NIK-­‐induced	  STAT	  phosphorylation.	  	  
A)	  Basal	  mRNA	  expression	  levels	  of	  IL6	  and	  IL21	  in	  PTCL	  cell	  lines.	  B)	  Recombinant	  IL-­‐6	  or	  IL21	  was	  
added	  to	  the	  culture	  medium	  after	  NIK	  knockdown	  and	  the	  levels	  of	  p-­‐STAT3	  and	  p-­‐STAT5	  were	  
analyzed.	   The	   addition	  of	   IL-­‐21	   restored	   the	   levels	   of	   p-­‐STAT3	  and	  p-­‐STAT5	   in	  both	   SR-­‐786	   and	  
My-­‐La	  cell	   lines.	  C)	  Cell	  viability	  assay	  96	  hours	  after	  NIK	  knockdown	  with	  or	  without	  addition	  of	  
IL-­‐21.	  D)	  Knockdown	  of	  STAT3	  in	  My-­‐La	  cells	  with	  siRNA	  shows	  effective	  knockdown	  levels	  but	  no	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Figure	  4.18	  Effect	  of	  NIK	  knockdown	  on	  KLF-­‐2.	  	  
A)	  Expression	  of	  KLF-­‐2	  mRNA	  48	  hours	  after	  NIK	  knockdown.	  Means	  of	  three	  independent	  experiments	  
+/-­‐	   SD	   are	   represented.	   B)	   Knockdown	   of	   KLF-­‐2	   in	  My-­‐La	   cells.	   The	   relative	   levels	   of	   KLF-­‐2	   mRNA,	  
obtained	   by	   RT-­‐qPCR,	   are	   shown	   in	   the	   graph.	   C)	   Levels	   	   (mRNA)	   of	   KLF-­‐2	   after	   NIK	   and	   KLF-­‐2	  
knockdown	  in	  My-­‐La.	  D)	  Analysis	  of	  cell	  death	  in	  cells	  silenced	  with	  siKLF2	  and	  siNIK,	  measured	  4	  days	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Cancer	   is	   characterized	   by	   an	   accumulation	   of	   genetic	   or	   epigenetic	   alterations	   affecting	  
regulatory	  circuits	  that	  manage	  normal	  cell	  proliferation	  and	  homeostasis.	  Cancer	  biology	  is	  
extremely	   complex,	   and	   it	   is	   important	   to	   bear	   in	  mind	   that	   cancer	   is	   not	   one	   but	  many	  
different	  diseases,	   each	  with	  distinct	   characteristics	   and	   therapeutic	   requirements.	  One	  of	  
the	   signaling	  pathways	   frequently	  associated	  with	  a	   range	  of	  different	  cancer	   types,	   is	   the	  
NF-­‐κB	  pathway.	  The	  numerous	  target	  genes	  regulated	  by	  NF-­‐κB	  transcription	  factors,	  are	  in	  
fact	  involved	  in	  the	  majority	  of	  the	  well-­‐known	  “Hallmarks	  of	  Cancer”(Hanahan	  et	  al.	  2000;	  
Hanahan	   et	   al.	   2011),	   necessary	   for	   tumor	   formation	   and	  propagation.	   Constitutive	  NF-­‐κB	  
activation	  has	  been	  reported	  in	  several	  hematological	  tumors	  and	  suggested	  as	  a	  key	  feature	  
in	  the	  pathogenesis	  of	  some	  lymphomas	  (Davis	  et	  al.	  2001;	  Jost	  et	  al.	  2007).	  However,	   the	  
complexity	   of	   the	   signaling	   network	   and	   the	   multiple	   biological	   functions	   of	   NF-­‐κB	   have	  
made	   its	   investigation	   and	   therapeutic	   targeting	   a	   challenge.	   In	   order	   to	   develop	   NF-­‐κB–	  
based	  cancer	  therapies	  efficiently	  and	  safely,	  it	  is	  necessary	  to	  identify	  molecular	  targets	  as	  
well	  as	  biomarkers	  with	  which	  to	  stratify	  patients	  who	  are	  likely	  to	  benefit	  from	  the	  therapy.	  
In	   the	  present	  work,	  we	  evaluated	   the	  expression	  of	  NF-­‐κB	   transcription	   factors	   in	  human	  
tumor	   biopsies,	   and	   analyzed	   their	   expression	   pattern,	   subtype-­‐specificity	   and	   clinical	  
impact.	  Furthermore,	  we	  aimed	  to	  identify	  novel	  molecular	  targets	  able	  to	  interfere	  with	  NF-­‐	  
κB	  activation	  and	  lymphoma	  cell	  survival.	  
	  
5.1	  Characterization	  of	  classical	  and	  alternative	  NF-­‐κB	  
activation	  in	  diffuse	  large	  B	  cell	  lymphoma	  	  
	  
5.1.1	  NF-­‐κB	  expression	  in	  lymphoma	  tumor	  samples	  
	  
There	   are	   few	   reports	   assessing	   the	   protein	   expression	   of	   NF-­‐κB	   in	   lymphoma	   tumor	  
samples,	  and	  to	  our	  knowledge,	  this	  is	  the	  first	  work	  reporting	  the	  expression	  of	  the	  entire	  
family.	   Since	   most	   studies	   regarding	   the	   NF-­‐κB	   pathway	   have	   been	   conducted	   in	   animal	  
models	  or	  in	  cell	  lines,	  the	  use	  of	  patient	  material	  in	  our	  study	  offers	  important	  translational	  
relevance	  to	  current	  and	  future	  studies.	  We	  showed	  by	  immunohistochemistry,	  that	  markers	  
of	  both	  classical	  and	  alternative	  NF-­‐κB	  activation	  are	  present	  in	  a	  range	  of	  lymphoma	  types,	  
and	  were	  especially	   frequent	   in	  Hodgkin	  Lymphoma,	  PTCL	  and	  DLBCL.	  We	  then	  performed	  
more	  detailed	  studies	  in	  PTCL	  and	  DLBCL,	  due	  to	  the	  observed	  extent	  of	  pathway	  activation	  
and	  its	  relevance	  in	  the	  pathobiology	  of	  these	  neoplasms.	  Both	  classical	  and	  alternative	  NF-­‐
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κB	  factors	  were	  often	  co-­‐expressed	  in	  the	  same	  sample,	  both	  in	  PTCL	  and	  DLBCL,	  suggesting	  
the	   simultaneous	   engagement	   of	   the	   two	   pathways.	   This	   is	   not	   surprising	   though,	   since	  
several	  NF-­‐κB	  activating	  signals	  featured	  in	  lymphocytes	  (such	  as	  CD40	  or	  BAFF)	  are	  capable	  
of	  inducing	  both	  signaling	  pathways	  (Coope	  et	  al.	  2002;	  Pham	  et	  al.	  2011).	  However,	  looking	  
closer	  at	  the	  expression	  of	  the	  different	  transcription	  factors	  in	  a	  large	  series	  of	  DLBCL	  cases,	  
we	   observed	   an	   intricate	   expression	   pattern.	   Even	   though	   the	   expression	   of	   the	   different	  
NF-­‐κB	  proteins	  was	  heterogeneous	  in	  DLBCL,	  the	  vast	  majority	  of	  tumors	  (87.6%)	  expressed	  
nuclear	  NF-­‐κB.	  Correlated	  expression	  between	  specific	  pairs	  of	  NF-­‐κB	  subunits,	  such	  as	  p50	  
and	  p52,	  p52	  and	  RelB,	  p52	  and	  p65,	  p50	  and	  RelB,	  and	  between	  p50	  and	  p65,	  was	  observed,	  
although	   simultaneous	   expression	   of	   other	   combinations	   also	   was	   present.	   This	   remark	  
suggests	   that	   the	   actual	  NF-­‐κB	   expression	   in	   tumors	   is	   far	   from	  being	   represented	   by	   the	  
prototypic	   NF-­‐κB	   model	   and	   that	   there	   is	   no	   precise	   line	   distinguishing	   the	   classical	   and	  
alternative	   pathways.	   However,	   apart	   from	   the	   most	   representative	   and	   frequent	  
dimerization	  complexes	   (p52/RelB,	  p50/p65	  and	  p50/c-­‐Rel),	  both	  homo-­‐dimers	  and	  dimers	  
including	   a	   variety	   of	   NF-­‐κB	   members	   as	   well	   as	   atypical	   partners,	   have	   already	   been	  
described	  (Hoffmann	  et	  al.	  2006).	  Interestingly,	  c-­‐Rel	  presented	  a	  distinct	  expression	  pattern	  
and	  even	  though	  an	  association	  between	  p50	  and	  c-­‐Rel	  could	  be	  perceived	  (not	  statistically	  
significant),	   around	   a	   third	   of	   the	   c-­‐Rel-­‐positive	   tumors	   did	   not	   express	   any	   other	   NF-­‐κB	  
member.	   Yet,	   nuclear	   dimers	   of	   CD40	   and	   c-­‐Rel	   have	   been	   described	   to	   activate	  
transcription	  of	  NF-­‐κB	  target	  genes	  in	  DLBCL	  (Zhou	  et	  al.	  2007).	  To	  determine	  the	  different	  
dimerization	   partners	   was	   though	   beyond	   the	   scope	   of	   this	   report.	   The	   complicated	  
expression	  pattern	  of	  the	  different	  subunits	  is	  also	  an	  indicator	  of	  that	  looking	  specifically	  at	  
only	   a	   single	   NF-­‐κB	   factor	   as	   an	   estimate	   of	   NF-­‐κB	   activation	   will	   probably	   lead	   to	   a	  
significant	   underestimation	   of	   the	   actual	   NF-­‐κB	   signaling.	   Another	   surprising	   remark	   from	  
our	  studies	  in	  DLBCL	  was	  that	  the	  NF-­‐κB	  member	  p65	  was	  only	  expressed	  in	  the	  nuclei	  of	  a	  
minority	  of	   cases	   (11.5%).	   In	  agreement	  with	   this	  observation,	   three	  previous	  publications	  
evaluating	  p65	  expression	  by	   immunohistochemistry	   in	  DLBCL,	  also	  report	   low	  nuclear	  p65	  
expression	   (Talwalkar	   et	   al.	   2006;	   Espinosa	   et	   al.	   2008;	   Bavi	   et	   al.	   2011).	   The	   conformity	  
between	  immunohistochemistry	  and	  DNA	  binding	  activity	  (as	  measured	  by	  TransAM	  ELISA)	  
in	  our	  study,	  and	  the	  fact	  that	  other	  studies	  have	  obtained	  similar	  results	  using	  distinct	  p65-­‐	  
antibodies,	  suggest	  that	  the	  low	  expression	  of	  p65	  observed	  in	  our	  series,	  is	  not	  an	  issue	  of	  
antibody	   specificity.	   The	   rare	   expression	   of	   p65	   is	   something	   that	   should	   been	   taken	   into	  
account	  when	  evaluating	  the	  role	  of	  p65	  in	  experimental	  models,	  or	  when	  using	  only	  p65	  as	  
a	  measure	   of	  NF-­‐κB	   activation.	   In	   the	   present	  work,	   only	   nuclear	   expression	   of	  NF-­‐κB	  has	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been	   considered,	   and	   even	   if	   nuclear	   p65	   expression	   is	   rare,	   p65	   was	   detected	   in	   the	  
cytoplasmic	   compartment	   in	   the	   majority	   of	   cases.	   Thus,	   the	   possibility	   that	   cytoplasmic	  
expression	   of	   NF-­‐κB	   might	   accomplish	   other	   functions	   in	   lymphomagenesis,	   can’t	   be	  
excluded.	  One	  could	  argue	  that	  analyzing	  the	  gene	  expression	  of	  NF-­‐κB	  target	  genes	  would	  
be	   a	   better	   approach	   to	   estimate	  NF-­‐κB	   activation.	   Indeed,	  with	   this	   approach	   you	  would	  
better	  deduct	  whether	  nuclear	  NF-­‐κB	   is	   transcriptionally	  active	  or	  not.	  On	   the	  other	  hand,	  
gene	   expression	   profiling	   does	   not	   give	   any	   information	   about	  which	   transcription	   factors	  
are	  involved	  and	  where	  they	  are	  expressed	  (tumoral	  cells	  or	  stromal	  cells).	  Moreover,	  NF-­‐κB	  
target	   gene	   regulation	   presents	   high	   complexity	   with	   context-­‐dependency	   and	   crosstalk	  
between	   non-­‐NF-­‐κB	   signaling	   pathways	   (Oeckinghaus	   et	   al.	   2009).	   These	   techniques	   thus	  
both	   provide	   valuable	   information	   about	   NF-­‐κB	   signaling	   and	   are	   complementary	   to	   each	  
other.	  
	  
Furthermore,	  we	   observed	   that	   the	   expression	   of	   nuclear	   p50	   and	   p52	  was	   a	  widespread	  
feature	   in	   EBV-­‐positive	   DLBCL.	   More	   concisely,	   NF-­‐κB	   was	   only	   associated	   with	   the	  
subpopulation	   of	   EBV-­‐positive	   cases	   expressing	   LMP1,	  where	   92.8%	   and	   85.7%	   expressed	  
nuclear	   p52	   or	   p50,	   respectively.	   Since	   only	   a	   small	   population	   of	   DLBCL	   patients	   is	   EBV-­‐	  
positive	  (8.1%	  in	  our	  study	  population),	  our	  studies	  are	  based	  on	  a	  relatively	  small	  number	  of	  
EBV-­‐positive	   cases.	   Even	   though	  an	   increased	  number	  of	   samples	  would	  be	  desirable,	   our	  
results	  are	  clear	  and	  highly	  significant.	  Previous	  studies	  establishing	  a	  link	  between	  EBV	  and	  
NF-­‐κB	   are	  mainly	   based	   on	   observations	   in	   cell	   lines	   or	  murine	  models	   (Sylla	   et	   al.	   1998;	  
Eliopoulos	  et	  al.	  2001;	  Atkinson	  et	  al.	  2003;	  Thornburg	  et	  al.	  2006).	  Here,	  we	  confirm	  that	  
LMP1	   is	  associated	  with	  both	  classical	  and	  alternative	  NF-­‐κB	  pathway	  activation	   in	  primary	  
DLBCL	  tumors.	  EBV-­‐associated	  DLBCL,	  which	  is	  typically	  present	  in	  elderly	  people,	  has	  worse	  
overall	   survival	   and	   poorer	   chemotherapy	   response	   than	   EBV-­‐negative	   DLBCL	   (Park	   et	   al.	  
2007;	  Morales	  et	  al.	  2010;	  Montes-­‐Moreno	  et	  al.	  2012),	  emphasizing	  the	  need	  for	  new	  and	  
effective	   treatments	   for	   these	   patients.	   Previous	   knowledge	   that	   NF-­‐κB	   is	   required	   for	  
survival	  of	  EBV-­‐transformed	  cells	  (Cahir-­‐McFarland	  et	  al.	  2000;	  He	  et	  al.	  2000)	  together	  with	  
our	  observation	   that	   LMP1-­‐expressing	   tumors	   from	  EBV-­‐positive	  DLBCL	  patients	  are	  highly	  
associated	  with	  NF-­‐κB	  activation,	   suggest	   the	  exploration	  of	  NF-­‐κB	   interfering	   therapies	   in	  
LMP1-­‐positive	  DLBCL.	  Due	  to	  the	  different	  clinical	  and	  biological	  profile	  of	  EBV-­‐related	  DLBCL,	  




Several	   factors	   are	   known	   to	   trigger	   NF-­‐κB	   activation	   in	   lymphomas.	   Some	   of	   these	   are	  
provided	  by	  the	  microenvironment	  (Herreros	  et	  al.	  2008)	  and	  others	  are	  intrinsic	  mutations	  
leading	   to	  constitutive	  activation	  of	   the	  pathway	   (Staudt	  2010).	   In	  DLBCL,	  apart	   from	  EBV,	  
several	  oncogenic	  mutations	  in	  the	  NF-­‐κB	  pathway	  have	  been	  reported	  which	  could	  explain	  
the	  activated	  pathway	  observed	   in	  a	  part	  of	   the	  cases	   (for	  more	  details,	  see	  section	  1.2	  of	  
the	   Introduction).	   However,	   the	   high	   frequency	   of	   nuclear	  NF-­‐κB	   expression	   can	   probably	  
not	   be	   explained	   solely	   by	   the	   previously	   reported	   oncogenic	   events,	   especially	   in	   GCB-­‐	  
DLBCL,	  where	  few	  NF-­‐κB-­‐activating	  mechanisms	  have	  been	  described.	  
	  
5.1.2	  NF-­‐κB	  in	  ABC/GCB	  DLBCL	  
	  
DLBCL	  is	  a	  clinically	  and	  molecularly	  heterogeneous	  disease	  with	  a	  cure	  rate	  of	  only	  40-­‐50%	  
(Coiffier	  et	  al.	  2010).	  The	  division	  of	  DLBCL	   into	   the	  molecular	   subtypes	  ABC	  and	  GCB,	  has	  
facilitated	   the	   molecular	   understanding	   of	   lymphoma	   pathogenesis	   and	   has	   permitted	   to	  
stratify	   the	   patients	   into	   a	   clinically	   favorable	   (GCB)	   and	   unfavorable	   (ABC)	   group	  
(Rosenwald	   et	   al.	   2002).	   This	   classification	   has	   been	   widely	   applied	   by	   researchers	  
(Swerdlow	  et	  al.	  2008;	  Lenz	  et	  al.	  2010)	  and	  is	  now	  also	  used	  for	  stratification	  in	  clinical	  trials	  
(Hernandez-­‐Ilizaliturri	  et	  al.	  2011;	  Yang	  et	  al.	  2012).	  A	  hallmark	  of	  ABC-­‐DLBCL	  is	  constitutive	  
NF-­‐κB	  activation,	  and	  a	  disruption	  of	  this	  activation	  induces	  apoptosis	  in	  ABC-­‐DLBCL	  cell	  lines	  
(Davis	  et	  al.	  2001;	  Lam	  et	  al.	  2005).	  Our	  analysis	  of	  NF-­‐κB	  expression	  in	  a	  series	  of	  113	  DLBCL	  
samples	  revealed	  that	   the	  majority	  of	  DLBCL	  tumors	  express	  nuclear	  NF-­‐κB,	   independently	  
of	   ABC/GCB	   subclassification.	   Surprisingly,	   we	   found	   no	   significant	   correlation	   between	  
ABC/GCB	  subtype	  and	  the	  expression	  of	  any	  of	  the	  five	  NF-­‐κB	  members,	  indicating	  that	  NF-­‐	  
κB	   signaling	   is	   present	   not	   only	   in	   ABC-­‐DLBCL,	   but	   also	   in	   GCB-­‐DLBCL.	   To	   discard	   the	  
possibility	  that	  this	  observation	  could	  be	  a	  result	  of	  using	  a	  suboptimal	  classification	  method	  
for	  ABC/GCB	  classification,	  we	  performed	   the	  analysis	   in	   two	   independent	   series	  of	  DLBCL	  
tumors,	  classified	  both	  by	  immunohistochemistry	  and	  gene	  expression	  profiling	  (considered	  
the	  gold	  standard	  for	  ABC/GCB	  classification).	  A	  concordance	  of	  91.7%	  was	  obtained	  when	  
immunohistochemistry	   and	   gene	   expression	   profiling	   were	   compared,	   indicating	   that	  
immunohistochemistry	   is	   a	   valid	  method	   for	   DLBCL	   classification	   in	   our	   study.	   These	   two	  
analyses	   both	   showed	   that	   NF-­‐κB	   was	   expressed	   equally	   in	   ABC-­‐	   and	   GCB-­‐DLBCL.	   In	  
agreement	  with	   our	   observation,	   previous	  works	   analyzing	   the	   expression	   of	   phopho-­‐p65	  
and	  p52	  as	  markers	  of	  an	  activated	  NF-­‐κB	  pathway	  in	  DLBCL	  tumors,	  reported	  expression	  of	  
these	  subunits	  in	  both	  DLBCL	  subtypes	  with	  similar	  frequencies	  (Espinosa	  et	  al.	  2008;	  Pham	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et	   al.	   2011).	  On	   the	   contrary,	   other	   studies	   associated	   the	  expression	  of	   nuclear	  p65,	   p50	  
and	  p52	  with	  the	  ABC-­‐subtype,	  although	  they	  were	  also	  present	  in	  a	  considerable	  fraction	  of	  
GCB-­‐DLBCL	   as	   well	   (Compagno	   et	   al.	   2009;	   Bavi	   et	   al.	   2011).	   An	   important	   difference	  
between	  our	  study	  and	  several	  others,	  was	  that	  EBV-­‐positive	  cases	  were	  excluded	  from	  the	  
analysis.	   Due	   to	   their	   distinct	  molecular	   and	   clinical	   profile,	   EBV-­‐positive	   DLBCL	   has	   been	  
suggested	  as	  a	  distinct	  DLBCL	  category	  (Swerdlow	  et	  al.	  2008).	  EBV-­‐associated	  DLBCLs	  have	  
been	   characterized	   by	   NF-­‐κB	   activation	   and	   they	   frequently	   present	   an	   ABC-­‐phenotype	  
(Montes-­‐Moreno	   et	   al.	   2012).	   Including	   this	   category	   together	   with	   EBV-­‐negative	   DLBCL,	  
probably	  gives	  rise	  to	  bias	  with	  an	  increased	  number	  of	  NF-­‐κB-­‐positive	  cases	  and	  a	  stronger	  
association	  with	  the	  ABC-­‐phenotype.	  Our	  observation	  that	  NF-­‐κB	  signaling	  is	  present	  in	  both	  
ABC	  and	  GCB	   subtypes,	   evokes	   several	   questions	   concerning	  whether	  NF-­‐κB	   is	   involved	   in	  
the	  underlying	  pathogenesis	  of	  GCB	  as	  well,	  and	  whether	  NF-­‐κB	  inhibition	  could	  be	  useful	  in	  
a	  subset	  of	  GCB-­‐DLBCL.	  In	  fact,	  even	  though	  mutations	  affecting	  NF-­‐κB	  regulator	  genes	  are	  
more	  frequent	  in	  ABC-­‐DLBCL,	  amplifications	  of	  CREL	  have	  been	  described	  in	  GCB	  (Rosenwald	  
et	   al.	   2002)	   and	   at	   least	   23%	   of	   GCB	   tumors	   harbor	   somatic	   mutations	   in	   several	   genes	  
involved	  in	  NF-­‐κB	  signaling,	  such	  as	  CARD11,	  A20	  and	  TRAF2	  (Compagno	  et	  al.	  2009).	  Since	  
the	   ABC	   and	   GCB	   subtypes	   partly	   present	   a	   distinct	   pattern	   of	   genetic	   abnormalities	   and	  
respond	  differently	  to	  therapy	  (Lenz	  et	  al.	  2008;	  Lenz	  et	  al.	  2010),	  the	  mechanisms	  leading	  to	  
NF-­‐κB	  signaling	  and	  the	  subsequent	   transcriptional	   response	  might	  be	  different	   in	   the	   two	  
subtypes.	   Moreover,	   the	   majority	   of	   published	   functional	   studies	   considering	   NF-­‐κB	   in	  
GCB/ABC	  DLBCL	  have	  been	  conducted	  in	  a	  specific	  set	  of	  DLBCL	  cell	  lines,	  where	  the	  GCB	  cell	  
lines	   are	   characterized	   by	   a	   lack	   of	   NF-­‐κB	   (Davis	   et	   al.	   2001;	   Lam	   et	   al.	   2005).	   In	   fact,	  
analyzing	   the	   expression	   of	   nuclear	   NF-­‐κB	   in	   these	   DLBCL	   cell	   lines,	   we	   also	   observed	   a	  
significant	   and	   positive	   association	   between	   NF-­‐κB	   and	   ABC	   subtype	   (data	   no	   shown).	  
Additionally,	  a	  study	  analyzing	  NF-­‐κB	  expression	  in	  a	  distinct	  set	  of	  DLBCL	  cell	   lines	  showed	  
that	   NF-­‐κB	   signaling	   was	   present	   in	   both	   subtypes,	   although	   p65	   expression	   was	   more	  
frequent	   in	  ABC-­‐DLBCL(Pham	  et	  al.	  2011).	  Having	  our	   results	   in	  mind,	   the	  use	  of	  ABC/GCB	  
cell	  lines	  might	  not	  reflect	  the	  actual	  situation	  in	  patient	  tumors	  and	  the	  extraction	  of	  these	  
results	   to	   the	  clinic	  may	  be	  questioned.	  The	  presence	  of	  NF-­‐κB	   signaling	   in	  both	  ABC-­‐	  and	  
GCB-­‐DLBCL	   is	   something	   to	   contemplate	   when	   evaluating	   molecular	   mechanisms	   and	  
putative	  therapeutic	  targets	  in	  future	  studies.	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5.1.3	  The	  impact	  of	  NF-­‐κB	  on	  clinical	  outcome	  in	  DLBCL	  patients	  
	  
There	   are	   only	   a	   few	   previous	   publications	   describing	   NF-­‐κB	   signaling	   and	   its	   clinical	  
correlation	  in	  lymphomas,	  and	  the	  results	  are	  contradictive	  (Espinosa	  et	  al.	  2008;	  Curry	  et	  al.	  
2009;	  Bavi	   et	   al.	   2011).	   In	   this	  work,	  we	   investigated	   the	   impact	  of	   all	  NF-­‐κB	  members	  on	  
patient	   overall	   survival,	   using	   nuclear	   expression	   as	   an	   estimate	   of	   NF-­‐κB	   activation.	   In	  
DLBCL,	  nuclear	  c-­‐Rel	  expression	  was	  seen	  to	  be	  a	  common	  feature	  and	  identified	  a	  subset	  of	  
patients	  with	  enhanced	  overall	  survival.	  The	  other	  four	  transcription	  factors	  did	  not	  have	  any	  
significant	  impact	  on	  DLBCL	  survival,	  although	  a	  trend	  towards	  superior	  overall	  survival	  was	  
observed	  in	  p52-­‐positive	  cases	  as	  well.	  Additionally,	  c-­‐Rel	  was	  identified	  as	  an	  independent	  
favorable	  prognostic	  factor	   in	  DLBCL	  and	  had	  a	  greater	   impact	  on	  overall	  survival	  than	  had	  
GCB/ABC	  classification	  in	  our	  series.	  The	  fact	  that	  c-­‐Rel-­‐positive	  tumors	  are	  associated	  with	  a	  
favorable	   overall	   survival,	   does	   not	   mean	   that	   NF-­‐κB-­‐targeted	   therapies	   could	   not	   be	   an	  
attractive	  molecular	  target	  in	  these	  malignancies,	  but	  the	  relatively	  favorable	  clinical	  course	  
of	  these	  patients	  in	  an	  R-­‐CHOP	  regimen,	  should	  be	  taken	  into	  consideration	  when	  evaluating	  
the	  effects	  of	  novel	  therapeutic	  strategies.	  C-­‐Rel	  is	  the	  only	  NF-­‐kB	  transcription	  factor	  that	  is	  
frequently	   amplified	   in	   human	   cancers	   and	   has	   also	   consistently	   been	   shown	   to	   have	  
transforming	  potential	  in	  culture	  (Gilmore	  et	  al.	  2001;	  Gilmore	  et	  al.	  2004).	  Amplification	  of	  
the	   REL	   locus	   (encoding	   c-­‐Rel)	   (Gilmore	   et	   al.	   2004)	   is	   commonly	   observed	   in	   DLBCL	   and	  
mainly	  associated	  with	  the	  GCB	  phenotype	  (Rosenwald	  et	  al.	  2002).	  In	  our	  study,	  nuclear	  c-­‐
Rel	   expression	   is	   though	  detected	   in	   both	  ABC-­‐	   and	  GCB-­‐	  DLBCL.	  However,	   no	   correlation	  
between	  REL	  amplification	  and	  nuclear	  c-­‐Rel	  expression	  was	  observed	  in	  DLBCL	  in	  a	  study	  by	  
Houldsworth	   et	   al	   (Houldsworth	   et	   al.	   2004).	   The	   fact	   that	   only	   c-­‐Rel	   expression	   has	  
prognostic	  impact	  on	  DLBCL	  suggests	  that	  different	  NF-­‐κB	  subunits	  have	  different	  roles	  and	  
activate	  different	  transcriptional	  programs.	  However,	  the	  subunit-­‐	  specific	  or	  dimer-­‐specific	  
functions	  of	  NF-­‐κB	  in	  regulating	  transcriptional	  selectivity	  are	  far	  from	  understood.	  Whether	  
c-­‐Rel	   is	   required	   for	   tumor	   cell	   survival	   in	   these	   tumors,	   is	   still	   unknown,	   and	  would	   be	   a	  
relevant	  subject	  for	  future	  studies.	  
	  
In	  line	  with	  our	  results,	  NF-­‐κB	  was	  also	  associated	  with	  enhanced	  patient	  survival	  in	  another	  
DLBCL	  study	  where	  phosphorylated	  p65	  was	  assessed	  (Espinosa	  et	  al.	  2008).	   In	  contrast	  to	  
our	   findings,	   p65	   expression	   was	   described	   as	   an	   adverse	   prognostic	   marker	   in	   DLBCL	   in	  
another	   report	   (Bavi	   et	   al.	   2011).	   Moreover,	   nuclear	   c-­‐Rel	   assessed	   by	  
immunohistochemistry,	   was	   associated	   with	   worse	   clinical	   outcome	   in	   GCB-­‐DLBCL	   in	   a	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previous	  publication	   (Curry	  et	  al.	  2009).	  Those	  studies	   though,	  were	  performed	   in	  biopsies	  
from	   patients	   treated	   with	   chemotherapy	   without	   Rituximab.	   Since	   the	   addition	   of	  
Rituximab	  has	  markedly	   improved	   the	  overall	   survival	   rates	   in	  DLBCL	   (Coiffier	  et	  al.	   2010),	  
and	   the	   outcome	   of	   survival	   analyses	   depends	   on	   the	   clinical	  management,	   this	   can	   be	   a	  
possible	  explanation	  for	  the	  observed	  differences.	  Our	  study	  is	  performed	  using	  a	  cohort	  of	  
patients	  that	  has	  uniformly	  been	  treated	  with	  R-­‐CHOP,	  which	  is	  the	  standard	  treatment	  for	  
DLBCL	  patients	  nowadays.	  
	  
5.2	  The	  NF-­‐κB	  pathway	  in	  T	  cell	  lymphomas:	  NIK	  as	  a	  regulator	  
of	  classical	  and	  alternative	  signaling	  and	  cell	  survival	  	  
	  
5.2.1	  The	  expression	  of	  NF-­‐κB	  in	  PTCL	  tumors	  and	  its	  clinical	  impact	  
	  
Analyzing	  the	  expression	  of	  the	  different	  NF-­‐κB	  members	  in	  patient	  material	  from	  the	  most	  
common	   subtypes	   of	   PTCL	   (PTCL-­‐NOS,	   AITL	   and	   ALCL),	  we	   found	  markers	   of	   activation	   of	  
both	  the	  classical	  and	  alternative	  pathways	  in	  a	  significant	  subset	  of	  samples,	  characterized	  
by	  the	  nuclear	  expression	  of	  p50,	  p52,	  RelB,	  and	  c-­‐Rel.	  As	  in	  DLBCL,	  the	  nuclear	  expression	  of	  
p65	  in	  PTCL	  was	  also	  uncommon	  and	  only	  present	  in	  a	  minority	  of	  the	  cases	  in	  our	  study	  (see	  
section	   5.1.1	   for	   further	   discussion).	   A	   few	   other	   publications	   have	   also	   reported	   NF-­‐κB	  
activation	  in	  PTCL	  (Izban	  et	  al.	  2000;	  Martinez-­‐Delgado	  et	  al.	  2005;	  Sors	  et	  al.	  2006),	  but	  the	  
trigger	  of	  this	  activation	  is	  still	  unknown.	  No	  mutations	  in	  the	  pathway	  have	  been	  described,	  
apart	   from	  TNFAIP3	  deletions	   in	  Sézary	  Syndrome(Braun	  et	  al.	  2011)	  and	  p100	  truncations	  
(Fracchiolla	  et	  al.	  1993;	  Derudder	  et	  al.	  2003),	  leaving	  a	  field	  of	  research	  ahead.	  Deciphering	  
the	  molecular	  mechanisms	  leading	  to	  pathogenic	  NF-­‐κB	  activation	  in	  PTCL	  will	  be	  important	  
in	  order	  to	  understand	  its	  molecular	  pathology	  and	  discover	  novel	  therapeutic	  targets.	  
	  
In	  PTCL	  patients	  (including	  PTCL-­‐NOS	  and	  AITL),	   in	  contrast	  to	  DLBCL,	  nuclear	  expression	  of	  
classical	  or	  alternative	  NF-­‐κB	  factors	  was	  significantly	  associated	  with	  worse	  OS	  compared	  to	  
NF-­‐κB-­‐negative	  tumors.	  In	  the	  ALCL	  subtype,	  NF-­‐κB	  was	  also	  associated	  with	  inferior	  overall	  
survival	   and	   was	   negatively	   correlated	   with	   ALK-­‐expression,	   being	   more	   frequent	   in	   the	  
more	  aggressive	  ALK-­‐negative	  ALCLs.	  In	  PTCL,	  no	  specific	  NF-­‐κB	  subunit	  was	  responsible	  for	  
the	  prognostic	   impact,	  but	  when	  NF-­‐κB	  was	  evaluated	  as	  a	  whole,	  patients	   lacking	  nuclear	  
expression	  of	  any	  NF-­‐κB	  had	  a	  favorable	  outcome.	  Looking	  at	  c-­‐Rel	  expression	  alone	  in	  PTCL,	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as	  done	  in	  DLBCL,	  positive	  cases	  had	  an	  extremely	  unfavorable	  survival	  curve,	  even	  though	  
the	  differences	  were	  not	  statistically	  significant	  due	  to	  the	  less	  frequent	  expression	  of	  c-­‐Rel	  
in	   PTCL	   (data	   not	   shown).	   In	   contrast	   with	   our	   results,	   Martinez-­‐Delgado	   and	   colleagues	  
(Martinez-­‐Delgado	  et	  al.	  2005)	  associated	  the	  expression	  of	  NF-­‐κB–related	  genes,	  using	  gene	  
expression	  microarrays,	  with	  a	  favorable	  clinical	  outcome	  in	  PTCL.	  These	  disparities	  might	  be	  
explained	  by	  the	  differences	  in	  PTCL	  subtypes	  included	  in	  our	  study	  (PTCL-­‐NOS	  and	  AITL,	  or	  
ALCL	  alone)	  and	  the	  study	  performed	  by	  Martínez-­‐Delgado	  (PTCL-­‐NOS,	  AITL,	  CTCL	  and	  NK/T	  
lymphomas	  in	  the	  same	  analysis)	  or	  by	  the	  variation	  and	  limitations	  of	  each	  of	  the	  employed	  
techniques	   for	   NF-­‐κB	   estimation	   (discussed	   in	   section	   5.1.1).	   A	   comparison	   of	   these	   two	  
techniques,	   including	   the	   gene	   expression	   profile	   of	   NF-­‐κB	   target	   genes	   as	   well	   as	   the	  
expression	   of	   the	   five	   different	   transcription	   factors,	   in	   the	   same	   patient	   cohort	   would	  
provide	   valuable	   information	   to	   clarify	   this	   issue.	   Apart	   from	   ALK,	   prognostic	   factors	   and	  
predictive	   markers	   for	   therapy	   outcome	   in	   PTCL	   are	   scarce.	   Our	   results	   led	   to	   the	  
identification	   of	   a	   group	   of	   PTCL	   with	   unfavorable	   clinical	   outcome,	   based	   on	   NF-­‐κB	  
expression,	   suggesting	   that	   aberrant	   NF-­‐κB	   activation	   may	   confer	   enhanced	   survival	   or	  
treatment	   resistance	  on	   these	   tumors.	  NF-­‐κB	  was	   thus	  an	   interesting	  candidate	   to	  explore	  
molecular	   targets	   for	   therapy.	   The	   different	   impact	   of	   NF-­‐κB	   in	   DLBCL	   and	   PTCL	   patients,	  
reflects	  the	  heterogeneity	  of	  human	  tumors	  and	  the	  NF-­‐κB	  signaling	  network,	  which	  is	  highly	  
dependent	  on	  the	  cell	  type,	  cellular	  context	  and	  parallel	  signaling	  mechanisms	  (Oeckinghaus	  
et	  al.	  2009)	  .	  
	  
	  
5.2.2	  NIK	  expression	  in	  PTCL	  
	  
NIK	  captured	  our	  attention	  in	  T	  cell	  lymphomas	  after	  the	  observations	  that	  recurrent	  NF-­‐κB	  
activation	  was	  present	  in	  PTCL	  tumor	  samples	  and	  highly	  expressed	  NIK	  levels	  were	  detected	  
in	  PTCL	  cell	  lines	  in	  an	  initial	  screening	  of	  different	  lymphoma	  cell	  lines.	  Even	  though	  NIK	  had	  
been	   studied	   in	   the	   context	   of	   other	   tumors,	   such	   as	  multiple	  myeloma(Annunziata	   et	   al.	  
2007),	   the	   role	  of	  NIK	   in	  T	   cell	   lymphomagenesis	  was	  unknown.	  Since	   the	  pathogenesis	  of	  
PTCL	   is	   largely	   undiscovered,	   studies	   clarifying	   oncogenic	   mechanisms	   and	   identifying	  
putative	  molecular	  targets	  are	  urgently	  required	  in	  order	  to	  improve	  their	  dismal	  prognosis.	  
The	  observation	   that	  NIK	  was	  overexpressed	   in	  a	   subset	  of	  T	   cell	   lymphoma	  cell	   lines	  and	  
primary	  Sézary	  syndrome	  samples,	  when	  compared	  to	  healthy	  T	  lymphocytes,	  indicated	  that	  
NIK	  might	  be	  involved	  in	  malignant	  signaling	  in	  PTCL	  and	  led	  us	  to	  further	  investigate	  its	  role	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in	   this	   neoplasm.	   NIK	   has	   previously	   been	   found	   to	   be	   overexpressed	   at	   the	   RNA	   and/or	  
protein	   level	   in	   other	   cancers,	   such	   as	   melanoma,	   multiple	   myeloma,	   DLBCL,	   mucosa-­‐	  
associated	   lymphoid	   tissue	   (MALT)	   lymphoma,	   and	   adult	   T-­‐cell	   leukemia	   and	   Hodgkin	  
lymphoma	   (Saitoh	   et	   al.	   2003;	   Annunziata	   et	   al.	   2007;	   Pham	   et	   al.	   2011;	   Rosebeck	   et	   al.	  
2011;	  Ranuncolo	  et	  al.	  2012;	  Thu	  et	  al.	  2012).	  In	  some	  cases,	  genetic	  alterations	  such	  as	  gene	  
amplifications,	   translocations,	   or	   mutations	   in	   NIK,	   or	   alterations	   in	   genes	   regulating	   the	  
stability	  of	  NIK	  protein	  (such	  as	  TRAF2,	  TRAF3	  and	  cIAP2/3),	  are	  described,	  emphasizing	  the	  
role	   of	  NIK	   in	   tumorigenesis	   (Annunziata	   et	   al.	   2007;	   Keats	   et	   al.	   2007;	   Rossi	   et	   al.	   2011).	  
Interestingly,	  we	  did	   observe	   an	   absent	   or	   strongly	   reduced	  expression	  of	   TRAF3,	   a	  major	  
negative	  regulator	  of	  NIK	  protein	  stability,	  in	  cell	  lines	  where	  NIK	  was	  highly	  expressed.	  This	  
observation	  suggests	  that	  this	  might	  be	  one	  of	  the	  mechanisms	  regulating	  NIK	  signaling	  in	  T	  
cell	  lymphoma	  cells,	  as	  described	  in	  other	  cell	  types	  (Keats	  et	  al.	  2007;	  Vallabhapurapu	  et	  al.	  
2008).	  Moreover,	  whole	  genome	  sequencing	  of	  four	  T	  cell	  lymphoma	  cell	  lines	  performed	  in	  
our	   group	   (My-­‐La,	  HuT	   78,	  HH	   and	  MJ),	   revealed	   a	   potentially	   deleterious	   point	  mutation	  
affecting	  TRAF3	  in	  My-­‐La	  cells,	  substituting	  a	  serine	  for	  an	  asparagine	  in	  position	  233	  (Vaque	  
et	  al.	  Submitted).	  The	  discovery	  of	  a	  TRAF3	  mutation	  in	  a	  T	  cell	   lymphoma	  cell	   line	  is	  novel	  
and	  of	  interest,	  but	  the	  heterozygous	  nature	  of	  the	  mutation	  however,	  does	  not	  explain	  the	  
complete	   absence	  of	   TRAF3	  protein	   in	  My-­‐La	   cells.	  Moreover,	   absence	  of	   TRAF3	  does	  not	  
explain	  the	  overexpression	  of	  NIK	  that	  we	  observed	  at	  the	  transcriptional	   level.	   In	  Hodgkin	  
lymphoma,	   the	   simultaneous	   existence	   of	   MAP3K14	   amplifications	   and	   TRAF3	   deletions	  
have	   been	   described	   to	   occur	   in	   tumor	   samples	   (Otto	   et	   al.	   2012),	   suggesting	   that	   both	  
protein	   stabilization	   and	   transcriptional	   overexpression	   of	   NIK	   might	   be	   complementary	  
mechanisms	  to	  potentiate	  NIK	  signaling.	  Copy-­‐number	  studies	  of	  both	  MAP3K14	  and	  TRAF3	  
would	   give	   valuable	   insight	   to	   the	   mechanisms	   causing	   NIK	   overexpression	   in	   PTCL.	   The	  
upstream	  mechanisms	  leading	  to	  NIK	  overexpression	  in	  T	  cell	  lymphomas	  are	  at	  the	  moment	  
unidentified.	  Possible	   contributions	   to	  NF-­‐κB	  activation	   in	  T-­‐cell	   lymphomas	  are	  oncogenic	  
viruses	   (de	   Oliveira	   et	   al.	   2010)	   and	   signals	   from	   CD30	   (Buchan	   et	   al.	   2012)	   or	   the	   T-­‐cell	  
receptor	  (Schulze-­‐Luehrmann	  et	  al.	  2006;	  Wright	  et	  al.	  2007),	  but	  whether	  NIK	  is	  involved	  in	  
transmitting	   these	   signals	   is	   still	   to	   be	   clarified.	   Recently,	   mir-­‐31	   was	   reported	   to	   be	  
regulating	  the	  levels	  of	  NIK	  in	  tumors,	  where	  polycomb-­‐mediated	  repression	  of	  mir-­‐31	  led	  to	  
an	  overexpression	  of	  NIK	  (Yamagishi	  et	  al.	  2012).	  Analyzing	  the	  levels	  of	  mir-­‐31	  in	  our	  PTCL	  
cell	   lines,	   we	   observed	   a	   lack	   of	   mir-­‐31	   in	   several	   cell	   lines,	   but	   this	   absence	   was	  
independent	  of	   the	   levels	  of	  NIK	   (data	  not	   shown).	   It	   could	   also	  be	  hypothesized	   that	   the	  
activation	   of	   NIK	   and	   NF-­‐κB	   can	   be	   an	   effect	   of	   deregulated	   signaling	   of	   other	   pathways	  
Discussion	  	  
	  108	  
linked	   to	   T-­‐cell	   lymphomagenesis,	   such	   as	   the	   PI3K/AKT,	   NOTCH,	   or	   JAK/STAT	   pathway,	  
which	  can	  all	  result	  in	  NF-­‐κB	  activation	  (Oeckinghaus	  et	  al.	  2009).	  
	  
A	  major	  gap	  in	  our	  study	  is	  the	  inability	  to	  detect	  endogenous	  NIK	  protein	  in	  tumor	  samples.	  
A	   few	   previous	   works	   report	   the	   detection	   of	   NIK	   by	   immunohistochemistry	   on	   paraffin-­‐	  
embedded	   tumors	   (Pham	   et	   al.	   2011;	   Ranuncolo	   et	   al.	   2012).	   However,	   when	   we	   tested	  
these	   antibodies,	   as	   well	   as	   a	   range	   of	   additional	   NIK	   antibodies,	   none	   of	   these	   showed	  
specificity	   for	   NIK	   when	   tested	   in	   paraffin-­‐embedded	   cell	   lines	   where	   NIK	   had	   previously	  
been	   genetically	   depleted.	   A	   couple	   of	   attempts	   of	   generating	   NIK-­‐specific	   monoclonal	  
antibodies	   at	   the	  Monoclonal	   Antibody	  Unit	   at	   the	   CNIO,	   have	   been	  maid.	  Unfortunately,	  
these	  antibodies	  also	  failed	  to	  detect	  endogenous	  NIK	  levels.	  Moreover,	  the	  detection	  of	  NIK	  
by	  western	  blot	   is	   also	   complicated,	   since	   the	  pre-­‐treatment	  of	   cells	  with	   the	  proteasome	  
inhibitor	  MG-­‐132	  is	  needed	  prior	  to	  protein	  extraction	  in	  order	  to	  obtain	  detectable	  levels	  of	  
the	   protein.	  Hence,	   there	   is	   still	   a	   need	   for	   the	   development	   of	   specific	   and	   sensitive	  NIK	  
antibodies,	  which	  will	  permit	  us	  to	  detect	  endogenous	  expression	  of	  the	  protein.	  
	  
	  
5.2.3	  NIK-­‐regulated	  NF-­‐κB	  signaling	  in	  PTCL	  
	  
Several	  approaches	  were	  performed	  demonstrating	  the	  role	  of	  NIK	  as	  a	  regulator	  of	  NF-­‐κB	  
signaling	  in	  PTCL.	  In	  PTCL	  tumor	  samples,	  we	  showed	  that	  NIK	  expression	  was	  positively	  and	  
significantly	  correlated	  with	  the	  expression	  of	  NF-­‐κB	  target	  genes,	  indicating	  that	  NIK	  might	  
be	   involved	   in	   NF-­‐κB	   signaling	   in	   PTCL.	   From	   previous	   reports,	   the	   role	   of	   NIK	   in	   the	  
alternative	   NF-­‐κB	   pathway	   is	   clear,	   but	   the	   involvement	   of	   NIK	   in	   the	   regulation	   of	   the	  
classical	  pathway	  seems	  to	  be	  signal	  and	  cell	  type	  dependent	  (Zarnegar	  et	  al.	  2008;	  Thu	  et	  al.	  
2010).	   For	   example,	   in	   melanoma	   and	   pancreatic	   cancer,	   NIK	   only	   affects	   the	   alternative	  
pathway	   (Nishina	   et	   al.	   2009;	   Thu	   et	   al.	   2012),	   whereas	   NIK	   regulates	   both	   pathways	   in	  
DLBCL	   and	   multiple	   myeloma	   (Annunziata	   et	   al.	   2007;	   Pham	   et	   al.	   2011).	   Our	   functional	  
studies	   based	   on	   genetic	   knockdown	   of	   NIK	   in	   different	   PTCL	   cell	   lines,	   were	   able	   to	  
demonstrate	   that	  NIK	  regulated	  the	  signaling	  of	  both	  the	  classical	  and	  alternative	  axis	   in	  T	  
cell	   lymphoma.	  NIK	   knockdown	   led	   to	  decreased	  processing	  of	   p100	   and	  p105,	   decreased	  
nuclear	   levels	  of	  p52	  and	  p50,	  as	  well	  as	  a	  decreased	  DNA-­‐binding	  activity	  of	  both	  classical	  
(p65,	  p50,	  and	  c-­‐Rel)	  and	  alternative	  (p52	  and	  Rel-­‐B)	  NF-­‐κB	  transcription	  factors.	  Futhermore,	  
silencing	   of	   NIK	   also	   gave	   rise	   to	   a	   significant	   downregulation	   of	   NF-­‐κB	   target	   genes,	   as	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measured	  by	  whole	  genome	  expression	  profiling.	  Some	  of	  these	  target	  genes,	  are	  commonly	  
associated	  with	  classical	  NF-­‐κB	  signaling,	   such	  as	   IL6,	   IL10,	  and	  NFKBIA	   (coding	   the	  protein	  
IκBα)	   (Libermann	   et	   al.	   1990;	   Sun	   et	   al.	   1993).	   NIK	   has	   not	   previously	   been	   reported	   to	  
regulate	  the	  processing	  of	  p105.	  The	  reduced	  levels	  of	  p50	  observed,	  might	  be	  an	  effect	  of	  
direct	   NIK	   signaling	   or	   an	   indirect	   effect	   due	   to	   reduced	   NF-­‐κB	   target	   expression	   (NFKB1,	  
encoding	  p105,	  is	  a	  NF-­‐κB	  target).	  Then	  again,	  even	  though	  the	  detection	  of	  p50	  reduction	  is	  
a	   later	   event	   than	   the	   reduction	   of	   p52,	   the	   consistent	   and	   reproducible	   upregulation	   of	  
p105	   upon	  NIK	   knockdown	   in	  My-­‐La	   and	   SR-­‐786	   cells,	   suggest	   that	   there	   is	   a	   blockage	   in	  
p105	  processing.	  The	  mechanisms	  involved	  in	  p105	  processing	  are	  only	  partly	  clarified.	  P105	  
is	  normally	  constitutively	  processed	  to	  p50	  in	  unstimulated	  cells	  (Fan	  et	  al.	  1991;	  Palombella	  
et	  al.	  1994).	  IKKβ	  have	  also	  been	  reported	  to	  phosphorylate	  p105,	  which	  can	  lead	  to	  either	  
p50	   formation	   or	   complete	   degradation	   (Cohen	   et	   al.	   2004;	   Oeckinghaus	   et	   al.	   2009).	  
However,	   IKKβ	   knockdown	  didn’t	   give	   rise	   to	   any	   consistent	   reduction	  of	   p50	   in	   our	   cells,	  
proposing	   that	  NIK	  might	   regulate	   the	  processing	   of	   p105	   independently	   of	   IKKβ.	   If	  NIK	   is	  
able	   to	   bind	   directly	   to	   p105	   and	   induce	   its	   proteolysis,	   or	   if	   this	   is	   an	   indirect	   effect,	   is	  
though	  still	  to	  be	  explored.	  From	  our	  NIK	  knockdown	  results,	  we	  could	  also	  observe	  that	  NIK	  
depletion	   led	   to	   a	   decrease	   in	   phosphorylation	   of	   both	   IKKα	   and	   IKKβ.	   Evidences	   for	  NIK-­‐	  
induced	   phosphorylation	   of	   IKKα	   and	   IKKβ	   have	   previously	   been	   published	   in	   other	  
experimental	   settings	   (Woronicz	   et	   al.	   1997;	   Ling	   et	   al.	   1998;	   Delhase	   et	   al.	   1999).	  
Interestingly,	   reduced	   levels	  of	   total	   IKKα	  and	   IKKβ	  were	  also	  detected	  upon	  NIK	  silencing.	  
The	  transcriptional	  regulation	  of	  the	  genes	  encoding	  IKKα	  and	  IKKβ	  is	  not	  known,	  and	  they	  
are	  not	  described	  as	  NF-­‐κB	  target	  genes.	  On	  the	  other	  hand,	  the	  fact	  that	  NIK	  knockdown	  led	  
to	   a	   more	   efficient	   reduction	   of	   p50	   and	   p52	   in	   PTCL,	   compared	   with	   IKKα	   or	   IKKβ	  
knockdown,	   suggests	   that	   NIK	   can,	   at	   least	   in	   part,	   regulate	   the	   NF-­‐κB	   pathway	   by	   IKK-­‐	  
independent	  mechanisms.	  Consistent	  with	   these	   results,	  direct	  phosphorylation	  of	  p100	   in	  
an	   IKKα-­‐independent	  manner	   has	   been	   reported	   (Xiao	   et	   al.	   2001).	   The	   role	   of	  NIK	   in	   the	  
regulation	   of	   NF-­‐κB-­‐induced	   gene	   transcription	   in	   PTCL,	   was	   further	   confirmed	   examining	  
the	   gene	   expression	   profile	   in	   NIK-­‐silenced	   T	   cell	   lymphoma	   cells	   by	   whole	   genome	  
expression	  microarrays,	  where	  NF-­‐κB	  target	  genes	  were	  found	  significantly	  downregulated.	  
However,	  NIK	  does	  not	  seem	  to	  be	  strictly	  essential	  for	  NF-­‐κB	  activation	  in	  all	  PTCL	  cells,	  as	  
we	  found	  that	  nuclear	  NF-­‐κB	  was	  not	  exclusively	  expressed	   in	  NIK-­‐overexpressing	  cell	   lines	  
andcells	  with	  absent/low	  expression	  of	  NIK	  presented	  at	   least	  classical	  pathway	  activation.	  
Thus,	   the	   pathway	   may	   be	   activated	   by	   different	   mechanisms	   in	   these	   cells.	   A	   proper	  
identification	   of	   upstream	   mechanisms	   is	   important	   for	   efficient	   NF-­‐κB	   inhibition.	   The	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alternative	  pathway	  however,	  was	  only	  seen	  to	  be	  activated	  in	  cell	  lines	  expressing	  NIK	  or	  a	  
truncated	  form	  of	  p100,	  which	  permits	  bypassing	  NIK	  for	  alternative	  pathway	  activation(Neri	  
et	  al.	  1991;	  Chang	  et	  al.	  1995).	  Taken	  together,	  our	  data	  show	  that	  NIK	  has	  a	  profound	  effect	  
on	   NF-­‐κB	   regulation	   in	   PTCL,	   being	   a	   major	   gate-­‐keeper	   of	   the	   activation	   of	   all	   NF-­‐κB	  
transription	  factors.	  
	  
5.2.4	  NIK	  signaling	  and	  its	  effect	  on	  PTCL	  cell	  survival	  
	  
The	  mechanisms	   underlying	   T	   cell	   lymphomagenesis	   are	   poorly	   defined,	   partly	   due	   to	   its	  
heterogeneous	   presentation	   and	   lack	   of	   representative	   study	   models.	   PTCL	   is	   a	   highly	  
aggressive	  malignancy	  where	  proper	   targeted	   therapies	   are	   lacking	  due	   to	   the	   insufficient	  
knowledge	   about	   implicated	   pathologic	   mechanisms.	   Hence,	   studies	   clarifying	   its	  
pathobiology	   and	   the	   discovery	   of	   candidate	   molecular	   targets	   are	   needed	   and	   are	  
underway.	  Aberrant	  signaling	  of	  pathways	  employed	  by	  T	  cells	  in	  their	  normal	  development	  
and	  proliferation	  has	  been	  described	   in	   T	   cell	   neoplasms,	   such	  as	  deregulated	   signaling	  of	  
PI3K/AKT,	  NOTCH,	  MAPK,	  JAK/STAT,	  NF-­‐κB	  or	  Calcineurin/Nuclear	  factor	  of	  activated	  T-­‐cells	  
(NFAT)	  pathway.	  (Zhao	  2010;	  Martin-­‐Sanchez	  et	  al.	  2013),	  However,	  most	  of	  these	  evidences,	  
come	  from	  reports	  of	  Adult	  T	  cell	  leukemia,	  a	  T	  cell	  neoplasm	  not	  included	  in	  our	  work.	  Hints	  
about	  malignant	  mechanisms	  in	  PTCL	  can	  also	  be	  provided	  from	  therapeutic	  studies	  of	  novel	  
treatment	   alternatives.	   For	   instance,	   clinical	   efficacy	   has	   been	   achieved	   by	   histone	  
deacetylase	  ihibitors,	  such	  as	  Vorinostat	  and	  Panobinostat,	  in	  CTCL	  and	  PTCL,	  indicating	  that	  
aberrant	   epigenetic	   mechanisms	   might	   be	   involved	   in	   T	   cell	   lymphoma	   pathogenesis	  
(Wozniak	   et	   al.	   2010;	   Foss	   2013).	   Moreover,	   the	   use	   of	   monoclonal	   CD30	   antibodies	   as	  
therapy	   in	  ALCL,	  suggests	  a	  role	  for	  CD30	   in	  malignant	  signaling	  (Forero-­‐Torres	  et	  al.	  2009;	  
Foss	  2013).	  
	  
PTCL-­‐NOS	   and	   AITL	   are	   the	  most	   common	   subtypes	   of	   PTCL.	   Nevertheless,	   evidences	   for	  
their	  malignant	  mechanisms	  are	  poor	  and	  mainly	  based	  on	  gene	  expression	  profiling	  studies,	  
due	   to	   the	   fact	   that	   no	   PTCL-­‐NOS	   or	   AITL	   cell	   lines	   or	   animal	   models	   are	   available.	   The	  
functional	   studies	   in	   our	  work	  were	   conducted	   in	   T	   cell	   lymphoma	   cell	   lines	   representing	  
different	   PTCL	   subtypes;	  Mycosis	   fungoides,	   anaplástic	   T	   cell	   lymphoma,	   Sézary	   Syndrome	  
and	  γδ	  hepatosplenic	  T	  cell	  lymphoma.	  On	  the	  other	  hand,	  our	  expression	  studies	  in	  primary	  
T	   cell	   lymphoma	   samples	   and	   the	   clinical	   correlation	   studies,	   were	   performed	   in	   samples	  
diagnosed	   as	   PTCL-­‐NOS,	   AITL,	   ALCL	   and	   Sézary	   syndrome.	   Even	   though	   NIK	   expression	   in	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these	   samples	  was	   demonstrated	   to	   correlate	  with	   NF-­‐κB	   activation,	   the	   possibility	   exists	  
that	  the	  functional	  studies	  performed	  in	  this	  work,	  might	  not	  be	  fully	  extrapolated	  to	  all	  of	  
these	  subtypes.	  Unfortunately,	  appropriate	  models	  are	  absent	  for	  most	  PTCL	  subtypes.	  
	  
The	  activated	  NF-­‐κB	  pathway	  reported	  in	  some	  subtypes	  of	  T	  cell	  lymphoma	  by	  us	  (Wozniak	  
et	  al.	  2009;	  Odqvist	  et	  al.	  2013)	  and	  others	  (Martinez-­‐Delgado	  et	  al.	  2005;	  Sors	  et	  al.	  2006),	  
together	  with	  studies	  showing	  that	  the	  inhibition	  of	  NF-­‐κB	  in	  PTCL	  cell	  lines	  leads	  to	  reduced	  
cell	   survival	   (Izban	   et	   al.	   2000;	   Sors	   et	   al.	   2006),	   points	   toward	   the	   possibility	   that	   NF-­‐κB	  
might	  be	  involved	  in	  PTCL	  pathogenesis.	  In	  CTCL	  cell	  lines,	  pharmacological	  inhibition	  of	  IKKβ	  
has	   been	   shown	   to	   induce	   apoptosis	   (Sors	   et	   al.	   2008).	  Moreover,	   Bortezomib	   has	   shown	  
clinical	  efficacy	  in	  some	  PTCL	  subtypes	  such	  as	  CTCL	  and	  PTCL-­‐NOS(Zinzani	  et	  al.	  2007;	  Foss	  
2013),	   and	   the	   antineoplastic	   activities	   of	   Bortezomib	   have	   partly	   been	   attributed	   to	   the	  
ability	  to	  block	  NF-­‐κB	  activation	  (McConkey	  et	  al.	  2008).	  In	  order	  to	  specifically	  and	  properly	  
block	   NF-­‐κB	   in	   tumors,	   key	   regulators	   of	   the	   pathological	   NF-­‐κB	   activation	   should	   be	  
identified.	   IKKβ	   inhibitors	  have	  been	  available	   for	   several	   years	  but	  have	  not	  been	  able	   to	  
make	  their	  way	  into	  the	  clinical	  setting,	  implying	  that	  novel	  targets	  in	  the	  signaling	  cascade	  
are	  desirable.	  
	  
The	  present	  study	  revealed	  a	  pivotal	  role	  for	  NIK	  in	  the	  survival	  of	  T-­‐cell	  lymphoma	  cells.	  NIK	  
knockdown	  strongly	  reduced	  the	  cell	  viability	  and	   induced	  apoptosis	   in	  PTCL	  cell	   lines.	  The	  
selective	   toxicity	   for	   siNIK	   to	   NIK-­‐overexpressing	   cells	   observed	   in	   this	   work,	   highlights	  
several	  important	  issues.	  First,	  it	  confirms	  the	  specificity	  of	  the	  siRNA	  sequences.	  Second,	  it	  
provides	  a	  tool	  for	  identifying	  potentially	  targetable	  tumors.	  And	  third,	  it	  suggests	  that	  NIK-­‐	  
targeting	  could	  have	  a	   selective	  effect	  on	  NIK-­‐expressing	  cells,	  while	   leaving	  cells	  with	   low	  
NIK	   levels,	   like	  healthy	  T	  cells,	  unaffected.	  The	  potent	  cell-­‐killing	  effect	  observed	  upon	  NIK	  
depletion	  in	  My-­‐La	  or	  SR-­‐786	  cells,	  could	  not	  be	  reproduced	  by	  knocking	  down	  either	  one	  or	  
both	  of	  its	  targets,	  IKKα	  or	  IKKβ.	  Even	  though	  the	  knockdown	  of	  these	  kinases	  also	  gave	  rise	  
to	  an	  increase	  in	  cell	  death,	  comparable	  or	  even	  lower	  efficiencies	  of	  NIK	  knockdown	  led	  to	  a	  
more	  profound	  effect	   on	   cell	   survival.	  Hence,	   other	  or	   additional	  mechanisms	  besides	   the	  
reduction	  of	   IKK	  activation,	   seen	  upon	  NIK	  depletion,	  must	  be	   responsible	   for	  NIK-­‐induced	  
cell	  death.	  Furthermore,	  the	  elimination	  of	  only	  the	  alternative	  NF-­‐κB	  factors,	  RelB	  and	  p100,	  
was	  not	  able	  to	  induce	  apoptosis	  in	  PTCL	  cell	  lines.	  This	  indicates	  that	  NIK-­‐induced	  survival	  is	  
not	  dependent	  solely	  on	  alternative	  NF-­‐κB	  activation,	  in	  contrast	  to	  other	  studies	  where	  RelB	  
has	  been	  described	  as	  critical	  for	  NIK-­‐induced	  survival	   in	  Hodgkin	  lymphoma	  (Ranuncolo	  et	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al.	  2012).	  Of	  the	  four	  NF-­‐κB	  factors	  expressed	  in	  PTCL,	  only	  the	  knockdown	  of	  c-­‐Rel	  showed	  
any	  significant	  effect	  on	  PTCL	  survival.	  As	  mentioned	  before,	  c-­‐Rel	  has	  transforming	  abilities	  
and	   its	   locus	   has	   been	   found	   amplified	   in	   several	   tumors	   (Martin-­‐	   Subero	   et	   al.	   2002;	  
Gilmore	   et	   al.	   2004).	   A	   small	   subgroup	   of	   PTCL-­‐NOS	   have	   recently	   been	   characterized	   by	  
chromosomal	  aberrations	  with	  REL	  locus	  amplifications(Hartmann	  et	  al.	  2010).	  However,	  its	  
importance	   and	   the	   role	   of	   c-­‐Rel	   in	   T	   cell	   lymphoma	   pathogenesis	   have	   not	   been	  
investigated.	   Since	   NIK	   reduces	   the	   levels	   of	   nuclear	   c-­‐Rel	   as	   well	   as	   c-­‐Rel	   DNA-­‐	   binding	  
activity,	   the	   role	   of	   NIK	   in	   PTCL	   survival	   signaling	  might	   partly	   be	  mediated	   by	   c-­‐Rel.	   The	  
combined	   effect	   of	   other	   NF-­‐κB	   members	   might	   also	   be	   important	   for	   PTCL	   survival,	  
although	   individual	   loss	  did	  not	  show	  any	  effect.	   It	  should	  also	  be	  mentioned	  that	  the	  full-­‐	  
length	  p100	  and	  p105	  proteins	  can	  act	  both	  as	  inhibitors	  of	  NF-­‐κB	  and	  as	  precursors	  for	  p52	  
and	   p50	   (Oeckinghaus	   et	   al.	   2009).	   For	   that	   reason,	   a	   knockdown	   of	   these	   precursors	   as	  
performed	  in	  our	  cell	  lines	  with	  siRNA	  (leading	  to	  reduced	  expression	  of	  both	  the	  precursors	  
and	  the	  processed	  proteins)	  might	  give	  a	  different	  outcome	  than	  the	  blocked	  processing	  of	  
p100	  and	  p105	  seen	  after	  NIK	  silencing	  (where	  the	  precursors	  were	  still	  expressed).	  
	  
To	   investigate	   the	   possible	   downstream	   effectors	   of	   NIK-­‐regulated	   signaling	   and	  
tumorigenesis,	  we	  conducted	  whole	  genome	  gene	  expression	  analysis	  of	  NIK-­‐silenced	  T-­‐cell	  
lymphoma	   cells.	   As	   expected,	   many	   of	   the	   genes	   differentially	   expressed	   between	   NIK-­‐	  
silenced	  and	  control	  cells	  were	  NF-­‐κB	  target	  genes	  known	  to	  be	  important	  in	  the	  regulation	  
of	  tumor	  growth	  and	  survival.	  The	  expression	  of	  anti-­‐apoptotic	  proteins,	  such	  as	  c-­‐FLIP,	  Mcl-­‐	  
1,	  Survivin	  and	  Bcl-­‐XL,	  is	  one	  of	  the	  mechanisms	  by	  which	  tumor	  cells	  manage	  to	  survive	  in	  
the	   environment	   and	   to	   resist	   chemotherapy	   (Kelly	   et	   al.	   2002).	   Overexpression	   of	   anti-­‐	  
apoptotic	  proteins	  has	  been	  suggested	  to	  be	  involved	  in	  the	  pathogenesis	  of	  PTCL	  (Jung	  et	  al.	  
2006).	   For	   instance,	   c-­‐FLIP	   has	   been	   described	   to	   protect	   ALCL	   cells	   from	   FAS-­‐induced	  
apoptosis	   (Oyarzo	   et	   al.	   2006)	   and	   to	   protect	   cutaneous	   T-­‐cell	   lymphoma	   cell	   lines	   from	  
antitumor	   treatment	   (Al-­‐Yacoub	   et	   al.	   2012).	   Furthermore,	   Bcl-­‐2–related	   anti-­‐apoptotic	  
proteins	   (Bcl-­‐2,	  Mcl-­‐1	  and	  Bcl-­‐XL)	  have	  been	   found	  highly	  expressed	   in	  PTCL	   tumor	   tissues	  
and	  their	  expression	  correlated	  with	  low	  apoptotic	  rate	  and	  high	  proliferation	  (Rassidakis	  et	  
al.	  2003).	  Upon	  NIK	  knockdown	  in	  T	  cell	  lymphoma	  cell	  lines,	  we	  observed	  a	  downregulation	  
of	  several	  anti-­‐apoptotic	  genes,	  such	  as	  CFLAR	  (encoding	  Bcl-­‐xl),	  BIRC3	  (cIAP2),	  and	  BCL2L1	  
(c-­‐FLIP).	  The	  downregulation	  of	  these	  genes,	  all	  NF-­‐κB	  targets	  (Kreuz	  et	  al.	  2001;	  Turner	  et	  al.	  
2007;	   Pradhan	   et	   al.	   2012),	   might	   explain	   the	   strong	   induction	   of	   apoptosis	   observed	   in	  
these	   cells	   after	  NIK	   inhibition.	   A	   differential	   effect	   on	   the	   expression	   of	   these	   genes	  was	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though	   observed	   in	   the	   cell	   lines.	   While,	   BCL2L1	   expression	   was	   reduced	   in	   My-­‐La	   and	  
remained	  unchanged	  in	  SR-­‐786	  after	  NIK	  knockdown,	  the	  levels	  of	  CFLAR	  were	  only	  reduced	  
in	  SR-­‐786.	   In	  a	  melanoma	  cell	   line,	  NIK	  was	  also	  shown	  to	   regulate	   the	  expression	  of	  anti-­‐	  
apoptotic	   factors,	   but	   in	   this	   case	   survivin	   and	   BCL2,	   and	   not	   the	   ones	   affectedin	   our	  
experimental	  setting	  (Thu	  et	  al.	  2012).	  In	  fact,	  the	  levels	  of	  survivin	  were	  unchanged	  in	  T	  cell	  
lymphoma	  cells	  after	  NIK	  depletion,	  indicating	  that	  NIK	  and	  NF-­‐κB	  can	  engage	  different	  anti-­‐	  
apoptotic	  players	  in	  different	  cellular	  contexts.	  
	  
Other	   NF-­‐κB	   target	   genes	   that	   were	   strongly	   and	   consistently	   downregulated	   after	   NIK	  
knockdown	  in	  MyLa	  and	  SR-­‐786	  cells,	  were	  the	  cytokines	  IL-­‐6	  and	  IL-­‐21.	  These	  cytokines	  are	  
involved	  in	  normal	  B-­‐	  and	  T-­‐cell	  development	  and	  a	  in	  the	  proper	  regulation	  of	  the	  immune	  
response,	  but	  have	  also	  been	  widely	  studied	  in	  several	  tumors	  owing	  to	  their	  protumorigenic	  
activity	  and	  their	  roles	  as	  targets	  for	  cancer	  therapy	  (Grivennikov	  et	  al.	  2009;	  Ma	  et	  al.	  2011).	  
IL-­‐6	  and	  IL-­‐21	  are	  involved	  in	  JAK/STAT	  signaling	  and	  can	  give	  rise	  to	  both	  STAT3	  and	  STAT5	  
phosphorylation	  (Dien	  Bard	  et	  al.	  2009;	  Sansone	  et	  al.	  2012;	  van	  der	  Fits	  et	  al.	  2012).	  STAT	  
transcription	   factors	   regulate	   cellular	   processes	   such	   as	   proliferation,	   cell	   migration	   and	  
survival	   and	   a	   deregulated	   JAK/STAT	   pathway	   has	   been	   described	   in	   several	   tumors,	  
including	  T	  cell	  lymphomas	  (Eriksen	  et	  al.	  2001;	  Vainchenker	  et	  al.	  2013).	  Curiously,	  in	  spite	  
of	   an	   activated	   NF-­‐κB	   pathway	   in	   NIK-­‐negative	   cell	   lines,	   only	   the	   NIK-­‐positive	   cell	   lines	  
expressed	  high	  levels	  of	  IL-­‐6	  and	  IL-­‐21	  as	  well	  as	  pSTAT3	  and	  pSTAT5,	  indicating	  a	  different	  
NF-­‐κB	   transcriptional	   program	   in	   NIK-­‐positive	   versus	   NIK-­‐negative	   cells.	   The	  
underrepresentation	  of	  JAK/STAT	  pathway	  genes	  in	  siNIK	  cells	  observed	  in	  the	  GSEA	  analysis	  
gave	   us	   a	   hint	   that	   NIK	   might	   be	   involved	   in	   the	   regulation	   of	   this	   pathway	   as	   well.	   To	  
confirm	  this,	  we	  observed	  reduced	  levels	  of	  both	  pSTAT3	  and	  pSTAT5	  after	  NIK	  knockdown	  
in	  T	  cell	  lymphoma	  cells.	  We	  further	  showed	  that	  exogenous	  IL-­‐21,	  but	  not	  IL-­‐6,	  was	  able	  to	  
induce	  STAT3	  phosphorylation	  and	  restore	  pSTAT3	   levels	   in	  siNIK	  cells,	  proposing	   IL21	  as	  a	  
possible	  intermediate	  between	  the	  NF-­‐κB	  and	  JAK/STAT	  pathways.	  However,	  further	  studies,	  
as	  for	  example	  IL21	  inhibition	  or	  knockdown,	  should	  be	  performed	  to	  verify	  that	  IL21	  is	  the	  
responsible	  mediator	  of	  STAT	  activation.	  The	  addition	  of	   IL21	  to	  siNIK	  cells	  was	  though	  not	  
sufficient	   to	   fully	  or	  even	  partly	   rescue	   the	  apoptosis	   induced	  by	  siNIK.	  Furthermore,	  even	  
though	   STAT3	   activation	   has	   been	   proposed	   as	   a	   possible	   oncogenic	   mechanism	   in	  
cutaneous	  T	  cell	   lymphomas(Nielsen	  et	  al.	  1999),	  effective	  silencing	  of	  STAT3	   in	  MyLa	  cells	  
was	  not	  able	  to	  induce	  cell	  death,	   indicating	  that	  STAT3	  inhibition	  alone	  is	  not	  sufficient	  to	  
induce	  apoptosis.	  These	  results	  describe	  for	  the	  first	  time	  an	   interesting	  crosstalk	  between	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NIK	   and	   the	   JAK/STAT	   pathway,	   integrating	   two	   important	   survival	   pathways	   in	   T	   cell	  
lymphomagenesis.	  IL6	  and	  IL21	  were	  though	  not	  the	  only	  cytokines	  with	  altered	  expression	  
in	   siNIK	   cells,	   since	   other	   cytokines	   such	   as	   IL15	   and	   IL1,	   also	   involved	   in	  malignant	   T	   cell	  
proliferation	   and	   survival	   pathways(Shirakawa	   et	   al.	   1989;	   Marzec	   et	   al.	   2008),	   were	  
downregulated	  in	  both	  MyLa	  and	  SR-­‐786	  cells	  after	  NIK	  knockdown	  as	  well.	  
	  
Interestingly,	  one	  of	   the	  NIK	  knockdown-­‐sensitive	  cell	   lines	   in	  our	  study,	  SR-­‐786,	  expresses	  
the	  oncogenic	  fusion	  protein	  NPM-­‐ALK,	  as	  a	  result	  of	  a	  chromosomal	  translocation	  occurring	  
frequently	   in	   a	   subset	   of	  ALCL	   patients	   (Morris	   et	   al.	   1994).	   The	   critical	   role	   of	  NIK	   in	   the	  
survival	  of	  SR-­‐786	  cells,	  indicates	  that	  NIK	  is	  involved	  either	  in	  the	  downstream	  signaling	  of	  
NPM-­‐ALK	  or	  in	  a	  complementary	  mechanism	  required	  to	  assure	  the	  survival	  of	  these	  cells.	  
	  
The	   expression	   of	   other	   genes	   involved	   in	   tumorigenesis,	   not	   described	   as	   NF-­‐κB	   targets,	  
was	   also	   modulated	   after	   NIK	   knockdown.	   Unexpectedly,	   one	   of	   the	   most	   significantly	  
downregulated	   gene	   sets	   in	   siNIK	   cells,	   was	   the	   XBP1	   targets.	  Moreover,	   XBP1	   itself	   was	  
downregulated	   in	   siNIK	  My-­‐La	  cells,	  but	  not	   in	  SR-­‐786.	  XBP1	   (X	  box-­‐binding	  protein	  1)	   is	  a	  
transcription	  factor	  involved	  in	  the	  regulation	  of	  endoplasmatic	  reticulum	  (ER)	  homeostasis,	  
including	  protein	  folding,	  trafficking	  and	  degradation(Acosta-­‐Alvear	  et	  al.	  2007).	   It	  was	  first	  
described	   as	   a	   transcription	   factor	   regulating	   the	  major	   histocompatibility	   complex	   (MHC)	  
genes	   in	   B	   cells(Liou	   et	   al.	   1990)	   and	   is	   also	   necessary	   for	   plasma	   cell	   differentiation	  
(Reimold	  et	  al.	  2001).	  In	  the	  last	  decade,	  a	  role	  for	  XBP1	  as	  a	  key	  transcription	  factor	  in	  the	  
unfolded	  protein	  response	  (UPR)	  has	  been	  established	  (He	  et	  al.	  2010).	  UPR	  has	  been	  linked	  
to	  human	  cancer,	  where	  XBP1	  has	  been	  shown	  to	  be	  activated	  and	  act	  as	  a	  survival	  factor,	  
for	   instance	   in	  multiple	  myeloma	   (Romero-­‐Ramirez	   et	   al.	   2004;	  Mimura	   et	   al.	   2012).	   The	  
activation	  of	  XBP1	  is	  controlled	  by	  a	  mRNA	  splicing	  reaction,	  generating	  a	  spliced	  and	  active	  
form	   of	   XBP1(Calfon	   et	   al.	   2002).	   To	   examine	   whether	   XBP1	   was	   activated	   in	   our	   T	   cell	  
lymphoma	   cell	   lines,	   we	   analyzed	   the	   expression	   of	   spliced	   (active)	   or	   unspliced	   XBP1	   by	  
semiquantitative	  PCR.	  However,	  only	  the	  unspliced	  variant	  was	  detected,	  suggesting	  that	  the	  
XBP-­‐1	  pathway	  is	  not	  activated	  in	  our	  panel	  of	  cell	   lines	  (data	  not	  shown).	  The	  explanation	  
and	   link	   between	   siNIK	   and	   the	   reduction	   of	   XBP1	   targets	   observed	   in	   our	   analysis	   thus	  
remain	  unclear.	  
	  
Another	  example	  of	  tumor-­‐associated	  genes	  with	  altered	  expression	  after	  NIK	  knockdown	  is	  
tumor	   suppressor	  KLF-­‐2,	  which	  was	   seen	   strongly	  upregulated	  after	  NIK	  knockdown.	  Since	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KLF-­‐2	   possesses	   antiproliferative	   and	   antitumor	   characteristics	   (Taniguchi	   et	   al.	   2012),	   we	  
explored	   the	   possibility	   that	   KLF-­‐2	   might	   be	   involved	   in	   mediating	   NIK-­‐induced	   survival.	  
However,	  the	  knockdown	  of	  KLF-­‐2	  together	  with	  NIK	  knockdown,	  was	  not	  able	  to	  influence	  
the	   phenotype	   induced	   by	   siNIK.	   Yet,	   only	   the	   effect	   on	   apoptosis	   was	   analyzed	   and	   it	  
cannot	   be	   excluded	   that	   a	   difference	   in	   the	   proliferative	   capacity	   of	   the	   cells	   would	   be	  
present.	  The	  effect	  of	  siNIK	  on	  non-­‐	  NF-­‐κB	  targets	  could	  either	  indicate	  NF-­‐κB-­‐independent	  
functions	   of	   NIK,	   or	   the	   presence	   of	   interactions	   between	   NF-­‐κB	   and	   other	   signaling	  
pathways.	  In	  fact,	  the	  involvement	  of	  NIK	  in	  non-­‐NF-­‐kB-­‐signaling	  has	  been	  described,	  such	  as	  
MAPK	   signaling	   in	   neural	   differentiation(Foehr	   et	   al.	   2000)	   and	   β-­‐catenin	   signaling	   in	  
melanoma	  (Thu	  et	  al.	  2012).	  
	  
In	  summary,	  NIK	  knockdown	  gave	  rise	  to	  reduced	  NF-­‐κB	  activation	  and	  to	  the	  simultaneous	  
deregulation	  of	  several	  important	  genes	  and	  pathways	  involved	  in	  tumorigenesis.	  We	  aimed	  
to	  explore	  a	   few	  of	  them	  with	  the	  hope	  to	  further	  explain	  the	  mechanisms	  of	  NIK-­‐induced	  
survival	  in	  PTCL.	  However,	  the	  multifunctional	  role	  of	  NIK	  observed	  in	  this	  analysis,	  could	  not	  
be	   explained	   or	   sustained	   by	   the	   modulation	   of	   single	   genes,	   and	   the	   function	   of	   NIK	   is	  
probably	   dependent	   on	   a	   coordinated	  network	   of	   signaling	   pathways	  where	  NIK	   acts	   as	   a	  
gatekeeper.	  
	  
5.2.5	  The	  NF-­‐κB	  pathway	  and	  NIK	  as	  therapeutic	  potentials	  in	  lymphomas	  
	  
Since	   the	   observation	   that	   NF-­‐κB	   is	   involved	   in	   the	   pathogenesis	   of	   a	   range	   of	   different	  
cancers,	  (Davis	  et	  al.	  2001;	  Annunziata	  et	  al.	  2007;	  DiDonato	  et	  al.	  2012)	  investigators	  have	  
been	   trying	   to	   inhibit	   the	   pathway	   in	   order	   to	   achieve	   anti-­‐tumor	   activity.	   The	   antitumor	  
activity	  of	  NF-­‐κB	  inhibition	  can	  be	  explained	  by	  the	  ability	  of	  NF-­‐κB	  to	  evade	  apoptosis	  and	  
to	   promote	   proliferation	   and	   survival(DiDonato	   et	   al.	   2012).	   Moreover,	   NF-­‐κB	   has	   been	  
shown	  to	  block	  the	  apoptotic	  action	  of	  cytotoxic	  agents,	  suggesting	  that	  the	  addition	  of	  NF-­‐	  
κB	   inhibitors	   to	  chemotherapy	  regimens	  would	  be	  worth	  exploring	   (Baldwin	  2001;	  Al-­‐Katib	  
et	  al.	  2010).	   In	  spite	  of	  tremendous	  efforts	   in	  clarifying	  the	  role	  of	  NF-­‐κB	  in	  normal	  biology	  
and	  disease	  over	  the	  past	  25-­‐30	  years,	  no	  specific	  NF-­‐κB	  inhibitor	  has	  made	  its	  way	  into	  the	  
clinical	  practice.	  Thus,	  the	  need	  remains	  to	  identify	  novel	  therapeutic	  targets	  in	  the	  pathway	  
that	   can	   be	   applied	   in	   a	   relevant	   characterized	   subtype	   of	   tumors.	   Likewise,	   the	  
development	  of	  specific	  NF-­‐κB	  inhibitor	  molecules	  has	  to	  progress	  in	  the	  same	  direction.	  The	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proteasome	  inhibitor	  Bortezomib	  has	  shown	  clinical	  efficacy	  in	  some	  tumors	  and	  is	  currently	  
being	   used	   in	   the	   treatment	   of	   multiple	   myeloma	   and	   relapsed	   ⁄	   refractory	   mantle	   cell	  
lymphoma(Chen	   et	   al.	   2011).	   Several	   studies	   suggest	   that	   NF-­‐κB	   plays	   a	   key	   role	   in	   the	  
mechanism	  of	   action	  and	   clinical	  outcome	  of	  Bortezomib	   (Adams	  2004;	  Chen	  et	   al.	   2011),	  
although	   this	   has	   been	   debated	   (Hideshima	   et	   al.	   2009).	   Given	   the	   diverse	   effects	   of	  
proteasome	  inhibition,	  it	  is	  difficult	  to	  define	  a	  clinically	  relevant	  mechanism	  of	  action	  of	  this	  
drug	   and	   hence,	   Bortezomib	   cannot	   be	   considered	   a	   true	   NF-­‐κB	   inhibitor	   drug.	   In	   the	  
preclinical	   setting,	   a	   large	   number	   of	   publications	   has	   investigated	   the	   rationale	   for	   IKKβ	  
inhibition	   in	   various	   tumors,	  using	  different	   synthetic	   small	  molecule	   inhibitors	   (Lam	  et	  al.	  
2005;	   Sors	   et	   al.	   2008;	   DiDonato	   et	   al.	   2012).	   In	   spite	   of	   the	   demonstrated	   efficacy	   in	  
experimental	   models,	   no	   IKKβ	   inhibitor	   has	   though	   been	   clinically	   approved.	   A	   few	   IKKβ	  
inhibitors	  have	  been	  tested	  in	  clinical	  trials	  against	  inflammatory	  diseases	  showing,	  however,	  
a	  concerning	  toxicity	  profile,	  partly	  due	  to	  the	   induced	  expression	  of	   IL1-­‐β(Liu	  et	  al.	  2012).	  
Moreover,	   a	   compensatory	   mechanism	   activating	   IKKα	   has	   been	   reported	   after	   IKKβ	  
inhibition	   in	   ABC-­‐DLBCL(Lam	   et	   al.	   2008).	   Novel	   targets	   in	   the	   NF-­‐κB	   pathway	   are	   now	  
emerging	   with	   the	   hope	   of	   a	   safe	   and	   specific	   anti-­‐tumor	   response.	   Inhibitors	   targeting	  
mutated	   or	   aberrantly	   expressed	   molecular	   targets	   in	   a	   particular	   tumor,	   might	   be	  
preferable	   to	   broad	   NF-­‐κB	   inhibition	   which	   also	   abolishes	   normal	   NF-­‐κB	   activation	   and	  
potentially	  present	  more	  severe	  adverse	  effects.	  The	  ideal	  situation	  would	  be	  an	  arsenal	  of	  
different	  compounds	  directed	  against	  specific	  molecular	  targets	  in	  the	  NF-­‐κB	  pathway,	  each	  
being	  uniquely	  suited	  for	  the	  use	  in	  a	  specific	  subset	  of	  tumors,	  identified	  by	  biomarkers.	  In	  
line	   with	   this,	   NF-­‐κB	   has	   been	   indirectly	   inhibited	   by	   targeting	   upstream	   pathological	  
mechanisms,	   such	   as	   Bruton	   tyrosine	   kinase	   (BTK)	   in	   ABC-­‐DLBCL	  with	   constitutively	   active	  
BCR	   signaling(Davis	   et	   al.	   2010;	   Honigberg	   et	   al.	   2010),	   or	   by	   inhibiting	   interleukin-­‐1	  
receptor-­‐associated	  kinase	  4	  (IRAK4)	  in	  Myd88	  driven	  DLBCL(Ngo	  et	  al.	  2011).	  
	  
PTCLs	  are	  highly	  aggressive	  malignancies	  that	  currently	  lack	  efficient	  therapies.	  We	  showed	  
that	   PTCL	   associated	   with	   NF-­‐κB	   activation,	   was	   characterized	   by	   an	   even	   worse	   clinical	  
outcome.	   IKKβ	   inhibition	   has	   previously	   been	   proposed	   as	   putative	   treatment	   strategy	   in	  
PTCL	   (Sors	   et	   al.	   2008).	   Accordingly,	  we	   also	   observed	   an	   increase	   in	   apoptosis	   after	   IKKß	  
knockdown	  in	  PTCL	  cell	  lines.	  IKKα	  depletion	  also	  gave	  rise	  to	  a	  significant	  increase	  in	  T	  cell	  
lymphoma	  cell	  death,	  but	  taken	  together,	  the	  effect	  of	  IKK	  knockdown	  was	  weak	  and	  p50	  
	  and	   p52	   expression	   still	   remained	   after	   IKK	   knockdown.	   Moreover,	   since	   IKKβ	   inhibition	  
presents	  considerable	  adverse	  effect	  in	  clinical	  use,	  other	  NF-­‐κB	  targets	  would	  be	  desirable.	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C-­‐Rel	  was	  also	  shown	  to	  be	  a	  mediator	  of	  survival	  in	  T	  cell	  lymphoma	  cell	  lines	  characterized	  
by	  NIK	  overexpression.	  However,	  since	  c-­‐Rel	  is	  a	  transcription	  factor,	  the	  development	  of	  a	  
specific	  inhibitor	  would	  be	  challenging.	  We	  propose	  NIK	  as	  a	  promising	  molecular	  target	  in	  T	  
cell	  lymphomas	  for	  several	  reasons.	  First,	  NIK	  is	  overexpressed	  in	  a	  subset	  of	  PTCL	  cell	  lines	  
and	  primary	  samples.	  Second,	  targeting	  NIK	  by	  siRNAs	  in	  T	  cell	  lymphoma	  cell	  lines	  led	  to	  a	  
massive	   induction	   of	   apoptosis.	   Third,	   reduced	   survival	   upon	   NIK	   knockdown	   was	   only	  
observed	   in	  NIK-­‐overexpressing	   cells.	   Forth,	  NIK	  was	   found	   to	  be	  a	   key	   regulator	  of	  NF-­‐κB	  
expression	  and	  was	  also	  seen	  to	   regulate	  other	   important	  pathways	   in	  PTCL	  pathogenesis.	  
Furthermore,	   since	  NIK	   is	   a	   kinase,	   it	   is	   druggable,	  which	   facilitates	   the	   development	   of	   a	  
pharmacological	  inhibitor.	  There	  are	  still	  no	  specific	  NIK	  inhibitors	  available	  today,	  although	  
they	  are	   in	   the	  developmental	  process	   in	   several	  pharmaceutical	   companies(Mortier	  et	  al.	  
2010).	   Moreover,	   although	   NIK-­‐deficient	   mice	   exhibit	   defects	   in	   lymphoid	   organogenesis,	  
they	   do	   not	   present	   any	   gross	   phenotypic	   changes	   (Yin	   et	   al.	   2001),	   suggesting	   that	  
pharmacologic	   inhibition	   of	   NIK	  might	   be	   safer	   than	   broad	   NF-­‐κB	   inhibition.	   Interestingly,	  
our	  group	  also	  identified	  NIK	  as	  one	  of	  the	  key	  markers	  for	  poor	  response	  in	  cutaneous	  T	  cell	  
lymphoma	  patients	  treated	  with	  interferon	  alpha	  and	  photo-­‐chemotherapy,	  where	  the	  gene	  
encoding	   NIK	   (MAP3K14)	   was	   upregulated	   in	   non-­‐responders(Wozniak	   et	   al.	   2009).	   This	  
observation	   suggests	   that	   NIK	   targeting	   could	   be	   interesting	   to	   further	   validate	   in	   tumors	  
from	   patients	   with	   poor	   response	   to	   conventional	   therapy.	   Clearly,	   additional	   studies	   are	  
required	   to	   fully	   explore	   the	   therapeutic	   potential	   of	   NIK,	   involving	   in	   vivo	   and	   ex	   vivo	  
models,	  as	  well	  as	  the	  use	  of	  pharmaceutical	  NIK	  inhibitors.	  Apparently,	  NIK	  is	  only	  involved	  
in	   NF-­‐κB	   activation	   in	   a	   subset	   of	   PTCLs,	   and	   the	   upstream	   mechanisms	   leading	   to	   the	  
activation	  of	  NF-­‐κB	  in	  other	  cases	  remain	  to	  be	  discovered.	  Our	  study,	  will	  hopefully	  provide	  
insight	  into	  the	  mechanisms	  and	  importance	  of	  NF-­‐κB	  activation	  in	  PTCL,	  and	  lead	  to	  further	  
validation	  of	  NIK	  as	  a	  potential	  target	  in	  NIK-­‐overexpressing	  PTCL.	  
 
 
5.3	  Final	  remarks	  and	  perspectives	  
	  
The	  work	  presented	  in	  this	  doctoral	  thesis	  integrates	  expression	  studies	  from	  human	  tumor	  
samples	  with	  functional	  experimental	  models,	  in	  order	  to	  gain	  a	  better	  insight	  into	  the	  role,	  
regulation	  and	   targeting	  potentials	  of	   the	  NF-­‐κB	  pathway	   in	   lymphomas.	  However,	   several	  
open	  questions	  and	  areas	  of	  future	  research	  remain.	  The	  complex	  expression	  pattern	  of	  NF-­‐	  
κB	  observed	  in	  primary	  lymphoma	  tumors	  is	  an	  example	  and	  an	  indication	  that	  the	  simplistic	  
view	  of	  NF-­‐κB,	  usually	  used	  in	  functional	  studies,	  is	  ambiguous.	  The	  diverse	  clinical	  impacts	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and	   functional	   roles	   of	   the	   distinct	   NF-­‐κB	   members	   observed	   in	   this	   work,	   indicate	   the	  
existence	  of	  subunit-­‐specific	  transcriptional	  programs.	  It	  would	  be	  interesting	  to	  characterize	  
the	   transcriptional	   programs	   induced	   by	   different	   NF-­‐κB	   factors	   in	   these	   tumors.	   The	  
heterogeneous	   behavior	   of	   NF-­‐κB	   in	   different	   tumors	   highlights	   the	   importance	   of	  
investigating	  signaling	  pathways	  in	  a	  context-­‐specific	  manner,	  and	  puts	  forward	  the	  difficulty	  
of	  extrapolating	  results	  between	  particular	  tumors	  and	  settings.	  The	  mechanisms	  leading	  to	  
NF-­‐κB	  activation	  are	  diverse	  and	  NF-­‐κB	   interfering	   strategies	  have	   to	  be	  evaluated	   in	  each	  
tumor	  subtype.	   In	  this	  manner,	  we	  believe	  that	  options	  for	  NF-­‐κB	   inhibition	   in	  GCB-­‐	  DLBCL	  
should	  be	  explored	  in	  future	  studies.	  The	  role	  of	  NIK	  in	  tumorigenesis,	  shown	  by	  us	  and	  by	  
others,	  will	  hopefully	  lead	  to	  the	  development	  of	  specific	  NIK	  inhibitors	  that	  will	  permit	  us	  to	  
fully	  explore	  its	  therapeutic	  potential.	  Still,	  further	  studies	  are	  required,	  including	  the	  use	  of	  
animal	   models	   and	   patient	   samples,	   to	   validate	   NIK	   as	   a	   target	   and	   to	   maximize	   its	  
therapeutic	   possibilities	   in	  PTCL.	   In	  order	   to	   achieve	   results	  with	   a	   translational	   character,	  
there	  is	  a	  need	  for	  the	  development	  of	  additional	  representative	  T	  cell	  lymphoma	  models.	  In	  
particular,	  there	  is	  a	  complete	  lack	  of	  experimental	  models	  of	  PTCL-­‐NOS	  and	  AITL,	  the	  most	  
commonly	   occurring	   T	   cell	   lymphoma	   subtypes	   in	   humans.	   It	   is	   also	   crucial	   to	   develop	   a	  
reliable	  method	  for	  NIK	  detection,	  especially	  in	  tumor	  samples,	  to	  explore	  its	  potential	  as	  a	  
predictive	  biomarker.	  Additionally,	  studies	  discovering	  the	  mutational	  landscape	  of	  PTCL	  are	  
underway,	  and	  will	  hopefully	  give	  us	  new	  insights	  into	  the	  molecular	  pathogenesis	  of	  these	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1.	  The	  expression	  of	  NF-­‐κB	   transcription	   factors	   in	   tumor	  samples	   from	  diffuse	   large	  B-­‐cell	  
lymphoma	  (DLBCL)	  patients	  shows	  a	  complex	  and	  heterogeneous	  pattern,	  which	  differs	  from	  
prototypic	  NF-­‐κB	  signaling.	  	  
	  
2.	  The	  expression	  of	  LMP1	  in	  Epstein-­‐Barr	  virus-­‐positive	  DLBCL	  samples,	  defines	  tumors	  with	  
highly	  frequent	  NF-­‐κB	  activation.	  	  
	  
3.	  No	  significant	  correlation	  was	  observed	  between	  NF-­‐κB	  expression	  and	  molecular	  subtype	  
of	  DLBCL.	  Classical	  and	  alternative	  NF-­‐κB	  members	  were	  extensively	  expressed	  in	  both	  ABC	  
and	  GCB	  subtypes.	  	  
	  
4.	   A	   subcohort	   of	  DLBCL	  with	   favorable	   clinical	   outcome	   could	   be	   identified	   based	  on	   the	  
nuclear	  expression	  of	  the	  NF-­‐κB	  member	  c-­‐Rel.	  	  
	  
5.	  In	  peripheral	  T-­‐cell	  lymphomas	  (PTCL),	  nuclear	  expression	  of	  NF-­‐κB	  defines	  a	  subgroup	  of	  
patients	  with	  significantly	  shorter	  overall	  survival.	  	  
	  
6.	  NIK	  is	  overexpressed	  in	  a	  subset	  of	  T	  cell	  lymphoma	  cell	  lines	  and	  tumor	  samples.	  	  
	  
7.	   NIK	   regulates	   both	   classical	   and	   alternative	   NF-­‐κB	   activation	   in	   T	   cell	   lymphomas.	   NIK	  
controls	  NF-­‐κB	  signaling	  at	  least	  in	  part,	  by	  IKK-­‐independent	  mechanisms.	  	  
	  
8.	   NIK	   is	   required	   for	   T	   cell	   lymphoma	   survival.	   NIK	   knockdown	   led	   to	   apoptosis	   in	   cells	  
presenting	  high	  basal	  levels	  of	  NIK,	  but	  not	  in	  cells	  with	  low	  NIK	  expression.	  NIK	  knockdown	  
produced	   a	  more	   potent	   and	   consistent	   decrease	   of	   PTCL	   cell	   viability	   than	   IKKβ	   or	   IKKα	  
knockdown.	  
	  
9.	  The	  NF-­‐κB	  member	  c-­‐Rel	  is	  required	  for	  survival	  in	  NIK-­‐positive	  PTCL	  cell	  lines.	  
	  
10.	  NIK	   controls	   the	  expression	  of	  multiple	   genes	   involved	   in	   PTCL	   survival,	   such	   as	   genes	  
encoding	  the	  anti-­‐apoptotic	  proteins	  Bcl-­‐XL	  and	  c-­‐Flip,	  the	  cytokines	  IL-­‐6	  and	  IL-­‐21,	  and	  the	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Supplementary	  Figure	  1.	  Validation	  of	  NIK	  knockdown	  for	  gene	  expression	  studies	   in	  cell	  
lines.	   NIK	   protein	   expression	   after	   NIK	   knockdown	   in	   My-­‐La	   and	   SR-­‐786	   in	   the	   three	  
independent	  experiments	  performed	  for	  the	  gene	  expression	  analysis.	  The	  first	  lane	  in	  each	  
membrane	   represent	   the	   non-­‐template	   control.	   The	   second	   lane	   is	   loaded	   with	   cells	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Supplementary	  Table	  1.	  	  Genes	  with	  altered	  expression	  after	  NIK	  knockdown	  	  
List	   of	   genes	   differentially	   expressed	   (paired	   t-­‐test)	   between	   control	   and	   NIK	   knockdown	  









(log2)	   FDR	  
PON2	   -­‐1.935	   0.000	  
YAP1	   -­‐1.922	   0.000	  
CTH	   -­‐1.852	   0.011	  
HOXB9	   -­‐1.554	   0.004	  
DDIT3	   -­‐1.516	   0.012	  
BTN3A3	   -­‐1.515	   0.000	  
RGS16	   -­‐1.463	   0.000	  
LARGE	   -­‐1.452	   0.002	  
NCRNA00176	   -­‐1.450	   0.000	  
TNFSF4	   -­‐1.427	   0.000	  
ATP8A2	   -­‐1.419	   0.001	  
ADAM8	   -­‐1.354	   0.004	  
RAB9A	   -­‐1.323	   0.001	  
OTOA	   -­‐1.321	   0.000	  
EDN2	   -­‐1.314	   0.002	  
LOC284561	   -­‐1.314	   0.004	  
TIFA	   -­‐1.254	   0.001	  
WARS	   -­‐1.240	   0.003	  
IL3RA	   -­‐1.239	   0.000	  
IL6	   -­‐1.235	   0.000	  
IL15	   -­‐1.232	   0.001	  
XBP1	   -­‐1.222	   0.003	  
LOC339047	   -­‐1.217	   0.007	  
PFKM	   -­‐1.214	   0.000	  
ATF3	   -­‐1.213	   0.003	  
NFKBIA	   -­‐1.211	   0.000	  
IFRD1	   -­‐1.210	   0.004	  
IL21	   -­‐1.178	   0.001	  
RAB9P1	   -­‐1.175	   0.001	  
SQRDL	   -­‐1.162	   0.000	  
OLAH	   -­‐1.161	   0.002	  
NCRNA00158	   -­‐1.157	   0.001	  
IL9	   -­‐1.138	   0.006	  
EMR1	   -­‐1.129	   0.001	  
PSAT1	   -­‐1.119	   0.009	  
C6orf105	   -­‐1.114	   0.001	  
GLUD1	   -­‐1.111	   0.002	  
RAI14	   -­‐1.099	   0.002	  
ZNF643	   -­‐1.092	   0.003	  
JMY	   -­‐1.070	   0.001	  
IFIH1	   -­‐1.066	   0.002	  
BBS12	   -­‐1.066	   0.014	  
AMICA1	   -­‐1.061	   0.000	  
C10orf116	   -­‐1.059	   0.000	  
GLUD2	   -­‐1.055	   0.001	  
GSDMB	   -­‐1.046	   0.001	  
PTP4A3	   -­‐1.024	   0.001	  
FHL2	   -­‐1.021	   0.012	  
ATF5	   -­‐1.012	   0.020	  
SH2B3	   -­‐1.008	   0.002	  
COL15A1	   -­‐1.008	   0.001	  
PGLYRP4	   -­‐0.999	   0.002	  
GARS	   -­‐0.995	   0.005	  
PLXDC2	   -­‐0.993	   0.001	  
CLIP2	   -­‐0.992	   0.004	  
LTA	   -­‐0.991	   0.004	  
LOR	   -­‐0.987	   0.001	  
CHAC1	   -­‐0.973	   0.011	  
RNGTT	   -­‐0.972	   0.004	  
DDX4	   -­‐0.969	   0.001	  
STRA6	   -­‐0.967	   0.002	  
FERMT2	   -­‐0.965	   0.003	  
MARS	   -­‐0.959	   0.004	  
GFPT2	   -­‐0.956	   0.000	  
CCL5	   -­‐0.954	   0.000	  
SLC26A9	   -­‐0.951	   0.002	  
SERPINB8	   -­‐0.947	   0.001	  
IL1R2	   -­‐0.943	   0.001	  
HYAL4	   -­‐0.942	   0.004	  
CARS	   -­‐0.937	   0.007	  
TRERF1	   -­‐0.934	   0.005	  
SHMT2	   -­‐0.933	   0.001	  
DARS2	   -­‐0.932	   0.008	  
ZG16B	   -­‐0.931	   0.005	  
HLA-­‐F	   -­‐0.930	   0.001	  
GPT2	   -­‐0.930	   0.014	  
PCK2	   -­‐0.929	   0.007	  
GAS7	   -­‐0.925	   0.000	  
MAP2K1	   -­‐0.920	   0.000	  
BEST1	   -­‐0.912	   0.038	  
IL1A	   -­‐0.910	   0.000	  
FAS	   -­‐0.907	   0.002	  
SLC1A5	   -­‐0.907	   0.004	  
DDR2	   -­‐0.906	   0.002	  
VDR	   -­‐0.906	   0.003	  
ICAM1	   -­‐0.892	   0.000	  
PLEKHG1	   -­‐0.891	   0.001	  
ZBED2	   -­‐0.887	   0.003	  
UBD	   -­‐0.881	   0.034	  
CCDC50	   -­‐0.878	   0.012	  
RHEBL1	   -­‐0.878	   0.001	  
CD302	   -­‐0.874	   0.000	  
PSME2	   -­‐0.874	   0.000	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FSCN1	   -­‐0.872	   0.000	  
CD44	   -­‐0.861	   0.002	  
CCNB1IP1	   -­‐0.861	   0.002	  
INSIG1	   -­‐0.857	   0.002	  
INHBA	   -­‐0.851	   0.001	  
TNFAIP6	   -­‐0.850	   0.001	  
MIR155HG	   -­‐0.844	   0.001	  
FCER2	   -­‐0.830	   0.003	  
TTC25	   -­‐0.828	   0.026	  
C7orf68	   -­‐0.818	   0.007	  
SGCA	   -­‐0.818	   0.008	  
TUBE1	   -­‐0.818	   0.007	  
TJP2	   -­‐0.814	   0.008	  
ERMN	   -­‐0.813	   0.001	  
GLT25D2	   -­‐0.808	   0.025	  
IGSF3	   -­‐0.805	   0.008	  
FDFT1	   -­‐0.805	   0.004	  
PSMB9	   -­‐0.802	   0.000	  
MID1IP1	   -­‐0.798	   0.004	  
DHCR7	   -­‐0.797	   0.001	  
FKBP11	   -­‐0.794	   0.004	  
RAD23A	   -­‐0.794	   0.004	  
DNAJC5B	   -­‐0.791	   0.010	  
KIF21B	   -­‐0.788	   0.006	  
EHD4	   -­‐0.788	   0.005	  
IARS	   -­‐0.788	   0.013	  
GBE1	   -­‐0.786	   0.014	  
RILPL2	   -­‐0.785	   0.002	  
AARS	   -­‐0.785	   0.009	  
LOC374491	   -­‐0.785	   0.036	  
SARS	   -­‐0.782	   0.014	  
CHRNA6	   -­‐0.780	   0.007	  
EIF4EBP1	   -­‐0.777	   0.007	  
B4GALT4	   -­‐0.776	   0.001	  
PSME1	   -­‐0.775	   0.002	  
ST8SIA1	   -­‐0.773	   0.001	  
BIRC3	   -­‐0.772	   0.001	  
GEM	   -­‐0.771	   0.001	  
ALPK1	   -­‐0.771	   0.004	  
CLDN16	   -­‐0.769	   0.001	  
LONP1	   -­‐0.768	   0.013	  
CNR1	   -­‐0.762	   0.001	  
NFKBIE	   -­‐0.761	   0.004	  
DHRS2	   -­‐0.759	   0.001	  
WIPI1	   -­‐0.752	   0.020	  
LGTN	   -­‐0.750	   0.007	  
MYO5C	   -­‐0.749	   0.007	  
YARS	   -­‐0.748	   0.005	  
FASN	   -­‐0.747	   0.001	  
SLC7A11	   -­‐0.746	   0.036	  
KCNH8	   -­‐0.744	   0.012	  
DNAJC7	   -­‐0.735	   0.008	  
LTB	   -­‐0.731	   0.046	  
RASGRF2	   -­‐0.730	   0.008	  
KDM4A	   -­‐0.730	   0.007	  
SESN2	   -­‐0.726	   0.004	  
SNHG5	   -­‐0.718	   0.009	  
ENOX1	   -­‐0.716	   0.003	  
EXTL2	   -­‐0.715	   0.001	  
ADARB2	   -­‐0.714	   0.003	  
RUNDC3B	   -­‐0.710	   0.011	  
BTNL8	   -­‐0.707	   0.035	  
IL18R1	   -­‐0.707	   0.003	  
ITLN2	   -­‐0.704	   0.003	  
PRR5L	   -­‐0.704	   0.001	  
VIM	   -­‐0.704	   0.034	  
ASNS	   -­‐0.703	   0.021	  
C10orf10	   -­‐0.703	   0.006	  
BTN3A1	   -­‐0.702	   0.002	  
SLC39A9	   -­‐0.700	   0.012	  
GNPDA1	   -­‐0.698	   0.002	  
PYCR1	   -­‐0.696	   0.001	  
KIAA1147	   -­‐0.694	   0.001	  
FKBP14	   -­‐0.692	   0.001	  
IL23R	   -­‐0.688	   0.008	  
CFLAR	   -­‐0.682	   0.001	  
LPIN2	   -­‐0.678	   0.002	  
UPK1B	   -­‐0.678	   0.004	  
LY75	   -­‐0.676	   0.002	  
MGST3	   -­‐0.673	   0.009	  
SLC3A2	   -­‐0.673	   0.010	  
ACAD11	   -­‐0.672	   0.004	  
EEF1A1	   -­‐0.671	   0.016	  
TPTE	   -­‐0.670	   0.003	  
PLA1A	   -­‐0.669	   0.002	  
RFX5	   -­‐0.666	   0.004	  
MVK	   -­‐0.666	   0.003	  
SEMA4A	   -­‐0.661	   0.036	  
HAX1	   -­‐0.660	   0.016	  
ATF4	   -­‐0.659	   0.008	  
VPS29	   -­‐0.654	   0.017	  
FAM122B	   -­‐0.652	   0.015	  
DNAJC12	   -­‐0.652	   0.004	  
BAZ2A	   -­‐0.652	   0.007	  
C20orf112	   -­‐0.652	   0.005	  
ACSM3	   -­‐0.650	   0.032	  
LIPA	   -­‐0.648	   0.045	  
IL4I1	   -­‐0.648	   0.004	  
CD80	   -­‐0.646	   0.001	  
DENND5A	   -­‐0.646	   0.001	  
ALDOC	   -­‐0.642	   0.012	  
C13orf23	   -­‐0.642	   0.002	  
CD83	   -­‐0.641	   0.001	  
HLA-­‐H	   -­‐0.640	   0.002	  
NPIP	   -­‐0.639	   0.034	  
NUDT15	   -­‐0.637	   0.001	  
TCAM1	   -­‐0.634	   0.007	  
C5orf23	   -­‐0.633	   0.015	  
LOC645676	   -­‐0.627	   0.002	  
GADD45A	   -­‐0.626	   0.022	  
GPR87	   -­‐0.626	   0.025	  
HERPUD1	   -­‐0.624	   0.011	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APOBEC3H	   -­‐0.624	   0.004	  
EPRS	   -­‐0.622	   0.019	  
C18orf58	   -­‐0.622	   0.032	  
CT45A5	   -­‐0.620	   0.002	  
MST1R	   -­‐0.619	   0.003	  
IL22	   -­‐0.618	   0.023	  
SLC7A5	   -­‐0.618	   0.004	  
SCD	   -­‐0.618	   0.001	  
MAGEB2	   -­‐0.618	   0.003	  
BCL2L1	   -­‐0.616	   0.001	  
CT45A1	   -­‐0.615	   0.003	  
KIF2C	   -­‐0.615	   0.013	  
WDR65	   -­‐0.614	   0.005	  
PDAP1	   -­‐0.613	   0.010	  
XPOT	   -­‐0.611	   0.012	  
TTC39A	   -­‐0.606	   0.001	  
DHRS11	   -­‐0.605	   0.017	  
HLA-­‐J	   -­‐0.605	   0.002	  
CPNE5	   -­‐0.604	   0.002	  
CHST12	   0.600	   0.006	  
IGFBP1	   0.602	   0.022	  
TPSG1	   0.603	   0.031	  
F5	   0.603	   0.020	  
MKL2	   0.604	   0.002	  
ZNF579	   0.604	   0.022	  
ASPRV1	   0.604	   0.002	  
OXCT1	   0.605	   0.002	  
PPP1R9A	   0.605	   0.006	  
SFRS6	   0.607	   0.038	  
MEGF6	   0.607	   0.019	  
C6orf225	   0.608	   0.001	  
CD7	   0.608	   0.025	  
ABR	   0.609	   0.001	  
AMY1C	   0.611	   0.013	  
C10orf140	   0.612	   0.003	  
CACNA1E	   0.614	   0.039	  
GRK5	   0.617	   0.003	  
MAF	   0.619	   0.019	  
ZMYND11	   0.622	   0.003	  
C18orf50	   0.622	   0.009	  
FLJ22184	   0.624	   0.031	  
WFDC1	   0.626	   0.005	  
CABYR	   0.628	   0.003	  
DAZAP2	   0.628	   0.002	  
JAZF1	   0.629	   0.010	  
TFPI	   0.629	   0.003	  
SLC19A2	   0.630	   0.008	  
E2F3	   0.631	   0.006	  
LOC100131998	   0.632	   0.006	  
FRAT2	   0.633	   0.004	  
SESN3	   0.633	   0.014	  
ATP6V1G1	   0.634	   0.001	  
PNMA1	   0.636	   0.001	  
HSPA2	   0.636	   0.012	  
CSGALNACT1	   0.637	   0.006	  
UTS2R	   0.638	   0.016	  
ZSCAN10	   0.638	   0.021	  
CDH1	   0.639	   0.002	  
C9orf62	   0.639	   0.049	  
ANKRD13C	   0.640	   0.012	  
TP53INP1	   0.640	   0.015	  
FAM176A	   0.642	   0.002	  
HCN4	   0.643	   0.018	  
ITGB1	   0.644	   0.001	  
CDKN1C	   0.645	   0.027	  
NKAIN1	   0.645	   0.029	  
CD96	   0.646	   0.019	  
IFI6	   0.647	   0.012	  
RELL1	   0.647	   0.004	  
SH3GL3	   0.648	   0.032	  
MTSS1	   0.649	   0.001	  
DEXI	   0.650	   0.003	  
RNF149	   0.650	   0.001	  
TMTC2	   0.653	   0.003	  
GPR78	   0.654	   0.041	  
WDR81	   0.655	   0.005	  
LOC338620	   0.655	   0.001	  
PIP5K1B	   0.657	   0.007	  
GRIN2D	   0.658	   0.022	  
GPR153	   0.661	   0.019	  
LOC439951	   0.666	   0.023	  
NCDN	   0.668	   0.004	  
SOX2	   0.670	   0.006	  
HOMER3	   0.674	   0.000	  
FAM116A	   0.675	   0.014	  
PM20D2	   0.675	   0.007	  
COX6A2	   0.675	   0.022	  
UTS2D	   0.677	   0.002	  
C9orf135	   0.679	   0.002	  
IL7R	   0.679	   0.005	  
C1orf53	   0.681	   0.002	  
GMNN	   0.686	   0.015	  
TIMM8B	   0.690	   0.010	  
DKFZP434I0714	   0.691	   0.021	  
CACNA1H	   0.691	   0.008	  
KIF25	   0.697	   0.007	  
ITM2A	   0.697	   0.001	  
FAIM	   0.698	   0.002	  
FBXL17	   0.699	   0.004	  
SOBP	   0.702	   0.006	  
ARL4C	   0.704	   0.001	  
PODXL	   0.706	   0.008	  
TNFRSF18	   0.714	   0.001	  
IFITM5	   0.718	   0.024	  
KLHDC7B	   0.718	   0.008	  
PPP2CB	   0.719	   0.001	  
VNN2	   0.722	   0.003	  
GPR150	   0.723	   0.018	  
GPR65	   0.725	   0.009	  
ARHGAP12	   0.725	   0.001	  
XYLT1	   0.732	   0.001	  
GPR137B	   0.734	   0.001	  
DUX4	   0.735	   0.017	  
ITM2C	   0.736	   0.002	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HCN2	   0.742	   0.020	  
ENTPD1	   0.754	   0.001	  
LOC644246	   0.756	   0.013	  
RTP4	   0.762	   0.002	  
KCNJ13	   0.762	   0.000	  
ITGB7	   0.770	   0.004	  
CORO2A	   0.771	   0.005	  
NUCB2	   0.777	   0.022	  
CEP70	   0.778	   0.001	  
TTC18	   0.779	   0.002	  
FAM46C	   0.782	   0.000	  
PGBD2	   0.785	   0.001	  
ZNF670	   0.789	   0.014	  
TXNDC3	   0.793	   0.001	  
NTNG2	   0.808	   0.019	  
TSHZ3	   0.809	   0.002	  
MUC20	   0.814	   0.007	  
MUC6	   0.817	   0.031	  
SLC26A11	   0.821	   0.001	  
ITM2B	   0.824	   0.001	  
SATB1	   0.824	   0.006	  
PSKH1	   0.830	   0.000	  
LIMA1	   0.837	   0.000	  
PTPRC	   0.842	   0.006	  
IRS1	   0.843	   0.004	  
CRABP2	   0.848	   0.011	  
GLCCI1	   0.853	   0.000	  
LAMB1	   0.863	   0.001	  
TULP4	   0.864	   0.006	  
CD28	   0.869	   0.000	  
KCNJ12	   0.879	   0.012	  
LOC541471	   0.880	   0.004	  
SLC44A1	   0.899	   0.000	  
TIPARP	   0.904	   0.007	  
CDKN2C	   0.905	   0.029	  
CASP7	   0.935	   0.005	  
FRY	   0.944	   0.001	  
SCG2	   0.961	   0.001	  
RGS9	   0.964	   0.017	  
CCR3	   0.964	   0.000	  
DMBT1	   0.970	   0.001	  
SLC9A9	   0.974	   0.001	  
SAMD9	   0.983	   0.000	  
KIAA1618	   0.994	   0.003	  
SLC7A8	   0.996	   0.007	  
BZRAP1	   1.008	   0.001	  
SLC39A10	   1.014	   0.005	  
HIST1H4A	   1.024	   0.007	  
SLC38A6	   1.047	   0.001	  
GZMB	   1.048	   0.008	  
RBP4	   1.088	   0.006	  
BFSP1	   1.117	   0.000	  
TOX2	   1.125	   0.000	  
TRBV5-­‐4	   1.149	   0.000	  
NME7	   1.160	   0.000	  
F2R	   1.183	   0.000	  
GPR15	   1.199	   0.004	  
FAM9B	   1.215	   0.000	  
LOC150759	   1.271	   0.000	  
ENPP2	   1.301	   0.003	  
ENC1	   1.319	   0.000	  
IER5L	   1.327	   0.004	  
CCR5	   1.380	   0.000	  
LOC283143	   1.415	   0.031	  
SMCR5	   1.467	   0.008	  
SAMD9L	   1.507	   0.000	  
ARNT2	   1.537	   0.000	  
HTR2B	   1.547	   0.000	  
CFHR3	   1.556	   0.000	  
MGC42105	   1.586	   0.001	  
KLF2	   1.639	   0.000	  
ANKRD55	   1.642	   0.001	  
LGR4	   1.728	   0.000	  
CFH	   1.743	   0.000	  
PMCHL1	   2.355	   0.000	  







(log2)	   FDR	  
IL6	   -­‐1.568	   0.000	  
IL21	   -­‐1.343	   0.001	  
ENOX1	   -­‐1.063	   0.002	  
ZBED2	   -­‐1.039	   0.006	  
HYAL4	   -­‐1.034	   0.003	  
OCA2	   -­‐1.025	   0.000	  
COL15A1	   -­‐1.006	   0.001	  
EDN2	   -­‐1.003	   0.007	  
IL22	   -­‐0.939	   0.033	  
ADAM8	   -­‐0.939	   0.006	  
OTOA	   -­‐0.929	   0.001	  
C7orf68	   -­‐0.911	   0.023	  
C6orf105	   -­‐0.868	   0.002	  
YAP1	   -­‐0.847	   0.002	  
RILPL2	   -­‐0.841	   0.005	  
SQRDL	   -­‐0.837	   0.008	  
DDIT3	   -­‐0.829	   0.040	  
IL26	   -­‐0.806	   0.002	  
PGLYRP4	   -­‐0.797	   0.007	  
GFPT2	   -­‐0.789	   0.002	  
CCL17	   -­‐0.778	   0.005	  
IL4I1	   -­‐0.770	   0.002	  
NEURL3	   -­‐0.758	   0.002	  
CNR1	   -­‐0.757	   0.001	  
HSD11B1	   -­‐0.754	   0.050	  
IFIH1	   -­‐0.742	   0.003	  
SLC2A14	   -­‐0.733	   0.008	  
C10orf116	   -­‐0.731	   0.002	  
BTN3A3	   -­‐0.719	   0.007	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RGS16	   -­‐0.718	   0.033	  
IL1A	   -­‐0.714	   0.002	  
MIR155HG	   -­‐0.713	   0.007	  
LOR	   -­‐0.709	   0.005	  
PLXDC2	   -­‐0.698	   0.012	  
BBS12	   -­‐0.687	   0.007	  
TNFSF4	   -­‐0.685	   0.007	  
EXTL2	   -­‐0.678	   0.002	  
CYP1A1	   -­‐0.675	   0.001	  
EEF1A2	   -­‐0.674	   0.007	  
INHBA	   -­‐0.674	   0.003	  
MGST3	   -­‐0.663	   0.007	  
PLEKHG1	   -­‐0.661	   0.007	  
IL9	   -­‐0.656	   0.026	  
TNFAIP6	   -­‐0.646	   0.004	  
KCNQ2	   -­‐0.643	   0.005	  
VDR	   -­‐0.641	   0.003	  
LTA	   -­‐0.638	   0.008	  
TIFA	   -­‐0.636	   0.009	  
NRCAM	   -­‐0.631	   0.002	  
BTNL8	   -­‐0.631	   0.026	  
WARS	   -­‐0.630	   0.027	  
NFKBIA	   -­‐0.618	   0.004	  
NCRNA00176	   -­‐0.613	   0.014	  
SLC45A3	   -­‐0.609	   0.011	  
ATP8A2	   -­‐0.608	   0.007	  
IL15	   -­‐0.605	   0.002	  
JMY	   -­‐0.605	   0.016	  
BIRC3	   -­‐0.603	   0.002	  
DAZAP2	   0.606	   0.007	  
TMTC2	   0.619	   0.014	  
CCR5	   0.629	   0.013	  
CDKN2C	   0.633	   0.018	  
CARHSP1	   0.647	   0.046	  
SLC9A9	   0.654	   0.013	  
POU2AF1	   0.666	   0.011	  
BFSP1	   0.668	   0.007	  
MGC42105	   0.685	   0.008	  
GLCCI1	   0.686	   0.008	  
TRBV5-­‐4	   0.688	   0.008	  
UTS2D	   0.692	   0.009	  
LGR4	   0.714	   0.008	  
SLC26A11	   0.734	   0.009	  
PIM2	   0.734	   0.007	  
SLC39A10	   0.752	   0.007	  
SLC38A6	   0.768	   0.005	  
IRS1	   0.769	   0.013	  
KCNJ12	   0.771	   0.007	  
RASGRP3	   0.807	   0.007	  
NME7	   0.808	   0.002	  
ENPP2	   0.819	   0.001	  
SAMD9	   0.837	   0.003	  
RTP4	   0.864	   0.005	  
GPR15	   0.922	   0.012	  
ARNT2	   0.935	   0.002	  
SAMD9L	   1.065	   0.001	  
ENC1	   1.100	   0.003	  
IGHM	   1.129	   0.000	  
DNAH12	   1.144	   0.001	  
KLF2	   1.217	   0.002	  
F2R	   1.336	   0.001	  
FAM9B	   1.506	   0.003	  
HTR2B	   1.663	   0.002	  
PMCHL1	   2.370	   0.001	  
PMCH	   3.062	   0.000	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Los	   linfomas	   constituyen	   un	   grupo	   amplio	   de	   neoplasias	   linfoproliferativas	   con	  
comportamiento	   y	   respuesta	   al	   tratamiento	   variados.	   En	   la	   actualidad,	   la	   terapia	   de	   los	  
linfomas	  está	  basada	  en	   fármacos	   citotóxicos	  o	  anticuerpos	  monoclonales	  dirigidos	   contra	  
marcadores	  de	  superficie	  de	  los	   linfocitos.	  En	  muchos	  casos,	  el	  tratamiento	  estándar	  no	  es	  
capaz	  de	  curar	  a	  los	  pacientes	  y	  presentan	  un	  porcentaje	  de	  recidivas	  muy	  alto.	  En	  esta	  tesis	  
doctoral	  se	  han	  estudiado	  principalmente	  dos	  tipos	  de	  linfomas:	   linfoma	  B	  difuso	  de	  célula	  
grande	   (LBDCG)	   y	   linfoma	   periférico	   de	   células	   T	   (LPCT).	   El	   LBDCG	   se	   caracteriza	   por	   una	  
proliferación	  descontrolada	  de	  linfocitos	  B	  maduros	  y	  es	  el	  linfoma	  más	  común	  en	  el	  adulto,	  
representando	  alrededor	  del	  30-­‐40	  %	  de	  todos	  los	  linfomas	  no-­‐Hodgkin	  (Lenz	  et	  al.	  2010).	  	  
	  
Basándose	   en	   el	   perfil	   de	   expresión	   génica,	   los	   LBDCGs	   se	   pueden	  dividir	   en	  dos	   subtipos	  
diferentes	  según	   la	  “supuesta”	  célula	  de	  origen:	  el	   subtipo	  ABC	   (por	   las	  siglas	  en	   inglés	  de	  
“Activated	   B-­‐cell”)	   que	   se	   caracteriza	   por	   un	   perfil	   de	   expresión	   génica	   parecido	   a	   los	  
linfocitos	  B	  activados,	  y	  el	  subtipo	  GCB	  (por	  las	  siglas	  en	  inglés	  de	  “Germinal	  Center	  C-­‐cell”),	  
definido	   por	   la	   expresión	   de	   genes	   típicamente	   expresados	   por	   las	   células	   B	   del	   centro	  
germinal	   (Alizadeh	   et	   al.	   2000).	   Los	   LBDCGs	   del	   tipo	   ABC	   presentan	   un	   curso	   clínico	  más	  
agresivo	  que	  los	  GCB	  y	  se	  ha	  propuesto	  que	  estos	  linfomas	  dependen	  de	  la	  activación	  de	  la	  
vía	  de	  NF-­‐κB	  para	  su	  supervivencia	  (Alizadeh	  et	  al.	  2000;	  Staudt	  et	  al.	  2005;	  Davis	  et	  al.	  2001).	  	  	  
	  
Los	   LPCTs	   forman	   un	   grupo	   muy	   heterogéneo	   de	   tumores	   caracterizados	   por	   una	  
proliferación	  maligna	  de	  los	  linfocitos	  T.	  Los	  LPCT	  constituyen	  alrededor	  del	  12%	  de	  todos	  los	  
linfomas	   no-­‐Hodgkin	   y	   el	   conocimiento	   de	   su	   origen	   y	   biología	   es	   escaso	   (Piccaluga	   et	   al.	  
2011;	  Vose	  et	   al.	   2008).	   Los	   LPCTs	   son	   tumores	  muy	  agresivos	  que	  hoy	  en	  día	   carecen	  de	  
terapias	  eficaces	  (Foss	  et	  al.	  2013).	  	  
	  
Con	  el	  objetivo	  de	  buscar	  nuevas	  dianas	  terapéuticas	  para	  el	  desarrollo	  de	  terapias	  dirigidas	  
efectivas	   en	   los	   pacientes	   de	   linfomas,	   es	   necesario	   identificar	   y	   caracterizar	   rutas	   de	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señalización	  que	  alimentan	  a	  estos	  tumores.	  Una	  de	  las	  rutas	  de	  señalización	  asociadas	  a	  los	  
tumores	  hematológicos	  es	   la	  vía	  de	  NF-­‐κB.	  La	   ruta	  de	  NF-­‐κB	  se	  ha	  encontrado	  activada	  en	  
varios	  tipos	  de	  linfomas,	  entre	  ellos	   linfoma	  de	  Hodgkin,	  LBDCG	  y	  linfomas	  de	  células	  T.	  Se	  
han	  descrito	  varias	  alteraciones	  genéticas	  en	  diferentes	  componentes	  de	  la	  vía,	  dando	  lugar	  
a	   su	   activación	   en	   estos	   tumores	   (Compagno	   et	   al.	   2009;	   Keats	   et	   al.	   2007;	   Schmitz	   et	   al	  
2009).	  Como	  consecuencia,	   terapias	  basadas	  en	   la	   inhibición	  de	  NF-­‐κB	  aparecen	  como	  una	  
estrategia	   terapéutica	   prometedora	   en	   ensayos	   preclínicos.	   Para	   llevar	   estas	   estrategias	  
adelante,	   es	   necesario	   realizar	   estudios	   adicionales	   que	   permitan	   identificar	   dianas	  
moleculares	  y	  tumores	  con	  mayor	  probabilidad	  de	  respuesta	  a	  estas	  terapias.	  	  
	  
NF-­‐κB	  es	  una	  familia	  de	  factores	  de	  transcripción	  constituida	  por	  cinco	  miembros;	  RelA	  (p65),	  
RelB,	  c-­‐Rel,	  p50	  (con	  su	  precursor	  p105),	  y	  p52	  (con	  su	  precursor	  p100)	  (Vallabhapurapu	  et	  
al.	   2009).	   Estos	   factores	   de	   transcripción	   regulan	   la	   expresión	   de	   cientos	   de	   genes	  
implicados	   en	   la	   regulación	   de	   la	   respuesta	   inmune,	   proliferación	   celular,	   apoptosis	   y	  
supervivencia	  celular	  (Hayden	  et	  al.	  2011).	  Por	  este	  motivo,	  una	  activación	  descontrolada	  de	  
NF-­‐κB	   puede	   resultar	   en	   el	   desarrollo	   de	   tumores.	   Existen	   dos	   cascadas	   principales	   de	  
activación	  de	  NF-­‐κB:	  la	  vía	  clásica/canónica	  y	  la	  vía	  alternativa/no	  canónica.	  Varios	  estímulos	  
pueden	  activar	  la	  vía,	  como	  la	  estimulación	  de	  los	  receptores	  de	  TNF	  (tumor	  necrosis	  factor),	  
los	   receptores	  de	   interleuquinas,	   los	  TLR	   (Toll-­‐like	   receptors)	  y	   los	   receptores	  de	  antígenos	  
BCR	  (el	  receptor	  de	  células	  B)	  y	  TCR	  (el	  receptor	  de	  células	  T)	  (Vallabhapurapu	  et	  al.	  2009).	  
Resumido,	  una	  activación	  de	  dichos	  receptores	  da	  lugar	  a	  la	  activación	  de	  un	  complejo	  IKK,	  
que	   incluye	   varias	   quinasas.	   Estas	   quinasas	   (IKKα	   y	   IKKβ)	   son	   capaces	   de	   fosforilar	  
inhibidores	  de	  NF-­‐κB,	  permitiendo	  así	  que	  dímeros	  de	  NF-­‐κB	  que	  se	  encuentran	  retenidos	  en	  
el	  citoplasma	  por	  estos	  inhibidores,	  se	  desplacen	  al	  núcleo	  y	  se	  unan	  al	  ADN	  (Oeckinghaus	  et	  
al.	   2009).	   La	   vía	   clásica	   de	   NF-­‐κB,	   se	   caracteriza	   por	   la	   activación	   de	   la	   quinasa	   IKKβ	   y	   la	  
translocación	   nuclear	   de	   los	   factores	   RelA,	   c-­‐Rel	   y	   p50.	   La	   vía	   alternativa	   por	   otro	   lado,	  
necesita	   la	   activación	  de	   las	   quinasas	  NIK	   y	   IKKα	   y	   termina	  en	   la	   translocación	  nuclear	   de	  
RelB	  y	  p52	  (Hayden	  et	  al.	  2008).	  En	  esta	  tesis	  doctoral,	  gran	  parte	  del	  trabajo	  está	  enfocado	  
en	   el	   estudio	   del	   papel	   de	   NIK	   como	   regulador	   de	   NF-­‐κB	   en	   linfomas.	   NIK	   es	   una	   serina-­‐
treonina	  quinasa	  capaz	  de	  activar	  tanto	  la	  vía	  clásica	  como	  la	  vía	  alternativa	  de	  NF-­‐κB.	  Aún	  
así,	   la	  presencia	  de	  NIK	  sólo	  es	  esencial	  para	  la	  activación	  de	  la	  vía	  alternativa,	  a	  diferencia	  
de	   la	   vía	   clásica	   que	   puede	   ser	   activada	   sin	   la	   presencia	   de	   NIK	   (Zarnegar	   et	   al.	   2008a;	  
Zarnetar	  et	  al.	  2008b).	  NIK	  actúa	  fosforilando	  a	  IKKα,	  dando	  lugar	  a	  la	  fosforilación	  de	  p100,	  
permitiendo	  de	   este	  modo	   su	   procesamiento	   a	   p52	   y	   su	   posterior	   translocación	   al	   núcleo	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donde	  regula	  la	  transcripción	  (Xiao	  et	  al.	  2001;	  Senftleben	  et	  al.	  2001).	  NIK	  está	  implicado	  en	  
la	  regulación	  de	  la	  vía	  de	  NF-­‐κB	  sólo	  en	  ciertos	  tipos	  celulares	  y	  en	  respuesta	  a	  un	  reducido	  
número	  de	  estímulos.	  La	  función	  de	  NIK	  en	  los	  LPCTs	  no	  está	  descrita.	  Sin	  embargo,	  NIK	  se	  
encuentra	  sobre-­‐expresado	  e	  implicado	  en	  la	  supervivencia	  tumoral	  en	  otras	  neoplasias,	  y	  se	  
ha	  propuesto	  como	  posible	  diana	  terapéutica	  en	  mieloma	  múltiple	  (Annunziata	  et	  al.	  2007;	  
Pham	  et	   al.	   2011;	   Thu	   et	   al.	   2012).	   Aunque	   la	   vía	   de	  NF-­‐κB	   se	   ha	   estudiado	   ampliamente	  
durante	   los	   últimos	   20	   años,	   su	   regulación	   y	   aplicación	   en	   el	   desarrollo	   de	   estrategias	  
antitumorales	   todavía	  no	  está	  clara.	  Tampoco	  está	  completamente	  claro	  como	  funciona	   la	  
señalización	  de	  NF-­‐κB	  en	  tumores	  primarios,	  su	  correlación	  clínica,	  y	  la	  relevancia	  clínica	  de	  
los	  hallazgos	  encontrados	  en	   líneas	   celulares	   y	  modelos	  animales.	  Actualmente	  no	  existen	  
inhibidores	   específicos	   para	   NF-­‐κB	   en	   la	   práctica	   clínica,	   lo	   que	   hace	   necesario	   realizar	  




El	   objetivo	   global	   de	   este	   trabajo	   es	   caracterizar	   la	   expresión	   de	   NF-­‐κB	   en	   linfomas	   e	  
identificar	  nuevas	  dianas	  moleculares	  con	  el	  fin	  de	  encontrar	  nuevos	  abordajes	  para	  inhibir	  
la	  activación	  maligna	  de	  NF-­‐κB	  en	  estos	  tumores.	  Los	  objetivos	  específicos	  en	  las	  dos	  partes	  
del	  proyecto	  son	  los	  siguientes:	  	  
	  
-­‐ Caracterizar	  la	  expresión	  de	  NF-­‐κB	  en	  muestras	  de	  pacientes	  de	  linfoma	  B	  difuso	  de	  
célula	  grande	  y	  establecer	  su	  correlación	  clínica	  y	  asociación	  a	  diferentes	  subtipos.	  	  
	  
-­‐ Analizar	  el	  papel	  de	  NIK	  en	  la	  regulación	  de	  NF-­‐κB	  y	  en	  la	  supervivencia	  celular	  	  con	  
el	   fin	   de	   testar	   NIK	   como	   posible	   diana	   molecular	   en	   los	   linfomas	   periféricos	   de	  
células	  T.	  	  
	  
	  
MATERIAL	  Y	  MÉTODOS	  
	  
Series	  amplias	  de	  muestras	  de	  pacientes	  diagnosticados	  con	  diferentes	  subtipos	  de	  linfomas	  
(LBDCG,	  LPCT	  del	  tipo	  no	  especificado,	  linfoma	  T	  angioinmunoblástico,	  linfoma	  anaplásico	  de	  
células	  grandes,	  linfoma	  de	  manto,	  linfoma	  esplénico	  de	  células	  marginales,	  linfoma	  folicular,	  
y	   linfoma	   de	   Hodgkin)	   fueron	   recogidas	   en	   varios	   hospitales	   de	   España.	   Para	   evaluar	   la	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expresión	   de	   las	   distintas	   subunidades	   de	   NF-­‐κB	   en	   estas	   muestras,	   se	   han	   empleado	  
técnicas	   de	   inmunohistoquímica	   sobre	   muestras	   parafinadas.	   También	   se	   han	   utilizado	  
micromatrices	  de	  expresión	  génica	  del	  genoma	  completo	  para	  estudiar	  el	  perfil	  de	  expresión	  
génica	  en	  estos	  tumores.	  Los	  estudios	  funcionales	  para	  la	  investigación	  del	  papel	  de	  NIK	  en	  
linfomas	  T	  se	  han	  llevado	  a	  cabo	  en	  un	  panel	  de	  líneas	  celulares,	  representando	  diferentes	  
tipos	  de	  LPTC.	  Para	  silenciar	  NIK	  u	  otros	  componentes	  de	  la	  vía	  de	  NF-­‐κB	  en	  líneas	  celulares	  
linfoides,	   se	  ha	  utilizado	  una	   técnica	  de	  electroporación,	   la	  microporación,	  para	   introducir	  
secuencias	   de	   ARN	   de	   interferencia	   en	   las	   células.	   Para	   estudiar	   los	   efectos	   moleculares	  
producidos	   en	   las	   células	   tras	   el	   silenciamiento	   de	   NIK,	   se	   han	   empleado	   técnicas	   de	  
expresión	   de	   ARN	   (PCR	   cuantitativa,	   micromatrices	   de	   expresión	   génica)	   y	   técnicas	   de	  
expresión	  de	  proteína	  (western	  blot,	  inmunohistoquímica,	  inmunofluorescencia,	  ELISA).	  Los	  
efectos	   sobre	   muerte	   celular	   se	   han	   evaluado	   utilizando	   citometría	   de	   flujo	   midiendo	  




La	  vía	  de	  NF-­‐κB	  	  ha	  sido	  ampliamente	  estudiada	  en	  LBDCG	  en	  modelos	  experimentales	  y	  se	  
ha	  descrito	  como	  un	  mecanismo	  fundamental	  en	  la	  patogénesis	  del	  subtipo	  ABC,	  pero	  no	  del	  
subtipo	  GCB	  (Davis	  et	  al.	  2001).	  Sin	  embargo,	  la	  relevancia	  clínica	  de	  estas	  observaciones	  no	  
está	  clara,	  y	  la	  expresión	  real	  de	  NF-­‐κB	  	  en	  muestras	  tumorales	  no	  está	  bien	  definida.	  En	  la	  
primera	  parte	  del	  trabajo,	  la	  expresión	  nuclear	  de	  los	  cinco	  factores	  de	  NF-­‐κB	  se	  evaluó	  por	  
inmunohistoquímica	  en	  113	  muestras	  de	  pacientes	  con	  LBDCG.	  Este	  estudio	  reveló	  un	  perfil	  
de	   expresión	   de	   los	   subunidades	   de	   NF-­‐κB	   complejo,	   mostrando	   gran	   heterogeneidad,	  
siendo	  la	  mayoría	  de	  tumores	  positivos	  para	  alguno	  de	  los	  factores	  de	  la	  familia.	  Se	  encontró	  
una	   correlación	   significativa	   entre	   la	   expresión	   de	   subunidades	   de	   la	   vía	   clásica	   y	   la	  
alternativa,	  sugiriendo	  que	  ambas	  vías	  frecuentemente	  se	  encuentran	  activadas	  en	  el	  mismo	  
tumor.	  Notablemente,	   la	  expresión	  nuclear	  de	  NF-­‐κB,	   se	  detectó	   tanto	  en	   los	  LBDCGs	   tipo	  
GCB,	   como	   en	   los	   tipo	   ABC.	   Esta	   observación	   se	   confirmó	   en	   dos	   series	   independientes,	  
donde	   la	   clasificación	   GCB/ABC	   se	   hizo	   utilizando	   dos	   abordajes	   diferentes:	   por	  
micromatrices	  de	  expresión	  génica,	  o	  por	  inmunohistoquímia.	  Además,	  se	  detectó	  expresión	  
nuclear	   de	   c-­‐Rel	   en	   una	   gran	   parte	   de	   los	   tumores	   (65%),	   siendo	   su	   patrón	   de	   expresión	  
diferente	  a	   la	  de	  los	  otros	  miembros	  de	  la	  familia	  ya	  que	  una	  tercera	  parte	  de	  los	  tumores	  
eran	  positivos	  únicamente	  para	  c-­‐Rel.	  La	  expresión	  nuclear	  de	  c-­‐Rel	  también	  mostró	  ser	  un	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marcador	   pronóstico	   favorable,	   asociado	   a	   una	   supervivencia	   más	   largo,	   en	   pacientes	   de	  
LBDCG	  tratados	  con	  R-­‐CHOP.	  	  
	  
En	   LBDCG	   asociado	   a	   VEB,	   vimos	   que	   la	   expresión	   de	   la	   proteína	   viral	   LMP1	   se	  
correlacionaba	  significativamente	  con	  una	  activación	  de	  NF-­‐κB,	  	  siendo	  el	  85.7%	  de	  los	  casos	  
positivos	   para	   marcadores	   de	   la	   vía	   clásica,	   y	   92.8%	   positivos	   para	   marcadores	   de	   la	   vía	  
alternativa.	  	  
	  
En	   una	   serie	   de	   77	  muestras	   de	   pacientes	   con	   LPTC,	   al	   contrario	   que	   en	   las	  muestras	   de	  
pacientes	   con	   LBDCG,	   la	   expresión	   de	   NF-­‐κB	   se	   asoció	   de	   forma	   significativa	   con	   una	  
supervivencia	   global	   más	   corta.	   Aunque	   los	   mecanismos	   moleculares	   de	   los	   LPTCs	   son	  
desconocidos	   en	   su	   mayor	   parte,	   se	   ha	   sugerido	   que	   la	   ruta	   de	   NF-­‐κB	   es	   uno	   de	   los	  
mecanismos	  que	  confieren	  supervivencia	  a	  las	  células	  T	  tumorales	  (Sors	  et	  al.	  2008;	  Zhao	  et	  
al.	   2010).	   Nuestra	   observación	   de	   que	   la	   vía	   de	   NF-­‐κB	   	   está	   activada	   en	   un	   subgrupo	   de	  
LPTCs	  con	  un	  curso	  clínico	  muy	  agresivo,	  nos	  llevó	  a	  investigar	  cómo	  interferir	  la	  activación	  
de	  NF-­‐κB	  de	  forma	  específica	  actuando	  sobre	  proteínas	  claves	  en	  la	  activación	  de	  la	  vía.	  	  
	  
Se	  analizó	  el	  papel	  de	   la	  quinasa	  NIK	  en	   los	  LPTCs	  con	  el	   fin	  de	   investigar	  su	   función	  en	   la	  
regulación	  de	  la	  vía	  de	  NF-­‐κB	  y	  en	  la	  supervivencia	  de	  células	  de	  LPTC.	  Para	  ello,	  se	  midió	  la	  
expresión	   de	   NIK	   a	   nivel	   de	   ARNm	   por	   PCR	   cuantitativa	   en	   líneas	   celulares	   de	   LPTC	   y	   en	  
células	  T	  de	  pacientes	  con	  síndrome	  de	  Sézary	  (un	  subtipo	  de	  LPTC).	  Se	  observó	  que	  NIK	  se	  
encontraba	  muy	  sobre-­‐expresado	  en	  un	  grupo	  de	  tumores	  y	  líneas	  celulares,	  comparado	  con	  
linfocitos	   T	   de	   donantes	   sanos.	   Esta	   sobre-­‐expresión	   de	   NIK	   a	   nivel	   de	   ARNm	   se	  
correlacionaba	   también	   con	   niveles	   más	   altos	   de	   la	   proteína	   NIK.	   Utilizando	   datos	   de	  
expresión	  génica	  de	  micromatrices,	  en	  una	  serie	  de	  27	  casos	  de	  LPTC,	  vimos	  que	  la	  expresión	  
de	  NIK	  en	  estos	  tumores	  se	  correlacionaba	  significativamente	  con	  la	  expresión	  de	  los	  genes	  
diana	  de	  NF-­‐κB,	  sugiriendo	  que	  NIK	  pueda	  estar	  implicado	  en	  la	  regulación	  de	  NF-­‐κB	  en	  LPTC.	  	  
	  
Esta	   observación	   se	   confirmó	   también	   en	   estudios	   funcionales.	   Utilizando	   ARN	   de	  
interferencia,	  silenciamos	  NIK	  en	  dos	  líneas	  celulares	  derivadas	  de	  LPTC.	  El	  silenciamiento	  de	  
NIK	  dio	  lugar	  a	  una	  reducción	  de	  los	  niveles	  de	  expresión	  tanto	  de	  p52	  (vía	  alternativa)	  como	  
de	  p50	  (vía	  clásica).	  Un	  ensayo	  ELISA	  específico	  para	  evaluar	  la	  actividad	  de	  unión	  al	  ADN	  de	  
los	  factores	  de	  NF-­‐κB,	  confirmó	  que	  la	  reducción	  observada	  de	  NF-­‐κB	  se	  correspondía	  a	  una	  
disminución	  de	  actividad	  tanto	  de	  la	  vía	  alternativa	  (p52	  y	  RelB)	  como	  de	  la	  vía	  clásica	  (p50,	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p65	  y	  c-­‐Rel).	  Estos	  resultados	  indican	  que	  NIK	  está	  implicado	  en	  la	  regulación	  de	  ambas	  vías.	  
Notablemente,	  sólo	  el	  silenciamiento	  de	  NIK	  y	  no	  el	  silenciamiento	  de	  IKKα	  o/y	  IKKβ,	  resultó	  
en	  una	  reducción	  fuerte	  de	  los	  niveles	  de	  p50	  y	  p52,	  indicando	  que	  la	  función	  de	  NIK	  en	  la	  
vía	  de	  NF-­‐κB	  está,	  al	  menos	  en	  parte,	   regulada	  por	  mecanismos	   independientes	  de	   IKKα	  y	  
IKKβ.	  	  
	  
Para	   validar	   NIK	   como	   posible	   diana	   terapéutica	   en	   LPTC,	   medimos	   el	   efecto	   del	  
silenciamiento	   de	   NIK	   sobre	   la	   apoptosis	   y	   la	   viabilidad	   celular.	   El	   silenciamiento	   de	   NIK	  
resultó	  en	  un	  incremento	  en	  muerte	  celular	  en	  células	  de	  LPTC,	  medido	  con	  AnnexinaV/DAPI	  
por	   citometría	   de	   flujo.	   Siete	   días	   tras	   la	   transfección	   con	   siNIK	   (el	   ARN	   de	   interferencia	  
usados	  para	  silenciar	  NIK),	  apenas	  el	  2%	  de	   las	  células	  permanecían	  vivas.	  La	  detección	  de	  
caspasa	  3	  y	  PARP	  procesadas,	   confirmó	   la	   inducción	  de	  apoptosis.	  Sólo	   las	   líneas	  celulares	  
con	  niveles	  basales	  altos	  de	  NIK	  se	  vieron	  afectadas	  por	  siNIK,	  mientras	  que	  las	  células	  con	  
bajos	   niveles	   de	   NIK	   no	   presentaban	   cambios	   en	   su	   viabilidad.	   El	   silenciamiento	   de	   otros	  
componentes	  de	   la	  ruta	  de	  NF-­‐κB,	  como	  IKKα	  y	  β,	  no	  dio	   lugar	  a	  una	  respuesta	  apoptótica	  
tan	  profunda	  como	   tras	  el	   silenciamiento	  de	  NIK,	   sugiriendo	  que	  NIK	  pueda	   ser	  una	  diana	  
terapéutica	   más	   eficaz	   incluso	   que	   IKK,	   la	   diana	   de	   inhibición	   de	   NF-­‐κB	   habitualmente	  
utilizada	  hasta	  ahora.	  	  
	  
Al	   silenciar	   las	   subunidades	   de	   NF-­‐κB	   expresados	   en	   LPTC	   (c-­‐Rel,	   RelB,	   p52	   y	   p50),	  
observamos	  que	  únicamente	  el	  silenciamiento	  de	  c-­‐Rel	  provocó	  una	  inducción	  de	  apoptosis	  
en	  las	  líneas	  celulares	  que	  eran	  sensibles	  para	  siNIK.	  La	  reducción	  de	  los	  niveles	  nucleares	  de	  
c-­‐Rel	  después	  de	  tratar	  las	  células	  con	  siNIK,	  sugiere	  que	  al	  menos	  parte	  de	  la	  supervivencia	  
inducida	   por	   NIK,	   podría	   ser	   mediada	   por	   c-­‐Rel.	   En	   cambio,	   la	   pérdida	   de	   la	   actividad	  
alternativa	  de	  NF-­‐κB,	  mediante	  ARN	  de	  interferencia	  contra	  RelB	  y	  p52,	  no	  pudo	  explicar	  los	  
efectos	  de	  siNIK	  sobre	  la	  viabilidad	  celular,	  descartando	  que	  el	  efecto	  de	  NIK	  esté	  mediado	  
únicamente	  por	  la	  vía	  alternativa.	  	  
	  
Para	   conocer	   mejor	   los	   mecanismos	   de	   supervivencia	   regulados	   por	   NIK,	   utilizamos	   la	  
técnica	  de	  micromatrices	  de	  expresión	  génica	  para	  comparar	  los	  perfiles	  de	  expresión	  entre	  
células	   control	   y	   células	   silenciadas	   con	   siNIK	   en	   dos	   líneas	   celulares.	   Utilizando	  Gene	   Set	  
Enrichment	  Analysis	   (GSEA)	  confirmamos	  que	  la	  expresión	  de	  los	  genes	  dianas	  de	  NF-­‐κB	  se	  
perdía	  tras	  el	  silenciamiento	  de	  NIK,	  validando	  el	  papel	  de	  NIK	  en	  la	  activación	  funcional	  de	  
la	  vía.	  Otras	  vías	  alteradas	  tras	   la	   inhibición	  de	  NIK	  fueron	  la	  vía	  de	  JAK/Stat,	   las	  dianas	  del	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factor	  de	  transcripción	  XBP1	  y	  la	  señalización	  por	  interleuquinas.	  Entre	  los	  genes	  perdidos	  en	  
las	  células	   transfectadas	  con	  siNIK,	  se	  encontraban	   los	  genes	  anti-­‐apoptoticos	  BCL2L1	   (Bcl-­‐
x(L))	   y	  CFLAR	   (c-­‐FLIP)	   y	   las	   interleuquinas	   relacionadas	   con	   cáncer,	   IL6	   y	   IL21.	  Otros	   genes	  
alterados	   no	   relacionados	   con	   NF-­‐κB	   fueron	   los	   oncogenes	   PON2	   y	   YAP1	   y	   el	   supresor	  
tumoral	   KLF2.	   Por	   lo	   tanto,	   el	   perfil	   génico	   tras	   silenciar	   NIK	   en	   estos	   linfomas,	   altera	   la	  
expresión	   de	   múltiples	   genes	   y	   rutas	   de	   señalización	   implicados	   en	   proliferación	   y	  
supervivencia.	   El	   efecto	   de	   siNIK	   sobre	   la	   vía	   de	   JAK/Stat	   se	   confirmó	   por	   western	   blot,	  
detectando	  niveles	  reducidos	  de	   las	   formas	  fosforilados	  de	  STAT3	  y	  STAT5.	  También	  se	  vio	  
que	   la	   adición	   de	   IL21	   al	   medio	   de	   cultivo	   tras	   el	   silenciamiento	   de	   NIK,	   provoca	   un	   re-­‐
establecimiento	  de	  los	  niveles	  de	  p-­‐STAT3	  y	  p-­‐STAT5,	  proponiendo	  un	  posible	  enlace	  entre	  




La	   mayoría	   de	   los	   estudios	   publicados	   sobre	   la	   vía	   de	   NF-­‐κB,	   se	   han	   realizado	   utilizando	  
líneas	  celulares	  o	  modelos	  animales.	  Nuestro	  estudio,	  al	  haberse	  realizado	  sobre	  muestras	  
de	  pacientes	  de	   linfoma,	  establece	  un	  enlace	  translacional	  de	  gran	  relevancia	  para	   futuros	  
estudios.	  También	  es	  el	  primer	  estudio	  que	  analiza	  el	  papel	  de	  los	  cinco	  subunidades	  de	  NF-­‐
κB	   en	   linfomas	   humanos,	   aportando	   así	   una	   visión	   más	   completa	   de	   la	   vía.	   La	  
heterogeneidad	   y	   complejidad	   observada	   en	   la	   expresión	   de	   los	   distintos	   factores	   de	  
transcripción,	   pone	   de	  manifiesto	   la	   diversidad	   que	   existe	   en	   la	   señalización	   por	   NF-­‐κB	   e	  
indica	  que	   la	   expresión	   real	   de	  NF-­‐κB	  en	   los	   tumores,	   no	   refleja	   el	   patrón	  de	   señalización	  
habitualmente	   descrito.	   Aún	   así,	   la	   formación	   de	   dímeros	   entre	   una	   variedad	   de	  
subunidades	  de	  NF-­‐κB	  y	  entre	  NF-­‐κB	  y	  factores	  atípicos,	  han	  sido	  descritos	  previamente	  (24).	  
Así	  mismo,	  la	  activación	  de	  la	  transcripción	  mediada	  por	  dímeros	  formados	  por	  CD40	  y	  c-­‐Rel,	  
ya	  habían	  sido	  descritos	  en	  LBDCG	  (Zhou	  et	  al.	  2007).	  Nuestra	  observación	  de	  que	  c-­‐Rel	  se	  
detecta	   frecuentemente	   en	   el	   núcleo	   en	   ausencia	   de	   otros	   factores	   de	   NF-­‐κB,	   podría	  
explicarse	   por	   este	  motivo,	   y	   la	   futura	   evaluación	   de	   CD40	   en	   esta	   serie	   de	  muestras	   de	  
LBDCG	  sería	  de	  gran	  interés.	  Estos	  resultados	  también	  nos	  demuestran	  que	  la	  evaluación	  de	  
sólo	  una	  o	  un	  par	  de	  subunidades	  de	  la	  familia	  de	  NF-­‐κB,	  llevaría	  a	  una	  subestimación	  de	  la	  
expresión	   real	   de	   NF-­‐κB.	   La	   observación	   de	   que	   la	   expresión	   de	   NF-­‐κB	   no	   sólo	   es	   una	  
característica	  del	  subtipo	  ABC,	  sino	  también	  del	  GCB,	  está	  apoyada	  por	  estudios	  previos	  que	  
también	   muestran	   que	   hay	   activación	   de	   NF-­‐κB	   en	   el	   subtipo	   GCB	   (Pham	   et	   al.	   2011;	  
Espinosa	   et	   al.	   2008).	   Otros	   estudios	   demuestran	   datos	   opuestos,	   correlacionando	   la	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activación	   de	   NF-­‐κB	   con	   el	   subtipo	   ABC	   (Compagno	   et	   al.	   2009;	   Bavi	   et	   al.	   2011).	   Una	  
diferencia	   importante	  entre	  nuestro	  trabajo	  y	  estudios	  previos,	  es	  que	  en	  nuestro	  estudio,	  
se	   han	   excluido	   los	   casos	   positivos	   para	   el	   virus	   de	   Epstein-­‐Barr	   (VEB),	   pero	   no	   en	   otros	  
estudios	  publicados.	  Los	  LBDCG	  asociados	  a	  VEB	  presentan	  un	  curso	  clínico	  y	  características	  
moleculares	   distintos	   a	   los	   casos	   VEB	   negativos,	   por	   lo	   que	   se	   ha	   propuesto	   que	   LBDCG	  
asociado	  a	  VEB	  ha	  de	  ser	  considerado	  como	  un	  subtipo	  de	  linfoma	  distinto	  (Swerdlow	  et	  al.	  
2008).	  Como	   los	   LBDCG	  asociados	  a	  EBV	  se	  caracterizan	  por	  una	  activación	  de	  NF-­‐κB	  y	  un	  
fenotipo	  ABC	  (Montes-­‐Moreno	  et	  al.	  2012),	   la	   inclusión	  de	  estos	  casos	  en	  el	  análisis	  puede	  
modificar	  significativamente	  los	  resultados.	  Existen	  pocas	  publicaciones	  sobre	  la	  correlación	  
clínica	  de	  NF-­‐κB,	  y	  los	  estudios	  que	  hay	  son	  contradictorios.	  En	  nuestra	  serie	  de	  pacientes,	  c-­‐
Rel	  es	  capaz	  de	  identificar	  a	  un	  subgrupo	  de	  casos	  asociado	  a	  supervivencia	  global	  mayor.	  La	  
expresión	  de	  c-­‐Rel	  se	  ha	  descrito	  anteriormente	  como	  un	  factor	  de	  pronóstico	  desfavorable	  
en	  una	  serie	  de	  pacientes	  de	  DLBCL	  tipo	  GCB	  (Curry	  et	  al.	  2009).	  Sin	  embargo,	  ese	  estudio	  se	  
realizó	  en	  pacientes	  tratados	  con	  CHOP,	  mientras	  que	  el	  presente	  análisis	  incluye	  solamente	  
pacientes	  tratados	  con	  R-­‐CHOP,	  la	  terapia	  estándar	  utilizada	  hoy	  en	  día.	  	  	  
	  
El	   linfoma	   periférico	   de	   células	   T	   es	   un	   tipo	   de	   linfoma	   con	   un	   curso	   clínico	   altamente	  
desfavorable	  para	  el	  que	  actualmente	  no	  existen	  terapias	  efectivas.	  Nuestra	  observación	  de	  
que	  la	  expresión	  nuclear	  de	  NF-­‐κB	  puede	  distinguir	  un	  subgrupo	  de	  estos	  tumores	  con	  una	  	  
supervivencia	  aún	  peor,	   junto	  con	  publicaciones	  previas	   indicando	   la	   implicación	  de	  NF-­‐κB	  
en	  la	  patogénesis	  de	  LPCT	  (Sors	  et	  al.	  2006;	  Foss	  et	  al.	  2011),	  nos	  llevó	  a	   investigar	  nuevos	  
abordajes	  para	  inhibir	  la	  activación	  de	  NF-­‐κB	  en	  estos	  tumores.	  La	  sobre-­‐expresión	  de	  NIK	  en	  
un	   grupo	  de	   líneas	   celulares	   y	  muestras	   de	   pacientes	   con	   LPCT,	   nos	   hizo	   centramos	   en	   el	  
estudio	   del	   papel	   de	   NIK.	   Utilizando	   varias	   técnicas	   diferentes,	   demostramos	   el	   papel	  
fundamental	  de	  NIK	  en	  la	  regulación	  tanto	  de	  la	  vía	  clásica	  como	  de	  la	  alternativa	  de	  NF-­‐κB	  
en	   LPCT.	   El	   silenciamiento	  de	  NIK	   indujo	  apoptosis	   en	   líneas	   celulares	  de	   LPCT	  de	  manera	  
selectiva,	   afectando	   sólo	   a	   las	   líneas	   caracterizadas	   por	   una	   sobre-­‐expresión	   de	   NIK.	   La	  
función	   fundamental	   de	   NIK	   en	   la	   supervivencia	   de	   estas	   células,	   viene	   reflejada	   por	   los	  
genes	  cuya	  expresión	  se	  alteró	  por	  el	  silenciamiento	  de	  NIK,	  incluyendo	  genes	  que	  codifican	  
para	  proteínas	  anti-­‐apoptoticas	   implicadas	  en	  el	  patogénesis	  de	  PTCL,	  como	  c-­‐Flip	  y	  Bcl-­‐XL	  
(Rassidakis	  et	  al.	  2003;	  Al-­‐Yacoub	  et	  al.	  2012),	  y	  las	  interleuquinas	  pro-­‐tumorales	  IL-­‐6	  y	  IL21	  
(Grivennikov	  et	  al.	  2009;	  Ma	  et	  al.	  2011).	  NIK	  también	  manifestó	  ser	  un	  regulador	  de	  la	  vía	  
de	  JAK/STAT	  ya	  que	  el	  silenciamiento	  de	  NIK	  resultó	  en	  una	  pérdida	  de	  expresión	  de	  genes	  
incluidos	   en	   la	   ruta	   de	   señalización	   de	   JAK/STAT	   (identificados	   por	   micromatrices	   de	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expresión	   génica),	   y	   en	  una	  disminución	  de	   los	  niveles	  de	   fosforilación	  de	   STAT3	   y	   STAT5.	  
Nuestros	   datos	   sugieren	  que	  un	  posible	  mediador	   entre	  NIK	   y	   la	   vía	   de	   JAK/STAT	   es	   IL21.	  
Aunque	   hemos	   demostrado	   que	   IL21	   puede	   inducir	   la	   fosforilación	   de	   STAT3	   y	   STAT5	   en	  
estos	  tumores,	  se	  necesitan	  estudios	  adicionales	  para	  verificar	  su	  papel	  en	  la	  señalización	  de	  
NIK.	  Además,	  la	  supervivencia	  inducida	  por	  NIK,	  se	  puede	  explicar	  en	  parte	  por	  su	  regulación	  
del	  factor	  de	  transcripción	  c-­‐Rel,	  cuya	  inhibición	  por	  sí	  sola	  produjo	  apoptosis	  en	  estas	  líneas	  
celulares.	  Por	  tanto,	  proponemos	  NIK	  como	  una	  posible	  diana	  terapéutica	  en	  LPCT	  por	  varios	  
motivos.	   Primero,	   el	   silenciamiento	   de	   NIK	   induce	   una	   fuerte	   respuesta	   de	   apoptosis	   en	  
células	   de	   LPCT.	   Segundo,	   el	   efecto	   citotóxico	   es	   selectivo	   sobre	   las	   células	   que	   expresan	  
altos	   niveles	   de	   NIK,	   lo	   que	   indica	   que	   NIK	   no	   es	   necesario	   para	   la	   supervivencia	   de	   los	  
linfocitos	  T	  normales	  y	   limitaría	  posibles	  efectos	   secundarios.	  Tercero,	   la	   inhibición	  de	  NIK	  
sería	  una	  buena	  estrategia	  para	   interferir	   la	  actividad	  de	  vías	  de	  supervivencia	  claves	  en	  el	  
patogénesis	  de	  varios	  tipos	  de	  LPCT,	  como	  son	  la	  vía	  de	  NF-­‐κB	  y	  la	  vía	  de	  JAK/STAT.	  Además,	  
el	  silenciamiento	  de	  NIK	  demostró	  ser	  más	  efectivo	  en	  la	  inducción	  de	  muerte	  celular	  que	  el	  
silenciamiento	  de	  IKKβ	  o	  IKKα.	  Y	  por	  último,	  aunque	  el	  knockout	  de	  NIK	  en	  ratones	  altera	  el	  
desarrollo	   de	   los	   órganos	   linfáticos,	   el	   fenotipo	   global	   no	   presenta	   mayores	  
incompatibilidades	   en	   las	   funciones	   vitales	   normales	   (Yin	   et	   al.	   2001),	   sugiriendo	   que	   una	  
inhibición	   de	   NIK	   puede	   ser	   un	   abordaje	   seguro.	   Distintos	   mecanismos	   dan	   lugar	   a	   una	  
activación	   de	   NF-­‐κB	   en	   los	   diferentes	   tipos	   tumorales,	   y	   la	   identificación	   de	   estos	  
mecanismos	   es	   fundamental	   para	   poder	   desarrollar	   estrategias	   terapéuticas	   seguras	   que	  




1.	   La	   expresión	   de	   NF-­‐κB	   en	   tejidos	   tumorales	   de	   LBDCG	   presenta	   un	   patrón	   complejo	   y	  
heterogéneo	  que	  no	  refleja	  la	  cascada	  prototípica	  de	  señalización	  de	  NF-­‐κB.	  	  
	  
2.	   La	   expresión	   de	   LMP1	   en	   LBDCG	   asociado	   al	   virus	   de	   Epstein-­‐Barr,	   define	   tumores	   con	  
activación	  de	  NF-­‐κB.	  	  
	  
3.	  No	  existe	  ninguna	  correlación	  significativa	  entre	  la	  expresión	  de	  NF-­‐κB	  y	  los	  subtipos	  ABC	  
o	  GCB	  de	  LGDCG.	  Componentes	  de	  la	  vía	  alternativa	  y	  clásica	  se	  expresan	  en	  ambos	  subtipos.	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4.	   La	   expresión	   nuclear	   de	   c-­‐Rel	   identifica	   un	   grupo	   de	   pacientes	   de	   LGDCG	   con	   un	  
pronóstico	  favorable.	  	  
	  
En	  la	  segunda	  parte	  del	  proyecto,	  dedicada	  al	  estudio	  de	  NIK	  y	  NF-­‐κB	  en	  linfomas	  periféricos	  
de	  células	  T,	  podemos	  concluir	  lo	  siguientes:	  	  
	  
5.	   Los	   pacientes	   cuyos	   tumores	   expresan	   NF-­‐κB	   nuclear,	   presentan	   un	   curso	   clínico	  
desfavorable	  con	  una	  supervivencia	  más	  corta	  que	  los	  pacientes	  con	  tumores	  negativos	  para	  
NF-­‐κB.	  	  
	  
6.	  NIK	  está	  sobreexpresado	  en	  un	  grupo	  de	  líneas	  celulares	  y	  muestras	  tumorales	  de	  LPCT.	  	  
	  
7.	  NIK	   regula	   la	   activación	  de	   la	   vía	   clásica	   y	   alternativa	  de	  NF-­‐κB	   in	   LPCT.	  NIK	   controla	   la	  
señalización	  de	  NF-­‐κB,	  al	  	  menos	  en	  parte,	  mediante	  mecanismos	  independientes	  de	  IKK.	  	  
	  
8.	  NIK	  es	  necesario	  para	  la	  supervivencia	  de	  células	  de	  LPCT.	  El	  silenciamiento	  de	  NIK	  resultó	  
en	   apoptosis	   en	   células	   con	   niveles	   basales	   altos	   de	   NIK,	   pero	   no	   en	   células	   con	   baja	  
expresión	  de	  NIK.	  El	  silenciamiento	  de	  NIK	  dio	  lugar	  una	  reducción	  de	  viabilidad	  celular	  más	  
potente	  que	  el	  silenciamiento	  de	  IKKβ	  o	  IKKα.	  	  
	  
9.	  C-­‐Rel	  es	  necesario	  para	  la	  supervivencia	  de	  células	  de	  LPCT	  positivas	  para	  NIK.	  	  
	  
10.	  NIK	  regula	   la	  expresión	  de	  múltiples	  genes	   implicados	  en	  supervivencia	  de	  LPCT,	  como	  
son	  los	  genes	  que	  codifican	  para	  las	  proteínas	  anti-­‐apoptoticas	  Bcl-­‐XL	  y	  c-­‐Flip,	  las	  citoquinas	  
IL-­‐6	   y	   IL-­‐21,	   y	   el	   supresor	   tumoral	   KLF-­‐2.	   NIK	   también	   está	   implicado	   en	   la	   ruta	   de	  
señalización	  de	  JAK/STAT.	  
	  
